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Abstract	
Mitochondria	regulate	crucial	cellular	processes	such	as	energy	production	in	the	form	of	adenosine	 triphosphate	 (ATP),	 Ca2+	 homeostasis,	 cellular	 redox	 status	 and	 cell	 death.	Consequently,	 cells	 and	 tissues	 that	 depend	 on	 these	 functions	 are	 susceptible	 to	mitochondrial	 dysfunction.	 Any	 insult	 or	 genetic	 predisposition	 that	 leads	 to	mitochondrial	dysfunction	can	 lead	 to	a	 range	of	disorders	 that	 can	manifest	 in	many	different	 tissues.	 Mitochondrial	 diseases,	 caused	 by	 mutations	 in	 mitochondrial	 DNA	typically	 demonstrate	 severe	 neurological	 pathologies.	 These	 disorders	 are	 usually	associated	 with	 defects	 in	 oxidative	 phosphorylation,	 reduced	 ATP	 levels,	 increased	oxidative	stress	and	decreased	cellular	viability.	A	class	of	compounds	known	as	quinones	are	 reported	 to	 protect	 against	 mitochondrial	 dysfunction.	 Currently,	 only	 one	benzoquinone,	 idebenone,	 is	 approved	 in	 Europe	 to	 specifically	 treat	 a	mitochondrial	disease,	 while	 a	 few	 other	 drug	 candidates	 are	 in	 clinical	 development.	 Idebenone	 is	reported	to	rescue	cellular	ATP	levels	and	act	as	an	antioxidant.	Despite	reported	pre-clinical	and	clinical	efficacy,	no	causative	mode	of	action	has	been	confirmed	for	this	class	of	molecules	that	goes	beyond	pure	associations.	It	is	thought	that	quinones	need	to	be	bio-activated	by	cellular	reductases	such	as	NAD(P)H	quinone	oxidoreductase	1	(NQO1)	for	their	therapeutic	activity.	Due	to	a	rapid	first	pass	metabolism	and	dependence	on	a	single	enzyme	(NQO1)	for	its	bio-activation,	the	clinical	efficacy	of	idebenone	is	limited.	Naphthoquinones,	 structural	 analogues	 of	 vitamin	 K,	 have	 also	 been	 investigated	 as	potential	therapeutic	molecules	to	treat	mitochondrial	dysfunction-induced	neurological	disorders.	In	fact,	growing	evidence	suggests	that	naphthoquinones	could	be	beneficial	to	counteract	mitochondrial	dysfunction	that	 is	associated	with	neurological	disorders	such	as	epilepsy	and	Parkinson’s	disease.	
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In	this	study,	I	characterised	more	than	110	novel	short-chain	naphthoquinones	(SCQs)	to	 protect	 against	 mitochondrial	 dysfunction	 while	 working	 towards	 a	 better	understanding	of	 their	mechanism	of	 action.	These	 SCQs	were	 characterized	 for	 their	ability	 to	 protect	 against	mitochondrial	 dysfunction	 in	 vitro.	 Consistent	with	previous	data	 from	benzoquinones,	most	novel	 SCQs	were	mainly	bioactivated	by	NQO1,	while	some	were	also	bio-activated	by	other	unidentified	cellular	 reductases.	 	Overall,	more	than	 20	 of	 our	 SCQs	 showed	 significantly	 better	 in	 vitro	 cytoprotection	 against	 the	mitochondrial	complex-I	(C-I)	inhibitor,	rotenone,	compared	to	idebenone.	For	the	first	time,	 together	with	my	collaborators	 from	Department	of	Chemistry,	we	established	a	clear	structure-activity	relationship	and	 identified	optimal	chemical	characteristics	 for	naphthoquinone-based	 SCQs.	 This	 included	 a	 specific	 solubility	 range	 with	 a	 defined	balance	 between	 side-chain	 polarity,	 fattiness	 and	 the	 presence	 of	 specific	 functional	groups	 attached	 to	 the	 quinone	 core.	 Interestingly,	more	 than	 half	 of	 the	 novel	 SCQs	significantly	 increased	 basal	 ketone	 levels	 in	 cellular	 supernatant	 suggesting	 possible	upregulation	of	 fatty	acid	metabolism.	 In	contrast	 to	what	 is	currently	believed	as	 the	mechanism	of	action	of	quinones,	a	striking	lack	of	correlation	between	cytoprotection	by	our	SCQs	and	their	effects	on	ATP	levels,	lipid	peroxidation,	lactate	or	ketone	levels	suggests	that	the	mechanism	of	action	of	these	compounds	is	likely	much	more	complex	than	previously	anticipated.	
One	 of	 the	 most	 common,	 maternally-inherited	 mitochondrial	 disorders,	 Leber’s	Hereditary	Optic	Neuropathy	(LHON)	is	caused	by	mutations	in	the	mitochondrial	DNA	that	encode	subunits	of	mitochondrial	C-I.	These	LHON	mutations	result	in	mitochondrial	C-I	 deficiency,	 decreased	 ATP	 generation	 and	 increased	 oxidative	 stress	 which	 causereduced	 retinal	 thickness	 and	 ultimately	 loss	 of	 retinal	 ganglion	 cells	 (RGC).	 LHON	patients	show	a	rapid	and	progressive	loss	of	visual	acuity.	However,	a	rare	possibility	of	
Abstract	
 Novel short-chain quinones against mitochondrial dysfunction                                                            xxxi 
 
partial	recovery	of	vision	was	reported	 for	some	patients,	sometimes	even	years	after	disease	 onset.	 Currently,	 idebenone	 is	 the	 only	 drug	 approved	 in	 the	 Europe	 for	 the	treatment	of	LHON.		In	order	to	translate	my	in	vitro	findings	to	a	disease	model,	two	of	the	most	promising	cytoprotective	novel	SCQs	that	also	significantly	rescued	ATP	levels	
in	vitro	 in	 the	presence	of	 the	C-I	 inhibitor,	 rotenone,	were	 tested	 in	an	 in	vivo	mouse	model	of	LHON.	Intraocular	injection	of	rotenone	in	wild-type	C57Bl/6	mice	significantly	(p<0.05)	reduced	both	retinal	RGC	counts	and	the	retinal	thickness,	which	was	associated	with	rapid	loss	of	visual	acuity.	After	70	days	of	oral	treatment	with	the	novel	SCQs,	visual	acuity	was	restored	significantly	(p<0.05)	better	than	sham	or	idebenone-treated	mice,	with	 improvements	 evident	 from	 the	 first	week	 of	 treatment.	 Both	 SCQs	 significantly	(p<0.05)	 protected	 against	 RGC	 loss	 and	 reduced	 retinal	 thickness	 under	 conditions	where	idebenone	showed	no	efficacy.	In	addition,	no	overt	signs	of	SCQ-induced	toxicity	were	observed	in	any	of	the	animals.	Overall,	my	 in	vitro	and	 in	vivo	data	suggest	that	these	 novel	 SCQs	 can	 be	 developed	 into	 superior,	 effective	 and	 safe	 drugs	 to	 treat	disorders	associated	with	mitochondrial	dysfunction.	
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1.1 Mitochondria	1 	2 Mitochondria	 are	 multifunctional	 organelles	 that	 were	 believed	 to	 be	 exclusively	3 maternally	inherited	until	a	recent	report	highlighted	that	this	might	be	incorrect	(Shiyu	4 et	al,	2018).	Mitochondria	display	a	high	degree	of	plasticity	and	interconnectivity	with	5 other	 organelles.	Mitochondria	 are	 double-membraned	 organelles	 that	 are	 the	 site	 of	6 many	metabolic	and	biosynthetic	processes	within	the	cell.	Apart	from	generating	energy	7 in	 the	 form	 of	 adenosine	 triphosphate	 (ATP),	 mitochondria	 are	 essential	 for	 many	8 processes	 including	 redox	 signalling,	 production	 and	 modulation	 of	 reactive	 oxygen	9 species	 (ROS)	 (Maurya	 et	 al.	 2015,	 Zorov	 et	 al.	 2014),	 maintenance	 of	 calcium	10 homeostasis	(Giorgio	et	al.	2017,	Ichas	et	al.	1994),	thermoregulation	(Chouchani	et	al.	11 2016,	 Nedergaard	 et	 al.	 2001)	 and	 regulating	 cell	 death	 (Davis	 and	 Williams	 2012,	12 Vakifahmetoglu-Norberg	 et	 al.	 2017,	 Wojtczak	 and	 Zabłocki	 2008).	 The	 number	 of	13 mitochondria	per	cell	varies	anywhere	between	hundreds	to	thousands	depending	on	the	14 metabolic	demand	by	the	cell	(Floros	et	al.	2018,	Robin	and	Wong	1988).		15 
Mitochondrial	morphology	varies	according	to	the	individual	needs	of	its	host	tissue.	For	16 example,	within	hepatocytes,	the	shape	of	mitochondria	varied	from	small	grain-like	to	17 branched,	 thread-like	 structures	 (Collins	 et	 al.	 2002).	 	 Proteomic	 analysis	 of	 rat	18 mitochondria	extracted	from	heart,	skeletal	muscle	and	liver	tissues	reveal	that	although	19 qualitatively	very	similar,	the	protein	abundance	in	mitochondria	of	different	tissue	was	20 quite	different	(Forner	et	al.	2006).	For	example,	mitochondrial	electron	transport	chain	21 (ETC)	complex	proteins	were	abundant	in	heart	mitochondria,	urea	cycle	enzymes	were	22 abundant	in	the	liver	whereas	in	the	skeletal	muscle,	several	phosphatases	and	kinases	23 that	regulate	energy	metabolism	were	abundant	(Forner	et	al.	2006).	24 
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Mitochondria	from	different	organs	perform	different	 functions,	which	are	dictated	by	1 the	 tissue’s	 metabolic	 demand	 under	 normal	 physiological	 conditions	 as	 well	 as	 in	2 environments	that	exert	different	form	of	stress	onto	the	cells	and	tissues	(Burté	et	al.	3 2015).	 For	 example,	 in	 organs	 with	 a	 high-energy	 demand,	 such	 as	 the	 heart,	 the	4 mitochondrial	 volume	 represents	 23-32	 %	 of	 the	 total	 myocellular	 volume	 of	 a	5 cardiomyocyte	 (Lopaschuk	 et	 al.	 2010,	 Murphy	 et	 al.	 2016).	 These	 mitochondria	 in	6 cardiomyocytes	predominantly	oxidise	either	free	fatty	acids	bound	to	albumin	or	fatty	7 acids	released	from	triacylglycerol	in	chylomicrons	or	very-low-density	lipoproteins,	to	8 generate	50-70	%	of	the	required	ATP	to	sustain	cardiac	function	(Lopaschuk	et	al.	2010,	9 Murphy	 et	 al.	 2016).	 Glycolysis,	 lactate	 and	 ketone	 bodies	 are	 also	 used	 if	 additional	10 energy	is	required	(Lopaschuk	et	al.	2010,	Murphy	et	al.	2016).	In	contrast	to	the	heart,	11 brain	mitochondria	use	glucose	as	a	primary	source	for	energy	generation	under	normal	12 physiological	conditions	(Magistretti	and	Chatton	2005).	Brain	mitochondria	use	almost	13 31	mmol	of	glucose	per	100	g	of	brain	weight/min	(Kety	and	Schmidt	1948).	In	the	brain,	14 apart	 from	energy	 generation,	 glucose	 is	 also	used	 as	 a	 substrate	 for	 the	 synthesis	 of	15 building	blocks	of	amino	acids,	proteins	and	neurotransmitters	by	the	pentose	phosphate	16 pathway	(Magistretti	and	Chatton	2005).	17 
Within	 healthy	 cells,	 mitochondria	 are	 dynamic	 organelles	 that	 undergo	 continuous	18 biogenesis,	repair	and	degeneration	by	mitophagy	to	maintain	cellular	health	and	ensure	19 metabolic	homeostasis.	The	dynamic	nature	of	mitochondrial	morphology	is	regulated	by	20 either	fusion	or	fission	where	two	organelles	merge	or	the	one	organelle	separates	into	21 two	or	more	successors	respectively	(Skulachev	2001).	Mitochondrial	fusion	facilitates	22 the	exchange	of	metabolites	between	the	intermembrane	space	and	mitochondrial	matrix.	23 Stressors,	 such	 as	 nutrient	 deprivation,	 force	 mitochondria	 to	 rely	 on	 oxidative	24 phosphorylation	(OXPHOS).	Such	conditions	stimulate	fusion	of	functional	mitochondria	25 
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with	dysfunctional	mitochondria	that	allows	the	sharing	of	components	to	keep	up	with	1 cellular	 energy	 demands	 (Rossignol	 et	 al.	 2004).	 Mitochondrial	 fission	 balances	2 mitochondrial	fusion	by	creating	daughter	mitochondria	of	appropriate	size	to	transport	3 them	 along	 the	 microtubule	 network.	 Hence,	 mitochondrial	 fusion	 and	 fission	 allow	4 reorganisation	and	division	to	daughter	mitochondria,	of	which	the	damaged	ones	can	be	5 eliminated	by	mitophagy.		(Twig	et	al.	2008,	Zimmermann	and	Reichert	2017).	Overall,	6 our	current	understanding	of	mitochondria	depicts	an	extremely	dynamic	organelle	that	7 rapidly	responds	to	cellular	and	environmental	stimuli	to	maintain	cellular	metabolism	8 and	homeostasis.	9 
	10 
1.1.1 Structure	and	organisation	of	mitochondria	11 	12 
Mitochondria	are	composed	two	phospholipid	membranes	that	contain	multiple	integral	13 and	peripheral	proteins	separated	by	an	inter	membrane	space.	The	outer	mitochondrial	14 membrane	 (OMM)	 separates	 the	 mitochondrion	 from	 the	 cytoplasm	 and	 the	 inner	15 mitochondrial	 membrane	 (IMM),	 which	 is	 folded	 into	 cristae.	 The	 IMM	 encloses	 the	16 mitochondrial	 matrix,	 which	 hosts	 ribosomes,	 mitochondrial	 DNA	 (mtDNA),	 various	17 soluble	enzymes,	membrane-bound	enzyme	complexes	of	 the	electron	transport	chain	18 that	 are	 responsible	 for	 generating	 energy,	 inorganic	 ions	 and	metabolites	 (Figure	 1)	19 (Campbell	and	Reece	2005).	The	OMM	contains	voltage-dependent	anion	channels	(VDAC)	20 which	regulate	membrane	permeability	by	allowing	compounds	of	up	to	5000	Da	to	pass	21 across	the	membrane	freely.	Due	to	the	impermeability	of	larger	molecules	through	the	22 OMM,	enzyme	composition	of	the	intermembrane	space	significantly	differs	to	that	of	the	23 cytoplasm	(Campbell	and	Reece	2005).		24 
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Cellular	ATP	production	mainly	takes	place	at	the	inner	mitochondrial	membrane	at	the	1 mitochondrial	matrix	side,	while	the	intermembrane	space	acts	as	a	proton	depository.		2 The	IMM	contains	the	entire	respiratory	chain	along	with	the	ATP	synthase	complex	and	3 several	specific	metabolite	transporters	for	ATP,	adenosine	diphosphate	(ADP),	inorganic	4 phosphate	and	other	respiratory	substrates.	5 
	6 
	7 
Figure	1:	Schematic	representation	of	mitochondrial	structure.	Mitochondria	are	organelles	8 surrounded	by	two	membranes.	The	inner	mitochondrial	membrane	that	is	folded	heavily	into	9 cristae	 hosts	 components	 of	 the	 mitochondrial	 electron	 transport	 chain	 (ETC).	 The	 matrix	10 contains	enzymes	and	co-enzymes	involved	in	various	energy	generation	pathways	apart	from	11 electron	mediators,	mitochondrial	deoxyribonucleic	acid	(mtDNA)	and	ribosomes.	12 	13 
	14 
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The	mitochondrial	ETC	complexes	(C-I	to	C-IV)	along	with	the	ATP	synthase	complex	(C-1 V)	are	localised	inside	the	IMM	(matrix	side)	and	are	specifically	aggregated	within	the	2 cristae	as	protein	super	complexes	(Davies	et	al.	2011,	Klotzsch	et	al.	2015,	Wilkens	et	al.	3 2013).	 Each	 mammalian	 cell	 contains	 between	 hundreds	 to	 thousands	 of	 mtDNA	4 molecules	(Robin	and	Wong	1988,	Satoh	and	Kuroiwa	1991,	Sender	et	al.	2016).	mtDNA	5 are	largely	believed	to	be	maternally	inherited	exclusively	from	the	mother	since	paternal	6 mtDNA	was	believed	to	be	destroyed	after	fertilisation	(Al	Rawi	et	al.	2011,	Politi	et	al.	7 2014).	However,	paternal	leakage	was	occasionally	observed	in	Drosophila	(Kondo	et	al,	8 1992;	Nunes	et	al,	2013)	and	mouse	(Gyllensten	et	al,	1991).	In	a	case	report,	a	single	9 male	 human	with	 exercise	 intolerance	 and	mitochondrial	 myopathy	 was	 reported	 to	10 possess	biparental	mtDNA	inheritance,	~90	%	identical	to	the	paternal	haplotype	in	the	11 skeletal	muscle	(Schwartz	&	Vissing,	2002).	However,	paternal	inheritance	was	not	seen	12 in	any	other	tissues	(Schwartz	&	Vissing,	2002).	In	a	recent	study,	biparental	inheritance	13 (24	%	to	76	%)	of	mtDNA	was	observed	in	17	members	in	3	separate	multigeneration	14 families	 (Shiyu	 et	 al,	 2018).	 Therefore,	 although	mitochondria	 are	 largely	maternally	15 inherited,	paternal	transmission	of	mtDNA	may	also	coexist.	16 
Mammalian	mitochondria	 are	 composed	 of	 over	 1500	 proteins,	 of	which	 only	 13	 are	17 encoded	 by	 the	mtDNA,	whereas	 the	 rest	 of	 them	 are	 nuclear	 encoded	 (Neupert	 and	18 Herrmann	 2007).	 The	 IMM	 is	 highly	 selective	 with	 regards	 to	 the	 permeability	 of	19 metabolites	 and	 substrates,	 which	 is	 one	 of	 the	 prerequisites	 for	 energy	 production	20 (Wojtczak	and	Zabłocki	2008).	 It	 is	 thought	 that	 its	 selectivity	 is	also	 reflected	by	 the	21 unique	 structural	 composition	 of	 the	 IMM	 of	 about	 80	 %	 proteins	 and	 only	 20	 %	22 phospholipids,	compared	to	the	outer	mitochondrial	membrane	with	a	protein:lipid	ratio	23 of	1:1	(Giorgi	et	al.	2015,	Wojtczak	and	Zabłocki	2008).	24 
Introduction	
Novel short-chain quinones against mitochondrial dysfunction                     7 
 
1.1.2 Energy	generating	pathways	1 
	2 
All	cells	need	energy	to	sustain	their	cellular	functions.	The	central	role	of	mitochondria	3 is	to	generate	chemical	energy	in	the	form	of	ATP.	The	energy	status	of	the	cell	is	sensed	4 by	multiple	transcription	factors,	cofactors,	hormones,	kinases	and	nuclear	receptors	in	5 the	form	of	the	adenosine	monophosphate	(AMP)	to	ATP	ratio,	the	ratio	of	oxidised	to	6 reduced	 nicotinamide	 adenine	 dinucleotide	 (NAD+:NADH)	 or	 the	 levels	 of	 acetyl	7 coenzyme	A	(acetyl-CoA)	(Nunnari	and	Suomalainen	2012).	Increased	energy	demands	8 can	be	met	by	increasing	the	activity	of	one	of	the	energy	generating	pathways	as	well	as	9 increasing	mitochondrial	mass	by	upregulating	mitochondrial	biogenesis	(Hoppeler	and	10 Flueck	 2003).	 Cells	 generate	 the	 majority	 of	 their	 ATP	 by	 mitochondrial	 respiration,	11 which	 metabolises	 fuel	 molecules	 such	 as	 sugars,	 fats	 and	 amino	 acids	 (Figure	 2).	12 However,	 the	 specific	 cell	 type,	 its	 physiological	 status	 and	 the	 availability	 of	 specific	13 nutrients	determine	the	type	of	fuel	molecules	and	the	pathway/s	used	to	meet	cellular	14 ATP	demand.	For	example,	mitochondria	from	the	heart	predominantly	use	β-oxidation	15 of	fatty	acids	to	produce	ATP	(Murphy	et	al.	2016),	in	contrast	to	brain	mitochondria	that	16 predominantly	use	glucose-derived	products	(Mergenthaler	et	al.	2013).	During	fasting	17 or	under	conditions	of	reduced	glucose	availability,	neurons	and	glial	cells	can	metabolise	18 ketones	 for	generating	energy.	Since	 the	blood-brain	barrier	 is	 impermeable	 to	 lipids,	19 these	are	first	catabolised	in	the	liver	to	ketone	bodies	that	are	then	transported	to	the	20 brain	to	be	used	for	energy	generation	(Morris	2005).	21 
	22 
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Figure	2:	Energy	generating	pathways.	Mitochondria	can	generate	energy	(adenosine	triphosphate,	ATP)	from	using	sugars,	fats	or	amino	acids	by	glycolysis	or	β-oxidation	pathways.	The	initial	products	of	glycolysis	and	fatty	acid	oxidation	can	enter	mitochondria	by	specialised	transporters	to	undergo	further	reactions	to	generate	acetyl	coenzyme	A	(acetyl-CoA)	that	feeds	into	tricarboxylic	acid	(TCA)	cycle	and	ultimately	to	the	mitochondrial	electron	transport	chain	(ETC)	generating	more	energy.	The	electron	donors,	like	nicotinamide	adenine	dinucleotide	(NAD+)	can	be	recycled	by	using	the	products	of	glycolysis	in	fermentation,	resulting	in	the	generation	of	lactate.		NADH,	Nicotinamide	adenine	dinucleotide,	reduced;	OXPHOS,	oxidative	phosphorylation.	
Acetyl	CoA
TCA	Cycle
OXPHOS
Glucose
Glycolysis
Pyruvate
Fermentation
Lactate
NAD+NADH
NADHNAD+
ATP
ATP
Fatty	acids
Carnitine	transporter
β-Oxidation
Acetyl	CoA
Amino	acids
Plasma	membrane
Cytoplasm
Mitochondria
Lactate
Ketone	bodies
Introduction	
Novel short-chain quinones against mitochondrial dysfunction                     9 
 
1.1.2.1 Glycolysis	1 
	2 
Glycolysis	 is	 the	 metabolism	 of	 glucose	 to	 pyruvate	 by	 a	 series	 of	 enzyme-catalysed	3 reactions	that	include	the	degradation	of	the	glucose	to	pyruvate,	phosphorylation	of	ADP	4 to	 ATP	 along	 with	 the	 formation	 of	 NADH	 from	 NAD+.	 Glycolysis,	 in	 the	 presence	 of	5 oxygen,	exhibits	a	high	ratio	of	ATP:ADP	and	NADH/NAD+	(Hume	and	Weidemann	1979,	6 Wojtczak	and	Zabłocki	2008).	In	the	first	step	of	glycolysis,	glucose	is	broken	down	to	7 glucose-6-phosphate	(G6P)	(Figure	3).	Depending	on	the	current	needs	of	the	cell	and	its	8 cytosolic	 nicotinamide	 adenine	 dinucleotide	 phosphate	 (NADP+)	 concentrations,	 G6P	9 either	enters	glycolysis	or	the	pentose	phosphate	pathway	(Vander	Heiden	et	al.	2001).	10 
	11 
Figure	3:	Glycolysis.	Glucose	is	metabolised	by	glycolysis	to	glucose-6-phosphate	(G6P)	at	the	12 expense	 of	 one	 molecule	 of	 adenosine	 tri-phosphate	 (ATP).	 G6P	 is	 further	 metabolised	 to	13 pyruvate,	ultimately	resulting	in	a	gain	of	two	molecules	of	each	ATP	and	nicotinamide	adenine	14 dinucleotide	(NAD+)	overall.	Pyruvate,	the	end-product	of	glycolysis	can	enter	the	mitochondria	15 to	be	metabolised	in	by	the	tricarboxylic	acid	(TCA)	cycle.	16 ADP,	Adenosine	diphosphate;	NADH,	Nicotinamide	adenine	dinucleotide,	reduced.	17 	18 	19 
Although	 glycolysis	 is	 a	 far	 less	 efficient	way	 to	 generate	 energy	 (two	 ATP	 for	 every	20 molecule	of	glucose)	when	compared	to	OXPHOS	(up	to	36	ATP),	proliferating	cells	 in	21 culture	with	a	constant	supply	of	glucose	nearly	exclusively	use	glycolysis	not	only	 to	22 
Glucose Glyceraldehyde-3-phosphate Pyruvate
ATP ADPGlucose-6-phosphate
Pentose	phosphate	pathway
OXPHOSATP ADP 4ADP 4ATP
2NAD+ 2NADH
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generate	ATP,	but	to	also	generate	glycolytic	intermediates	that	are	shuttled	and	used	to	1 support	 anabolic	 reactions	 in	 cells	 and	 for	 the	 synthesis	 of	 building	 blocks	 of	 cell	2 proliferation	(DeBerardinis	et	al.,	2008;	Lunt	and	Vander	2011).	The	G6P	can	enter	the	3 pentose	 phosphate	 pathway	 (PPP)	 to	 produce	DNA,	 RNA	 and	 electron	 donors	NADH,	4 FADH2	(Patra	and	Hay,	2014).	Other	glycolytic	intermediate,	3-phosphoglycerate	can	be	5 used	for	the	synthesis	of	nucleotides	and	proteins	via	serine	synthesis	pathway	(Yang	and	6 Vousden,	2016;	DeBerardinis	et	al.,	2008).		7 
The	 glycolytic	 pathway	 of	 energy	 generation	 is	 preferred	 by	 the	 cultured	 cells	 in	8 conditions	where	 only	 about	 5	%	 or	 the	 entire	 pyruvate	 is	 used	 by	mitochondria	 for	9 OXPHOS	 (Nelson	 et	 al.	 2008).	 Apart	 from	 that,	 cells	 can	 also	 generate	 energy	 during	10 hypoxic	conditions	by	anaerobic	glycolysis	(Nelson	et	al.	2008).	Importantly,	given	that	11 most	cells	used	for	in	vitro	cell	culture	experiments	are	of	cancerous	origin,	it	is	necessary	12 to	 point	 out	 that	 regardless	 of	 oxygen	 availability,	 cancer	 cells	 predominantly	 use	13 glycolysis	for	ATP	production,	which	results	in	the	production	of	significant	amounts	of	14 lactate.	This	process	is	known	as	aerobic	glycolysis	or	Warburg	effect	(Potter	et	al.	2016,	15 Vander	et	al.	2009,	Warburg	et	al.	1927).	16 
The	 end-product	 of	 glycolysis,	 pyruvate,	 still	 contains	 the	 majority	 of	 the	 potential	17 chemical	 energy	of	 glucose	and	 can	 therefore	be	used	 in	 subsequent	 reactions.	 In	 the	18 presence	of	oxygen,	pyruvate	is	converted	to	acetyl	CoA	before	being	fully	metabolised	in	19 the	mitochondrial	OXPHOS.	In	contrast,	in	the	absence	of	oxygen,	pyruvate	is	converted	20 to	lactate	to	recycle	NAD+	from	NADH,	which	is	essential	to	sustain	the	initial	steps	of	21 glycolysis	(Vander	et	al.	2009).	For	cells	solely	relying	on	glycolysis	as	a	source	of	energy,	22 protons	released	from	the	breakdown	of	ATP	accumulate	within	these	cells	since	they	23 cannot	 be	 buffered	 by	 glycolytic	 cells.	 This	 resultant	 proton	 accumulation	 leads	 to	 a	24 
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decrease	 in	 cellular	 as	 well	 as	 blood	 pH	 causing	 acidosis	 (Fall	 and	 Szerlip	 2005).	1 Increased	glycolysis	is	accompanied	by	the	release	of	lactate	into	the	systemic	circulation	2 which	can,	in	severe	cases,	lead	to	the	clinical	symptom	of	lactic	acidosis	(Robergs	et	al.	3 2004).	4 
	5 
	6 
1.1.2.2	 Pentose	phosphate	pathway	7 	8 In	animal	cells,	glucose	is	broken	down	to	G6P	during	the	first	step	in	glycolysis	before	9 being	metabolised	to	pyruvate	(Nelson	et	al.	2008).	However,	depending	on	the	cellular	10 metabolic	demands	and	environmental	factors,	G6P	can	enter	into	the	pentose	phosphate	11 pathway	(PPP),	also	known	as	phospho-gluconate	pathway	or	hexose	monophosphate	12 shunt.	All	PPP	enzymes	are	located	in	the	cytosol	where	they	generate	the	nucleotide-13 precursor,	ribose-5-phosphate	that	is	required	to	synthesise	RNA	and	DNA	(Kruger	and	14 von	Schaewen	2003).	The	PPP	is	a	major	source	of	NADPH	generation	and	is	also	involved	15 in	the	production	of	precursors	for	the	synthesis	of	aromatic	amino	acids.	Therefore,	not	16 surprisingly,	 the	PPP	is	mainly	active	 in	cells	and	tissues	that	are	rapidly	proliferating	17 and/or	 are	 associated	 with	 higher	 levels	 of	 oxidative	 stress	 (Du	 et	 al.	 2013).	 In	 the	18 presence	 of	 oxidative	 stress,	 NADPH	 generated	 by	 PPP	 is	 used	 to	 regenerate	 the	19 endogenous	antioxidant,	glutathione	from	the	oxidised	glutathione	disulphide	(GSSG)	to	20 the	reduced	glutathione	(GSH)	(Nelson	et	al.	2008)	(See	section	1.1.4	and	Figure	11).		21 
NADPH,	generated	by	the	PPP	is	also	required	by	tissues	that	synthesise	fatty	acids,	like	22 the	liver	and	adipose	gland	as	well	as	tissues	involved	in	cholesterol	and	steroid	hormone	23 synthesis	like	the	adrenal	gland	and	gonads	(Patra	and	Hay	2014,	Raıs̈	et	al.	1999).	The	24 
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PPP	is	composed	of	two	phases,	the	oxidative	and	non-oxidative	phase.	In	the	first	step	of	1 the	PPP,	G6P	is	oxidised	to	ribulose-5-phosphate	(Ru5P)	while	two	molecules	of	NADP+	2 are	reduced	to	NADPH	(Figure	4).	The	resultant	Ru5P	can	either	be	converted	to	ribose-3 5-phosphate	as	a	precursor	for	nucleotides,	coenzymes,	DNA	and	RNA	synthesis	or	it	can	4 be	recycled	to	G6P	in	the	second,	non-oxidative	phase	of	the	PPP	(Horecker	2002,	Nelson	5 et	al.	2008,	Riganti	et	al.	2012).		6 
	7 
Figure	 4:	 Pentose	 phosphate	 pathway.	 The	 pentose	 phosphate	 pathway	 (PPP)	 uses	 the	8 intermediate	of	glycolysis,	glucose-6-phosphate	to	generate	ribulose-5-phosphate	(Ru5P)	while	9 reducing	NADP+	to	NADPH.	This	reduced	form	of	nicotinamide	adenine	dinucleotide	phosphate	10 (NADPH)	can	be	used	to	convert	oxidised	glutathione	(GSSG)	to	reduced	glutathione	(GSH)	which	11 can	detoxify	oxidative	radical	species.	NADPH	is	also	used	to	synthesise	fatty	acids.	Ru5P	can	be	12 further	metabolised	 into	 ribose-5-phosphate	 that	 is	 used	 for	 the	 synthesis	 of	 nucleotides	 for	13 deoxyribonucleic	acid	(DNA)	and	ribonucleic	acid	(RNA).	14 	15 
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1.1.2.3	 β-oxidation	of	fatty	acids	1 	2 
In	addition	to	glucose,	fatty	acids	are	an	important,	abundant	source	of	cellular	energy.	3 Under	physiological	conditions	tissues	under	physiological	conditions	use	sugar	and	fatty	4 acids	at	different	rates	for	mitochondrial	ATP	production.	However,	it	is	possible	to	adapt	5 the	body	to	near	exclusive	use	of	fatty	acid-dependent	respiration	by	dietary	modification	6 (Rho	and	Stafstrom	2012).	Fatty	acids	are	oxidised	to	acetyl-CoA	by	β-oxidation	and	the	7 resultant	acetyl-CoA	feeds	into	the	TCA	cycle	for	further	oxidation	by	OXPHOS	to	produce	8 chemical	energy	(Figure	5)	(Nelson	et	al.	2008).	Cells	obtain	fatty	acids	either	from	the	9 diet,	from	cellular	storage	vesicles	or	from	fat	that	is	synthesised	de-novo	in	tissues	such	10 as	the	liver.	The	enzymes	for	β-oxidation	of	fatty	acids	are	located	in	the	mitochondrial	11 matrix	as	well	as	in	the	liver	peroxisomes	(Schulz	1991).	12 
Fatty	acids	containing	12	or	less	carbons	can	easily	enter	the	mitochondria	without	any	13 transporters.	However,	most	of	the	dietary	fats	as	well	as	the	ones	that	originate	from	14 adipose	tissue	are	composed	of	14	or	more	carbons.	These	fatty	acids	require	a	special	15 transport	system	known	as	the	carnitine	shuttle	to	transport	them	into	mitochondria	for	16 metabolic	 degradation	 (Kerner	 and	 Hoppel	 2000,	 Schulz	 1991).	 This	 mitochondrial	17 shuttle	occurs	in	three	steps.	In	the	first	step,	fatty	acids	are	converted	to	fatty	acyl-CoA,	18 at	 the	 expense	 of	 one	 ATP	 molecule,	 catalysed	 by	 the	 enzyme	 acyl-CoA	 synthetase	19 (thiokinase)	located	on	the	OMM.	Subsequently,	fatty-acyl	CoA	is	transiently	attached	to	20 the	 hydroxyl	 group	 of	 carnitine	 located	 on	 the	 OMM	 forming	 fatty-acyl-carnitine	21 catalysed	by	 carnitine	acyl	 transferase-1	before	 forming	a	 carnitine	ester	at	 the	outer	22 surface	of	the	IMM.	This	fatty	acyl	carnitine	ester	then	enters	the	mitochondrial	matrix	23 via	the	carnitine	transporter	located	on	the	IMM.	In	the	final	step	of	the	carnitine	shuttle,	24 
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with	the	help	of	coenzymes	located	on	the	IMM,	fatty-acyl-CoA	is	regenerated	and	free	1 carnitine	is	released	(Figure	5)	(Kerner	and	Hoppel	2000,	Schulz	1991).		2 
	3 
Figure	 5:	 Mitochondrial	 β-oxidation	 of	 fatty	 acids.	 Fatty	 acids,	 converted	 to	 fatty	 acyl	4 coenzyme	A	(fatty-acyl-CoA)	enter	mitochondria	with	the	help	of	the	carnitine	transporter.	Once	5 inside	 the	 mitochondrial	 matrix,	 fatty-acyl-CoA	 is	 oxidised	 by	 β-oxidation	 resulting	 in	 the	6 generation	of	the	acetyl	coenzyme	A	(Acetyl-CoA)	and	reduced	electron	carriers’	nicotinamide	7 adenine	dinucleotide	 (NADH)	and	 flavin	 adenine	dinucleotide	 (FADH2).	Acetyl-CoA	enters	 the	8 tricarboxylic	acid	cycle	(TCA),	NADH	feeds	electrons	into	complex-I	of	the	mitochondrial	electron	9 transport	 chain	 (ETC),	 whereas	 FADH2	 feeds	 to	 complex	 III	 of	 ETC	 via	 electron	 transport	10 flavoprotein	dehydrogenase	(ETFDH)	ultimately	resulting	in	the	generation	of	energy	(adenosine	11 triphosphate,	ATP).	12 	13 
This	carnitine	mediated	fatty	acid	entry	process	is	the	rate-limiting	step	of	β-oxidation	of	14 fatty	acids.	Once	in	the	matrix,	fatty-acyl-CoA	undergoes	multiple	repeats	of	a	four-step	15 dehydrogenation	process	called	β-oxidation,	generating	acetyl-CoA,	NADH	and	reduced	16 flavin	adenine	dinucleotide	 (FADH2)	until	 the	entire	 fatty	acyl-CoA	 is	broken	down	 to	17 acetyl-CoA	(Figure	5)	(Longo	et	al.	2006,	Stephens	et	al.	2013).	18 
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The	generated	acetyl–CoA	enters	the	TCA	cycle	whereas	the	electron	carriers	donate	the	1 electrons	to	mitochondrial	ETC.	While	NADH	feeds	electrons	to	C-I	of	ETC,	the	reduced	2 flavoprotein,	 FADH2	 is	 re-oxidised	 by	 electron	 transport	 flavoprotein	 (ETF)	 and	3 subsequently	transferred	to	ETF	dehydrogenase	(ETFDH)	embedded	in	the	IMM	(Figure	4 5).	ETFDH	is	a	flavoprotein	that	feeds	electrons	to	C-III	of	the	mitochondrial	ETC	via	the	5 electron	carrier	coenzyme	Q10	(CoQ10)	(Gregersen	et	al.	2008,	Houten	and	Wanders	2010).		6 
In	the	 liver,	β-oxidation	of	 fatty	acids	also	occurs	 in	the	peroxisomes,	where	very	 long	7 chain	 fatty	 acids	 are	 broken	 down	 to	 medium	 chain	 fatty	 acids	 that	 are	 further	8 metabolised	 in	 the	 mitochondria	 to	 ketone	 bodies	 which	 are	 used	 as	 energy-rich	9 molecules	(Lazarow	1978).	The	process	of	peroxisomal	degradation	of	fatty	acids	is	very	10 similar	to	the	mitochondrial	pathway.	In	the	first	step	of	converting	fatty	acids	to	acyl-11 CoA	 in	 the	 peroxisomes,	 an	 electron	 transfer	 occurs	 from	 acyl-CoA	 via	 FADH2	 to	12 molecular	oxygen,	which	generates	hydrogen	peroxide	(H2O2)	with	the	potential	to	cause	13 oxidative	 damage.	 To	 prevent	 this	 liability,	 peroxisomes	 contain	 the	 endogenous	14 antioxidant	catalase	that	cleaves	the	generated	H2O2	to	molecular	oxygen	and	water	and	15 CoQ10	that	prevents	lipid	peroxidation	due	to	the	oxidative	stress	(Schulz	1991).	16 
Overall,	 each	 cycle	 of	 β-oxidation	 yields	 an	 acetyl-CoA,	 one	 NADH	 and	 two	 FADH2	17 molecules	as	energy	rich	electron	molecules.	Acetyl-CoA	is	further	oxidised	by	entering	18 into	TCA	cycle	 to	generate	one	ATP,	 three	NADH	and	 two	FADH2	molecules.	 For	each	19 molecule	of	NADH	and	FADH2	donated	to	the	mitochondrial	ETC,	2.5	and	1.5	molecules	20 of	 ATP	 are	 generated	 respectively.	 Therefore,	 for	 each	 acetyl	 CoA	 oxidised,	 11.5	21 molecules	 of	 ATP	 are	 generated	 (Longo	 et	 al.	 2006,	 Nelson	 et	 al.	 2008,	 Houten	 and	22 Wanders	2010).	23 
	24 
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1.1.2.4	 Tricarboxylic	acid	cycle	1 	2 
Energy-rich	 molecules	 including	 glucose,	 fats	 and	 some	 amino	 acids	 are	 oxidised	 to	3 acetyl-CoA	 as	 a	 first	 step	 of	 cellular	 respiration	 prior	 to	 feeding	 acetyl-CoA	 into	 the	4 tricarboxylic	acid	(TCA)	cycle	(also	known	as	citric	acid	cycle	or	Krebs	cycle)	(Briere	et	5 al.	2006).	6 
As	the	first	step,	pyruvate,	derived	from	sugars	via	glycolysis	is	oxidised	to	acetyl-CoA	in	7 an	 irreversible	 reaction	 known	 as	 oxidative	 carboxylation	 by	 the	 enzyme	 pyruvate	8 dehydrogenase	(PDH)	located	in	the	mitochondria.	During	this	reaction,	NAD+	is	reduced	9 to	NADH,	which	in	turn	feeds	electrons	into	C-I	of	the	mitochondrial	ETC.	The	generated	10 acetyl-CoA	is	oxidised	in	the	TCA	cycle	by	a	series	of	reactions	(Figure	6).	While	only	one	11 molecule	of	ATP	is	directly	generated	in	the	TCA	cycle,	during	the	conversion	of	succinyl	12 CoA	to	succinate,	 four	energy-rich	electron	carriers	are	generated	in	the	form	of	three	13 molecules	of	NADH	and	one	molecule	of	FADH2,	which	are	fed	into	the	ETC	to	use	this	14 energy	for	ATP	production.		For	each	molecule	of	NADH	and	FADH2	fed	into	the	ETC,	2.5	15 and	1.5	molecules	of	ATP	are	generated	(Nelson	et	al.	2008).	16 
Apart	from	generating	energy-rich	electron	carriers,	the	metabolites	of	the	TCA	cycle	are	17 also	 important	 biosynthetic	 intermediates.	 For	 example,	 citrate	 is	 used	 in	 fatty	 acid	18 biosynthesis	(Bhaduri	and	Srere	1963,	Kuhajda	2000),	α-ketoglutarate	and	oxaloacetate	19 are	precursors	 for	amino	acid	synthesis	(Krappmann	and	Braus	2002,	Xu	et	al.	2018),	20 while	oxaloacetate	is	also	be	used	for	gluconeogenesis	(Sepa-Kishi	et	al.	2018,	Yoon	et	al.	21 2001).	 Succinyl-CoA	 is	 a	 key	 intermediate	 for	 synthesising	 the	 porphyrin	 ring	 of	22 haemoglobin,	myoglobin	and	is	also	used	to	produce	electron	carriers	like	cytochrome	23 (Nelson	et	al.	2008,	Vakifahmetoglu-Norberg	et	al.	2017).	24 
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	1 
Figure	6:	Tricarboxylic	acid	cycle.	Energy	rich	substrates	such	as	glucose,	fatty	acids	and	amino	2 acids	 are	 broken	 down	 to	 acetyl	 coenzyme	 A	 (acetyl-CoA)	 that	 is	 subsequently	 fed	 into	 the	3 tricarboxylic	acid	(TCA)	cycle.	This	set	of	subsequent	reactions	directly	generates	one	molecule	4 of	 adenosine	 triphosphate	 (ATP)	 for	 every	 acetyl-CoA.	 TCA	 cycle	 also	 generates	 the	 reduced	5 electron	carriers,	three	molecules	of	nicotinamide	adenine	dinucleotide	phosphate	(NADH)	and	6 one	molecule	 of	 flavin	 adenine	 dinucleotide	 (FADH2)	 that	 are	 oxidised	 by	 the	 mitochondrial	7 electron	transport	chain	(ETC)	to	generate	nine	additional	molecules	of	ATP.	8 	9 
In	the	absence	of	OXPHOS	in	the	mitochondrial	matrix,	succinyl-CoA	ligase,	an	enzyme	of	10 the	 TCA	 cycle,	 produces	 high	 energy	 phosphates	 via	 substrate-level	 phosphorylation	11 (Johnson	et	al.,	1998).	During	respiration	inhibition	due	to	ETC	dysfunction	in	mouse	liver,	12 mitochondrial	diaphorases	contribute	to	regeneration	of	majority	of	the	NAD+	pool	(Kiss	13 et	 al.,	 2014).	 This	 NAD+	 pool	 in-turn	 supports	 the	 function	 of	 a-ketoglutarate	14 dehydrogenase	complex	(KGDHC)	in	providing	succinyl-CoA	to	succinyl-CoA	ligase	in	the	15 
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TCA	 cycle,	 therefore	maintaining	 substrate-level	 phosphorylation	 and	 generating	ATP	1 (Chinopoulos	et	al.,	2010;	Kiss	et	al.,	2013).	Therefore,	even	in	the	absence	of	OXPHOS,	2 substrate-level	phosphorylation	generates	ATP	that	is	expelled	into	the	cytosol	therefore	3 preventing	 ATP	 consumption	 by	 the	 mitochondria	 and	 hence	 avoiding	 cellular	4 bioenergetic	catastrophe	(Chinopoulos	et	al.,	2010;	Chinopoulos,	2011).	5 
	6 
	7 
1.1.2.5 Oxidative	phosphorylation	8 	9 
Mitochondrial	OXPHOS	utilises	 the	products	of	 glycolysis	 and	 the	TCA	cycle	 to	 satisfy	10 about	95	%	of	cellular	ATP	requirements	in	vivo.	Energy-rich	electrons	derived	from	the	11 breakdown	of	organic	starting	materials	are	sent	via	the	mitochondrial	ETC	over	multiple	12 complexes	and	protein	subunits	 to	 finally	 react	with	molecular	oxygen	(Campbell	and	13 Reece	2005).	The	process	of	the	transferring	electrons	from	one	molecule	to	another	is	14 known	 as	 a	 redox	 reaction.	 The	 resultant	 energy	 from	 these	 reactions	 is	 used	 in	 the	15 mitochondrial	ETC	to	transport	protons	from	the	mitochondrial	matrix,	through	the	IMM	16 to	the	intermembrane	space.	This	process	generates	an	electrochemical	gradient	across	17 the	 IMM	that	 is	subsequently	used	by	 the	mitochondrial	ATP	synthase	(complex	V)	 to	18 synthesise	ATP	(Wojtczak	and	Zabłocki	2008).		19 
The	electron	carriers	of	the	mitochondrial	ETC	are	composed	of	more	than	85	proteins	20 assembled	 into	 four	 membrane-embedded	 supramolecular	 complexes	 (Frey	 and	21 Mannella	 2000).	 Diffusible	 electron	 acceptors	 and	 donors	 connect	 these	 complexes,	22 located	in	the	cristae	of	the	IMM.	Briefly,	electrons	from	NADH	(C-I)	and	succinate	(C-II)	23 
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are	used	to	reduce	CoQ10.	The	reduced	CoQ10	transfers	electrons	to	cytochrome	C	(Cyt	C)	1 via	C-III.	Finally,	C-IV	completes	the	sequence	of	reactions	by	transferring	electrons	to	2 molecular	oxygen	(Nelson	et	al.	2008,	Wojtczak	and	Zabłocki	2008).		3 
The	 largest	 complex	 of	 the	 ETC,	 C-I	 (NADH-ubiquinone	 oxidoreductase	 or	 NADH	4 dehydrogenase),	is	composed	of	43	proteins	whose	subunits	are	encoded	by	both	nuclear	5 and	mitochondrial	genes	(Frey	and	Mannella	2000).	NADH	is	oxidised	by	C-I	by	delivering	6 its	electrons	 to	 the	 flavin	mononucleotide	 (FMN)	site	on	C-1	 (Figure	7).	The	resultant	7 electrons	from	this	reaction	are	then	transported	via	iron-sulphur	(Fe-S)	clusters	to	the	8 electron	carrier	CoQ10,	hence	reducing	 it	 to	the	quinol	(QH2)	 form	in	the	process.	This	9 reaction	is	coupled	to	the	pumping	four	protons	from	matrix	to	the	intermembrane	space	10 by	separate	subunits	of	C-I	(Brandt	et	al.	2003,	Ohnishi	and	Salerno	2005).	Inhibition	of	11 C-I	by	drugs	or	mutations	in	essential	C-I	subunits	typically	hinders	the	flow	of	electrons	12 to	 ubiquinone,	 which	 leads	 to	 the	 accumulation	 of	 NADH	 and	 an	 increase	 in	 ROS	 by	13 electrons	 that	 leak	 from	 C-I	 onto	 oxygen	 (Figure	 7).	 (Wojtczak	 and	 Zabłocki	 2008).	14 Ubiquinone,	 an	 electron	 carrier	 accepts	 electrons	 from	 both	 C-I	 and	 succinate	15 dehydrogenase,	which	 is	an	essential	part	of	C-II.	The	only	complex	which	 is	encoded	16 entirely	by	nuclear	DNA,	C-II,	is	composed	of	four	subunits,	one	containing	flavin	adenine	17 dinucleotide	 (FAD)	 which	 is	 required	 for	 the	 oxidation	 of	 succinate	 to	 fumarate.	 In	18 addition,	 a	membrane	 subunit,	 containing	 three	Fe-S	 clusters,	 aide	 in	 the	 transport	of	19 electrons	to	the	next	subunits.	The	electrons	from	the	reduced	ubiquinol	are	transported	20 C-III	 (ubiquinol-cytochrome	 C	 oxidoreductase),	 where	 it	 is	 re-oxidised	 to	 Q,	 ready	 to	21 diffuse	back	to	C-I.	C-III	reduces	ubiquinol	to	Q	by	a	two-step	process	that	involves	the	22 highly	reactive	intermediate	semiquinone	radical,	which	is	associated	with	increased	ROS	23 formation.	 Four	 protons	 are	 released	 into	 the	 intermembrane	 space	 during	 the	 re-24 oxidation	of	ubiquinone	(Wojtczak	and	Zabłocki	2008).	In	the	last	step	of	ETC,	C-IV	(Cyt	25 
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C	 oxidase)	 catalyses	 irreversible	 transfer	 of	 electrons	 from	 reduced	 Cyt	 C	 to	 oxygen	1 resulting	 in	 the	 formation	of	water	 (Wojtczak	et	al.	2008).	To	reduce	one	molecule	of	2 oxygen,	four	molecules	of	reduced	Cyt	C	and	four	protons	are	required.	This	last	step	of	3 ETC	adds	four	protons	to	the	intermembrane	space	adding	to	the	existing	proton	gradient.	4 The	resultant	proton-motive	force	drives	the	conformational	changes	that	allow	ADP	to	5 react	with	inorganic	phosphate	to	generate	ATP	by	the	enzyme	ATP	synthase	(ATPase),	6 which	is	sometimes	also	referred	to	as	C-V	(Figure	7)	(Wojtczak	and	Zabłocki	2008).	7 
	8 
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Figure	7:	Schematic	diagram	of	the	mitochondrial	electron	transport	chain.	As	a	 first	step	of	oxidative	phosphorylation	(OXPHOS),	a	proton	gradient	is	generated	across	the	IMM,	which	drives	the	synthesis	of	adenosine	triphosphate	(ATP).	Reduced	electron	carriers	like	nicotinamide	adenine	dinucleotide	(NADH)	and	flavin	adenine	dinucleotide	(FADH2)	donate	electrons	(e-)	to	the	complex	I	and	complex	II	of	the	ETC	respectively.	These	electrons	are	subsequently	transferred	to	ubiquinone	(Q)	thereby	reducing	it	to	ubiquinol	(QH2).	The	electrons	are	then	transferred	to	complex	III	via	cytochrome	C	and	then	to	molecular	oxygen	(O2)	via	complex	IV	to	form	water	(H2O).	Following	these	reactions,	the	protons	(H+)	that	were	transferred	to	the	intermembrane	space	are	shuttled	back	to	the	mitochondrial	matrix	by	complex	V	(ATP	synthase)	by	making	conformational	changes	to	F1F0	ATP	synthase	that	results	in	the	production	of	ATP	from	adenosine	diphosphate	(ADP)	and	inorganic	phosphate	(Pi).	
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1.1.2.6 Anaerobic	energy	generation	1 
	2 
Under	conditions	of	hypoxia	or	under	conditions	of	dysfunctional	mitochondria,	NADH	3 cannot	be	re-oxidised	to	NAD+,	which	 is	required	to	sustain	 further	glycolysis	 for	ATP	4 generation	(Schurr	2006).		Under	these	conditions,	the	product	of	glycolysis,	pyruvate	is	5 reduced	 to	 lactate.	 During	 this	 process	 no	 ATP	 is	 synthesised,	 but	 instead	 NAD+	 is	6 regenerated	from	NADH,	which	is	required	for	the	initial	steps	of	glycolysis	and	thereby	7 supports	 glycolytic	 ATP	 generation	 (Figure	 8)	 (Ido	 et	 al.	 2011).	 Lactate	 was	 once	8 considered	as	the	toxic,	waste	product	of	glycolysis.	However,	lately	lactate	production	9 has	been	recognised	to	not	only	regenerate	NAD+	but	also	as	a	regulator	of	cellular	redox	10 status	(Gao	et	al.	2018,	Ido	et	al.	2011).			11 
	12 
Figure	8:	Lactate	formation.	Lactate	is	generated	from	the	product	of	glycolysis,	pyruvate.	This	13 process	uses	electrons	 from	oxidising	 the	reduced	nicotinamide	adenine	dinucleotide	(NADH)	14 generated	during	glycolysis	to	recycle	nicotinamide	adenine	dinucleotide	(NAD+)	that	is	required	15 to	sustain	the	process	of	glycolysis.	16 ADP,	adenosine	diphosphate;	ATP,	adenosine	triphosphate	17 	18 
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During	 anaerobic	 physical	 exercise,	 sympathetic	 stimulation	 of	muscle	 glycogenolysis	1 results	in	lactate	generation	to	keep	up	with	the	high	ATP	demand,	which	results	in	high	2 lactate	flux	(Brooks	2009).	The	accumulated	lactate	can	act	as	a	gluconeogenic	precursor	3 during	sustained	exercise,	by	regenerating	glucose	from	lactate	in	the	liver	at	an	expense	4 of	six	molecules	of	ATP	by	a	process	known	as	Cori	cycle	(Jorge	et	al.	2017,	Waterhouse	5 and	 Keilson	 1969).	 Lactate	 consumed	 by	 distal	 tissues	 or	 organs	 also	 affects	 the	 pH	6 balance	 of	 the	 cells	 (Brooks	2009).	Recent	 evidence	 supports	 the	use	 of	 lactate	 as	 an	7 alternative	 oxidative	 substrate	 for	 neurons	 along	 with	 ketone	 bodies	 (Pellerin	 and	8 Magistretti	2012,	Voutsinos-Porche	et	al.	2003).	In	fact,	some	studies	report	a	preference	9 of	lactate	over	glucose	as	an	oxidative	substrate	for	neurons	(Bouzier-Sore	et	al.	2006,	10 Itoh	 et	 al.	 2003,	 Ivanov	 et	 al.	 2011)	 and	 glial	 cells	 (Drulis-Fajdasz	 et	 al.	 2018).	 In	11 astrocytes,	lactate	derived	from	glycogen	in	the	astrocytes	is	also	known	to	support	the	12 neuronal	metabolism	and	neuronal	plasticity	by	directly	increasing	ATP	synthesis	and/or	13 by	increasing	the	availability	of	NADH	(Béland-Millar	and	Messier	2018).	Although	the	14 use	of	lactate	as	energy	source	for	brain	metabolism	is	generally	agreed	on,	it	remains	15 unclear	 whether	 lactate	 undergoes	 direct	 metabolism	 in	 the	 astrocytes	 or	 indirect	16 metabolism	by	gluconeogenesis.	17 
Overall,	 the	 fundamental	 roles	 of	 extra	 mitochondrial	 and	 mitochondrial	 energy	18 generation	involve	different	pathways.	The	choice	of	individual	cells	to	generate	energy	19 by	a	particular	mechanism	depends	on	availability	and	type	of	nutrients,	environmental	20 factors	 as	 well	 as	 mitochondrial	 dynamics.	 Other	 prominent	 mitochondrial	 functions	21 include	 the	 regulation	 of	 cellular	 redox	 status	 and	 the	 role	 of	 mitochondria	 in	22 programmed	cell	death,	which	are	discussed	in	the	following	sections.	23 
	24 
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1.1.3 Mitochondrial	redox	environment	1 	2 
The	production	of	ROS	by	mitochondria	was	first	described	in	1966	(Jensen	1966).	Most	3 of	the	ROS	generated	endogenously	by	mitochondria	under	physiological	conditions	are	4 the	 by-product	 of	 OXPHOS.	 However,	 due	 to	 their	 potentially	 damaging	 nature,	 ROS	5 production	 is	 highly	 regulated	 by	 the	 mitochondria	 under	 normal	 physiological	6 conditions	 (Turrens	 2003).	 Only	 about	 2	 %	 of	 the	 total	 oxygen	 consumed	 by	7 mitochondria	 is	 converted	 to	 ROS	 under	 normal	 physiological	 conditions,	which	 is	 in	8 contrast	to	levels	as	high	as	11	%	under	pathological	conditions	(Aon	et	al.	2012,	Zorov	9 et	al.	2014).	10 
Most	electrons	that	enter	the	mitochondrial	ETC	are	used	to	reduce	molecular	oxygen	to	11 water.	However,	some	electrons	leak	from	the	redox	sites	in	the	ETC,	predominantly	in	12 C-I	 and	 C-III,	 which	 results	 in	 the	 one-electron	 reduction	 of	 molecular	 oxygen	 that	13 generates	superoxide	(O2˙-)	(Adam-Vizi	and	Chinopoulos	2006).	Due	to	the	high	reactivity	14 of	O2˙-,	H2O2	is	generated	in	the	presence	of	the	enzyme	superoxide	dismutase	(SOD).	The	15 resultant	H2O2	reacts	with	metal	cations	in	a	Fenton	reaction	that	produces	the	extremely	16 reactive	 hydroxyl	 radical	 (HO˙).	 Superoxide	 anion,	 hydroxyl,	 alkoxyl,	 peroxyl	 radicals	17 along	with	hydrogen	peroxide	generated	within	the	cell	together	constitute	the	majority	18 of	ROS.	19 
The	main	sites	of	ROS	generation	within	mitochondria	are	C-I	and	C-III	(Figure	9)	(Zorov	20 et	al.	2014).	However,	practically	all	other	major	mitochondrial	protein	complexes	also	21 have	the	potential	to	add	to	the	production	of	ROS.	Recent	studies	also	demonstrated	the	22 involvement	of	C-II	as	well,	but	to	a	lesser	degree	(Korge	et	al.	2017,	Quinlan	et	al.	2012).	23 C-I	and	C-III	inhibitors,	like	rotenone	and	antimycin	respectively	further	exacerbate	the	24 
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production	of	ROS	(Chen	et	al.	2003).	For	example,	C-I	inhibition	by	rotenone	enhances	1 the	reduction	of	the	NADH	reductase	site,	which	increases	the	electron	leak	from	C-I	and	2 results	in	the	generation	of	ROS	towards	the	mitochondrial	matrix	side	(Li	et	al.	2003).	3 Supporting	 the	 involvement	 of	 C-IV	 and	 C-V	 in	 ROS	 generation,	 addition	 of	 specific	4 inhibitors	KCN	and	oligomycin	blocked	ROS	generation	(Reichart	et	al.,	2018;	Ricci	et	al.,	5 2003;	Yoon	et	al.,	2005).	6 
Another	mitochondrial	enzyme,	dihydroorotate	(DHO)	dehydrogenase	(DHOdh),	located	7 in	 the	 IMM	 is	 also	 reported	 to	 generate	ROS	during	 the	oxidation	of	DHO	 (Evans	 and	8 Hedeel,	 2004).	 This	 is	 supported	 by	 reduced	 ROS	 generation	 and	 apoptosis	 by	9 downregulating	or	chemically	 inhibiting	DHOdh	 in	cancer	cell	 lines	 (Hail	et	al.,	2010).		10 Other	 mitochondrial	 enzymes	 that	 are	 responsible	 for	 ROS	 generation	 include	11 monoamine	 oxidase	 (MAO),	 α-ketoglutarate	 dehydrogenase	 (α-KGDH)	 and	 pyruvate	12 dehydrogenase	(PDH)	(DiLisa	et	al.,	2009).	Apart	from	these	enzymes,	the	senescence-13 related	 protein	 p66shc	 upon	 interaction	 with	 CytC	 serves	 as	 another	 site	 for	14 mitochondrial	ROS	generation	(Giorgio	et	al.,	2005).	15 
Mitochondrial	ROS	are	either	detoxified	by	antioxidant	defence	mechanisms	within	the	16 mitochondria	 or	 at	 higher	 concentrations	 have	 the	 potential	 to	 cause	 mitochondrial	17 damage	(Chen	et	al.	2003).	Mitochondrial	ROS	production	is	also	induced	by	other	factors	18 like	ubiquinone	pools	that	can	undergo	incomplete,	one-electron	reduction	resulting	in	19 the	generation	of	semiquinone	that	can	cause	further	cell	damage	(Murphy	2009).	This	20 was	 further	 confirmed	 by	 the	 fact	 that	 prevention	 of	 semiquinones	 also	 suppressed	21 superoxide	 formation.	 For	 example,	 supplementing	 succinate	 as	 an	 electron	 donor	 to	22 rodent	heart	mitochondria	 in	 the	presence	of	C-III	 inhibitor,	antimycin,	prevented	 the	23 formation	of	O2˙-	(Rigoulet	et	al.	2011,	Turrens	et	al.	1985).	24 
Introduction	
Novel short-chain quinones against mitochondrial dysfunction                     26 
 
ROS	are	 generated	outside	 the	mitochondria	under	 conditions	where	H2O2	 enters	 the	1 cytosol.	There,	 it	generates	HO˙	 in	 the	presence	of	 transition	metal	 cations	via	Fenton	2 chemistry	as	follows	(Wojtczak	and	Zabłocki	2008):	3 
H2O2	+	Fe2+	→	HO˙	+	OH-	+	Fe3+		4 
Studies	 also	 reported	 the	 efflux	 of	 H2O2	 from	 mitochondria	 to	 the	 cytosol	 under	5 conditions	of	a	high	NADH/NAD+	ratio	in	the	mitochondrial	matrix.	This	effect	also	occurs	6 in	 the	 presence	 of	 high	 levels	 of	 ubiquinone	 electron	 transport	 coupled	 with	 high	7 membrane	potential	and	lack	of	ATP	synthesis	in	the	mitochondrial	matrix	(Angelova	and	8 Abramov	2016,	Murphy	2009).	Several	other	mitochondrial	enzymes	such	as	cytochrome	9 P450	enzymes	(CYP450),	monoamine	oxidase	(MAO),	α-ketoglutarate	dehydrogenase	(α-10 KGDH),	PDH,	ETFDH	and	aconitase	are	also	known	to	produce	ROS	(Zorov	et	al.	2014).	11 Chronic	elevated	levels	of	ROS	can	be	deleterious	to	cells	and	tissues	by	causing	oxidative	12 damage	 to	 cellular	 macromolecules	 and	 can	 eventually	 lead	 to	 cell	 death.	 Lower	13 concentrations	of	ROS	still	have	the	potential	to	cause	cell	damage;	however,	this	damage	14 is	typically	repaired	by	cellular	defence	mechanisms	that	are	discussed	in	the	following	15 sections.	 In	 contrast	 to	 the	 largely	 negative	 view	 of	 cellular	 ROS	 as	 something	 to	 be	16 avoided,	 there	 is	 mounting	 evidence	 that	 low	 concentrations	 of	 ROS	 act	 as	 essential	17 signalling	 molecules	 required	 for	 adaptation	 and	 repair	 (see	 section	 1.1.3.1).	 Hence,	18 under	 physiological	 conditions,	 cellular	 mechanisms	 aim	 to	 maintain	 a	 tight	 balance	19 between	ROS-induced	signalling	and	pathological	levels	of	ROS.			20 
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Figure	9:	Sites	of	mitochondrial	reactive	oxygen	species	(ROS)	generation.	Major	sites	of	mitochondrial	superoxide	(O2˙-)	generation	are	complex	I	(C-I)	and	complex	III	(C-III)	of	the	mitochondrial	electron	transport	chain	(ETC),	while	complex	II	(C-II),	complex	IV	(C-IV)	and	complex	V	(C-V)	are	also	 involved.	 Other	 enzymes	 like	 monoamine	 oxidase	 (MAO),	 cytochrome	 C	 (Cyt	 C),	 α-ketoglutarate	 dehydrogenase	 (α-KGDH),	 pyruvate	dehydrogenase	(PDH)	and	dihydroorotate	dehydrogenase	(DHO-dh)	are	also	responsible	for	ROS	generation.
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1.1.3.1	 Regulatory	role	of	mitochondrial	ROS	1 	2 
For	 a	 long	 time,	 ROS	 were	 generally	 believed	 to	 be	 detrimental	 to	 cellular	 function.	3 However,	 recent	 evidence	 changes	 this	 picture	 significantly.	 Mitochondrial	 ROS,	 at	4 elevated,	but	sub-lethal	concentrations	play	an	important	role	as	cell	signalling	molecules	5 that	for	example	regulate	cell	cycle	progression	(Holmström	and	Finkel	2014).	It	is	now	6 established	 that	 the	 redox	 environment	 of	 the	 cell	 defines	 its	 fate	 and	 can	 induce	7 proliferation,	differentiation	or	even	cell	death	(Ray	et	al.	2012).	Furthermore,	different	8 cellular	 compartments	 require	 different	 redox	 status	 for	 their	 function.	 For	 example,	9 reducing	 conditions	 are	 typically	 associated	 with	 the	 cytoplasm,	 while	 in	 contrast	10 lysosomes	are	characterised	by	an	oxidative	environment	(Alberts	et	al.	2000).		11 
The	 mitogen	 activated	 protein	 kinase	 (MAPK)	 cascade	 includes	 apoptosis	 signal-12 regulated	 kinase	 1	 (ASK1)	 that	 is	 activated	 under	 stressful	 conditions	 (including	13 oxidative	 stress).	 In	 resting	state,	ASK1,	 through	 its	C-terminal	 coiled	domain	 forms	a	14 homo-oligomer.	 In	 the	presence	of	oxidative	stress,	ASK1	undergoes	a	conformational	15 change	and	an	additional	interface	is	pre-formed	on	the	existing	oligomer	that	leads	to	its	16 auto-phosphorylation,	which	activates	ASK1	(Tobiume	et	al.	2002)	17 
The	redox	protein,	thioredoxin,	in	its	reduced	form	interacts	with	ASK1	and	inhibits	its	18 subsequent	activation	(Fujino	et	al.	2007).	In	the	presence	of	low	levels	of	oxidative	stress,	19 ASK1	 is	 activated	 and	 induces	 p38	 signalling,	which	 leads	 to	 non-apoptotic	 outcomes	20 such	as	cell	differentiation	(Choi	et	al.	2011)	and	immune	signalling	(Matsuzawa	et	al.	21 2005).	22 
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Phosphoinositide-3-kinase	(PI3K)	is	another	signalling	pathway	that	plays	a	major	role	1 in	cell	proliferation	and	stimulation	by	growth	factors.	Endogenously	generated	ROS	can	2 activate	PI3K	 similar	 to	 the	MAPK	pathways	by	oxidation,	which	ultimately	 results	 in	3 sustained	activation	of	the	signalling	pathways	(Kwon	et	al.	2004).				4 
Low	doses	of	H2O2	can	also	promote	the	release	of	Ca2+	and	therefore	increase	cellular	5 calcium	signalling	(Giorgio	et	al.	2017).	Furthermore,	H2O2-mediated	lipid	peroxidation	6 was	demonstrated	to	activate	different	isoforms	of	phospholipases	in	the	mitochondria,	7 cytosol	and	liposomes.	Although	the	precise	mechanism	is	so	far	unknown,	oxidised	lipids	8 are	 proposed	 to	 act	 as	 a	 substrate	 to	 phospholipase-C	 and	 phospholipase-A	 that	 can	9 further	increase	the	release	of	Ca2+	from	the	endoplasmic	reticulum	(Domijan	et	al.	2014).	10 Calcium	 signalling	 is	 also	 evoked	 by	 the	 generation	 of	 O2˙-	 under	 conditions	 of	 mild	11 hypoxia	where	 the	mitochondrial	ETC	 is	 inhibited	 (Song	et	al.	2017).	These	 increased	12 cytoplasmic	Ca2+	levels	can	induce	the	translocation	and	binding	of	phospholipase	to	the	13 OMM	 that	 leads	 to	 the	 release	 of	 Cyt	 C	 and	 other	 proapoptotic	 factors	 from	 the	14 mitochondria,	which	initiates	cell	death	(Domijan	et	al.	2014,	Halliwell	2006,	van	Rossum	15 et	 al.	 2004).	 The	 indirect	 release	 of	 Ca2+,	 mediated	 by	 ROS-activated	 phospholipase	16 isoforms	 also	 plays	 an	 important	 signalling	 role	 in	 the	 brain.	 The	 neurotransmitter	17 dopamine	also	induces	the	release	of	intracellular	calcium	as	a	secondary	event.	In	this	18 system,	the	mitochondrial	enzyme	MAO	metabolises	dopamine	which	releases	H2O2	 in	19 the	process.	This	in-turn	results	in	lipid	peroxidation,	activation	of	phospholipases	and	20 generating	IP3-dependent	calcium	signalling	(Vaarmann	et	al.	2010).		21 
Another	important	role	of	ROS	includes	the	regulation	of	cardiomyocyte	(Li	et	al.	2012)	22 and	neuron	excitability	(Angelova	and	Müller	2006)	by	modulating	gating	properties	of	23 various	ion	channels	(Tang	et	al.	2001).	ROS	can	oxidise	cysteine	and	methionine	residues	24 
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of	 ion	 channels	 and	 their	 associated	 receptor	 protein	 subunits,	 which	 ultimately	1 modulates	the	excitability	of	muscles	and	neuronal	cells	(Kolbe	et	al.	2010).	ROS-induced	2 oxidation	 of	 cysteine	 residues	 in	 ion	 channels	 can	 also	 disrupt	 calcium-dependant	3 activation	 of	 those	 channels,	 which	 therefore	 can	 impair	 muscle	 vascular	 tone,	4 responsible	for	some	vascular	disorders	(Donoso	et	al.	2011,	Tang	et	al.	2004).	In	neurons,	5 calcium	flux	influences	neurotransmitter	release,	plasticity	of	neurons	and	neurogenesis	6 (Thanawala	and	Regehr	2013).	Mitochondrial	ATP	along	with	TCA	cycle	intermediates	7 act	as	building	blocks	for	the	synthesis	of	neurotransmitters	including	glutamate	and	γ-8 amino	 butyric	 acid	 (GABA)	 (Wallace	 et	 al.	 2010).	 Hence,	 compromised	 oxidative	9 metabolism	coupled	with	 increased	oxidative	stress	 is	 likely	 to	alter	neurotransmitter	10 levels	and	affect	brain	function.	11 
	12 
1.1.3.2	 Cellular	damage	due	to	oxidative	stress	13 	14 Oxidative	stress	is	the	excessive	generation	of	free	radicals	in	biological	systems	to	the	15 extent	 at	 which	 cellular	 protective	 mechanisms	 fail	 to	 rescue,	 leads	 to	 the	 perilous	16 alterations	of	cellular	lipids	and	proteins.	Mitochondria	generate	ROS	as	a	by-product	of	17 OXPHOS.	 However,	 mitochondrial	 dysfunction	 exacerbates	 the	 generation	 and	18 accumulation	of	ROS	(Zorov	et	al.	2014).	Accumulation	of	exogenous	toxic	molecules	in	19 mitochondria	also	lead	to	the	generation	of	ROS	(Zorov	et	al.	2014).	Although	ROS	can	act	20 as	cellular	signalling	molecules,	they	are	harmful	to	cells	after	chronic	exposure	or	higher	21 levels.	 The	HO˙	 generated	 from	H2O2	 can	 react	with	 almost	 any	macromolecule	 in	 its	22 vicinity.	The	O2˙-	 can	attack	 the	double	bonds	 in	unsaturated	 fatty	acids	and	proteins,	23 producing	 lipid	 peroxides	 that	 ultimately	 destabilize	membranes	 (Schumacker	 2015).	24 
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Free	radicals,	unlike	normal	cellular	substrates	do	not	depend	on	enzymatic	activity	of	1 cells,	 but	 are	 aggressive,	 highly	 reactive	molecules	 involved	 in	 spontaneous	 reactions	2 (Figure	10)	(Turrens	2003).	Cellular	macromolecules	such	as	lipids,	proteins	and	DNA	3 are	highly	susceptible	to	ROS-induced	damage.	Damage	to	proteins	would	reduce	their	4 affinity	 towards	enzymes,	coenzymes	and	substrates	and	will	ultimately	affect	protein	5 function	(Bandyopadhyay	et	al.	1999,	Klaunig	et	al.	2010).	Accumulation	of	mitochondrial	6 ROS	 is	 implicated	 in	 many	 pathological	 conditions	 including	 neurodegenerative	7 disorders	 (Feitosa	 2018,	 Hatziagapiou	 et	 al.	 2018).	 ROS-induced	 oxidative	 damage	 to	8 mitochondria	functions	as	a	vicious	cycle,	where	the	resultant	damage	to	ETC	complexes	9 further	exacerbates	the	generation	of	ROS	causing	additional	damage	to	cell	(Zorov	et	al.	10 2014).	For	example,	free	radicals	generated	by	C-I	and	C-III	of	the	mitochondrial	ETC	have	11 access	to	the	mitochondrial	membrane.	These	radicals	can	oxidise	the	phospholipids	on	12 the	 mitochondrial	 membrane.	 The	 resulting	 formation	 of	 lipid	 peroxides	 derails	 the	13 composition,	fluidity	and	barrier	function	of	the	mitochondrial	membrane.	The	addition	14 of	 such	 polar,	 peroxyl	 groups	 also	 modifies	 the	 arrangement	 of	 fatty	 acids	 in	 the	15 membrane,	 which	 increases	 its	 permeability	 and	 can	 ultimately	 leading	 to	 cell	 death	16 (Kagan	et	al.	2005).		17 
Cardiolipin,	 an	 anionic	 phospholipid,	 is	 found	 primarily	 on	 the	 IMM	 bound	 to	 Cyt	 C.	18 Cardiolipin	has	a	unique	structure	among	phospholipids	by	containing	four	acyl	chains	in	19 contrast	to	most	lipids	that	are	composed	of	only	two	acyl	chains.	It	is	required	for	the	20 stability	 and	 fluidity	 of	 the	 mitochondrial	 membrane,	 but	 also	 for	 the	 formation	 of	21 mitochondrial	cristae	(Mannella	2006,	Schlame	et	al.	2000).	In	the	presence	of	oxidative	22 stress,	cardiolipin	is	oxidised	by	cardiolipin	peroxidase	and	results	in	the	mobilisation	of	23 Cyt	C	from	the	IMM.	Decrease	in	intact	cardiolipin	content	leads	to	increased	membrane	24 permeabilisation,	which	provides	access	for	proapoptotic	factors	in	to	the	mitochondria	25 
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along	with	the	release	of	Cyt	C	as	a	key	feature	for	the	induction	of	apoptosis	(Kagan	et	al.	1 2005).	Apart	from	its	role	in	mitochondrial	membrane	integrity,	cardiolipin	is	also	shown	2 to	bind	to	the	ETC	complexes,	C-I,	C-III,	C-IV,	whose	activity	is	decreased	in	the	absence	3 of	cardiolipin.	Cardiolipin	facilitates	the	association	of	mitochondrial	C-III	and	C-IV	into	4 super-complexes	that	is	believed	to	improve	OXPHOS	efficiency	(Zhang	et	al.	2002).	The	5 presence	 of	 super-complexes	 eliminates	 the	 need	 for	 substrates	 to	 diffuse	 substrates	6 between	 individual	 components	 of	 the	 mitochondrial	 ETC.	 Hence,	 in	 the	 presence	 of	7 oxidative	 stress,	 the	 activity	 of	 ETC	 complexes	 is	 directly	 impaired	 by	 cardiolipin	8 oxidation	apart	from	increasing	membrane	permeabilisation	and	inducing	the	release	of	9 proapoptotic	factors	(Bhat	et	al.	2015).	10 
mtDNA	is	significantly	more	susceptible	to	oxidative	damage	since	it	is	not	protected	by	11 histones,	lacks	introns	and	has	DNA	repair	mechanism	that	are	less	effective	compared	12 to	 nuclear	 DNA	 (nDNA)	 (Lenaz	 1998,	 Chan	 2006).	 Therefore,	 prolonged	 exposure	 of	13 mitochondria	 to	 non-physiological	 concentration	 of	 ROS	 significantly	 increases	 the	14 likelihood	of	mutations	in	the	mtDNA	(Wenzel	et	al.	2008).	These	mtDNA	mutations,	that	15 constitute	 point	mutation	 and	deletions	 of	 different	 length	will	 not	 only	 decrease	 the	16 mitochondrial	 oxidative	 phosphorylation	 capacity	 but	 also	 increase	 the	 generation	 of	17 ROS	even	further	(Zorov	et	al.	2014).	18 
	19 
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Figure	10:	Damage	due	to	reactive	oxygen	species.	Reactive	oxygen	species	(ROS)	are	highly	4 aggressive	molecules	and	can	involve	in	spontaneous	reactions.	ROS	can	damage	DNA	and	cause	5 alterations	to	proteins,	lipids	causing	cardiolipin	peroxidation	and	membrane	damage.	These	lead	6 to	 decreased	 mitochondrial	 oxidative	 phosphorylation	 (OXPHOS)	 which	 in	 turn	 causes	7 mitochondrial	dysfunction.	All	these	processes	can	ultimately	lead	to	cell	death.	8 	9 	10 
1.1.4	 Cellular	defence	mechanisms	against	ROS-induced	damage	11 	12 
ROS,	 generated	 as	 a	 by-product	 of	 cellular	 aerobic	 metabolism,	 can	 be	 extremely	13 detrimental	to	cells	at	higher	concentrations.	To	counteract	oxidative	stress,	cells	have	14 developed	or	use	defence	mechanisms	 involving	 a	plethora	of	 enzymatic	 antioxidants	15 
Introduction	
Novel short-chain quinones against mitochondrial dysfunction                     34 
 
such	 as	 SOD,	 catalase,	 glutathione-peroxidase,	 peroxiredoxins	 (Lebovitz	 et	 al.	 1996,	1 Skulachev	1996)	and	small-molecule	antioxidants	including	vitamins	such	as	b-carotene	2 (vitamin	 A),	 ascorbic	 acid	 (vitamin	 C)	 and	a-tocopherol	 (vitamin	 E)	 (Do	 et	 al.	 2015,	3 Kasperczyk	et	al.	2014).	4 SOD	detoxifies	O2˙-	and	 is	 present	 as	 two	distinct	 cellular	 isoenzymes	 in	 different	 cell	5 compartments.	Cytosolic	SOD	is	coupled	with	zinc	and	copper	atoms	(Zn-SOD,	Cu-SOD)	6 as	cofactors	(Okado-Matsumoto	and	Fridovich	2001)	in	contrast	to	mitochondrial	SOD,	7 which	 utilises	 manganese	 (Mn-SOD)	 (Govatati	 et	 al.	 2016).	 SOD	 reacts	 with	 O2˙-	 and	8 converts	it	into	H2O2.	Although	not	a	free	radical	itself,	H2O2	is	sufficiently	reactive	to	be	9 damaging	and	in	the	presence	of	ferrous	ions	and	generates	HO˙.	In	addition,	H2O2	is	able	10 to	 easily	 cross	 membranes	 which	 makes	 this	 molecule	 a	 potent	 toxin	 at	 higher	11 concentrations	 (Murphy	2009).	 Cells	 therefore	detoxify	H2O2	 by	 a	 catalase-dependent	12 reaction	that	converts	it	into	water	and	oxygen:	13 
2H2O2	®	2H2O	+	O2	14 
Catalase	 is	 located	mainly	 in	 the	 peroxisomes.	 In	 addition	 to	 catalase,	 other	 enzymes	15 classified	as	peroxidases,	 like	glutathione	peroxidase	 (GPx1)	are	common	cytoplasmic	16 enzymes	that	detoxify	H2O2.	Glutathione	(L-g-glutamyl-L-cysteinyl-glycine;	GSH)	is	one	of	17 the	most	abundant	cellular	antioxidants.	It	 is	the	major	mitochondrial	ROS-detoxifying	18 agent	due	to	its	high	millimolar	intra-mitochondrial	concentrations	(Montero	et	al.	2009).	19 The	 GSH	 tripeptide	 which	 is	 linked	 with	 a	 g-bond	 is	 claimed	 to	 be	 resistant	 against	20 degradation	 reactions	 (Sheehan	 et	 al.	 2001).	 In	 the	 presence	 of	 pro-oxidants,	 the	21 sulphydryl	 group	 of	 GSH,	which	 is	 the	 redox	 active	moiety,	 is	 oxidised	 to	 glutathione	22 disulphide	(GSSG),	a	homodimer	of	GSH.	As	a	result,	H2O2	 is	converted	to	water	in	the	23 presence	of	GPx1	(Figure	11)	(Nelson	et	al.	2008).	However,	the	sulphydryl	group	can	24 
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also	react	with	the	cysteine	residue	on	proteins	to	form	PSSG	(glutathionylated	protein)	1 that	 often	 results	 in	 inhibition	of	 their	 activity	 or	 changes	 in	protein	 stability	 (Ghezzi	2 2013).		3 
	4 
	5 
Figure	11:	Cellular	defence	mechanisms.	Due	to	the	high	reactivity	of	O2˙-,	hydrogen	peroxide	6 (H2O2)	is	generated	by	superoxide	dismutase	(SOD).	The	resultant	H2O2	is	further	detoxified	to	7 water	(H2O)	by	glutathione	peroxidase	(GPx1)	utilising	reducing	equivalents	from	the	oxidation	8 of	glutathione	 (GSH)	 to	glutathione-disulphide	 (GSSG)	 in	 the	presence	of	GSH-reductase	 (GR).	9 H2O2	can	also	be	detoxified	by	peroxiredoxin	(Prx)	pathway	that	is	further	reduced	by	utilising	10 electron	equivalents	from	thioredoxin	(Trx)	in	the	presence	of	Trx-reductase	(TrxR).	Both	GSH	11 and	 Trx	 can	 be	 further	 regenerated	 by	 utilising	 electron	 equivalents	 from	 reduced	 form	 of	12 nicotinamide	adenine	dinucleotide	phosphate	(NADPH).	13 	14 Intracellular	GSH	is	regenerated	from	GSSG	by	the	enzyme	GSH	reductase	(GR)	by	using	15 NADPH	from	PPP	(Nelson	et	al.	2008).	In	fact,	GSH	is	also	involved	in	the	reactivation	of	16 vitamin	C,	ascorbic	acid	from	dehyro-ascorbic	acid	(Meister	1992).	17 Dehydroascorbic	acid	+	2GSH®	Ascorbic	acid	+	GSSG	18 
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Another	class	of	enzymes,	peroxiredoxins	(Prx)	are	involved	in	detoxifying	H2O2	in	the	1 presence	of	thioredoxin	(Trx)	and	the	enzyme	thioredoxin	reductase	(TrxR)	(Figure	11)	2 (Perkins	et	al.	2015).	3 Cyt	C,	located	on	the	inner	mitochondrial	membrane	acts	as	an	essential	electron	carrier	4 in	the	mitochondrial	ETC.	This	form	of	Cyt	C	can	detoxify	O2˙-	and	H2O2	converting	it	into	5 molecular	oxygen	and	water.	The	reduced	Cyt	C	is	then	re-oxidised	by	C-IV	of	the	ETC	6 providing	electrons	to	the	final	step	of	ETC	(Pereverzev	et	al.	2003,	Skulachev	1998).	7 	8 
1.1.5	 Quality	control	of	mitochondria	9 	10 
In	 general,	 mitochondrial	 energy	 production	 is	 regulated	 tightly	 in	 line	 with	 other	11 metabolic	activities	such	as	maintaining	redox	homeostasis	and	supplying	intermediates	12 for	 protein	 and	 DNA	 synthesis.	 For	 this	 purpose,	 mitochondria	 undergo	 not	 only	13 metabolic	 but	 also	 morphological	 changes	 depending	 on	 the	 cellular	 environment.	14 Mitochondrial	 network	 fragmentation	 (mitochondrial	 fission)	 is	 promoted	 by	 the	15 oversupply	of	substrate,	in	contrast	to	substrate	shortage,	which	promotes	mitochondrial	16 elongation	(mitochondrial	fusion)	(Gomes	et	al.	2011,	Molina	et	al.	2009).		17 
Dynamin-related-protein-1	 (Drp1),	 a	 large	 dynamin-related	 GTPase	 regulates	18 mitochondrial	 fission	 (Hoppins	 et	 al.	 2007).	 Fission	occurs	when	Drp1,	 located	 in	 the	19 cytosol	translocates	to	the	OMM	and	binds	to	the	integral	OMM	proteins	Fis-1,	Mff	and	20 MIEF1,	followed	by	post-translational	modifications.	However,	the	exact	mechanism	of	21 this	 interaction	 is	 not	 fully	 understood	 yet	 (Gottlieb	 and	 Bernstein	 2016).	 Drp-1,	 has	22 recently	been	reported	to	also	play	a	role	in	cristae	remodelling	and	result	in	dramatic	23 fragmentation	of	mitochondria	(Große	et	al.	2016).	24 
Introduction	
Novel short-chain quinones against mitochondrial dysfunction                     37 
 
Mitochondrial	 fusion	 is	 essential	 to	 allow	 the	 exchange	 of	 intermembrane	 space	 and	1 matrix	 contents	 including	 the	 mtDNA,	 between	 mitochondria	 (Chen	 et	 al.	 2007).	2 Mitochondrial	 fusion	 is	 mediated	 by	 mitofusins	 (MFN1,	 MFN2)	 and	 optic	 atrophy-1	3 (OPA1)	 proteins	 located	 in	 the	 OMM	 and	 IMM	 respectively.	 Mitofusins	 promote	4 mitochondrial	fusion	by	the	formation	of	dimers	by	activating	GTPase	and	in	the	presence	5 of	 OPA1.	 In	 the	 absence	 of	 MFN2,	 another	 protein	 named	 mitochondrial	 elongation	6 factor-1	 (MIEF1)	 promotes	 the	 fusion	 of	 mitochondria	 (Gottlieb	 and	 Bernstein	 2016,	7 Zhao	et	al.	2013).	8 
Mitochondrial	 fusion	 and	 fission,	 as	 key	 morphological	 responses	 are	 collectively	9 controlled	by	energy	status,	the	activity	of	mitochondrial	ETC,	environmental	factors	such	10 as	 toxins	 and	 cellular	 kinases	 (Mishra	 and	 Chan	 2016).	 Impaired	 processes	 of	11 mitochondrial	fusion	or	fission	lead	to	mitochondrial	dysfunction	and	are	responsible	for	12 a	variety	of	degenerative	disorders	(Reddy	2014,	Wang	et	al.	2009).	Exposure	of	cultured	13 cells	 to	 stress	 in	 the	 form	 of	 toxins	 or	 ultraviolet	 (UV)	 rays	 promotes	mitochondrial	14 fission,	which	is	balanced	by	mitochondrial	fusion	in	order	to	improve	cellular	viability.		15 Inhibition	of	mitochondrial	fusion	can	lead	to	loss	of	mtDNA,	OXPHOS	deficiencies	and	a	16 significantly	increased	ROS	levels	(Chen	and	Chan	2009).	Defects	in	Drp-1	are	associated	17 with	cardiomyopathy	and	in	vivo	lethality	(Ashrafian	et	al.	2010)	whereas	mutations	in	18 mitofusins	and	OPA1	cause	neurodegenerative	diseases	such	as	dominant	optic	atrophy	19 respectively	(Alexander	et	al.	2000,	Züchner	et	al.	2004).	20 
Under	conditions	of	high-energy	demand,	transient	hypoxia	or	a	lack	of	respiratory	units	21 (ETC	complexes)	 result	 in	energy	deficit.	 In	 these	 scenarios,	mitochondrial	biogenesis	22 (mitogenesis)	and	cellular	glycolysis	are	typically	upregulated.	A	coordinated	synthesis	23 and	assembly	of	both	nuclear	and	mitochondrial	encoded	subunits	of	the	ETC	complexes	24 
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are	 required	 for	mitogenesis.	Nuclear-encoded	proteins	 are	 translated	by	 cytoplasmic	1 ribosomes	 and	 are	 subsequently	 imported	 into	 the	 mitochondria.	 This	 process	 is	2 governed	by	 the	mitochondrial	membrane	potential	hence	 facilitating	 the	assembly	of	3 both	 mitochondrial	 and	 nuclear	 encoded	 subunits	 into	 functional	 complexes	 that	4 constitute	the	ETC	(Jornayvaz	and	Shulman	2010).	Specific	assembly	factors	like	nuclear	5 respiratory	 factor	 1	 and	 2	 activate	mitochondrial	 transcription	 factor	 that	 allows	 the	6 replication	of	mtDNA.	Excess	or	unincorporated	subunits	are	degraded	by	proteases	in	7 the	mitochondrial	 matrix	 (Palikaras	 et	 al.	 2015).	 The	major	 regulator	 of	mitogenesis	8 belong	 to	 peroxisome	 proliferator-activated	 receptor	 gamma	 (PPARγ)	 family,	 mainly	9 PPARγ	 coactivator-1-alpha	 (PGC-1α),	 which	 is	 upregulated	 in	 response	 to	 increased	10 energy	demands	(Lehman	et	al.	2000).	PGC-1α	is	activated	by	exogenous	cues	such	as	11 stress,	ROS,	calorie	restriction	that	in-turn	increases	the	transcription	of	genes	involved	12 in	 metabolic	 pathways	 including	 mitogenesis	 (Fernandez-Marcos	 and	 Auwerx	 2011).	13 Cellular	kinases	such	as	p38	MAPK,	the	homologue	of	silent	information	regulator	protein	14 (SIRT1)	as	well	as	the	energy	sensor	AMP-activated	protein	kinase	(AMPK)	induce	PGC-15 1α	expression	and	enhance	its	activation	when	ATP	levels	are	low	(Reznick	et	al.	2007).		16 
In	contrast	to	mitogenesis,	an	autophagic	process	called	mitophagy,	removes	defective	17 mitochondria.	 Following	 the	 release	 of	 signals	 like	 ROS,	 DNA	 damage	 etc.,	 the	18 mitochondrial	outer	membrane	becomes	permeable	to	Cyt	C,	endonucleases	apart	from	19 other	proteins	in	the	intermembrane	space	that	activate	caspases	to	carry	out	apoptosis.	20 Mitophagy	 is	 a	degradation	process	 that	 effectively	 eliminates	damaged	mitochondria	21 from	healthy	ones	 (Youle	and	Narendra	2011).	Mitophagy	not	only	removes	defective	22 mitochondria	that	harbour	risk	of	excess	ROS	production,	but	also	provides	an	additional	23 source	 of	 energy	 via	 the	metabolic	 use	 of	 energy-rich	 amino	 acids	 (Kim	 et	 al.	 2007).	24 Mitophagy	 is	 regulated	 by	 cellular	 kinases	 such	 as	 PTEN-induced	 putative	 kinase-1	25 
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(PINK1)	located	on	the	OMM	and	a	cytoplasmic	ligase,	parkin.	Other	proteins	such	as	Nix	1 and	BH-3-proapoptotic	proteins	(Bnip3)	act	as	receptors	by	binding	to	LC3	located	on	the	2 autophagosome	 that	 aids	 targeting	 mitochondria	 to	 the	 autophagosome	 (Youle	 and	3 Narendra	2011).	4 
Permeabilisation	 of	 the	 mitochondrial	 outer	 membrane	 occurs	 by	 the	 opening	 of	5 mitochondrial	permeability	transition	pore	(mPTP)	(Bernardi	1999,	Mnatsakanyan	et	al.	6 2017).	The	mPTP	permits	the	passage	of	molecules	smaller	than	15kDa	and	is	sensitive	7 to	intracellular	calcium	homeostasis	(Elrod	and	Molkentin	2013).	This	pore	allows	entry	8 of	metabolites	into	the	mitochondrial	matrix.	However,	prolonged	opening	of	the	mPTP	9 may	 lead	 to	 osmotic	 dysregulation	 in	 the	 inner	 mitochondrial	 membrane,	 leading	 to	10 uncoupling	of	the	electron	transport	system	from	ATP	synthase	which	leads	to	reduced	11 ATP	 generation	 and	 ultimately	 resulting	 in	 cell	 death	 (Mnatsakanyan	 et	 al.	 2017).	 In	12 cultured	cells,	upon	induction	of	apoptosis	(by	toxins	like	actinomycin	or	UV	radiation),	13 pores	in	mitochondrial	outer	membrane	open	to	release	Cyt	C	into	the	cytosol,	followed	14 by	 decreased	 ETC	 activity,	 suppression	 of	 respiration	 rate,	 decreased	 membrane	15 potential,	cleavage	of	OPA1	and	disassembly	of	cristae	junctions	that	ultimately	lead	to	16 cell	death.	However,	in	the	presence	of	caspase	inhibitors,	apoptosis	is	blocked	(Burke	17 2017).	Collectively,	mitochondrial	fission,	fusion,	mitogenesis	and	mitophagy	regulate	the	18 morphology	of	mitochondria	 and	 is	 referred	 to	 as	mitochondrial	 dynamics	 (Chen	and	19 Chan	2009).	20 
	21 
	22 
	23 
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1.2 Mitochondrial	dysfunction	and	disease	1 	2 Mitochondria	 are	multi-functional	 organelles,	 serving	many	 roles	 that	 involve	 energy	3 generation,	Ca2+	homeostasis,	intermediate	biosynthesis,	regulation	of	cell	death	that	in	4 summary	 determine	 cellular	 survival.	 Therefore,	 not	 surprisingly,	 dysfunctional	5 mitochondria	are	implicated	in	a	large	range	of	diseases	that	can	affect	nearly	every	tissue	6 in	either	children	or	adults	(Figure	12).	Although	it	would	be	tempting	to	connect	specific	7 pathological	 conditions	 to	 specific	 mitochondrial	 pathways,	 the	 current	 literature	8 suggests	a	more	complex	scenario.	At	present,	there	is	good	evidence	that	mitochondrial	9 dysfunction-induced	disorders	involve	multiple	interrelated	pathways	and	mechanisms	10 such	as	oxidative	stress,	calcium	dysregulation,	age-related	and	inherited	DNA	mutations	11 that	cause	mitochondrial	dysfunction	(Boczonadi	and	Horvath	2014,	Burté	et	al.	2015).			12 
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	1 
	2 
Figure	 12:	 Clinical	 complexity	 of	 mitochondrial	 diseases.	 Mitochondrial	 dysfunction	 can	3 affect	any	organ	in	the	body	either	solely	or	as	a	multi-system	disorder.	4 	5 
	6 
 7 
 8 
 9 
 10 
 11 
NeurodegenerationEpilepsyAtaxiaParkinsonismCognitive	declineDementia
Visual	impairmentHearing	impairment
CardiomyopathyLiver	disease Diabetes
Muscle	weaknessMyopathy
Neuropathy
Kidney	dysfunction
Infertility
DiarrhoeaAcid	reflux
Anaemia
Introduction	
Novel short-chain quinones against mitochondrial dysfunction                     42 
 
1.2.1		 Diseases	due	to	mitochondrial	dysfunction	1 	2 
Genetic	 disorders	 with	 a	 mitochondrial	 phenotype	 could	 be	 caused	 either	 due	 to	3 mutations	 in	 mitochondrial	 genes	 (mtDNA	 or	 nDNA)	 or	 by	 the	 impairment	 of	4 mitochondrial	 function	 is	 impaired	by	external	 factors	 (i.e.	drugs,	oxygen	deprivation,	5 ROS	etc.).	For	normal	function,	mitochondria	require	more	than	1500	proteins,	of	which	6 only	 13	 proteins	 are	 encoded	 by	 the	mtDNA	while	 the	 vast	 majority	 of	 proteins	 are	7 encoded	in	the	nucleus	(Neupert	and	Herrmann	2007).	These	nuclear	encoded	proteins	8 are	 translated	 in	 the	 cytoplasm	 before	 being	 imported	 into	 the	 mitochondria.	 Since	9 mitochondria	are	solely	maternally	inherited,	mutations	in	mitochondrial	genome	do	not	10 follow	classic	Mendelian	rules	of	inheritance	(Al	Rawi	et	al.	2011,	Politi	et	al.	2014).	Each	11 cell	contains	several	hundreds	to	thousands	copies	of	mtDNA	that	may	differ	in	sequence,	12 hence	 referred	 to	 as	 heteroplasmy	 (Robin	 and	Wong	1988,	 Satoh	 and	Kuroiwa	1991,	13 Sender	et	al.	2016).	 It	 is	believed	that	during	mitosis,	 the	distribution	of	mitochondria	14 into	daughter	cells	occurs	randomly,	which	can	accumulate	specific	mtDNA	mutations	to	15 different	extent	in	specific	cells	that	can	include	oocytes	(Sproule	and	Kaufmann	2008).	16 As	a	result,	the	accumulation	of	a	mutation	in	any	specific	cell	occurs	incidentally	and	the	17 same	mutation	might	not	manifest	 itself	 in	the	same	way	in	two	carriers	(Sproule	and	18 Kaufmann	2008).	Therefore,	 a	diverse	 clinical	phenotype	 is	observed	 in	patients	with	19 mitochondrial	mutation.	20 
Mutations	in	mtDNA	can	lead	to	an	extensive	array	of	symptoms	that	can	affect	nearly	all	21 tissues	 in	 the	 body	 but	 mainly	 affects	 tissues	 that	 are	 characterised	 by	 large	 energy	22 demands.	Mutations	in	mtDNA	resulting	in	primary	mitochondrial	diseases	either	encode	23 for	 OXPHOS	 proteins	 directly	 or	 impact	 their	 function	 by	 altering	 the	 production	 of	24 
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machinery	 required	 to	 run	 OXPHOS.	 The	 pathological	 symptoms	 of	 mitochondrial	1 dysfunction	 typically	 include	blindness	 and	other	vision	disorders,	deafness,	diabetes,	2 muscle	atrophy,	exercise	intolerance	and	impaired	cognitive	function.	These	symptoms	3 can	sometimes	show	a	significant	degree	of	overlap	between	different	diseases	such	as	4 Mitochondrial	 Encephalomyopathy	 with	 Lactic	 Acidosis	 and	 Stroke-like	 Episodes	5 (MELAS)	 or	 optical	 neuropathies	 like	 Leber’s	 hereditary	 optic	 neuropathy	 (LHON),	6 neuropathy,	 ataxia	and	 retinitis	pigmentosa	 (NARP)	and	macular	degeneration,	which	7 complicates	 diagnosis	 based	 on	 patient	 characteristics	 alone	 (Table	 1)	 (Sproule	 and	8 Kaufmann	 2008).	 Therefore,	 diagnosis	 is	 predominantly	 based	 on	 detection	 of	9 characteristic	disease-specific	mutations	and	DNA	modifications.	For	example,	 specific	10 mtDNA	deletions	are	observed	in	Kearns-Sayre	syndrome	and	Pearson	syndrome	(Wong	11 2001),	while	mutations	 in	 genes	 encoding	 ribosomal	 RNA	 can	 cause	 aminoglycoside-12 induced	non-syndromic	deafness	(Zhu	et	al.	2006).	13 
Mutations	in	nuclear-encoded	genes	that	encode	for	mitochondrial	proteins	can	also	lead	14 to	disorders	with	a	mitochondrial	phenotype.	For	example,	Friedreich’s	ataxia	(FRDA),	a	15 neurodegenerative	disease	is	caused	by	the	loss	of	frataxin	protein	that	localizes	in	the	16 mitochondria	 and	 is	 involved	 in	 the	 iron-sulphur	 cluster	 biosynthesis	 within	17 mitochondria	 (Vanlander	 and	 Van	 Coster	 2018).	 Point	 mutations	 in	 nDNA	 (NDUFS1,	18 SURF1)	can	cause	Leigh	syndrome	(LS)	(Martín	et	al.	2005).	19 
	20 
	21 
	22 
	23 
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Table	1:	Some	representative	examples	of	mitochondrial	diseases		1 
	2 
Disease	
Mutations	in	
Disease	features	 References	mtDNA	 nDNA	LHON	 ü	 	 Acute	loss	of	visual	acuity	 (Gueven	2014,	Catarino	et	al.	2017)	MELAS	 ü	 	 Encephalomyopathy,	 lactic	acidosis,	stroke-like	episodes	 (Lin	et	al.	2017)	MERRF	 ü	 	 Myoclonic	 epilepsy,	 myopathy,	ataxia,	dementia	 (Hirano	et	al.	2006,	Chiu	et	al.	2017)	
LS	 ü	 ü	
mtDNA	 effect:	 Cardiomyopathy,	grey	 and	 white	 matter	abnormalities	nDNA	 effect:	 Cardiomyopathy,	encephalomyopathy,	 hepatic	dysfunction	
(Thorburn	et	al.	2017)	
ANS	 ü	 	 Sensory	 ataxia	 neuropathy,	ophthalmoplegia,	epilepsy,	cerebral	ataxia	 (Ahola	et	al.	2014)	FRDA	 	 ü	 Ataxia,	 cardiomyopathy,	 optic	atrophy,	diabetes	mellitus	 (Abeti	et	al.	2016)	Kearns-Sayre	syndrome	 ü	 	 Pigmentary	 retinopathy,	 heart	block	 (Kabunga	et	al.	2015)	LHON,	 Leber’s	 hereditary	 optic	 neuropathy;	 MELAS,	 Mitochondrial	 encephalomyopathy	 with	3 lactic	acidosis	and	stroke	like	episodes;	MERRF,	Myoclonic	epilepsy	and	ragged	red	fibres;	AD,	4 Alzheimer’s	disease;	LS,	Leigh	syndrome;	ANS,	Ataxia	neuropathy	spectrum;	FRDA,	Friedrich’s	5 ataxia.	6 	7 	8 	9 	10 	11 	12 	13 	14 	15 	16 
Introduction	
Novel short-chain quinones against mitochondrial dysfunction                     45 
 
1.2.2		 Diseases	with	mitochondrial	dysfunction	1 	2 
Many	inherited	or	acquired	diseases	are	also	associated	with	deletions	in	mtDNA	that	are	3 secondary	to	the	actual	disease	pathology	(i.e.	occurs	much	later	in	the	disease)	hence	4 leading	to	mitochondrial	dysfunction,	which	can	affect	the	ability	to	generate	ATP	or	even	5 the	 mitochondrial	 dynamics.	 For	 example,	 multifactorial	 diseases	 such	 as	 diabetes	6 (Archer	 2013),	 cardiac	 (Ong	 et	 al.	 2013)	 and	 kidney	 diseases	 (Zhan	 et	 al.	 2013)	 are	7 believed	to	be	associated	with	mitochondrial	dysfunction	and	also	affect	the	fission	and	8 fusion	of	mitochondria.	9 
A	 range	 of	 myopathies	 including	 muscular	 atrophy,	 spinal	 muscle	 atrophy	 (SMA),	10 inflammatory	myopathies,	drug-induced	peripheral	neuropathies	(Katsetos	et	al.	2013)	11 involve	mitochondrial	dysfunction	(Table	2).	mtDNA	depletion	was	shown	in	molecular	12 studies	 of	muscle	 samples	 from	neuromuscular	 diseases	 (Komulainen	 et	 al.	 2015).	 In	13 diseases	like	Down	syndrome,	chromosomal	rearrangements	can	disrupt	nuclear	genes	14 that	 encode	 for	 mitochondrial	 proteins,	 which	 can	 cause	 secondary	 mitochondrial	15 dysfunction	(Valenti	et	al.	2011,	Pagano	and	Castello	2012).	Mitochondrial	dysfunction	16 has	also	been	noted	in	autoimmune	disorders	like	lupus	(Morris	et	al.	2014,	Morris	et	al.	17 2015),	pemphigus	vulgaris	(Feichtinger	et	al.	2014).	In	fact,	mitochondrial	dysfunction	is	18 also	 implicated	 in	 children	with	 neurodevelopmental	 disorders	 and	 autism	 spectrum	19 disorders	(Rossignol	and	Frye	2012;	Rose	et	al.	2014).		20 
On	the	other	hand,	mutations	in	the	genes	encoding	for	mitochondrial	proteins	are	also	21 linked	to	some	types	of	cancer.	For	example,	mutations	in	C-II	of	ETC	have	been	linked	to	22 cancers	 like	 paraganglioma	 and	 pheochromocytoma	 (Baysal	 et	 al.	 2000,	 Astuti	 et	 al.	23 2001).	24 
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Table	2:	Some	representative	examples	of	diseases	with	mitochondrial	dysfunction	1 
Disease	 Tissue	affected	 Disease	features	 References	SMA	 Spinal	cord	 Hypotonia,	muscle	weakness,	loss	of	motor	neurons	 (Ripolone	 et	 al.	2015)	Down	syndrome	 Multisystem	disorder	 Hypotonia,	 epicanthal	 folds	cognitive	impairment,	hearing	loss	 (Valenti	 et	 al.	2014)	ASD	 CNS,	 immune	system,	endocrine	 Sensory	modulation	symptoms	 (Hollis,	et	al.	2017)	AD	 CNS	 Slow,	 progressive	 loss	 of	 cognition,	memory	and	intellectual	function	 (Chhetri	 et	 al.	2018)	PD	 Multisystem	disorder	 Tremor,	loss	of	motor,	cognitive	and	limbic	function	 (Ryan	et	al.	2015)	MS	 CNS	 Demyelination,	 progressive	 axonal	degeneration,	loss	of	visual	acuity	 (Patergnani	 et	 al.	2017)	SMA,	spinal	muscle	atrophy;	ASD,	autism	spectrum	disorder;	CNS,	central	nervous	system;	AD,	2 Alzheimer’s	disease;	PD,	Parkinson’s	disease;	Multiple	sclerosis	3 	4 
Mitochondrial	dysfunction	can	also	result	as	a	consequence	of	exposure	to	environmental	5 stressors	and	xenobiotics	not	related	to	the	mitochondria	per	se.	Oxidative	damage	to	6 brain	mitochondria	of	rats	decreased	the	activities	of	C-IV	and	C-V	of	ETC,	apart	from	a	7 decrease	in	binding	affinity,	coupled	with	reduced	activity	in	C-I	(Long	et	al.	2009).	These	8 effects	 lead	 to	 mitochondrial	 dysfunction	 that	 can	 ultimately	 accelerate	 the	 ageing	9 process	 (Long	 et	 al.	 2009).	 Mitochondrial	 membrane	 disruption	 as	 a	 result	 of	10 dysregulated	calcium	homeostasis	is	believed	to	result	in	Duchenne	Muscular	Dystrophy	11 (DMD)	 (Allen	 and	Whitehead	2011).	Mitochondrial	 toxicity	 has	 been	 shown	 for	 some	12 drugs	such	as	statins,	that	are	used	to	treat	hyper-cholersterolemia	are	known	to	induce	13 myopathy	by	depleting	 tissue	CoQ10	stores	 (Joy	and	Hegele	2009).	For	example,	high	14 levels	 of	 ROS	 induce	 alterations	 in	 the	 differentiation	 and	 number	 of	 CD4	 cells	 that	15 contribute	 to	 the	 development	 of	 neurodegenerative	 diseases	 such	 as	 Alzheimer’s	16 disease	(AD),	Parkinson’s	disease	(PD)	and	multiple	sclerosis	(MS)	(Solleiro-Villavicencio	17 
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and	Rivas-Arancibia	2018).	Many	other	drugs	such	as	antibiotics,	inhalation	narcotics	and	1 non-steroid	 anti-inflammatories	 are	 also	 long	 known	 to	 induce	 mitochondrial	2 dysfunction	(Chan	et	al.	2005,	Labbe	et	al.	2008).	3 
Mitochondrial	dysfunction	can	also	be	caused	due	to	metabolic	dysregulation.	Deficiency	4 in	micronutrients	 accelerates	mitochondrial	decay	 since	 the	mitochondrial	 function	 is	5 supported	 by	 enzymes,	 cofactors	 and	 metabolites	 synthesised	 from	 vitamins	 and	6 minerals	(Ames	2010).	Elevated	mitochondrial	iron	levels	also	decrease	mitochondrial	7 activity	by	increasing	oxidative	stress	(Liddell	and	White	2017).	8 
To	stay	within	the	scope	of	the	thesis,	only	one	mitochondrial	disease,	LHON,	is	discussed	9 in	detail	in	the	next	section.	10 
	11 
1.2.3			 Leber’s	hereditary	optic	neuropathy	12 	13 
LHON,	although	a	rare	disease,	it	is	one	of	the	most	common	mitochondrial	disorders	with	14 an	 incidence	 of	 approximately	 1:45,000	 in	 Europe	 (Mascialino	 et	 al.	 2012),	 1:31,000	15 people	in	North-East	England	(Man	et	al.	2003)	and	1:50,000	in	Finland	(Puomila	et	al.	16 2007).	 In	 about	 95%	 of	 the	 cases,	 LHON	 is	 caused	 by	 three	 characteristic	mutations	17 (m.11778G>A	in	the	ND4	gene	or	m.3460G>A	in	the	ND1	gene	or	m.14484T>C	in	the	ND6	18 gene)	(Howell	1998,	Pilz	et	al.	2017).		In	the	remaining	5	%	of	the	cases,	mutations	in	ND5	19 gene	(m.13730AG>A),	ND6	gene	(m.14459G>A,	m.14482C>G,	m.14495A>G,	m.14498C>T,	20 m.14568C>T	 and	 m.14596T>A)	 have	 been	 described	 (Man	 et	 al.	 2002).	 Recently,	21 additional	mutation	in	ND4	gene	(m.10663T>C)	was	reported	in	a	case	study	(Jørstad	et	22 al.	2018).	Apart	from	primary	mutations	in	mtDNA,	the	individual	genetic	haplotype	in	23 mitochondria	also	play	a	huge	role	in	the	onset	and	severity	of	the	disease	(Hudson	et	al.	24 
Introduction	
Novel short-chain quinones against mitochondrial dysfunction                     48 
 
2007).	 In	 individuals	 with	 haplogroup	 J,	 mutations	 in	m.11778G>A	 and	m.14484T>C	1 were	 found	 to	 be	 associated	 with	 a	 significantly	 higher	 risk	 of	 vision	 loss	 whereas	2 haplogroup	H	appeared	to	protect	individuals	with	the	m.11778G>A	mutation	(Hudson	3 et	al.	2007).	4 
Intriguingly,	only	about	50	%	of	males	and	10	%	of	females	that	harbor	mutations	in	these	5 genes,	actually	develop	optic	neuropathy	(Man	et	al.	2002).	This	incomplete	penetrance	6 is	 not	 understood	 at	 present.	While	 environmental	 risk	 factors	 such	 as	 smoking	 and	7 alcohol	are	 thought	 to	be	 implicated	as	 they	can	dose-dependently	elevate	 the	energy	8 deficit	either	directly	by	compromising	the	activity	of	C-I	or	indirectly	by	reducing	arterial	9 oxygen	content	(Giordano	et	al.	2015,	Kirkman	et	al.	2009),	there	is	some	experimental	10 evidence	in	vitro	that	oestrogen	could	have	neuroprotective	effects	(Giordano	et	al.	2010).	11 This	observation	could	at	 least	partially	explain	the	significantly	 lower	risk	to	develop	12 retinopathy	observed	 in	 female	mutation	 carriers.	Overall,	 the	 incomplete	penetrance	13 indicates	that	the	disease	onset	likely	involves	a	plethora	of	interacting	factors	that	apart	14 from	mitochondrial	dysfunction,	energy	deficiency,	excess	ROS	include	secondary	genetic,	15 hormonal,	 anatomical,	 physiological	 variations	 and/or	 environmental	 factors	 play	 a	16 significant	role	in	disease	development	(Man	et	al.	2002).	17 
LHON	mutation	carriers	are	typically	asymptomatic	until	they	experience	rapid	unilateral	18 clouding	 or	 blurring	 of	 vision	 in	 one	 eye	 followed	 by	 acute	 vision	 loss	 in	 one	 eye.	19 Simultaneously,	loss	of	visual	acuity	is	seen	in	the	other	eye	within	weeks	or	months	(Yu-20 Wai-Man	 et	 al.	 2009,	 Fraser	 et	 al.	 2010).	 However,	 in	 some	 rare	 cases,	 second	 eye	21 involvement	was	 reported	 to	be	as	 long	be	delayed	up	 to	18	years	 (Milea	et	al.	2010,	22 Ohden	et	al.	2016).	Decreased	visual	acuity,	4-6	weeks	after	onset	can	reduce	to	6/60	or	23 
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worse	and	is	typically	accompanied	by	marked	impairment	in	colour	vision	(Yu-Wai-Man	1 et	al.	2011).		2 
The	 disease	 progression	 of	 LHON	 can	 be	 divided	 into	 three	 stages.	 The	 first,	 pre-3 symptomatic	 phase	 of	 LHON	 is	 characterised	 by	 peripapillary	 angiopathy	 without	4 affecting	 visual	 acuity.	 The	 second,	 acute	 phase	 of	 the	 disease	 is	 initiated	 by	 LHON	5 mutations	in	combination	with	secondary	genetic	and	environmental	factors.	This	phase	6 is	typically	characterised	by	loss	of	visual	acuity	which	is	also	associated	with	the	swelling	7 of	 retinal	 nerve	 fibre	 layer	 (RNFL),	 vascular	 tortuosity	 of	 retinal	 vessels	 and	8 circumpapillary	telangiectatic	microangiopathy,	energy	deficiency	and	oxidative	stress.		9 (Gonz  lez	 et	 al.	 2017).	 In	 some	 patients,	 increased	 intraocular	 pressure	 was	 also	10 observed,	similar	to	glaucoma	(Abu-Amero	et	al.	2006,	Thouin	et	al.	2013).	As	a	result	of	11 these	cellular	pathologies,	the	retinal	ganglion	cells	(RGC)	become	dysfunctional	and	are	12 unable	to	transmit	information	to	the	brain	despite	being	alive.	The	loss	of	RGCs	occurs	13 in	 the	 final,	 atrophic	 phase	where	 the	 optic	 nerve	 is	 functionally	 impaired	 leading	 to	14 atrophy	of	the	nerve	(Barboni	et	al.	2010,	Barcella	et	al.	2010).	During	the	chronic	phase	15 of	the	disease,	increasing	deterioration	of	visual	acuity	in	most	cases	eventually	leads	to	16 blindness	(Brown	et	al.	2001).	This	is	supported	by	histological	post-mortem	analysis	of	17 optic	nerve	of	LHON	patients	that	shows	degeneration	of	RGC	axons	largely	limited	to	the	18 central,	 inferonasal	 sector	 (Saadati	 et	 al.	 1998).	 This	 three-phase	 model	 indicates	 a	19 window	 of	 opportunity	 that	 includes	 viable	 but	 dysfunctional	 cells	 during	 which	20 spontaneous	 recovery	 could	 be	 possible.	 In	 some	 rare	 patients,	 spontaneous	 vision	21 recovery	has	been	described	in	the	first	year	after	disease	onset.	This	phenomenon	was	22 even	 seen	 in	 some	 patients	 after	 several	 years	 (Stone	 et	 al.	 1992),	 depending	 on	 the	23 underlying	 mutation.	 Between	 one	 to	 four	 years	 after	 disease	 onset,	 the	 lowest	24 
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spontaneous	 recovery	 rates	 (15.4%)	were	 observed	 in	 patients	 with	 the	m.3460G>A	1 mutation.	 In	 contrast,	 patients	 with	 m.11778G>A	 and	 m.14484T>C	 mutation	 that	2 exhibited	 intermediate	 (22%)	 and	 highest	 (>50%)	 chances	 of	 recovery	 respectively	3 (Spruijt	et	al.	2006).	Although,	the	underlying	mechanisms	of	spontaneous	recovery	of	4 vision	are	not	understood,	 it	nevertheless	 indicates	the	possibility	to	employ	potential	5 therapeutic	 approaches	 in	 this	 time	window	 to	 restore	 visual	 acuity	 in	 patients	 after	6 disease	onset.	7 
Although	 LHON	 is	 uniquely	 characterised	 by	 loss	 of	 vision,	 patients	 sometimes	 also	8 present	 with	 cardiac	 arrhythmias,	 myopathy,	 encephalopathy,	 epilepsy,	 dystonia,	9 psychiatric	disturbances	(Chalmers	and	Harding	1996,	Finsterer	et	al.	2017)	and	in	some	10 very	rare	cases,	a	condition	characterised	as	LHON-MS-overlap	syndrome	(Harding	et	al.	11 1992).	Vitamin	B12	deficiency	was	also	observed	in	a	case	study	of	three	patients	with	12 LHON;	however,	the	role	of	B12	in	development	of	LHON	is	unknown	(Pott	and	Wong	13 2006).		14 	15 
Biochemical	defects	in	LHON	16 
All	 major	 LHON	 mutations	 result	 in	 amino	 acid	 changes	 in	 the	 subunits	 of	 C-I	 of	17 mitochondrial	ETC.	Mitochondrial	C-I	dysfunction	is	connected	to	decreased	membrane	18 potential,	reduced	ATP	synthesis	as	a	result	of	compromised	OXPHOS	(Barrientos	and	19 Moraes	 1999).	 Phosphorous	 magnetic	 resonance	 spectroscopy	 studies	 carried	 out	 in	20 whole	body	of	LHON	patients	have	reported	maximum	reduction	in	mitochondrial	ATP	21 synthesis	 in	 LHON	 with	 m.11778G>A	 mutation,	 followed	 by	 m.14484T>C	 and	22 m.3460G>A	 (Lodi	 et	 al.	 2002).	 Transmitochondrial	 cybrids	 carrying	 one	 of	 the	 three	23 
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LHON	mutations	also	showed	C-I-dysfunction-induced	oxidative	stress	(Carelli	et	al.	2004,	1 Floreani	et	al.	2005,	Wong	et	al.	2002).		2 
Compromised	OXPHOS	is	also	associated	with	elevated	levels	of	ROS	(Carelli	et	al.	2004).	3 This	was	supported	by	results	from	in	vitro	LHON	cybrids	that	harbour	one	of	the	primary	4 LHON	mutations.	Consistent	with	these	data,	blood	leucocytes	of	LHON	patients	showed	5 elevated	levels	of	biomarkers	of	oxidative	stress	(Chen	et	al.	2004,	Klivenyi	et	al.	2001).	6 LHON	 cybrids	 also	 have	 impaired	 excitatory	 amino	 acid	 transporter-1	 activity	 that	 is	7 crucial	for	glutamate	uptake	into	the	muller	cells	of	the	inner	retina,	hence	resulting	in	8 increased	excitotoxic	injury	to	RGCs	(Baracca	et	al.	2005,	Beretta	et	al.	2004).	Increased	9 ROS	 and	 glutamate	 excitotoxicity	 can	 lead	 to	 RGC	 dysfunction	 hence	 impairing	 the	10 transmission	 of	 optic	 signals	 to	 the	 brain.	 Exposure	 to	 this	 toxic	 environment	 over	 a	11 prolonged	period	of	time	during	the	acute	phase	of	the	disease	is	believed	to	lead	to	the	12 death	 of	 RGCs	 by	 a	 specific	 form	 of	 FAS-dependent	 apoptosis	 that	 is	 independent	 of	13 caspase	(Ghelli	et	al.	2003).	This	apoptotic	loss	of	RGC	is	believed	to	be	responsible	for	14 the	permanent	loss	of	vision	in	the	final,	atrophic	stage	of	LHON.	15 
	16 
	17 
	18 
	19 
	20 
	21 
	22 
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1.3		 Therapeutics	approaches	for	mitochondrial	diseases	1 	2 Despite	an	increased	understanding	of	the	underlying	defects	of	mitochondrial	diseases	3 and	 significant	 improvements	 in	 diagnostic	 possibilities,	 unfortunately,	 no	 effective	4 treatments	 have	 been	 approved	 for	 mitochondrial	 diseases	 so	 far.	 Treatments	 of	5 mitochondrial	disorders	are	either	disease-specific	 to	correct	 the	underlying	defect	or	6 aim	to	alleviate	disease	symptoms,	supplement	and/or	support	mitochondrial	function	7 in	general.	Clinical	 and	molecular	 features	of	 individual	patients	determine	 the	use	of	8 symptomatic	treatments,	but	this	approach	can	pose	significant	difficulties	to	clinicians.	9 For	example,	a	typical	approach	to	treat	seizures	in	paediatric	patients	includes	valproic	10 acid.	However,	in	patients	with	mitochondrial	DNA	polymerase	gamma	(POLG)	mutations	11 valproic	acid	should	be	avoided	as	it	is	associated	with	significant	adverse	effects	such	as	12 severe	 liver	disease	in	these	patients	(Cohen	et	al.	2014).	There	is	some	evidence	that	13 valproic	acid	impairs	the	proton	flow	through	the	mitochondrial	ETC	complexes,	which	14 could	be	the	reason	that	it	can	exacerbate	the	symptoms	of	mitochondrial	dysfunction	15 (Lin	and	Thajeb	2007,	Nanau	and	Neuman	2013).		16 
In	 this	 chapter,	 I	 focused	 on	 recently	 emerging	 therapeutic	 options	 for	 treating	17 mitochondrial	 diseases.	 One	 of	 the	 general	 treatment	 approaches	 aims	 to	 reduce	 the	18 elevated	levels	of	oxidative	stress	associated	with	mitochondrial	dysfunction.	This	can	be	19 done	directly	by	using	antioxidant	molecules	or	indirectly	by	strategies	to	increase	the	20 regeneration	 of	 endogenous	 antioxidants	 such	 as	 glutathione	 (Table	 3).	 Another	21 approach	 to	 alleviate	 mitochondrial	 dysfunction	 is	 by	 increasing	 the	 number	 of	22 mitochondria	by	compounds	such	as	bezafibrate	and	RTA-408	or	by	upregulating	energy	23 generation	by	molecules	such	as	carnitine	and	dichloroacetate	that	supplement	substrate	24 supply	 for	 energy	 generation	 pathways	 (Table	 3).	 To	 enhance	 mitochondrial	25 
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accumulation	of	the	drug	molecules,	compounds	such	as	Mitoquinone,	SkQ1	and	MTP-1 131	(Figure	13)	have	been	developed,	which	have	integrated	chemical	moieties	such	as	2 the	charged	triphenyl	phosphonium	ion	or	peptides	that	are	known	to	target	specifically	3 to	 the	 mitochondria	 (Table	 3).	 Short-chain	 quinones,	 like	 idebenone	 (Figure	 13)	 are	4 proposed	to	 target	 the	mitochondrial	ETC	by	bypassing	respiratory	C-I	and	ultimately	5 improving	energy	generation	but	also	act	as	antioxidants	(Table	3).		6 
Dietary	 modifications	 and	 exercise	 are	 also	 suggested	 as	 supportive	 treatment	 to	7 mitochondrial	 disorders.	 Ketogenic	 diet	 (KD)	 is	 characterised	 by	 high	 fat	 content	8 combined	with	 low	protein	and	carbohydrate	content.	There	 is	some	 limited	evidence	9 that	KD	can	beneficially	affect	respiratory	chain	defects	in	patients	with	MELAS,	epilepsy	10 and	other	diseases	associated	with	dysfunctional	OXPHOS	(Geffroy	et	al.	2018).	KD	is	a	11 well-tolerated	long-term	treatment	option	not	only	in	pre-clinical	disease	models	(Douris	12 et	al.	2015)	but	also	in	patients	(Bergqvist	et	al.	2005).	13 
Several	small-molecule	treatment	options	for	mitochondrial	diseases	are	in	development,	14 with	some	of	them	in	clinical	trials	(Table	4)	and	some	on	the	market	(Gueven	et	al.	2017).	15 The	following	sections	focus	on	the	most	progressed	compounds,	to	stay	within	the	scope	16 of	the	thesis.	Although	the	bulk	of	the	data	discussed	in	the	following	sections	is	derived	17 from	 pre-clinical	 experiments,	 some	 drugs	 have	 also	 been	 assessed	 in	 clinical	 trials.	18 Unfortunately,	the	results	from	only	few	studies	are	published,	while	the	rest	are	either	19 ongoing	or	terminated	(Table	4).	Wherever	available,	results	from	clinical	trials	are	also	20 discussed.	21 
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Figure	13:	Structures	of	few	drug	candidates	that	are	under	investigation	to	treat	mitochondrial	diseases.	
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Table	3:	Therapeutics	for	mitochondrial	disorders	classified	based	on	their	mechanism	of	
action	
Proposed	mode	of	action	 Agents	 References	
Modification	of	redox	environment	
CoQ10	Idebenone	KH176	α-lipoic	acid	Dimethylglycine	EPI743	RP103	MitoQ	SkQ1	MTP-131	Nicotinamide	riboside	Epicatechin	
(Rodriguez	et	al.	2007)	(Erb	et	al.	2012)	(Koene	et	al.	2017)	(Rodriguez	et	al.	2007)	(Bai	et	al.	2016)	(Enns	et	al.	2012)	(Enns	and	Cohen	2017)	(Smith	and	Murphy	2010)	(Anisimov	et	al.	2008)	(Chen	et	al.	2017)	(Khan	et	al.	2014)		(Bettaieb	et	al.	2014)	Regeneration	of	glutathione	 EPI743	RP103	 (Enns	et	al.	2012)	(Enns	and	Cohen	2017)	
Increasing	substrate	supply	
Carnitine	Niacin	Thiamine	Dichloroacetate	SRT2104	
(Marcovina	et	al.	2013)	(Perumal	et	al.	2005)	(Venhoff	et	al.	2002)	(Stacpoole	et	al.	2008)	(Mercken	et	al.	2014)	
Mitochondria	targeted	molecules	
MitoQ	SkQ1	MTP-131	Hemigramicidin-TEMPO	conjugates	
(Smith	and	Murphy	2010)	(Anisimov	et	al.	2008)	(Chen	et	al.	2017)	(Fink	et	al.	2007)	Bypassing	respiratory	complexes	 Idebenone	 (Haefeli	et	al.	2011,	Erb	et	al.	2012)	Increasing	mitochondrial	numbers	 Bezafibrate	RTA-408	 (Yatsuga	and	Suomalainen	2011)	(Liu	et	al.	2016)	Modifying	mitochondrial	dynamics	 P110	 (Qi	et	al.	2012)		
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Table	4:	Quinones	and	mitochondrial	targeted	molecules	tested	in	clinical	trials	to	treat	mitochondrial	dysfunction	(Status	May	2018).	
Drug	 Clinical	trials	
Name	 Current	status	 Target	disease	 Identifier	 Status	 Sponsor	
Coenzyme	Q10	 Dietary	supplement	 Progressive	Supranuclear	Palsy	 NCT00328874	 Completed	 German	 Parkinson	 Study	 Group	(GPS)	Mitochondrial	diseases	 NCT00432744	 University	of	Florida	Dyslipidemia	 NCT02407548	 Sun	Yat-sen	University	
Idebenone	 Approved	by	EMA	to	treat	LHON;	Raxone®	
LHON	 NCT00747487	NCT01421381	 Completed	 Santhera	Pharmaceuticals	NCT02774005	 Ongoing	NCT02771379	
Friedreich's	Ataxia	
NCT00905268	NCT00993967	NCT00697073	NCT00537680	 Completed	NCT00015808	NCT00078481	NCT00229632	 Completed	 National	 Institute	 of	 Neurological	Disorders	and	Stroke	MELAS	 NCT00887562	 Santhera	Pharmaceuticals	KH176	 In	clinical	development	 Mitochondrial	diseases	 NCT02544217	NCT02909400	 Completed	 Khondrion	BV	
EPI-743	 In	clinical	development	 Friedreich's	Ataxia	 NCT01962363	NCT01728064	 Completed	 Edison	Pharmaceuticals	Rett	syndrome	 NCT01822249	Parkinson’s	disease	 NCT01923584	
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Mitochondrial	and	metabolic	diseases	 NCT01642056	 Ongoing	Mitochondrial	respiratory	chain	diseases	 NCT01370447	Leigh	syndrome	 NCT02352896	 Terminated	Pearson	syndrome	 NCT02104336	A0001	 In	clinical	development	 Friedreich's	Ataxia	 NCT01035671	 Completed	 Penwest	Pharmaceuticals	Co.	EPI-589	 In	clinical	development	 Leigh	syndrome	 NCT01721733	 Completed	 Edison	Pharmaceuticals	Parkinson's	disease	 NCT02462603	 Ongoing	RP103	 Approved	in	US	to	treat	cystinosis;	Procysbi®	 Inherited	mitochondrial	disease	 NCT02023866	NCT02473445	 Completed	 Horizon	Pharma	USA,	Inc	
MitoQ	 In	clinical	development	
Parkinson’s	disease	 NCT00329056	 Completed	 Antipodean	Pharmaceuticals,	Inc.	Chronic	hepatitis	C	 NCT00433108	Multiple	sclerosis	 NCT03166800	 Ongoing	 Oregon	 Health	 and	 Science	University	Chronic	kidney	disease	 NCT02364648	 University	of	Delaware	Aging	 NCT02597023	 University	of	Colorado,	Boulder	Non-alcoholic	fatty	liver	disease	 NCT01167088	 Terminated	 Antipodean	Pharmaceuticals,	Inc.	SkQ1	 Approved	in	Russia	to	treat	dry	eye	syndrome;	Visomitin®	 Mild-moderate	dry	eye	syndrome	 NCT02121301	 Completed	 Mitotech	S.A	
MTP131	 In	clinical	development	 Mitochondrial	myopathy	
NCT02367014	 Completed	
Stealth	Bio	Therapeutics	Inc.	NCT03323749	 Ongoing	Primary	mitochondrial	disease	 NCT02805790	NCT02976038	LHON	 NCT02693119	
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1.3.1	 Coenzyme	Q10	1 	2 
Coenzyme	Q10	(CoQ10),	and	its	species-specific	analogues	(CoQ9	in	rats)	belong	to	a	group	3 of	lipid	soluble	molecules	present	in	lipid	membranes	of	most	mammalian	cells.	CoQ10	is	4 the	most	common	ubiquinone	in	humans,	composed	of	a	long	isoprenoid	chain	attached	5 to	a	benzoquinone	head,	that	renders	the	molecule	extremely	hydrophobic	(Figure	13).	6 CoQ10	 is	 also	 a	 pivotal	 component	 of	 the	 mitochondrial	 ETC	 and	 is	 present	 in	 the	7 mitochondrial	inner	membrane.	Upon	reduction	of	the	quinone	(Q)	by	cellular	reductases	8 to	its	hydroquinone	form	(QH2),	this	essential	molecule	helps	to	shuttle	electrons	from	C-9 I	and	C-II	to	C-III	of	mitochondrial	ETC.	In	its	reduced	form,	CoQ10	also	acts	as	an	effective	10 antioxidant	 by	 scavenging	 free	 radicals	 and	 hence	 preventing	 membrane	 lipid	11 peroxidation.	12 
Low	CoQ10	levels	are	associated	with	many	neurodegenerative	and	age-related	disorders	13 (Chhetri	and	Gueven	2016)	and	are	also	associated	with	reduced	energy	production	and	14 oxidative	 stress.	A	 significant	 reduction	of	 retinal	CoQ10	 levels	has	been	described	 for	15 many	 ocular	 diseases	 such	 as	 glaucoma,	 diabetic	 retinopathy,	 age-related	 macular	16 degeneration	and	cataract	formation	and	is	reflected	by	significant	increases	in	oxidative	17 damage	(Williams	2008,	Qu	et	al.	2009,	Chhetri	and	Gueven	2016).	Pre-clinical	studies	18 hypothesised	 some	 beneficial	 effects	 of	 CoQ10	 treatment	 in	 preventing	 premature	19 cataractogenesis	in	human	lens	epithelial	cells	based	on	the	ability	of	CoQ10	to	prevent	20 light-induced	oxidative	stress	and	cell	death	 in	human	 lens	epithelial	 cell	 line,	 in	vitro	21 (Kernt	et	al.	2010).	The	antioxidant	capacity	of	the	reduced	form	of	CoQ10	in	mitochondria	22 also	 protects	 cells	 from	 chemically	 induced	 apoptosis,	 depolarisation	 of	mitochondria	23 and	caspase	activation	in	pre-clinical	studies	(Alleva	et	al.	2001,	Chen	et	al.	2011).	CoQ10,	24 
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owing	to	its	antioxidant	properties,	reportedly	also	protects	against	cardiac	apoptosis	in	1 rats	 with	 ischemia-induced	 injury	 by	 upregulating	 Bcl2	 gene	 expression	 (Khan	 et	 al.	2 2017).	 In	 a	 prospective,	 randomised,	 placebo-controlled	 study	 including	 215	 elderly	3 individuals	 with	 cardiovascular	 diseases,	 supplementation	 with	 CoQ10	 lowered	 lipid	4 peroxidation	of	low-density	lipoproteins	which	are	known	contribute	to	atherosclerosis	5 (Alehagen	et	al.	2017,	Thomas	et	al.	1997).		6 
Although	a	number	of	pre-clinical	studies	indicate	the	efficacy	of	CoQ10	in	treating	various	7 disorders,	there	are	very	few,	well-controlled	clinical	trials	to	prove	its	efficacy	in	patients	8 (Table	4).	A	randomised,	placebo-controlled	study	conducted	in	patients	with	inherited	9 mitochondrial	 cytopathies	 (Glover	 et	 al.	 2010)	 and	 progressive	 supranuclear	 palsy	10 (Stamelou	et	al.	2008)	showed	mild	benefits	of	CoQ10	supplementation.	Another	phase	3	11 trial	 was	 conducted	 (trial	 concluded	 in	 2017)	 to	 determine	 the	 efficacy	 of	 CoQ10	 on	12 patients	with	mitochondrial	diseases,	however,	the	results	of	this	study	have	not	been	13 published	 so	 far.	A	meta-analysis	 conducted	on	 randomised	 controlled	 trials	 of	 CoQ10	14 supplementation	in	healthy	adults	at	risk	of	cardiovascular	diseases	suggests	that	there	15 is	insufficient	evidence	to	draw	any	conclusions	(Flowers	et	al.	2014).	The	overall	lack	of	16 measurable	 therapeutic	effectiveness	of	CoQ10	 can	 likely	be	attributed	 to	 its	very	high	17 hydrophobicity	 that	 is	 thought	 to	 interfere	with	 drug	 absorption	 and	 distribution.	 To	18 address	 this	 issue,	 several	 short-chain	 quinones	 are	 in	 development	 to	 treat	19 mitochondrial	diseases.	20 
	21 
	22 
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1.3.2	 Idebenone	1 	2 
To	address	the	major	limitation	of	CoQ10,	its	extreme	hydrophobicity,	newer	short-chain	3 quinone	analogues	have	been	developed	aiming	to	increase	their	therapeutic	potential	4 by	 improving	 the	 bioavailability	 of	 the	 drug.	 One	 of	 those	 analogues,	 idebenone,	was	5 developed	 in	 the	 1980’s	 by	 Takeda	 Pharmaceuticals	 for	 the	 treatment	 of	 Alzheimer’s	6 disease.	However,	due	to	inconclusive	trial	results,	idebenone	was	never	approved	in	this	7 indication	(Thal	et	al.	2003).	8 
Idebenone	is	characterised	by	a	much	shorter	(10C	when	compared	to	>40C	in	CoQ10),	9 unbranched	side-chain	with	a	terminal	hydroxyl	group	(Figure	13).	When	compared	to	10 CoQ10,	 idebenone	being	significantly	 less	 lipophilic	 (logD	of	3.9	versus	19.1)	results	 in	11 improved	 solubility	 of	 the	 molecule.	 This	 physicochemical	 difference	 affects	 its	12 interaction	with	 cellular	 enzymes,	 proteins	 and	 pathways	 and	 is	 believed	 to	 have	 an	13 entirely	 different	 pharmacodynamic	 profile	 when	 compared	 to	 CoQ10	 (Gueven	 et	 al.	14 2015).	Similar	to	CoQ10,	 idebenone	can	act	as	an	electron	carrier	by	carrying	electrons	15 from	C-I	and	C-II	to	C-III	in	the	mitochondrial	ETC	and	act	as	an	antioxidant.		Since	the	16 vast	majority	of	studies	concentrated	to	assess	these	activities	in	vitro	and	not	in	vivo,	the	17 exact	 mode	 of	 action	 of	 idebenone	 remains	 unclear	 at	 present.	 It	 is	 thought	 that	18 idebenone	similar	to	CoQ10,	has	to	be	bio-activated	by	cellular	reductases	from	the	Q	to	19 QH2	 form	before	it	is	able	to	act	as	an	electron	donor	and	antioxidant	(Erb	et	al.	2012,	20 Haefeli	 et	 al.	 2011).	 In	 contrast	 to	 CoQ10,	 idebenone	 is	 predominantly	 reduced	 in	 the	21 cytoplasm	by	NQO1	(Erb	et	al.	2012,	Giorgio	et	al.	2012,	Haefeli	et	al.	2011)	and	not	by	22 the	 mitochondrial	 ETC.	 Many	 mitochondrial	 disorders	 are	 characterised	 by	23 mitochondrial	 C-I	 dysfunction	 (Chhetri	 and	 Gueven	 2016)	 and	 in	 this	 context	 it	 was	24 
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reported	 that	 the	 reduced	 form	 of	 idebenone	 can	 bypass	 C-I	 dysfunction	 by	 directly	1 carrying	electrons	from	the	cytoplasm	to	C-III.	This	process	was	proposed	to	reactivate	2 electron	flow	in	the	ETC	to	support	ATP	synthesis	in	the	presence	of	dysfunctional	C-I	3 (Erb	et	al.	2012,	Haefeli	et	al.	2011).	Idebenone	maintained	membrane	potential	and	ATP	4 synthesis	 even	 in	 the	 presence	 of	 C-I	 inhibitor,	 rotenone	 (Giorgio	 et	 al.	 2012).	5 Independent	of	C-I,	idebenone	stimulates	other	metabolic	pathways	such	as	the	glycerol-6 phosphate	shuttle,	which	utilises	NADH	to	generate	high-energy	electron	equivalents	for	7 the	mitochondrial	ETC	(Rauchová	et	al.	2006,	Rauchová	et	al.	2011,	Rauchová	et	al.	2012).	8 Consistent	with	 other	 quinones,	 idebenone	 also	 acts	 as	 a	 potent	 antioxidant	 that	 can	9 prevent	lipid	peroxidation	in	rat	myoblasts	and	human	liver	cells	(Erb	et	al.	2012,	Haefeli	10 et	al.	2011)	and	 isolated	brain	mitochondria	(Jaber	and	Polster	2015).	 Intraperitoneal	11 administration	of	200	mg/kg	idebenone	significantly	reduced	lipid	peroxides	in	rats	with	12 pilocarpine-induced	seizures	(Ahmed	2014).	However,	at	higher	concentrations	and	in	13 some	 specific	 cell	 lines,	 idebenone	 is	 reported	 to	 inhibit	 C-I	 and	 act	 as	 a	 pro-oxidant,	14 which	is	an	observation	that	remains	poorly	understood	(Gueven	et	al.	2015,	Yu-Wai-Man	15 et	 al.	 2017).	 One	 explanation	 for	 the	 reported	 pro-oxidative	 activity	 is	 that	 this	16 observation	was	described	for	cell	lines	with	extremely	low	levels	such	as	NQO1,	SHSY-17 5Y	(Tai	et	al.	2011).	While	benzoquinones	like	idebenone	need	to	undergo	a	two-electron	18 reduction	 by	 cellular	 reductases	 like	 NQO1	 to	 be	 activated,	 in	 the	 absence	 of	 NQO1,	19 idebenone	undergoes	a	one-electron	reduction	to	the	unstable	semiquinone	that	results	20 in	 elevated	 levels	of	oxidative	 stress	 and	 toxicity.	However,	 the	 relevance	of	 this	one-21 electron	reduction	in	a	clinical	scenario	is	unclear	as	idebenone-induced	ROS	damage	or	22 significant	toxicity	was	never	reported	in	patients.	23 
Based	on	promising	pre-clinical	results	(Buyse	et	al.	2008,	Jauslin	et	al.	2002,	Rustin	et	al.	24 1999),	idebenone	was	used	in	clinical	trials	of	various	mitochondrial	diseases	(Table	4).	25 
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Idebenone	 was	 initially	 trialled	 in	 FRDA	 patients.	 In	 general,	 idebenone	 was	 well	1 tolerated	 without	 any	 dose-limiting	 toxicity	 and	 improved	 neurological	 function	 in	2 patients	in	a	dose	dependent	manner	(Di	Prospero	et	al.	2007),	but	the	improvement	did	3 not	 reach	 statistically	 significance	 (Lynch	 et	 al.	 2010).	 Idebenone	 also	 reportedly	4 stabilised	overall	neurological	function	and	improved	speech	and	fine	motor	skills	in	68	5 paediatric	 patients	 with	 FRDA	 in	 an	 open	 label	 study	 (Meier	 et	 al.	 2012).	 Although	6 idebenone	was	also	trialled	in	patients	with	MELAS	(Table	4),	the	study	results	are	not	7 yet	published,	which	suggest	that	no	statistically	significant	effects	were	observed.	8 
An	 initial,	 phase	 2a	 trial	 conducted	 to	 assess	 the	 safety,	 efficacy	 and	 tolerability	 of	9 idebenone	in	LHON	patients	showed	minimal	side	effects	even	in	high	doses	(Klopstock	10 et	al.	2011).	Although	best	recovery	of	visual	acuity	was	not	statistically	significant,	there	11 was	 a	 consistent	 trend	 of	 therapeutic	 benefit	 (Klopstock	 et	 al.	 2011).	 Idebenone	 also	12 protected	 from	 the	 loss	 of	 colour	 vision	 (Rudolph	 et	 al.	 2013).	 These	 benefits	 from	13 idebenone	persisted	despite	 the	discontinuation	of	 treatment	 for	a	median	 time	of	30	14 months	in	a	observational,	prospective,	cohort	follow-up	study	(Klopstock	et	al.	2013).	In	15 these	patients,	a	larger	treatment	effect	was	observed	in	patients	to	whom	treatment	was	16 commenced	less	than	1	year	after	the	onset	of	disease	(Klopstock	et	al.	2013)	suggesting	17 a	narrow	window	of	opportunity.	18 
Based	on	these	data,	idebenone	was	approved	to	treat	visual	impairment	in	LHON	by	the	19 European	Medial	Agencies	(EMA)	in	September	2015.		20 
	21 
	22 
	23 
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1.3.3	 KH-176	1 	2 
Trolox,	 an	 antioxidant	 analogue	 of	 vitamin	 E	 (α-tocopherol),	 reduced	 ROS	 levels	 and	3 normalised	 mitochondrial	 function	 in	 skin	 fibroblasts	 derived	 from	 patients	 with	4 mitochondrial	C-I	deficiency	(Koopman	et	al.	2008).	Based	on	this	observation	with	trolox,	5 structural	 modifications	 were	 made	 to	 improve	 the	 efficacy,	 potency,	 chemical	 and	6 metabolic	stability	of	Trolox,	which	led	to	the	development	of	the	Trolox	analogue	KH176	7 by	Khondrion	(Figure	13).	Although	the	developmental	stages	of	the	lead	molecule	are	8 published,	 the	 characterisation	 of	 the	 physicochemical	 properties	 of	 KH176	 are	 not	9 detailed	(Koopman	et	al.	2016).	KH176	is	reported	to	reduce	ROS	levels,	normalise	lipid	10 peroxidation	levels	and	significantly	reduce	the	degeneration	of	retinal	ganglion	cells	in	11 a	mitochondrial	C-I	deficient	mouse	model	of	Leigh	disease,	Ndufs4-/-	(Haas	et	al.	2017).	12 Although	the	detailed	mode	of	action	for	this	molecule	is	unclear,	it	is	generally	portrayed	13 as	an	antioxidant.	Based	on	the	in	vitro	and	in	vivo	evidence,	KH176	was	progressed	to	a	14 phase-1	clinical	trial	in	healthy	volunteers	(Table	4),	where	it	was	found	to	be	safe	and	15 well	tolerated	with	doses	of	up	to	800	mg/day	over	1	week	(Koene	et	al.	2017).	However,	16 detailed	 pre-clinical	 efficacy	 data	 for	 KH176	 are	 largely	 missing,	 which	 prevents	17 speculation	about	its	potential	to	alleviate	symptoms	of	specific	mitochondrial	diseases.	18 
	19 
	20 
	21 
	22 
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1.3.4	 EPI-743	1 	2 
EPI-743,	α-tocotrienol	quinone,	is	a	para-benzoquinone	analogue	of	Vitamin	E	that	is	also	3 structurally	closely	 related	 to	KH176	 (Figure	13)	Tocotrienols	are	naturally	occurring	4 compounds	isolated	from	plants	and	pre-clinical	studies	suggest	that	it	possesses	strong	5 antioxidant,	anti-inflammatory,	anticancer,	and	neuroprotective	properties	(Packer	et	al.	6 2001,	 Serbinova	 et	 al.	 1991).	 Edison	 Pharmaceuticals	 developed	 EPI-743	 to	 treat	7 inherited	mitochondrial	ETC	diseases	such	as	Leigh	syndrome,	LHON	and	FRDA	(Shrader	8 et	 al.	 2011).	 EPI-743	 is	 claimed	 to	 bind	 to	 cellular	 reductases	 like	 NQO1	 and	 donate	9 electrons	 in	 its	 reduced	 state,	 similar	 to	 other	 short-chain	 quinones;	 however,	10 experimental	evidence	for	this	statement	has	not	been	published.	With	an	EC50	of	about	11 20	nM,	EPI-743	is	claimed	to	be	significantly	more	potent	as	an	antioxidant	compared	to	12 CoQ10	 or	 idebenone	 (Enns	 et	 al.	 2012).	 EPI-743	 is	 believed	 to	 protect	 from	 oxidative	13 stress	by	increasing	cellular	levels	of	reduced	glutathione	by	influencing	the	transcription	14 of	 genes	 involved	 in	 glutathione	 homeostasis,	 which	 ultimately	 improves	 the	 cellular	15 redox	status	(Pastore	et	al.	2013,	Sadun	et	al.	2012).	This	hypothesis	is	supported	by	the	16 results	from	a	clinical	trial,	where	after	six	months	of	treatment	with	EPI-743	significantly	17 increased	reduced	glutathione	 levels	 in	 lymphocytes	of	Leigh	syndrome	patients	were	18 detected	(Pastore	et	al.	2013).		19 
Similar	to	idebenone,	EPI-743	has	intermediate	oral	bioavailability,	which	can	be	further	20 increased	by	co-administration	of	food	(Shrader	et	al.	2011).	In	a	small,	open-label	study	21 in	 14	 patients	 (13	 children,	 1	 adult)	 with	 various	 mitochondrial	 diseases	 at	 risk	 of	22 progressing	 to	end-of-life	care	within	90	d,	12	patients	survived,	of	which	11	patients	23 showed	clinical	improvement	and	10	patients	reported	improved	quality	of	life.	However,	24 
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partial	relapse	was	seen	in	three	patients	(Enns	et	al.	2012).	In	another	case	report	that	1 included	two	siblings	with	LHON	(m.14487T>C	mutation),	without	any	prior	treatment,	2 some	 spontaneous	 recovery	 in	 visual	 acuity	 was	 seen	 in	 both,	 which	 is	 common	 in	3 patients	with	 that	mutation.	However,	after	7	weeks	of	 treatment,	 the	younger	sibling	4 showed	a	more	rapid	recovery	of	vision,	where	visual	acuity	 improved	 from	20/50	to	5 20/20	 OD;	 20/20	 OS	when	 compared	 to	 the	 untreated,	more	 severely	 affected	 older	6 sibling	with	visual	acuity	of	CF2	feet	OD	and	20/200	OS	(Chicani	et	al.	2013).	Including	7 the	 patient	 from	 the	 above	 study,	 another	 small	 open-label	 trial	with	 four	 additional	8 LHON	 patients	 (3	 with	 m.14484T>C,	 1	 with	 m.3460G>A	 mutation)	 was	 conducted.	9 Reportedly,	 one	 mildly	 affected	 patient	 (with	 m.14484T>C,	 ND6	 mutation)	 showed	10 complete	vision	recovery	while	disease	progression	was	arrested	in	the	other	4	patients	11 (Sadun	et	al.	2012).	12 
EPI-743	was	also	trialled	in	Leigh	syndrome	patients	in	a	small	open-label	study	with	10	13 affected	children	(Table	4).	Increased	in	the	cellular	levels	of	reduced	glutathione	were	14 associated	with	 improvements	 in	 the	mitochondrial	 disease	 scale	 and	motor	 function	15 measures	(Pastore	et	al.	2013).	A	drug	closely	related	to	EPI-743,	A0001	(α-tocopheryl	16 quinone),	 previously	developed	by	Edison	Pharmaceuticals,	 showed	a	dose-dependent	17 improvement	in	Friedrich’s	ataxia	rating	scale	(FARS)	in	a	small,	phase	2	double-blinded	18 study	 trial	 that	 included	 31	 adults	 with	 FRDA	 (Lynch	 et	 al.	 2012).	 A	 significant	19 improvement	in	disease	progression	and	neurological	function	after	400	mg	t.i.d	EPI-743	20 treatment	for	2	years	was	reported	in	another	phase	2	trial	with	60	FRDA	patients	(Enns	21 and	 Cohen	 2017).	 However,	 this	 information	was	 obtained	 from	 a	 review	 by	 Enns	&	22 Cohen,	who	gathered	the	information	by	personal	communication	from	the	responsible	23 investigator,	the	complete	results	from	this	study	are	not	published	yet.	24 
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EPI-743	also	 improved	motor	 function,	 decreased	glutamine	 levels	 in	CNS	apart	 from	1 combating	 oxidative	 stress	 in	 an	 open-label	 trail	 conducted	 on	 10	 patients	 with	2 Parkinson’s	 disease	 (Zesiewicz	 et	 al.	 2016).	 Another	 phase-2,	 randomised,	 placebo-3 controlled	 clinical	 trial	 using	 EPI-743	 to	 treat	 Rett	 syndrome,	 a	 progressive	4 neurodevelopmental	disorder	is	completed,	however,	results	from	this	study	are	not	yet	5 published.	 A	 structural	 analogue	 of	 EPI-743,	 EPI-589	 ((R)-troloxamine	 quinone),	 is	6 currently	tested	in	a	phase	2,	open	label	trial	to	treat	Parkinson’s	disease	(Trial	identifier:	7 NCT02462603).	8 
Overall,	since	most	trials	using	EPI-743	were	conducted	with	very	small	patient	numbers	9 and	 mostly	 as	 open	 label	 trials,	 the	 effectiveness	 of	 EPI-743	 to	 treat	 mitochondrial	10 diseases	is	unclear	at	the	moment.	11 
	12 
1.3.5	 RP-103	13 
	14 
N-acetyl	 cysteine	 (NAC)	 is	 a	 well-known	molecule	 that,	 similar	 to	 EPI-743,	 increases	15 levels	of	 the	antioxidant,	reduced	glutathione	(Atkuri	et	al.	2007,	Moreira	et	al.	2007).	16 RP103	 (cysteamine	 bitartrate),	 which	 is	 structurally	 similar	 to	 NAC	 also	 increases	17 glutathione	 levels	 (Figure	13).	However,	despite	reducing	oxidative	stress	 levels	 in	27	18 patients	with	mitochondrial	diseases,	RP103	did	not	improve	disease	status	or	the	quality	19 of	life	(Mancuso	et	al.	2010).	RP103	is	also	tested	in	a	couple	of	open-label	trials	to	test	20 its	safety	and	efficacy	 in	children	with	mitochondrial	diseases,	however,	 the	results	of	21 these	studies	are	not	published	yet.	Currently,	there	is	no	real	evidence	to	support	any	22 therapeutic	effects	of	RP103	in	mitochondrial	disease	patients.	23 
	24 
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1.3.6	 Mitoquinone		1 	2 
Traditionally,	 antioxidant	 molecules	 are	 known	 for	 their	 ability	 to	 combat	 oxidative	3 stress	in	cells	(Finkel	and	Holbrook	2000,	Valko	et	al.	2007).	To	target	drugs	directly	into	4 the	 mitochondria	 aiming	 to	 improve	 their	 efficacy,	 the	 charged	 lipophilic	 triphenyl	5 phosphonium	 (TPP+)	 cation	 was	 conjugated	 to	 the	 hydroxyl	 moiety	 of	 idebenone	6 resulting	in	mitoquinone	mesylate	(MitoQ,	Figure	13)	(Gruber	et	al.	2013,	Murphy	2001).	7 It	 is	 thought	 that	 the	 positive	 charge	 of	 TPP+	 allows	 the	 molecule	 to	 enter	 the	8 mitochondrial	matrix	 in	a	membrane	potential	dependent	manner	(Murphy	and	Smith	9 2007).	 Similar	 to	 other	 short-chain	 quinones,	 like	 idebenone,	 MitoQ	 has	 to	 be	 bio-10 activated,	i.e.	reduced	to	its	active	quinol	form	in	order	to	act	as	an	antioxidant	(James	et	11 al.	2005).	This	reduced	form	of	MitoQ	is	described	as	an	effective	antioxidant	that	protects	12 against	lipid	peroxidation	and	apoptosis	induced	by	H2O2	(James	et	al.	2005,	Lowes	et	al.	13 2008).	 Unlike	 other	 short-chain	 quinones	 such	 as	 idebenone	 and	 EPI-743,	 the	 bio-14 activation	of	MitoQ	is	entirely	dependent	on	the	activity	of	mitochondrial	C-I	due	to	its	15 mitochondrial	localisation.	In	the	presence	of	rotenone,	a	C-I	inhibitor,	MitoQ	was	unable	16 to	 prevent	 lipid	 peroxidation,	 which	 supports	 the	 hypothesis	 that	 MitoQ	 is	 activated	17 exclusively	by	C-I	of	mitochondrial	ETC	(Kelso	et	al.	2001).	Given	that	most	mitochondrial	18 disorders	show	a	C-I	deficiency,	it	questions	the	suitability	of	MitoQ	for	these	disorders.	19 Despite	MitoQ	being	non-toxic	to	cells	(in	vitro)	at	concentrations	of	up	to	10	µM	(Kelso	20 et	al.	2001),	 it	appears	 to	 increase	oxidative	stress	by	upregulating	ROS	generation	 in	21 endothelial	 cells	 as	 well	 as	 in	 isolated	 mitochondria,	 which	 can	 lead	 to	 apoptosis	22 (Doughan	and	Dikalov	2007).	Furthermore,	the	charge	dependent	uptake	of	MitoQ	into	23 mitochondria	harbours	the	risk	to	reduce	the	mitochondrial	membrane	potential	further,	24 which	could	be	detrimental	in	some	mitochondrial	diseases.	25 
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Irrespectively,	MitoQ	was	reported	to	improve	survival	in	a	mouse	model	of	amyotrophic	1 lateral	sclerosis	(ALS)	along	with	a	reduction	in	oxidative	stress	markers	and	neuronal	2 loss	in	the	spinal	cord	(Miquel	et	al.	2014).	Beneficial,	protective	effects	of	MitoQ	were	3 also	seen	in	the	mouse	models	of	Parkinson’s	and	Alzheimer’s	disease	(Smith	and	Murphy	4 2010).	MitoQ	also	reportedly	delayed	disease	progression	by	reducing	neuronal	cell	loss	5 apart	from	a	significant	reduction	in	inflammatory	markers	in	a	mouse	model	of	multiple	6 sclerosis	(Mao	et	al.	2013).	However,	in	another	mouse	model	of	inherited	photoreceptor	7 degeneration,	MitoQ	failed	to	restore	mitochondrial	C-I	activity	or	glutathione	levels.	In	8 fact,	in	this	study,	MitoQ	increased	the	levels	of	reactive	oxygen	species	(Vlachantoni	et	9 al.	2010).	Despite	the	contradictory	pre-clinical	evidence,	MitoQ	was	tested	in	a	double-10 blind,	 placebo-controlled	 clinical	 trial	 with	 128	 newly	 diagnosed	 patients	 with	11 Parkinson’s	diseases	(Table	4).	In	this	trial,	MitoQ	failed	to	influence	disease	progression	12 compared	to	placebo	(Snow	et	al.	2010).	Although	there	is	no	evidence	supporting	the	13 use	of	MitoQ	use	in	mitochondrial	disease	patients,	MitoQ	is	currently	tested	in	patients	14 with	multiple	sclerosis,	age-related	disorders,	chronic	kidney	disease	and	non-alcoholic	15 fatty	liver	disease	(Table	4).	16 
	17 
1.3.7	 SkQ1			18 	19 
To	improve	the	antioxidant	capacity	of	the	mitochondrial	targeted	quinones,	similar	to	20 MitoQ,	TPP+	anion	was	conjugated	to	a	plastoquinone	to	generate	a	compound	known	as	21 SkQ1	 (Figure	 13).	 SkQ1	 was	 reported	 to	 act	 as	 an	 antioxidant	 at	 sub-micromolar	22 concentrations	 on	 isolated	 rat	 heart	 mitochondria	 (Skulachev	 et	 al.	 2009).	 SkQ1	23 administered	at	5	nmol/kg/day	decreased	intracellular	ROS	levels	by	two-fold	in	mice	24 
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and	did	not	show	any	carcinogenic	activity	at	that	dosage	(Skulachev	et	al.	2009).	The	1 reduced	form	of	SkQ1,	showed	higher	anti-oxidative	and	significantly	lower	pro-oxidative	2 capacity	 when	 compared	 MitoQ	 (Skulachev	 et	 al.	 2009).	 SkQ1	 also	 prevented	 H2O2-3 induced	 apoptosis	 and	 was	 reported	 to	 prevent	 cardiolipin	 oxidation	 in	 the	 inner	4 mitochondrial	membrane	 (Skulachev	 et	 al.	 2009).	Without	 inducing	 liver	 cytochrome	5 P450	 enzymes,	 SkQ1	 also	 reportedly	 prevented	 lipid	 peroxidation	 and	 prevented	6 retinopathy	and	cataract	formation	in	a	OXYS	rat	model	of	accelerated	ageing	(Skulachev	7 et	al.	2009).	The	photoreceptor	layer	was	also	retained	in	these	rats,	which	was	lost	in	8 untreated	animals	(Gruber	et	al.	2013).	This	activity	was	supported	by	another	study	in	9 OXYS	 rats,	 where	 SkQ1	 increased	 behavioural	 activity	 and	 reduced	 mitochondrial	10 damage	 without	 influencing	 mitochondrial	 numbers	 (Kolosova	 et	 al.	 2017).	 It	 was	11 hypothesised	that	due	to	its	cytoprotective	abilities,	SkQ1	prolonged	the	life	span	of	mice,	12 crustacean	and	fungi	at	nM	concentrations	(Anisimov	et	al.	2008).	13 
However,	in	another	mouse	model	of	polymicrobial	sepsis,	SkQ1	did	not	protect	against	14 reactive	nitrogen	species	and	did	not	improve	mitochondrial	autophagy.	In	contrast,	in	15 this	study,	SkQ1	exacerbated	the	mortality	rate	of	the	animals	by	almost	29	%	(Rademann	16 et	al.	2017).	SkQ1	also	prevented	dry	eye	syndrome	induced	by	anaesthesia	in	rabbits,	by	17 suppressing	 oxidative	 stress	 and	 increasing	 glutathione	 levels.	 In	 these	 rabbits,	 SkQ1	18 decreased	TNFα	and	IL6	levels	and	hence	was	described	as	an	anti-inflammatory	agent	19 (Zernii	et	al.	2017).	In	another	mouse	study	of	drug	induced	acute	inflammation,	SkQ1	20 reduced	the	total	number	of	inflammatory	cells	(Chelombitko	et	al.	2017).	A	randomised	21 double-blind	study	of	240	patients	reported	the	safety	and	efficacy	of	the	use	of	SkQ1	in	22 treating	 dry	 eye	 syndrome	 (Brzheskiy	 et	 al.	 2015).	 However,	 in	 this	 study,	 the	 exact	23 method	of	assessing	the	severity	of	dry	eye	by	the	investigator	was	not	described	in	detail	24 
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and	environmental	factors	that	could	conceivably	influence	dry	eyes	were	not	taken	into	1 consideration	(Brzheskiy	et	al.	2015).		2 
Based	on	these	overall	results,	Mitotec	S.A.	developed	SkQ1	as	an	eye	drop	formulation,	3 marketed	under	the	trade	name	VisomitinTM	for	treating	dry	eye	syndrome,	age-related	4 macular	degeneration	and	uveitis.	Currently,	VisomitinTM	is	only	approved	and	marketed	5 in	Russia,	while	phase	III	trials	are	being	planned	in	the	US.	Currently,	there	is	 limited	6 evidence	supporting	the	efficacy	of	SkQ1	in	mitochondrial	diseases.	7 
	8 
1.3.8	 MTP-131	9 	10 
An	 entirely	 different	 strategy	 to	 improve	 mitochondrial	 function	 involves	 the	 use	 of	11 peptides	 instead	of	small	molecules.	Szeto-Schiller	(SS)	peptides	selectively	target	and	12 accumulate	in	the	mitochondrial	inner	membrane	by	a	membrane	potential-independent	13 manner	 (Szeto	 2008).	 These	 peptides	 were	 initially	 developed	 as	 synthetic	 opioid	14 receptor	 agonists	 to	 target	 the	 opioid	 receptor.	 SS	 peptides	 are	 characterised	by	 four	15 amino	acids	that	include	two	basic	amino	acids	that	alternate	with	two	aromatic	amino	16 acids	(Zhao	et	al.	2003).	MTP-131	was	selected	from	a	large	family	of	peptides	with	this	17 basic	motive	by	optimising	its	protective	and	antioxidant	activities.	MTP-131	(Figure	13,	18 also	referred	to	as	Bendavia,	Ocluvia	or	Elamipreide)	is	described	as	a	potent	antioxidant	19 tetrapeptide,	that	locates	to	the	inner	mitochondrial	membrane	with	high	affinity	but	by	20 an	unknown	mechanism	(Roestenberg	et	al.	2012).	MTP-131	 is	 reported	 to	 target	 the	21 mitochondria-specific	lipid	cardiolipin	in	the	IMM	and	prevents	its	peroxidation	(Szeto	22 2008).	This	in-turn	preserves	the	electron	transfer	function	in	the	mitochondrial	ETC	and	23 promotes	OXPHOS	and	ATP	synthesis	(Birk	et	al.	2013).	24 
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MTP-131,	 with	 an	 in	 vitro	 IC50	 in	 the	 nM	 range,	 scavenges	 H2O2,	 prevents	 lipid	1 peroxidation	and	protects	cell	viability	in	a	dose	dependent	manner	(Szeto	2008).	The	2 inherent	antioxidant	properties	of	MTP-131	are	believed	to	be	due	to	the	2,6-dimethyl	3 tyrosine	(DMT)	moiety	located	in	its	structure.	This	is	supported	by	reports	where	the	4 substitution	of	DMT	eliminated	the	antioxidant	properties	of	MTP-131	(Zhao	et	al.	2004).	5 The	antioxidant	property	of	MTP-131	is	believed	to	be	responsible	for	in	vivo	protection	6 against	high-pressure	induced	cardiac	failure	(Dai	et	al.	2013)	and	ischemic	renal	injury	7 (Szeto	 et	 al.	 2011).	 MTP-131	 also	 protected	 in	 a	 dose-dependent	 manner	 against	8 chemically	 induced	 neurotoxicity	 in	 mice,	 increased	 ATP	 levels	 and	 prevented	9 mitochondrial	swelling	at	nM	concentrations	(Yang	et	al.	2009).	In	cultured	retinal	cells	10 exposed	 to	 high-glucose	 levels,	 MTP-131	 protected	 cell	 injury	 by	 attenuating	 ROS	11 generation,	stabilising	membrane	potential	and	decreasing	the	release	of	pro-apoptotic	12 factors	from	the	mitochondria	(Li	et	al.	2011).	MTP-131,	in	a	rat	model	of	drug-induced	13 diabetes,	protected	the	retinal	structure	apart	from	other	diabetes-induced	pathological	14 changes	 (Huang	et	 al.	 2013).	MTP-131,	when	administered	by	 subcutaneous	 injection	15 normalised	visual	acuity	as	well	as	diabetes	in	mice,	whereas,	when	administered	by	eye	16 drops,	MTP-131	normalised	only	the	visual	acuity	in	diabetic	mice	(Alam	et	al.	2015).	The	17 antioxidant	activity	of	MTP-131	also	improved	neurovascular	coupling	response,	which	18 is	important	in	maintaining	healthy	cognitive	function	and	also	improved	memory	and	19 motor	skills	in	aged	mice	(Tarantini	et	al.	2018).	20 
Based	on	these	promising	pre-clinical	results,	MTP-131	is	currently	tested	in	a	number	of	21 clinical	 trials	 to	 treat	mitochondrial	 and	 related	 disorders	 such	 as	 LHON,	 age-related	22 macular	degeneration,	corneal	disorders	and	mitochondrial	myopathy	(Table	4).	Despite	23 the	 availability	 of	 pre-clinical	 data,	 the	 results	 from	 these	 trials	 are	 required	 to	24 substantiate	the	therapeutic	potential	of	MTP-131	in	mitochondrial	disorders.	However,	25 
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one	major	 and	 obvious	 disadvantage	 of	 this	 approach	 is	 that	 peptides	 are	 not	 orally	1 bioavailable	and	have	to	be	injected	systemically,	which	could	hinder	the	development	of	2 this	drug	candidate	for	certain	indications.	3 
	4 
1.3.9	 P-110	5 	6 
Under	conditions	of	mitochondrial	stress,	hyper-activation	of	the	protein	Drp1	leads	to	7 the	 excessive	 mitochondrial	 fission	 that	 is	 associated	 with	 a	 number	 of	8 neurodegenerative	 diseases	 (Reddy	2014).	 To	 treat	 excessive	mitochondrial	 fission,	 a	9 peptide	inhibitor	P110	that	specifically	targets	the	mitochondrial	fission-related	protein,	10 Drp1	was	 recently	developed	by	 the	pharmaceutical	 company,	Mitoconix	Bio	 (Qi	et	al.	11 2012).	 P110	was	 shown	 to	 inhibit	mitochondrial	 and	 neuronal	 damage	 in	 an	 in	 vitro	12 model	of	PD	(Qi	et	al.	2012),	reduced	biomarkers	of	Huntington’s	disease	(Guo	et	al.	2013)	13 and	reduced	energy	failure	and	oxidative	stress	while	inhibiting	mitochondrial	fission	in	14 
in	vitro	models	of	AD	(Joshi	et	al.	2018)	and	ALS	(Joshi	et	al.	2018).	It	is	worth	noting	that	15 these	studies	were	conducted	on	cultured	cells	derived	from	patients	with	diseases	with	16 mitochondrial	 dysfunction,	 but	 they	 do	 not	 replicate	 the	 development	 of	 the	 chronic	17 pathology	as	seen	in	humans.	Intraperitoneal	injection	of	P110	improved	bioenergetics	18 and	decreased	mitochondrial	fission	in	a	in	vivo	model	of	ischemic	reperfusion	injury	and	19 myocardial	 infarction	 (Disatnik	 et	 al.	 2013).	 Although	 p110	 may	 seem	 a	 promising	20 strategy	 to	 treat	neurodegenerative	diseases,	 current	evidence	 is	still	preliminary	and	21 additional	research	is	needed.	22 
	23 
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1.3.10		 Gene	therapy	1 	2 
Gene	therapy	is	the	only	curative	approach	that	has	been	proposed	to	treat	mitochondrial	3 diseases	caused	by	mtDNA	and	nDNA	mutations	that	could	correct	the	underlying	defect	4 in	 patients.	 For	 heteroplasmic	 mtDNA	 mutations,	 mitochondrial	 genome	 editing	 by	5 delivering	 restriction	 endonucleases	 can	 be	 used	 to	 eliminate	 the	 mutant	 mtDNA	6 sequences	to	re-populate	the	cells	with	wild-type	mtDNA	(Tanaka	et	al.	2002).	Especially,	7 TALENs	 and	 heterodimeric	 zinc	 finger	 nucleases	 have	 been	 used	 to	 target	 restriction	8 endonucleases	into	the	mitochondrion	in	a	few	proof-of-concept	studies	(Bacman	et	al.	9 2013,	Gammage	 et	 al.	 2014,	Hashimoto	 et	 al.	 2015).	Mutations	 in	mtDNA	 can	 also	be	10 compensated	by	allotropic	expression.	This	strategy	 involves	 inserting	a	vector	within	11 the	corresponding	mitochondrial	gene	into	the	cells	that	is	translated	in	the	cytoplasm	12 before	 the	 gene	 product	 has	 to	 be	 incorporated	 into	 the	 mitochondrial	 machinery.	13 Intravitreal	 injection	 of	 an	 adeno-associated	 virus	 carrying	 the	 sequence	 for	 the	 C-I	14 subunit	ND4	was	trialled	 in	a	small	study	on	six	LHON	patients	with	the	m.11778G>A	15 mutation.	This	approach	resulted	in	an	enlargement	of	visual	field	but	no	other	significant	16 changes	in	outcome	measures	(Wan,	Pei	et	al.	2016).	For	nDNA	mutations,	delivering	the	17 correct	copy	of	the	mutant	gene	by	vectors	such	as	the	adeno-associated	virus	(AVV)	has	18 been	trialled	in	a	mouse	model	of	LS	and	mitochondrial	encephalomyopathy	with	varying	19 degree	of	success	(Meo	et	al.	2017,	Torres-Torronteras	et	al.	2011).	However,	the	main	20 challenge	in	delivering	gene	products	to	the	mitochondria	is	the	hydrophobic	nature	of	21 the	specific	proteins	(Martin	and	Quigley	2004).	Moreover,	although	it	is	assumed	that	22 the	protein	expressed	by	such	genes	integrates	into	the	mitochondria	and	normalises	its	23 function,	definitive	proof	is	still	missing.		24 
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Recently,	a	pluripotent	stem	cell	model	of	primary	CoQ10	deficiency	that	was	caused	due	1 to	CoQ4	mutation	was	developed	by	CRISPR-Cas9	gene	editing	in	pluripotent	stem	cells	2 that	could	be	used	as	a	model	for	gene	therapy	(Romero-Moya	et	al.	2017).	Based	on	these	3 proof-of-concept	 studies,	 several	 clinical	 trials	 are	 also	underway	 to	 trial	 this	 form	of	4 therapy	(NCT02064569,	NCT02161380).	However,	considering	the	significant	number	of	5 gene	defects	(>350)	associated	with	mitochondrial	diseases	(Rahman	and	Rahman	2018),	6 developing	gene	therapies	for	every	individual	mutation	and	attracting	investment	for	7 such	single-dose	therapies	can	be	challenging.	8 
	9 
1.3.11		 Dietary	modification	10 	11 
Mitochondria	are	at	 the	heart	of	metabolic	 function	of	an	organism	to	convert	dietary	12 nutrients	 into	 chemical	 energy.	 Consequently,	 dietary	 modifications	 have	 also	 been	13 trialled	to	counteract	pathology	and	disease	severity	of	mitochondrial	diseases.	The	most	14 widely	known	and	best	studied	of	those	is	the	ketogenic	diet	(KD).		15 
KD	predominantly	consists	of	high	fat	(>90%),	adequate	amount	of	proteins,	minerals,	16 vitamins	and	very	low	carbohydrate	content	(Neal	et	al.	2008).	In	transgenic,	AD	mice	(3	17 X	 TgAD),	 KD	 upregulated	 TCA	 cycle	 metabolites,	 lowered	 lipid	 peroxidation	 in	 the	18 hippocampi	(Pawlosky	et	al.	2017).	KD	also	protected	mice	from	sound-induced	seizures,	19 without	 affecting	mitochondrial	 respiration	when	 compared	 to	 a	 controlled-diet	with	20 intermittent	fasting	(Dolce	et	al.	2018).	KD	was	also	reported	to	alleviate	seizure	severity	21 and	decreased	the	percentage	of	damaged	mitochondria	which	 is	believed	to	occur	by	22 upregulating	mitochondrial	Cyt	C	(Wang	et	al.	2018).	In	clinical	trials,	KD	was	reported	23 to	reduce	body	weight	in	overweight	and	obese	adults,	however,	no	significant	changes	24 
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in	cardiovascular	risk	factors	were	observed	over	up	to	two-year	follow	up	period	in	a	1 meta-analysis	conducted	on	19	randomised	controlled	trials	(Brouns	2018,	Naude	et	al.	2 2014).	 In	 contrast	 to	 the	 overweight	 but	 mostly	 healthy	 individuals,	 initiation	 of	 KD	3 resulted	in	improved	disease	symptoms	including	consciousness	and	muscle	strength	in	4 a	21-year-old	patient	with	Leigh	disease	(Malojcic	et	al.	2004).	5 
Despite	 good	 pre-clinical	 evidence	 that	 diverting	 energy	 generation	 away	 from	6 carbohydrates	to	lipids	can	have	beneficial	effects	in	a	potentially	wide	range	of	diseases	7 that	are	associated	with	mitochondrial	dysfunction	(Brouns	2018,	Gano	et	al.	2014,	Lutas	8 and	Yellen	2013,	Naude	et	al.	2014,	Zhao	et	al.	2006)	the	exact	molecular	mechanisms	for	9 this	effect	are	not	clear.	Therefore,	at	present,	it	remains	unclear	if	and	to	what	extent	KD	10 could	be	beneficial	for	which	specific	mitochondrial	disease	patients.	11 Vitamin	K	(VK),	an	essential	nutrient,	known	for	its	role	as	a	cofactor	in	blood	coagulation	12 (Suttie	and	Nelsestuen	1980).	In	the	mitochondria,	VK2	is	reported	to	serve	as	an	electron	13 carrier	and	maintains	ATP	levels	in	fruit	flies	(Vos	et	al.	2012).	Synthetic	VK2	was	also	14 reported	 to	 prevent	 oxidative	 stress-induced	 cell	 death	 in	 vitro	 in	 cultured	15 oligodendrocytes	and	neurons	by	blocking	the	accumulation	of	ROS	and	preventing	cell	16 death	(Li	et	al.	2003,	Sakaue	et	al.	2011).	Supplementation	of	synthetic	VK	was	reported	17 to	 be	 beneficial	 in	 counteracting	 mitochondrial	 dysfunction-induced	 neurological	18 disorders	such	as	AD	(Allison	2001)	and	to	support	neurocognitive	functions	(Ferland	19 2012).	20 Green	leafy	vegetables,	certain	plant	oils	such	as	canola,	soybean	and	fish	oil	are	the	most	21 common	sources	of	dietary	VK	(Thane	et	al.,	2006).	The	extracts	of	food	rich	in	VK	such	22 as	green	leafy	vegetables	were	reported	for	their	antioxidant	activity	(Gupta	et	al.,	2009)	23 and	their	role	in	improving	bone	health.	However,	the	exact	role	of	VK	from	such	dietary	24 sources	on	mitochondrial	function	has	not	been	reported	yet.	25 
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1.3.12		 Other	therapeutic	approaches	to	treat	mitochondrial	diseases	1 	2 
Several	 other	 therapeutic	 approaches	 have	been	 tested	 or	 are	 underway	 in	 both	pre-3 clinical	as	well	as	clinical	trials	to	treat	mitochondrial	diseases	(Table	5).	Although	these	4 compounds	 are	 believed	 to	 show	 a	 down-stream	 effect	 of	 improving	 mitochondrial	5 function,	most	of	these	compounds	have	multiple	modes	of	action.		6 
Resveratrol,	that	is	known	to	promote	biogenesis	mediated	by	sirtunin	(Sirt1,	Sirt3	and	7 Sirt5)	 activation	 (Menzies	 et	 al.	 2013)	 is	 also	 known	 to	 act	 as	 an	 antioxidant,	8 anticarcinogenic	and	neuroprotective	agent	(Albani	et	al.	2010,	Athar	et	al.	2009,	Gülçin	9 2010).	Based	on	these	pre-clinical	results,	resveratrol	was	progressed	to	a	clinical	trial	in	10 treating	FRDA	(NCT01339884).	However,	resveratrol	failed	to	improve	frataxin	levels	in	11 peripheral	blood	mononuclear	cells	(Yiu	et	al.	2015).	Other	redox-active	compounds	such	12 as	curcumin	and	methylene	blue	have	also	been	tested	to	treat	mitochondrial	disease,	but	13 with	very	 little	 success	 (Jariyakosol	et	al.	2011).	Anti-inflammatory	molecules	such	as	14 methyl	 prednisolone	 was	 also	 trialled	 in	 treating	 MS	 hypothesising	 that	 the	 anti-15 inflammatory	response	prevents	relapse	during	acute	phase	of	 the	disease	 (Sloka	and	16 Stefanelli	2005).	However,	the	results	from	this	trial	is	so	far	unavailable	(NCT02424435).	17 Clinical	 trials	 using	 antioxidants	 such	 as	 vitamin	 E	 and	 RG	 2133	 were	 terminated,	18 suggesting	none	of	them	had	any	positive	effects	(Table	5).	PPAR-γ	agonist	pioglitazone,	19 that	was	reported	to	increase	mitochondrial	mass	and	provide	neuroprotection	was	also	20 trialled	in	treating	mitochondrial	diseases	(Sauerbeck	et	al.	2011).	However,	the	results	21 from	this	study	is	also	unavailable	(Table	5).	Compounds	like	cyclosporine	that	bind	to	22 mitochondrial	 permeability	 transition	 pore,	 control	 the	 influx	 of	 Ca2+	 ions	 and	23 mitochondrial	swelling	induced	dysfunction	also	did	not	show	any	beneficial	effects	in	an	24 
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open-label,	 non-randomised	 trial	 in	 24	 LHON	 patients	 (Leruez	 et	 al.	 2018).	 Similarly,	1 increased	 oxygen	 supply	 by	 using	 epoetin	 alfa	 also	 did	 not	 show	 any	 acute	 effects	 in	2 patients	with	FRDA	(Saccà	et	al.	2011).	3 
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Table	5:	Additional	therapeutic	approaches	to	treat	mitochondrial	dysfunction	(Status	May	2018).	
Drug	
Clinical	trials	
Target	disease	 Identifier	 Study	type	 Status	 Sponsor	
Resveratrol	 FRDA	 NCT01339884	 Phase	 1/2,	 interventional,	 non-randomised,	 open	 label,	 parallel	assignment	
Completed.		End-point	 not	 met,	 no	improvement	 in	 frataxin	levels	 in	 peripheral	 blood	mononuclear	cells	(Yiu	et	al.	2015).	
Murdoch	Children’s	Research	Institute	
Curcumin	 LHON	 NCT00528151	 Phase	 3,	 randomised,	 double-blind,	placebo-controlled,	 parallel	assignment	
Completed.	End-point	not	met,	no	data	on	 visual	 acuity.	 However,	antioxidant	levels	increased	(Jariyakosol	et	al.	2011).	
Mahidol	University	
Bezafibrate	 Mitochondrial	myopathy	 NCT02398201	 Phase	 2,	 interventional,	 open	 label,	single	group	assignment	
Completed.	End-point	 not	 met.	However,	 LDL	 and	triglyceride	 levels	 were	decreased	 (Ørngreen	 et	 al.	2014).	
Newcastle-upon-Tyne	Hospitals	
Epoetin	alfa	 FRDA	 NCT00631202	 Phase	 2,	 interventional,	 non-randomised,	open	label,	single	group	assignment,	safety	efficacy	study	
Completed.	End-point	 not	 met,	 no	improvement	 in	 frataxin	levels.	 However,	 treatment	well	 tolerated	 (Saccà	 et	 al.	2011).	
Federico	 II	University	
Cyclosporine	 Cardiac	arrest	 NCT01595958	 Phase	3,	interventional,	randomised,	parallel	assignment	 Completed.	 Hospices	Civils	de	Lyon	
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Endpoint	 not	 met.	Cyclosporine	 did	 not	prevent	 second-eye	involvement	 (Leruez	 et	 al.	2018).	EGb761	 FRDA	 NCT00824512	 Phase	2,	interventional,	randomised,	double	 blind,	 placebo-controlled,	parallel	assignment	
Completed,	 results	unavailable	
Ipsen	
VP	20629	 FRDA	 NCT01898884	 Phase	1,	interventional,	randomised,	double	 blind,	 placebo-controlled,	parallel	assignment	 Shire	Epicatechin	 Muscular	dystrophy	 NCT03236662	 Phase	 2,	 open-label,	 single-group	assignment	 University	 of	California	Methyl	prednisolone	 FRDA	 NCT02424435	 Phase	 1,	 interventional,	 open	 label,	single-group	assignment	 Children’s	Hospital	 of	Philadelphia	RG	2133	 Mitochondrial	diseases	 NCT00060515	 Phase	1,	open	label,	dose-escalation,	safety,	tolerability,	PK,	PD	 Terminated	
Repligen	Corporation	Vitamin	E	 Peripheral	neuropathy,	MTPD	 NCT00840112	 Interventional,	 open	 label,	 single	group	assignment	 Oregon	 Health	and	 Science	University	Varenicline	 FRDA	 NCT00803868	 Phase	 2/3,	 randomised,	 double-blind,	parallel	assignment	 University	 of	South	Florida	RTA	408	 FRDA	 NCT02255435	 Phase	 2,	 randomised,	 double-blind,	parallel	assignment	 Ongoing	
Reata	Pharmaceutical,	Inc.	Arginine,	citrulline	 Mitochondrial	diseases	 NCT02809170	 Interventional,	open	label,	cross-over	assignment	 Tawam	Hospital	Dichloroacetate	 PDCD	 NCT02616484	 Phase	3,	interventional,	randomised,	double-blind,	cross-over	assignment	 University	 of	Florida	
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Nicotinamide	riboside	 Mitochondrial	diseases	 NCT03432871	 Interventional,	 open	 label,	 single-group	assignment	 Cambridge	University	Hospitals	 NHS	Foundation	Trust	TAK	831	 FRDA	 NCT03214588	 Phase	2,	interventional,	randomised,	double-blind,	cross-over	assignment	 Takeda	Mitochondrial	cocktail	 Gulf	war	illness	 NCT02804828	 Interventional,	placebo	controlled	 Unknown	 University	 of	California	Pioglitazone	 Type	II	Diabetes	 NCT01165190	 Observational,	cohort,	prospective	 Arizona	 State	University	FRDA,	Friedrich’s	Ataxia;	MTPD,	Mitochondrial	Trifunctional	Protein	Deficiency;	PDCD,	Pyruvate	Dehydrogenase	Complex	Deficiency	
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1.3.13		 Summary	1 
		2 Overall,	the	results	from	a	small	number	of	clinical	trials	support	the	large	amount	of	pre-3 clinical	results	that	support	the	hypothesis	that	targeting	mitochondrial	function	could	4 be	beneficial	to	treat	diseases	associated	with	mitochondrial	dysfunction.	However,	there	5 is	only	very	limited	evidence	that	supports	the	notion	that	the	pre-clinical	results	can	be	6 easily	translated	to	therapeutic	outcomes	in	patients	with	mitochondrial	diseases	at	the	7 moment.	Therefore,	apart	from	a	real	need	to	develop	additional	drug	candidates	tailored	8 to	patients	with	specific	mitochondrial	diseases,	this	process	has	to	be	based	on	a	detailed	9 understanding	 around	 a	 molecular	 mode	 of	 action	 that	 is	 most	 likely	 to	 improve	10 mitochondrial	function	or	at	least	compensate	for	its	loss.	11 
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Chapter	 2:	 In	 vitro	 characterisation	 of	 novel	 short-chain	
quinones	 	
In	vitro	characterisation	
Novel short-chain quinones against mitochondrial dysfunction                     83 
 
2.1 		 Overview	and	rationale	1 	2 Mitochondria	 are	 organelles	 that	 satisfy	 the	 energy	 demands	 of	 eukaryotic	 cells	 by	3 synthesizing	the	majority	of	chemical	energy	in	the	form	of	adenosine	triphosphate	(ATP)	4 by	oxidative	phosphorylation	(OXPHOS)	(Campbell	and	Reece	2005,	Wallace	et	al.	2010).	5 As	 a	 by-product,	 mitochondria	 also	 generate	 reactive	 oxygen	 species	 (ROS)	 under	6 physiological	 conditions	 (Maurya	 et	 al.	 2015,	 Zorov	 et	 al.	 2014).	 Apart	 from	 energy	7 generation	and	ROS	production,	mitochondria	provide	thermogenesis	(Chouchani	et	al.	8 2016,	 Nedergaard	 et	 al.	 2001),	maintain	 cellular	 Ca2+	 homeostasis	 (Ichas	 et	 al.	 1994,	9 Giorgio	 et	 al.	 2017)	 and	 regulate	 cell	 death	 (Vakifahmetoglu-Norberg	 et	 al.	 2017,	10 Wojtczak	and	Zabłocki	2008).	Tissues	and	cells	that	heavily	depend	on	these	functions,	11 such	 as	 neurons	 (Leon	 et	 al.	 2016)	 and	muscle	 cells	 are	 therefore	more	 sensitive	 to	12 mitochondrial	 dysfunction	 (Zhang	 et	 al.	 2016).	 Any	 physical	 or	 chemical	 insult	 or	 a	13 genetic	predisposition	that	 leads	to	mitochondrial	dysfunction	can	result	 in	a	range	of	14 disorders.	 These	 include	 true	 mitochondrial	 disorders	 such	 as	 Leigh	 syndrome	 (LS)	15 (Legault	et	al.	2015),	Mitochondrial	Encephalomyopathy	with	Lactic	Acidosis	and	Stroke-16 like	Episodes	(MELAS),	Leber’s	hereditary	optic	neuropathy	(LHON)	(Gueven	2014)	and	17 Dominant	 Optic	 Atrophy	 (DOA)	 (Kushnareva	 et	 al.	 2016).	 In	 addition,	 mitochondrial	18 dysfunction	 is	 also	 present	 in	 a	 large	 number	 of	 neurological	 conditions	 such	 as	19 Alzheimer’s	Disease	(AD)	(Lee	et	al.	2018),	Parkinson	Disease	(PD)	(Pickrell	and	Youle	20 2015)	and	Multiple	Sclerosis	(MS)	(Dutta	et	al.	2006,	Chhetri	et	al.	2018).	21 	22 The	chemical	class	of	quinones	is	known	for	their	antioxidant	capacity	apart	from	acting	23 as	signaling	molecules	and	enzymatic	co-factors	(Ahmed	2014,	Gueven	et	al.	2017,	Smith	24 and	Murphy	2010,	Stelmashook	et	al.	2015).	Coenzyme	Q10	(CoQ10,	Figure	14	i),	a	natural	25 
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ubiquinone	that	belongs	to	the	class	of	benzoquinones	is	present	in	the	lipid	membranes	1 of	most	 cells	 and	 is	a	major	 component	of	 the	mitochondrial	 electron	 transport	 chain	2 (ETC)	(Wallace	et	al.	2010).	CoQ10	in	its	reduced	form,	scavenges	free	radicals,	acts	as	an	3 effective	 antioxidant	 and	 prevents	 lipid	 peroxidation	 (Kernt	 et	 al.	 2010).	 Due	 to	 its	4 antioxidant	ability	along	with	lowered	levels	of	CoQ10	in	older	individuals	and	patients	5 with	 neurodegenerative	 disorders,	 CoQ10	 has	 been	 widely	 proposed	 and	 tested	 as	 a	6 therapeutic	agent	(Noh	et	al.	2013,	Stamelou	et	al.	2008,	Zhang	et	al.	2017).	However,	no	7 significant	improvement	was	observed	upon	the	use	of	CoQ10	in	clinical	trials	in	patients	8 with	cardiovascular	diseases	(Flowers	et	al.	2014)	(See	section	1.3.1	for	details).	One	of	9 the	main	 limitations	of	CoQ10	 is	 its	 size	 combined	with	a	 very	high	 lipophilicity	 (logD	10 19.12),	which	in	turn	affects	its	absorption	and	distribution	and	bioavailability	(Gueven	11 et	al.	2015).	Therefore,	smaller	variants	of	CoQ10	with	higher	solubility	were	developed.	12 	13 The	 short-chain	 benzoquinone	 idebenone	 (Figure	 14	 ii)	 was	 developed	 by	 Takeda	14 Pharmaceuticals	with	 the	 aim	 to	 retain	 the	 fundamental	 activities	 of	 CoQ10	 in	 energy	15 generation	and	as	an	antioxidant.	This	was	approached	by	significantly	 improving	 the	16 hydrophilicity	of	 the	compound.	Takeda	unsuccessfully	tried	to	develop	idebenone	for	17 the	treatment	of	Alzheimer’s	disease	(Miyamoto	et	al.	1999).	Similar	to	CoQ10,	idebenone	18 contains	a	benzoquinone	moiety	 that	 is	attached	to	a	much	shorter,	 less	 lipophilic	 tail	19 with	a	terminal	hydroxyl	group	to	improve	solubility	(logD	3.91,	compared	to	CoQ10	logD	20 19.12).	 Although	 structurally	 similar,	 it	 is	 now	 known	 that	 CoQ10	 and	 idebenone	21 significantly	differ	 in	their	pharmacokinetics,	bio-activation	and	modulation	of	cellular	22 energy	generation	(Gueven	et	al.	2015).	In	the	presence	of	physiological	levels	of	CoQ10,	23 idebenone	 modulates	 mitochondrial	 energy	 generation,	 which	 suggests	 that	 the	 two	24 molecules	 possess	 different	 functions	 (Haefeli	 et	 al.	 2011).	 In	 fact,	 idebenone	 is	 an	25 
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efficient	substrate	for	both	C-II	and	C-III	of	the	ETC	when	compared	to	CoQ10.	However,	1 in	 contrast	 to	 CoQ10,	 idebenone	 acts	 as	 a	 competitive	 inhibitor	 of	 C-I	 at	 higher	2 concentrations	 (IC50=5.9	 µM),	 which	 is	 thought	 to	 be	 the	 consequence	 of	 a	 relatively	3 slower	off-rate	at	C-I	compared	to	CoQ10	(Esposti	et	al.	1996,	James	et	al.	2005,	Sugiyama	4 and	Fujita	1985).	Unlike	CoQ10,	idebenone	also	engages	in	redox	reactions	outside	of	the	5 mitochondria	(Erb	et	al.	2012,	Haefeli	et	al.	2011).		6 	7 
	8 
	9 
Figure	14:	Molecular	structures	of	(i)	Coenzyme	Q10,	(ii)	Idebenone,	(iii)	Vitamin	K1	and	(iv)	10 Novel	short	chain	naphthoquinone	(SCQ),	#2	11 	12 	13 	14 
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Idebenone	 is	 part	 of	 a	 larger	 class	 of	 so-called	 short-chain	 quinones	 (SCQs)	 that	 are	1 described	 to	 show	 neuro-	 and	 mito-protective	 properties.	 In	 general,	 all	 of	 these	2 compounds	have	been	associated	with	different	degrees	of	antioxidant	activity	and	for	3 some,	a	direct	effect	on	cellular	respiration	has	been	reported	(Erb	et	al.	2012,	Geromel	4 et	al.	2002,	Giorgio	et	al.	2012,	Haefeli	et	al.	2011,	Yu-Wai-Man	et	al.	2017).	However,	so	5 far,	no	causative	mode(s)	of	action	has	(have)	been	confirmed	for	this	class	of	molecules	6 that	 goes	 beyond	 pure	 associations.	 Xenobiotics	 are	 usually	 detoxified	 in	 the	 liver	 by	7 enzymes	such	as	the	cytochrome	P450	(CYP450)	class	of	enzymes.	However,	CYP450	can	8 reduce	quinones	by	a	one-electron	reduction	to	the	unstable	semiquinone,	which	gives	9 rise	 to	 superoxide.	 This	 quinone-induced	 superoxide	 production	 can	 damage	 cellular	10 macromolecules	and	can	lead	to	cell	death	(Erb	et	al.	2012,	Ishihara	et	al.	2012,	O'brien	11 1991).	 Therefore,	 most	 cells	 express	 cellular	 reductases	 like	 NAD(P)H	 quinone	12 oxidoreductase-1	(NQO1)	that	competes	with	the	CYP450	enzymes	and	catalyses	a	two-13 electron	reduction	to	convert	the	quinone	into	its	bioactive	hydroquinone	moiety	(Haefeli	14 et	al.	2011).	Hence,	benzoquinones	like	idebenone	would	theoretically	be	safe	only	in	the	15 presence	of	NQO1.	Unfortunately,	some	ethnic	populations	are	associated	with	frequent	16 NQO1	polymorphisms	that	result	 in	either	decreased	or	even	complete	absence	of	 the	17 enzyme	activity	 (Hirai	 et	 al.	 1998,	Nebert	 et	 al.	 2002,	Hishida	 et	 al.	 2005).	Therefore,	18 despite	 being	 effective	 antioxidants	 and	 protecting	 mitochondrial	 function,	19 benzoquinones	may	not	be	effective	in	all	individuals	and	in	fact,	they	could	cause	ROS-20 induced	toxicity.	Apart	from	the	dependence	of	idebenone	on	NQO1	for	its	bio-activation,	21 clinical	 studies	 of	 idebenone	 revealed	 a	 very	 high	 first-pass	metabolism	 (99	%)	 that	22 significantly	limits	the	amount	of	pharmacologically	active	drug	in	the	plasma	(Bodmer	23 et	al.	2009,	Becker	et	al.	2010).		24 
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Apart	from	NQO1,	quinones	can	also	be	reduced	by	additional	member	of	the	NQO	gene	1 family,	NQO2	and	NADH:CYP450	oxidoreductase.	NQO2	is	described	to	have	substantially	2 different	 substrate	 specificity	 and	 expression	 patterns.	While	 NQO1	 utilises	 NADH	 or	3 NADPH	as	the	electron	donor,	NQO2	prefers	dihydro-nicotinamide	riboside	(Long	and	4 Jaiswal,	2000).	Unlike	NQO1,	that	is	expressed	ubiquitously,	NQO2	is	only	expressed	in	5 selective	tissues	such	as	heart,	kidney,	lung,	liver	and	skeletal	muscle	(Wu	et	al.,	1997).	6 However,	 the	 exact	 physiological	 role	 pf	 this	 enzyme	 has	 not	 been	 studied	 in	 detail.	7 Idebenone	 and	 related	 short-chain	 quinones	 are	 shown	 to	 be	 excellent	 substrates	 for	8 reduction	by	NQO1	(Haefeli	et	al.,	2011;	Erb	et	al.,	2012),	which	therefore	has	been	the	9 focal	point	in	this	study.	10 
Vitamin	K	(VK,	Figure	14	iii),	an	essential	nutrient,	known	for	its	role	as	a	cofactor	in	blood	11 coagulation	(Suttie	and	Nelsestuen	1980).	VK	also	plays	a	role	during	development	and	12 aging	 by	 modulating	 phosphorylation	 and	 regulating	 the	 activity	 of	 VK-dependent	13 carboxylation	 of	 glutamate	 residues	 (Tsaioun	 1999,	 Vermeer	 and	 Theuwissen	 2011).	14 Growing	evidences	suggest	 that	VK2	exhibits	anticancer	activity	 in	various	cancer	cell	15 lines	 (Yoshida	 et	 al.	 2003,	Wei	 et	 al.	 2010).	 This	 effect	 is	 thought	 to	 be	mediated	 by	16 blocking	cell	proliferation	in	the	G1	phase	of	cell	cycle	(Tokita	et	al.	2006,	Guerra	et	al.	17 2017).	Some	naturally	occurring	naphthoquinones	 like	shikonin	 induce	mitochondria-18 mediated	 apoptosis	 in	 human	 ovarian	 cancer	 cells,	 which	 supports	 its	 use	 as	 a	19 chemotherapeutic	in	ovarian	cancer	(Shilnikova	et	al.	2018).	Another	study	reported	that	20 injecting	VK2	directly	into	the	tumor-induced	apoptosis	of	cancer	cells	in	a	ROS-mediated	21 mechanism	in	a	mouse	model	of	human	bladder	cancer	cells	(Duan	et	al.	2016).	However,	22 the	precise	mechanism	of	action	for	this	effect	is	still	unknown.	Synthetic	VK	analogues	23 were	developed	to	be	selectively	more	toxic	to	cancerous	cell	lines	(IC50	0.24	–	3.83	μM)	24 as	opposed	to	non-cancerous	cell	line	(IC50	11.9	–	17.1	μM)	(Prati	et	al.	2015).		25 
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On	the	other	hand,	VK	is	also	reported	to	play	a	regulatory	role	in	the	maturing	brain	by	1 upregulating	the	sulphatide	turn-over	in	mouse	brain	(Sundaram	and	Lev	1990).	In	the	2 mitochondria,	VK	is	reported	to	serve	as	an	electron	carrier	and	maintains	ATP	levels	in	3 fruit	flies	(Vos	et	al.	2012).	VK2	was	also	reported	to	prevent	oxidative	stress-induced	cell	4 death	in	vitro	in	cultured	oligodendrocytes	and	neurons	by	blocking	the	accumulation	of	5 ROS	and	preventing	cell	death	(Li	et	al.	2003,	Sakaue	et	al.	2011).	Bearing	these	diverse	6 roles	of	VK	in	mind,	coupled	with	VK	deficiency	in	the	ageing	population,	it	is	believed	7 that	 the	 supplementation	 of	 VK	 may	 be	 beneficial	 to	 counteract	 mitochondrial	8 dysfunction-induced	neurological	disorders	 such	as	AD	 (Allison	2001)	and	 to	 support	9 neurocognitive	functions	(Ferland	2012).	For	this	purpose,	synthetic	VK	analogues	have	10 been	 developed.	 Naphthoquinones	 such	 as	 VK	 (Figure	 14	 iii),	 are	 structurally	 closely	11 related	to	benzoquinones	(Figure	14	ii).	However,	in	contrast	to	benzoquinones,	they	are	12 bio-activated	not	only	by	NQO1,	but	also	by	additional	enzymes	such	as	Vitamin	K	oxido-13 reductase	 isoenzymes	 (VKORCS1,	 VKORL2).	 Based	 on	 this	 activation	 by	 multiple	14 reductases,	 naphthoquinones	 should	 be	 at	 least	 theoretically	 in	 the	 absence	 of	 NQO1	15 show	less	ROS-induced	toxicity	compared	to	benzoquinones.		16 	17 Synthetic	 1,4-naphthoquinone	 derivatives	 substituted	 at	 the	 2’	 and	 3’	 position	 were	18 shown	to	be	protective	against	in	vitro	oxidative	stress	in	a	neuronal	cells	line	(Josey	et	19 al.	2013).	 In	 fact,	VK3	and	 its	synthetically	developed	analogues	 increased	the	 in	vitro	20 mitochondrial	ATP	turn-over	and	overall	respiration	in	a	mouse	neuronal	cell-line	and	21 reduced	seizure	activity	in	both	zebrafish	and	mouse	models	(Chou	et	al.	2013,	Rahn	et	22 al.	2014).	These	results	suggest	that	energy	production	and	mitochondrial	function	can	23 be	 a	 good	 target	 to	 develop	 new	 naphthoquinone-based	 therapeutics	 to	 treat	24 mitochondrial	dysfunction.		25 
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Based	on	this	reasoning,	in	the	current	study	we	synthesised	and	characterised	118	novel	1 short-chain	 naphthoquinones	 (SCQs,	 Figure	 14	 iv,.	 See	 appendix	 1	 for	 full	 list	 of	2 structures)	to	protect	against	mitochondrial	dysfunction.	3 
	4 
	5 
	6 
	7 
	8 
	9 
	10 
	11 
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2.2	 Aims	and	objectives	1 	2 The	precise	protective	mechanism	of	action	of	quinones	is	still	unclear.	The	majority	of	3 the	literature	suggest	that	the	ability	to	restore	ATP	levels	and	the	antioxidant	capacity	4 of	quinones	is	responsible	for	their	mito-protective	effects	(Erb	et	al.	2012,	James	et	al.	5 2005,	Krylova	et	al.	2016,	Skulachev	et	al.	2009,	Suno	and	Nagaoka	1984).	In	this	study,	6 we	aimed	to	generate	effective	SCQs	that	protect	against	mitochondrial	dysfunction	and	7 work	towards	a	better	understanding	of	their	molecular	mode	of	action.	8 To	achieve	this	aim,	in	this	chapter,	experiments	were	conducted	to	fulfill	the	following	9 objectives:	10 
v To	characterise*	118	novel	SCQs	for	their	ability	to	protect	against	mitochondrial	11 dysfunction	and	to	protect	cellular	viability	12 
v To	 evaluate	 the	 dependence	 of	 SCQs	 on	 NQO1	 for	 their	 bioactivation	 and	13 understand	their	relation	to	the	cytoprotective	ability	of	the	SCQ	14 
v To	 investigate	 the	 influence	 of	 SCQs	 on	 various	 parameters	 of	 cellular	 energy	15 generation	to	improve	our	understanding	of	the	mechanism(s)	of	action	16 
v To	work	towards	a	structure	activity	relationship	of	our	novel	SCQs	with	regards	17 to	their	cytoprotective	activity	in	the	presence	of	a	mitochondrial	toxin	18 	19 
	20 
	21 
(*Note:	All	novel	SCQs	were	synthesised	by	Dr.	Krystel	Woolley,	Department	of	Chemistry,	22 
School	of	Natural	Sciences,	College	of	Sciences	and	Engineering,	University	of	Tasmania,	23 
Hobart,	Australia,	as	a	part	of	her	PhD	thesis.)	24 
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2.3	 Methods	1 
 2 
2.3.1		 	 Cell	culture	3 
	4 
Regular	maintenance	of	cells	5 
The	human	hepatic	carcinoma	cell	line,	HepG2	was	sourced	from	the	European	Collection	6 of	Authenticated	 Cell	 Cultures	 (ECACC,	 Salisbury,	 UK).	HepG2	 cells	were	 cultivated	 in	7 regular	growth	medium	composed	of	Dulbecco’s	Modified	Eagle	Medium	(DMEM,	Sigma	8 Aldrich,	 Castle	 Hill,	 Australia)	 containing	 1	 g/l	 glucose	 and	 0.584	 g/l	 glutamine,	9 supplemented	 with	 10	 %	 heat	 inactivated	 fetal	 bovine	 serum	 (FBS,	 Gibco,	 Life	10 Technologies,	 VIC,	 Australia)	 and	 100	 U/ml	 penicillin-streptomycin	 (Gibco,	 Life	11 Technologies,	VIC,	Australia).	Standard	conditions	for	culturing	cells	were	used	i.e.	37°	C,	12 5	%	CO2,	95	%	humidity.		13 
HepG2	cells	were	cultivated	either	in	a	T25	(25	cm2)	or	T75	(75	cm2)	flask	containing	a	14 total	volume	of	5	ml	or	15	ml	regular	growth	media	respectively.	For	routine	passaging	15 of	cells,	HepG2	cells	at	about	80	%	confluency,	were	first	washed	with	10	ml	phosphate	16 buffered	saline	(PBS,	Sigma	Aldrich,	Castle	Hill,	Australia)	to	remove	cellular	wastes	and	17 media.	 Cells	 were	 then	 washed	 quickly	 with	 1	 ml	 ethylene	 diamine	 tetra-acetic	 acid	18 (EDTA,	 1	mg/ml)	 before	 adding	 1	ml	 trypsin	 solution	 (Gibco,	 Life	 Technologies,	 VIC,	19 Australia).	Cells	were	allowed	to	detach	from	the	flask	by	incubating	them	at	37°	C	for	20 about	 3-5	 min	 in	 the	 incubator.	 The	 cells	 were	 checked	 under	 the	 microscope	 for	21 detachment	before	trypsin	was	neutralised	with	9	ml	regular	growth	media.	Cells	were	22 immediately	resuspended	to	a	single-cell	suspension.	The	cells	were	then	counted	using	23 
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a	haemocytometer	and	2*106	cells	were	seeded	in	a	T25	flask	in	a	total	volume	of	5	ml	1 and	placed	in	the	incubator	for	future	use.	2 
Freezing	and	thawing	cells	3 
HepG2	cells	were	cultivated	in	T75	flask	and	harvested	at	80	%	confluency.	Cells	were	4 detached	 from	 the	 flask	 using	 trypsin,	 followed	 by	 neutralising	 trypsin	 using	 regular	5 growth	media	(see	section	2.3.1)	before	collecting	the	suspension	in	a	10	ml	centrifuge	6 tube.	The	cell	suspension	was	then	pelleted	using	a	bucket	centrifuge	(Elmi,	Skyline	Ltd,	7 Latvia)	at	500	g	for	5	min.	After	removing	the	supernatant,	the	resultant	cell	pellet	was	8 resuspended	in	1	ml	of	cryomedia	(DMEM,	20	%	FBS,	10	%	dimethyl	sulphoxide	(DMSO,	9 Sigma	Aldrich,	Castle	Hill,	Australia).	The	cell	suspension	(containing	about	8-10*106	cells	10 /	ml)	 was	 then	 transferred	 to	 a	 cryotube	 and	 cooled	 in	 a	 Mr.	 Frosty	 box	 containing	11 isopropanol,	to	enable	gradual	cooling	to	-80°	C	at	a	constant	rate	of	1°	C	/	min.	After	24	12 h,	the	cryotubes	were	then	transferred	to	liquid	nitrogen	for	long-term	storage.	13 
To	revive	frozen	cells,	the	cell	suspension	in	a	cryotube	was	rapidly	thawed	in	a	water-14 bath	at	37°	C	until	the	pellet	began	to	show	first	signs	of	melting.	The	ice-plug	containing	15 the	still	frozen	cells	was	immediately	transferred	to	a	sterile,	T75	flask	containing	15	ml	16 of	pre-warmed	regular	growth	media	and	placed	in	an	incubator.	The	cells	were	allowed	17 to	 adhere	 for	 24	 h	 before	 the	 culture	media	was	 replaced	with	 fresh,	 regular	 growth	18 medium	 to	 remove	 any	 residual	 DMSO	 and	 cell	 debris.	 Standard	 harvesting	 and	 sub-19 culturing	of	cells	was	performed	after	this	point.	20 
	21 
	22 
	23 
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2.3.2 	Preparing	test	compounds	1 	2 
All	novel	SCQs	were	synthesised	by	Dr.	Krystel	Woolley	at	the	Department	of	Chemistry,	3 School	of	Natural	Sciences,	College	of	Sciences	and	Engineering,	University	of	Tasmania,	4 Australia,	 while	 Santhera	 Pharmaceuticals	 (Pratteln,	 Switzerland)	 kindly	 donated	5 idebenone.	All	compounds	were	dissolved	 in	DMSO	to	prepare	10	mM	stock	solutions	6 that	were	aliquoted	as	single-use-vials	and	stored	at	-20°	C	for	future	use.	On	the	day	of	7 the	 experiment,	 10	μM	working	drug	 solutions	were	prepared	by	diluting	 the	10	mM	8 stock	solution	1:1000	 in	growth	media	 followed	by	 intensive	vortexing	over	10	sec	 to	9 ensure	equal	distribution.	For	all	 experiments,	 the	 final	 concentration	of	DMSO	 in	 the	10 growth	media	was	below	0.5	%	v/v.		11 
	12 
2.3.3 SCQs	characterisation	assays	13 	14 
Several	in	vitro	assays	were	conducted	to	measure	the	effect	of	novel	SCQs	on	different	15 cellular,	 metabolic	 and	 mitochondrial	 parameters.	 Although	 143	 compounds	 were	16 synthesised,	 some	 compounds	 could	not	 be	 tested	due	 to	 troubles	while	 synthesizing	17 them.	Therefore,	 out	 of	 the	 118	 compounds	 tested	 (Complete	 list	 of	 compounds	with	18 structures	 in	 Appendix	 1,	 Table	 A1-A9),	 up	 to	 the	 SCQ	 #98,	 the	 compounds	 had	 a	19 naphthoquinone	 core,	 with	 different	 side	 chains,	 hence,	 were	 used	 in	 functional	20 characterisation	assays.	Compounds	#99	onwards,	had	a	modified	naphthoquinone	core,	21 and	were	therefore	used	in	structural	characterisation	assays.	Although	all	compounds	22 were	screened	using	the	same	assay,	the	results	for	compounds	up	to	#98	were	discussed	23 in	 section	 2.3.1,	 that	 shows	 the	 functional	 characterisation,	 while	 the	 subsequent	24 
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compounds	are	discussed	in	section	2.3.2,	that	reports	the	structural	characterisation	of	1 the	novel	SCQs.	2 
	3 
2.3.3.1 Protection	of	cell	viability	4 	5 
Cytoprotection	of	HepG2	cells	by	the	test	compounds	in	the	presence	of	the	mitochondrial	6 toxin,	rotenone,	was	quantified	as	previously	described	with	modifications	(Heitz	et	al.	7 2012).	Briefly,	HepG2	cells	were	seeded	 in	96-well	plates	at	5000	cells/well	 in	100	μl	8 regular	growth	medium.	After	overnight	incubation	under	standard	conditions,	the	cells	9 were	treated	with	test	compounds	at	10	μM	in	100	μl	fresh	regular	growth	medium.	After	10 2	days	of	pre-incubation,	cells	were	challenged	with	1	μM	rotenone	in	the	presence	of	10	11 μM	 test	 compound	 in	 100	 μl	 Hank’s	 balanced	 salt	 solution	 (HBSS,	 Life	 Technologies,	12 Australia)	for	6	h.	This	was	followed	by	post-incubation	for	additional	18	h	with	only	10	13 μM	test	compound	in	100	μl	HBSS	(Figure	15	i).		14 
For	ATP	measurements,	cells	were	washed	with	100	μl	PBS	twice	and	then	lysed	in	40	μl	15 lysis	solution	(4	mM	EDTA,	0.2	%	Triton	X-100)	for	5	min	at	room	temperature	(RT)	on	16 an	orbital	shaker	at	200	rpm.	Then,	10	μl	of	the	lysate	was	mixed	with	90	μl	of	1:1	enzyme-17 substrate	(E-S)	mixture.	This	E-S	mixture	was	composed	of	enzyme,	luciferase	solution	18 (10	μg/ml	firefly	luciferase,	75	μM	DL-dithiothreitol	(DTT),	6.25	mM	magnesium	chloride	19 (MgCl2),	 625	 μM	 EDTA,	 1	 mg/ml	 bovine	 serum	 albumin	 (BSA)	 in	 25	 mM	 4-(2-20 hydroxyethyl)piperazine-1-ethanesulfonic	 acid	 (HEPES)	 buffer,	 pH	 7.25)	 and	 the	21 substrate,	 luciferin	solution	 (600	μM	D-luciferin,	75	μM	DTT,	6.25	mM	MgCl2,	625	μM	22 EDTA,	 1	 mg/ml	 BSA	 in	 25	 mM	 HEPES	 buffer,	 pH	 7.25)	 in	 a	 white	 96-well	 plate.	23 Luminescence	produced	from	the	ATP-dependent	oxidation	of	luciferin	by	the	luciferase	24 
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enzyme	(Figure	15	ii)	was	measured	immediately	using	a	Fluoroskan	Ascent	FL	multi-1 mode	 plate-reader	 (Thermo	 scientific,	 VIC,	 Australia).	 Data	 is	 expressed	 as	 %	 of	 the	2 untreated	(no-rotenone)	control.	Data	are	presented	as	mean	±	standard	deviation	(S.D.)	3 from	at	least	three	independent	experiments	(n=3)	with	six	replicate	wells/experiment.	4 
	5 
	6 
	7 
Figure	15:	Assay	for	measuring	cellular	viability.	(i)	Schematic	representation	of	the	viability	8 assay	method	and	(ii)	the	chemical	reaction	involved.		9 ATP,	adenosine	triphosphate;	AMP,	adenosine	monophosphate;	PPi,	inorganic	phosphate	10 	11 
	12 
	13 
48	h	pre-incubation	with	test	compound
6	h	rotenone	+	test	compound 18	h	test	compound ATP	measured
(i)
D-luciferin	+	ATP	+	O2
Oxy-luciferin	+	AMP	+	PPi	+	CO2
Firefly	luciferase	+	Mg2+ Lumi-
nescence
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2.3.3.2		 Acute	rescue	of	ATP	levels	1 	2 
In	order	to	understand	the	extent	to	which	novel	SCQs	are	able	to	rescue	ATP	levels	under	3 conditions	of	mitochondrial	dysfunction,	mitochondrial	C-I	dependent	respiration	was	4 selectively	 inhibited	 by	 rotenone.	 Since	 cells	 in	 culture	 typically	 generate	 energy	 by	5 glycolysis,	 glucose-free	media	 was	 used	 to	 reduce	 this	 effect	 as	 previously	 described	6 (Haefeli	et	al.	2011).	Therefore,	the	acute	rescue	of	ATP	levels	by	the	test	compounds	was	7 measured	by	co-treating	HepG2	cells	with	SCQs	(10	μM)	and	rotenone	(10	μM)	in	glucose-8 free	media	(containing	2	%	FBS).	The	resultant	ATP	levels	were	measured	using	the	same	9 luciferase/luciferin	assay	system	as	described	under	section	2.3.3.1.		10 
Briefly,	HepG2	cells	were	seeded	in	96-well	plates	at	15,000	cells/well	in	100	μl	regular	11 growth	medium.	 After	 an	 overnight	 incubation	 under	 standard	 conditions,	 cells	were	12 treated	with	10	μM	rotenone	in	the	presence	of	10	μM	test	compounds	in	100	μl	of	fresh	13 glucose-free	DMEM	containing	2	%	FBS	for	1	h.	For	the	measurement	of	ATP,	cells	were	14 washed	with	100	μl	PBS	twice	and	then	lysed	in	40	μl	lysis	solution	(4	mM	EDTA,	0.2	%	15 Triton	X-100)	for	5	min	at	RT	on	an	orbital	shaker	at	200	rpm.	Then,	10	μl	of	the	cell	lysate	16 was	mixed	with	 90	 μl	 of	 1:1	 E-S	mixture	 in	 a	 white	 96-well	 plate	 and	 luminescence	17 produced	from	the	ATP-dependent	oxidation	of	luciferin	by	the	enzyme	luciferase	was	18 measured	 immediately	 using	 a	 Fluoroskan	Ascent	 FL	multimode	plate-reader.	Data	 is	19 expressed	 as	 %	 viability	 compared	 to	 the	 untreated	 (no-rotenone)	 control.	 Data	 are	20 presented	as	mean	±	S.D.	 from	at	 least	 three	 independent	experiments	 (n=3)	with	six	21 replicate	wells/experiment.	22 
	23 
	24 
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2.3.3.3		 NQO1	dependent	reduction	of	quinones	1 	2 
Reduction	of	quinones	by	NQO1	was	measured	using	a	water-soluble	 tetrazolium	dye	3 (WST-1,	 2-(4-iodophenly)-3-(4-nitrophenyl)-5-(2,4-disulphonly)-2H-tetrazolium,	 Santa	4 Cruz	Biotechnology,	USA)	as	previously	described	with	modifications	(Haefeli	et	al.	2011,	5 Tan	and	Berridge	2010).	HepG2	cells	were	seeded	at	10,000	cells/well	in	a	96-well	plate	6 in	100	μl	of	regular	growth	media.	After	6	h	of	incubation,	regular	media	was	replaced	7 with	100	μl	fresh	DMEM	containing	0.3	g/L	glucose	and	2	%	FBS	and	incubated	further	8 for	18	h.	Later,	media	was	replaced	with	100	μl	fresh	DMEM	containing	0.3	g/L	glucose	9 and	 2	%	 FBS	with/without	 quinones	 (10	 µM)	with/without	 dicoumarol	 (10	 µM)	 and	10 incubated	 for	1	h,	before	growth	media	was	 replaced	with	100	μl	HBSS	with/without	11 quinones	 (10	 µM)	 containing	 WST-1	 reagent	 (450	 µM)	 without	 electron	 mediator	12 (phenazine	methosulphate,	PMS)	solution.	Absorbance	was	measured	at	450	nm	every	2	13 min	 for	2	h	 at	 37°	C	with	 a	Multiskan	GO	 spectrophotometer	 (Thermo	Scientific,	 VIC,	14 Australia).	The	difference	between	maximum	and	minimum	absorbance	in	the	absence	15 of	dicoumarol	was	defined	as	the	total	reduction	of	test	compound	by	cellular	reductases	16 (Figure	16).		17 
NQO1-dependent	reduction	of	test	compounds	was	defined	as	total	reduction	minus	the	18 difference	between	maximum	and	minimum	absorbance	in	the	presence	of	dicoumarol.	19 The	 reduction	 by	 other	 reductases	 was	 defined	 as	 total	 reduction	 minus	 NQO1-20 dependent	 reduction	 of	 test	 compounds.	 Data	 are	 presented	 as	mean	 ±	 S.D.	 of	 three	21 independent	experiments	(n=3)	with	six	replicate	wells/experiment.	22 
	23 
	24 
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	1 
Figure	 16:	 Schematic	 representation	 of	 the	 WST-1	 assay	 for	 measuring	 reduction	 of	2 
quinones.	 Q,	 quinone;	 QH2,	 hydroquinone;	 NAD+,	 nicotinamide	 adenine	 dinucleotide;	 NADH,	3 reduced	NAD;	WST1,	water	soluble	tetrazolium	dye.		4 	5 
2.3.3.4		 Accumulation	of	lactate	in	cell	culture	supernatant	6 	7 
Under	normal	 conditions,	 cultured	 cells	 predominantly	 generate	 energy	by	 glycolysis,	8 which	requires	nicotinamide	adenine	dinucleotide	(NAD+)	for	conversion	of	glucose	to	9 pyruvate	(Campbell	and	Reece	2005,	Wallace	et	al.	2010).	The	NAD+	required	to	maintain	10 the	 glycolysis	 process	 is	 generated	 from	 the	 reduced	 NAD+	 (NADH)	 during	 the	11 subsequent	oxidation	of	pyruvate	to	lactate	(Figure	17)	(Vander	et	al.	2009).	Therefore,	12 the	 effect	 of	 SCQs	 on	 lactate	 accumulation	 in	 cellular	 supernatant	 was	 measured	 as	13 previously	described	with	modifications	(Dykens	et	al.	2008,	Haefeli	et	al.	2011).	Briefly,	14 HepG2	cells	were	seeded	at	a	density	of	150,000	cells/well	in	a	6-well	plate	in	1	ml	regular	15 growth	media.	After	24	h,	 the	media	was	replaced	with	1	ml	challenge	media	 (DMEM	16 containing	25	mM	glucose,	8	mM	L-glutamine,	sodium	bicarbonate,	pyridoxine	HCl,	100	17 U/ml	penicillin-streptomycin	and	1	mM	pyruvate)	with/without	test	compounds	at	10	18 
Q
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NAD(P)H
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µM	final	concentration.	After	48	h,	supernatant	was	collected	for	 lactate	measurement	1 and	the	cells	were	lysed	in	lysis	solution	for	protein	measurement.	For	measuring	lactate,	2 10	µl	of	supernatant	was	added	to	90	µl	of	reaction	buffer	(10	mM	potassium	dihydrogen	3 phosphate	(KH2PO4)	pH	7.8,	1	mg/ml	BSA,	0.5	mM	phenazine	methosulphate	(PMS),	2	4 mM	 EDTA,	 0.3	 mM	 dichlorophenolindophenol	 (DCPIP),	 0.08	 mM	 NAD+,	 0.5	 U/ml	5 glutamate-pyruvate-transaminase	 (GPT),	 1.5	 mM	 glutamate,	 1.25	 U/ml	 lactate	6 dehydrogenase,	LDH)	 in	a	96-well	plate	 (Figure	17).	Absorbance	was	measured	using	7 Multiskan	GO	spectrophotometer	(Thermo	Scientific,	VIC,	Australia)	at	600	nm	every	2	8 min	over	a	period	of	60	min,	at	30°	C.	Data	is	calculated	as	Lactate/Protein	compared	to	9 the	untreated	(no-quinone)	control.	Since	the	lactate	levels	were	measure	as	mM	and	the	10 protein	as	mg/ml,	the	overall	data	is	presented	as	lactate	levels	(µmol/mg	protein),	mean	11 ±	S.D.	of	three	independent	experiments	(n=3)	with	three	replicate	wells/experiment.	12 
	13 
	14 
Figure	17:	Schematic	representation	of	the	lactate	assay.		15 LDH,	lactate	dehydrogenase;	GPT,	glutamate	pyruvate	transaminase;	NAD+,	nicotinamide	adenine	16 dinucleotide;	 NADH,	 reduced	 NAD;	 PMS,	 phenazine	 methosulphate;	 DCPIP, 17 dichlorophenolindophenol.		18 
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2.3.3.5		 Accumulation	of	β-hydroxy	butyrate	in	cell	culture	supernatant	1 	2 
The	effect	of	quinones	on	fatty	acid	metabolism	was	measured	by	quantifying	β-hydroxy	3 butyrate	(BHB),	a	by-product	of	fatty	acid	metabolism,	in	the	cell	culture	media.	Briefly,	4 HepG2	cells	were	seeded	at	10,000	cells/well	in	100	µl	regular	growth	media	in	a	96-well	5 plate.	After	24	h	incubation,	media	was	replaced	with	100	µl	fresh	media	containing	test	6 compounds	(10	µM)	and	incubated	for	further	72	h.	After	incubation,	supernatant	was	7 collected	for	quantifying	BHB	levels.	To	50	µl	of	reaction	mixture	(containing	0.5	mM	PMS,	8 2.5	mM	NAD+,	0.00625	U	BHB-dehydrogenase	(BHB-dh),	10	µM	DCPIP	in	100	mM	Trizma	9 hydrochloride	(Tris	HCl)	buffer,	pH	7.8),	50	µl	of	cell	supernatant	was	added	to	initiate	10 the	reaction	(Figure	18).	Absorbance	was	measured	at	600	nm	every	30	sec	for	10	min	at	11 RT	 using	 a	 Multiskan	 GO	 spectrophotometer	 (Thermo	 Scientific,	 VIC,	 Australia).	 A	12 standard	curve	was	plotted	with	known	concentrations	of	BHB	to	estimate	the	BHB	levels	13 in	the	supernatants	of	test	compounds-treated	cells.	Data	represents	the	mean	±	S.D.	of	14 three	independent	experiments	(n=3)	with	six	replicate	wells	each.	15 
	16 
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	1 
Figure	18:	Schematic	representation	of	the	beta-hydroxybutyrate	measurement	assay.		2 NAD+,	nicotinamide	adenine	dinucleotide;	NADH,	reduced	NAD;	Q,	quinone;	QH2,	hydroquinone;	3 PMS,	phenazine	methosulphate;	DCPIP, dichlorophenolindophenol.	4 	5 	6 
2.3.3.6		 Mitochondrial	mass	7 	8 The	mitochondrial	mass	 of	 normal	 cells	 is	 continuously	 changing	 during	 growth	 and	9 differentiation	 of	 cells.	 Under	 conditions	 of	 mitochondrial	 dysfunction,	 cells	 can	10 upregulate	 mitochondrial	 mass	 as	 a	 compensatory	 mechanism	 to	 keep	 up	 with	 the	11 cellular	metabolic	and	ATP	demands	(Lee	et	al.	2002,	Noh	et	al.	2013).	Therefore,	 the	12 influence	of	novel	SCQs	on	mitochondrial	mass	was	measured	as	previously	described	13 (Erb	 et	 al.	 2012).	 Mitochondrial	 mass	 was	 measured	 using	 the	 fluorescent	 dye	14 MitoTracker	Green	(Life	Technologies	Australia	Pty	Ltd,	VIC,	Australia).	Briefly,	HepG2	15 cells	were	seeded	in	96-well	plates	at	20,000	cells/well	in	100	μl	regular	growth	media.	16 After	 6	 h	 incubation	 under	 standard	 conditions,	 cells	 were	 treated	 with	 10	 μM	 test	17 compounds	in	100	μl	regular	growth	medium	for	72	h.	For	the	measurement,	cells	were	18 
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washed	with	100	μL	HBSS	per	well	once	before	incubating	for	30	min	under	standard	1 conditions	with	 400	 nM	MitoTracker	 Green	 (Life	 Technologies	 Australia	 Pty	 Ltd,	 VIC,	2 Australia)	in	100	μL	HBSS	per	well.	Subsequently,	cells	were	washed	twice	with	50	μL	3 PBS	per	well	and	then	fluorescence	was	quantified	immediately	in	50	μL	PBS	per	well	4 (485	nm	excitation	and	538	nm	emission)	using	a	Fluoroskan	Ascent	FL	multimode	plate-5 reader	 (Thermo	scientific,	VIC,	Australia).	Data	 is	expressed	as	%	mitochondrial	mass	6 compared	to	the	untreated	(no-test	compound)	control.	Data	represents	the	mean	±	S.D.	7 of	three	independent	experiments	(n=3)	with	six	replicate	wells	each.	8 
	9 
2.3.3.7		 Oxidative	stress	10 	11 
To	quantify	the	effect	of	quinones	on	levels	of	basal	lipid	peroxidation,	HepG2	cells	were	12 seeded	at	a	density	of	20,000	cells/well	in	a	black	96-well	plates	in	100	μL	regular	growth	13 medium.	After	24	h,	cells	were	loaded	with	10	µM	BODIPY	581/591	C11	(Thermo	Fisher	14 Scientific,	 VIC,	 Australia)	 in	 100	 μL	 of	 fresh	HBSS	 per	well	 for	 30	min.	 Subsequently,	15 excess	dye	was	removed	by	washing	once	with	HBSS	once	before	the	cells	were	incubated	16 with/without	 test	compounds	(10	μM)	and	 incubated	 for	1	h.	Cells	were	then	washed	17 three	times	with	100	μl	PBS	before	 fluorescence	was	quantified	(Ex/Em	490/520	and	18 Ex/Em	 490/600)	 in	 50	 μl	 PBS	 using	 Fluoroskan	 Ascent	 FL	 multimode	 plate-reader	19 (Thermo	scientific,	VIC,	Australia).	The	ratio	of	red	to	green	fluorescence	was	calculated	20 as	described	by	the	manufacturer	and	presented	as	%	of	untreated	(no-test	compound)	21 control	cells.	Data	represents	the	mean	±	S.D.	of	three	independent	experiments	(n=3)	22 with	six	replicate	wells	each.	23 
	24 
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2.3.4 Protein	quantification	1 	2 
Protein	 content	per	well	was	used	 to	 standardise	 the	 individual	values	of	 the	96	well	3 assays	described	above.	For	this	purpose,	HepG2	cells	were	first	washed	with	100	µl/well	4 PBS	and	lysed	using	40	μL	lysis	solution	(see	section	2.3.3.1	for	details).	The	DC	protein	5 assay	 kit	 (Bio-Rad	 laboratories	 Pty	 Ltd,	 NSW,	 Australia)	 was	 used	 according	 to	6 manufacturer’s	instructions.	Briefly,	10	μl	of	cell	lysate	or	protein	standards,	0-2	mg/ml	7 BSA	(Sigma	Aldrich,	Castle	Hill,	Australia)	were	added	in	triplicate	to	a	transparent	96-8 well	plate.	Reagent	A’	was	prepared	by	mixing	20	μl	of	reagent	S	(surfactant)	with	1	ml	of	9 reagent	A	(alkaline	copper	tartrate).	To	each	well	containing	cell	lysate/protein	standard,	10 25	μl	of	reagent	A’	and	subsequently	200	μl	of	reagent	B	(folin’s	agent)	was	added.	The	11 96-well	plate	was	kept	on	an	orbital	shaker	at	200	rpm	for	5	min	followed	by	incubation	12 at	RT	 for	another	10	min.	The	resulting	absorbance	at	750	nm	was	measured	using	a	13 Multiskan	GO	spectrophotometer.	Protein	levels	in	cell	lysate	were	calculated	using	the	14 protein	standard	curve	plotted	from	the	absorbance	derived	from	known	BSA	standards	15 as	described	by	the	manufacturer.	16 
	17 
2.3.5 Statistical	analysis	18 
 19 All	 data	 are	 represented	 as	 mean	 ±	 S.D.	 as	 denoted	 in	 the	 figure	 legends.	 Statistical	20 analysis	 to	 measure	 the	 significance	 between	 different	 groups	 was	 performed	 using	21 Student	t-test	using	GraphPad	prism	software	(GraphPad	Software	Inc.,	CA,	USA).	22 
	23 
In	vitro	characterisation	
Novel short-chain quinones against mitochondrial dysfunction                     104 
 
2.4 		 Results	1 	2 
2.4.1 Functional	characterisation	of	novel	SCQ’s	3 	4 
The	 following	 assays	were	 designed	 to	 understand	 the	 effect	 of	 SCQs	 on	 cellular	 and	5 metabolic	parameters	that	can	be	affected	as	a	consequence	of	mitochondrial	dysfunction.	6 The	novel	SCQs	up	to	compound	#98	were	generated	by	changing	the	functional	group	7 attached	to	the	side	chain,	while	maintaining	the	same	naphthoquinone	core.	To	analyse	8 their	biological	effects,	they	were	divided	based	on	the	terminal	functional	groups	into	9 slightly-polar	(A),	aliphatic	(B),	acids	(C),	aliphatic	esters	(D),	amino	esters	(E),	amino	10 acids	 (F)	 and	 amino	 alcohols	 (G)	 (see	 representative	 example	 structures	 in	 Table	 6,	11 complete	list	of	compounds	and	structures	in	Appendix	1,	Table	A1-A7).		12 
In	the	current	section,	only	the	results	for	SCQs	up	to	#98	are	discussed.	Compounds	from	13 SCQ	 #113	 onwards,	 displayed	 a	 modified	 naphthoquinone	 core	 and	 were	 used	 for	14 structural	characterisation	assays;	the	results	of	which	are	discussed	in	section	2.4.3.	15 
	16 
	17 
	18 
	19 
	20 
	21 
	22 
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Table	6:	Structures	of	representative	novel	short-chain	quinones	classified	based	on	the	1 functional	group	attached	on	the	side	chain	2 	3 
Category	 Compound	number	 Structure	
Novel	SCQ	skeleton	 N/A	 	
(A)	Slightly	polar	 #24	 	
(B)	Aliphatic	 #26	 	
(C)	Acid	 #23	 	
(D)	Aliphatic	ester	 #34	 	
(E)	Amino	ester	 #36	 	
(F)	Amino	acid	 #37	 	
(G)	Amino	alcohol	 #74	 	
	4 
	5 
	6 
	7 
	8 
	9 
	10 
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2.4.1.1 Cytoprotective	effects	of	novel	SCQs	under	conditions	of	mitochondrial	1 
dysfunction	2 	3 As	an	initial	screen	for	the	novel	SCQs,	their	effect	on	cellular	viability	in	the	presence	of	4 rotenone-induced	mitochondrial	dysfunction	was	measured	(Figure	15).	All	SCQs	were	5 initially	screened	at	10	µM,	comparable	to	previously	published	studies	that	used	similar	6 compounds	(Erb	et	al.	2012,	Yu-Wai-Man	et	al.	2017).	Over	a	total	period	of	five	days,	7 rotenone	 (1	 µM)	 decreased	 cellular	 viability	 to	 26.9	 ±	 7.9	%	 compared	 to	 the	 sham-8 treated	 cells	 (red-dotted	 line,	 Figure	 19	 i).	 The	 presence	 of	 idebenone	 (Id,	 10	 µM)	9 protected	cell	viability	up	to	66.2	±	12.0	%	of	the	sham-treated	cells	(purple-dotted	line,	10 Figure	19	 i).	 Strikingly,	 out	 of	 the	 screened	87	novel	 SCQs,	more	 than	20	 compounds	11 improved	cell	viability	significantly	better	than	idebenone	(pink	data	points,	Figure	19	i).	12 While	more	than	half	of	the	compounds	protected	cell	viability	to	levels	above	rotenone-13 treated	cells,	nine	SCQs	were	cytotoxic	at	10	µM	and	reduced	cell	viability	further	than	14 rotenone	alone	(#,	Figure	19	i).	15 When	SCQs	were	grouped	according	to	their	functional	groups,	all	groups	except	B	and	D	16 significantly	increased	cell	viability	when	compared	to	rotenone-treated	(no	SCQ)	cells	17 (Figure	19	ii).	Compounds	in	group	A	protected	cell	viability	up	to	42.6	±	23.7	%,	while	18 group	C	to	49.9	±	21.8	%,	group	E	64.8	±	8.2	%,	group	F	to	69.7	±	25.6	%	and	group	G	to	19 76.5	±	15.9	%	(Figure	19	 ii).	Complete	data	of	 individual	 test	compounds	are	 listed	 in	20 appendix	2,	Table	A10-A16.	21 	22 
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(ii)	1 
	2 
	3 
Figure	19:	Cytoprotection	by	novel	short-chain	naphthoquinones	(SCQs)	in	the	presence	of	4 
rotenone.	Cytoprotection	by	test	compounds	(10	µM)	in	the	presence	of	rotenone	(1	µM)	was	5 expressed	as	percentage	of	sham-treated	(no	rotenone	or	SCQ)	HepG2	cells.	Black,	red	and	purple	6 dotted	lines	represent	the	viability	of	sham,	rotenone	and	idebenone	(Id,	10	µM)-treated	cells,	7 respectively.	(i)	Pink	data	points	represent	the	SCQs	that	improve	viability	significantly	better	8 than	 Id.	 Significance	 was	 calculated	 by	 using	 Student	 t-test	 (p*	 <0.05,	 p**<0.01,	 p***<0.001	9 cytoprotection	 by	 SCQs	 against	 Id-treated	 cells,	 p#<0.05	 cytoprotection	 by	 SCQs	 against	10 rotenone-only	treated	cells)	(ii)	Cytoprotection	by	test	compounds	categorised	according	to	their	11 functional	groups	(p*	<0.05,	p**<0.01,	p***<0.001	cytoprotection	by	SCQs	against	rotenone-only	12 treated	cells).		13 Significance	was	calculated	by	using	Student	t-test.	14 Each	data	point	represents	one	SCQ,	data	is	expressed	as	mean	±	S.D.	of	at	least	three	independent	15 experiments	 (n=3)	 with	 six	 replicates	 within	 each	 experiment.	 Error	 bars	 were	 omitted	 for	16 clarity.	Complete	data	of	individual	test	compounds	are	listed	in	appendix	2,	Table	A10-A16.	17 Mn,	Menadione;	VK,	Vitamin	K;	A,	Slight	polarity;	B,	Aliphatic;	C,	Acid;	D,	Aliphatic	ester;	E,	Amino	18 ester;	F,	Amino	acid;	G,	Amino	alcohol.			19 	20 	21 	22 	23 
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2.4.1.2 Dose	dependency	1 	2 
Some	 SCQs	 like	 #37,	 #61,	 #62,	 #77	 (10	 µM)	 restored	 viability	 of	 HepG2	 cells	 in	 the	3 presence	 of	 rotenone	 (1	 µM)	 to	 almost	 100	%,	when	 compared	 to	 sham-treated	 cells	4 (Figure	19).	It	was	therefore	of	interest	to	measure	how	effective	these	SCQs	would	be	at	5 lower	doses.	For	this	purpose,	cell	viability	was	measured	by	using	SCQ	concentrations	6 ranging	from	0.01	µM	to	10	µM.	Six	out	of	the	nine	tested	SCQs	including	#37,	#62,	#74,	7 #77,	#80	and	#81	showed	significantly	better	cytoprotective	activity	at	5	µM	compared	8 to	idebenone	(Figure	20	i,	ii).	In	fact,	#62	also	showed	significantly	better	cytoprotection	9 than	idebenone	at	1	µM	(Figure	20	i).	Compared	to	idebenone,	compounds	#74	and	#77	10 showed	 significantly	 better	 cytoprotection	 at	 0.01,	 0.05	 and	 0.1	 µM	 (Figure	 20	 ii).	11 However,	three	of	the	nine	tested	SCQs	(#72,	#73	and	#91)	did	not	protect	viability	better	12 than	idebenone	at	5	µM	or	less	(Figure	20	iii).		13 
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Figure	20:	Dose	dependency	of	 short-chain	naphthoquinones	 (SCQs)	 for	protecting	 cell	4 
viability.	Cytoprotection	by	selected	SCQs,	(i)	Idebenone	(Id),	#37,	#62,	#74,	(ii)	Id,	#77,	#80,	5 #81	and	(iii)	Id,	#72,	#91	and	#74	at	0.01	µM	to	10	µM,	in	the	presence	of	rotenone	(1	µM)	was	6 measured	and	expressed	as	percentage	of	sham-treated	HepG2	cells.	Each	coloured,	solid	 line	7 represents	one	SCQ,	black	and	red	dotted	line	represent	sham-	and	rotenone-treated	cells.	Data	8 from	one	representative	out	of	three	experiments	(n=3)	is	presented	and	is	expressed	as	mean	of	9 six	replicates.	Significance	was	calculated	by	using	Student	t-test	to	compare	cytoprotection	by	10 SCQs	against	Id	treated	cells	(p*	<0.05).	Error	bars	were	omitted	for	clarity.	11 	12 	13 	14 	15 	16 	17 	18 	19 
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2.4.1.3 Acute	rescue	of	ATP	 levels	by	novel	SCQs	 in	 the	presence	of	high-dose	1 
rotenone	2 
 3 
One	 of	 the	 first	 and	 dominant	 parameters	 affected	 by	 mitochondrial	 dysfunction	 is	4 typically	cellular	ATP	synthesis.	Hence,	after	assessing	cytoprotection	by	the	novel	SCQs,	5 acute	 rescue	 of	 ATP	 levels	 in	 the	 presence	 of	 drug-induced	 (rotenone,	 10	 µM)	6 mitochondrial	 dysfunction	 was	 measured	 as	 previously	 described	 for	 a	 panel	 of	7 benzoquinones	 (Erb	 et	 al.	 2012).	 A	 high	 dose	 of	 rotenone	 (10	 µM),	 acutely	 reduced	8 cellular	ATP	levels	down	to	33.6	±	11.1	%	compared	to	sham-treated	cells	(red-dotted	9 line,	Figure	21	i)	within	1	h.	Under	these	conditions,	the	presence	of	idebenone	(Id,	10	10 µM)	rescued	cellular	ATP	levels	to	81	±	9.4	%	of	the	sham-treated	cells	(purple-dotted	11 line,	Figure	21	i).	Out	of	the	87	screened	novel	SCQs	(10	µM),	seven	compounds	rescued	12 ATP	levels	significantly	better	than	idebenone	(pink	data	points,	Figure	21	i)	and	more	13 than	half	of	the	compounds	rescued	ATP	to	levels	above	rotenone-treated	cells.	However,	14 for	18	SCQs,	the	combination	of	SCQ	and	rotenone	reduced	ATP	levels	significantly	lower	15 than	rotenone	treated	(no	SCQ)	cells	(Figure	21	i).			16 
When	SCQs	were	grouped	according	to	their	functional	groups,	all	groups	except	B	and	D	17 significantly	 increased	ATP	 levels	when	 compared	 to	 rotenone-treated	 (no	 SCQ)	 cells	18 (Group	A:	49.2	±	30.9	%,	Group	C:	51.7	±	33.8	%,	Group	E:	81.9	±	12.6	%,	Group	F:	59.4	±	19 12.6	 %	 and	 Group	 G:	 84.3	 ±	 9.0	 %)	 (Figure	 21	 ii).	 Complete	 data	 of	 individual	 test	20 compounds	are	listed	in	appendix	2,	Table	A10-A16.	21 
	22 
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(ii)	1 
	2 
	3 
Figure	 21:	 Acute	 rescue	 of	 adenosine	 triphosphate	 (ATP)	 levels	 by	 novel	 short-chain	4 
naphthoquinones	(SCQs)	in	the	presence	of	rotenone.	Rescue	of	adenosine	triphosphate	(ATP)	5 levels	 by	 test	 compounds	 (10	 µM)	 in	 the	 presence	 of	 rotenone	 (10	 µM)	 was	 measured	 and	6 expressed	as	percentage	of	sham-treated	(no	rotenone	or	SCQ)	HepG2	cells.	Black,	red	and	purple	7 dotted	 lines	 represent	 the	 rescue	of	ATP	 levels	 in	 sham,	 rotenone	and	 idebenone	 (Id,	10µM)-8 treated	 cells,	 respectively.	 (i)	 Pink	 data	 points	 represent	 the	 SCQs	 that	 improve	 viability	9 significantly	better	than	Id.	Significance	was	calculated	by	using	Student	t-test	(p*	<0.05,	p**<0.01,	10 
p***<0.001	ATP	 rescue	by	 SCQs	against	 Id-treated	 cells,	p#<0.05	ATP	 rescue	by	SCQs	against	11 rotenone-only	treated	cells)	(ii)	Rescue	of	ATP	levels	by	test	compounds	categorised	according	12 to	their	functional	groups.	Significance	was	calculated	by	using	Student	t-test.	(p*	<0.05,	p**<0.01,	13 
p***<0.001	ATP	rescue	by	SCQs	against	rotenone-only	treated	cells).	14 Each	data	point	represents	one	SCQ,	data	is	expressed	as	mean	±	S.D.	of	at	least	3	independent	15 experiments	 with	 6	 replicates	 within	 each	 experiment.	 Error	 bars	 were	 omitted	 for	 clarity.	16 Complete	data	of	individual	test	compounds	are	listed	in	appendix	2,	Table	A10-A16.	17 Mn,	Menadione;	VK,	Vitamin	K;	A,	Slight	polarity;	B,	Aliphatic;	C,	Acid;	D,	Aliphatic	ester;	E,	Amino	18 ester;	F,	Amino	acid;	G,	Amino	alcohol.	19 
	20 
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2.4.1.4 Chemical	reduction	of	SCQs	to	hydroquinone	by	NQO1	and	other	cellular	1 
reductases		2 	3 
To	measure	 in	vitro	 reduction	of	novel	SCQs	by	 the	cellular	 reductases,	a	 colorimetric	4 assay	employing	a	water-soluble,	cell-impermeable,	electron	accepting,	tetrazolium	dye	5 (WST-1)	was	used.	The	reduction	of	quinones	by	cellular	reductases	was	measured	by	a	6 change	in	absorbance	of	the	WST-1	dye	(Figure	16).	It	was	previously	reported	that	the	7 WST-1	dye	can	accept	electrons	generated	 from	the	 reduction	of	quinones	by	cellular	8 reductases	to	undergo	an	irreversible	reduction	to	formazan.	Therefore,	the	difference	in	9 absorbance	 of	 WST-1	 corresponding	 to	 the	 reduction	 of	 dye	 directly	 reflects	 the	10 reduction	of	quinones	(Tan	and	Berridge	2004,	Tan	and	Berridge	2010).	11 
The	 reduction	 of	 SCQ	 by	 cellular	 reductases	 was	 calculated	 from	 the	 difference	 in	12 absorbance	 of	 the	 WST-1	 dye	 upon	 SCQ	 treatment	 (△A450	 nm).	 When	 SCQs	 were	13 categorised	by	their	functional	groups,	the	reduction	of	SCQs	within	A	to	G	groups	was	14 0.175	±	0.19,	0.053	±	0.057,	0.019	±	0.033,	0.021	±	0.016,	0.150	±	0.115,	0.031	±	0.017,	15 0.223	±	0.104	respectively	(Figure	22	i).	16 
To	understand	 if	 the	 reduction	 of	 SCQ	was	 dependent	 on	 the	 reductase	NQO1,	NQO1	17 enzyme	activity	was	inhibited	by	dicoumarol,	as	previously	described	(Haefeli	et	al.	2011).	18 As	previously	reported,	idebenone	(Ide)	is	largely	(93.9	%)	reduced	by	the	enzyme	NQO1	19 (Figure	22	ii)	(Haefeli	et	al.	2011).	When	the	reduction	of	SCQs	was	compared,	significant	20 differences	 were	 observed	 with	 regards	 to	 their	 dependence	 on	 NQO1.	 Similar	 to	21 idebenone,	compounds	#36,	#40	and	#41	were	 largely	reduced	by	NQO1,	while	other	22 compounds	like	#37	and	#43	were	equally	reduced	by	other	cellular	reductases	as	well	23 as	NQO1	(Figure	22	ii).	Interestingly,	some	compounds	such	as	#1,	#30,	and	#34	were	24 
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completely	 reduced	 in	 the	 absence	 of	 NQO1	 activity	 (Figure	 22	 ii).	Complete	 data	 of	1 individual	test	compounds	are	listed	in	appendix	2,	Table	A10-A16.	2 
(i)	3 
	4 
	5 
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	7 
	8 
	9 
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	11 
	12 
	13 
	14 
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(ii)1 
	2 
	3 
	4 
Figure	 22:	 Bio-activation	 of	 novel	 short-chain	 naphthoquinones	 (SCQs)	 by	 cellular	5 
reductases.	 (i)	 Reduction	 of	 all	 SCQs	 by	 cellular	 reductases,	 categorised	 according	 to	 their	6 functional	 groups.	 (ii)	 Reduction	 of	 few	 representative	 SCQs	 (10	 µM)	 by	 NAD(P)H	 quinone	7 oxidoreductase-1	(NQO1)	was	measured	and	expressed	as	percentage	of	 total	reduction.	Each	8 data	point/bar	represents	the	mean	±	S.D.	for	each	SCQ	(n=3	independent	experiments	with	6	9 replicates	within	each	experiment).	Error	bars	were	omitted	for	clarity.	Complete	data	set	for	all	10 test	compounds	are	listed	in	appendix	2,	Table	A10-A16.	11 Ide,	Idebenone;	VK,	Vitamin	K;	Mn,	Menadione;	A,	Slight	polarity;	B,	Aliphatic;	C,	Acid;	D,	Aliphatic	12 ester;	E,	Amino	ester;	F,	Amino	acid;	G,	Amino	alcohol.	13 	14 	15 	16 	17 	18 
In	vitro	characterisation	
Novel short-chain quinones against mitochondrial dysfunction                     118 
 
2.4.1.5 The	effect	of	novel	SCQs	on	basal	levels	of	cellular	lipid	peroxidation		1 	2 
Most	of	 the	SCQs	 that	 are	developed	as	potential	 therapeutics	 are	described	 to	 act	 as	3 antioxidants	and	have	been	reported	 to	prevent	 lipid	peroxidation	 (James	et	al.	2005,	4 Skulachev	et	al.	2009,	Suno	and	Nagaoka	1984).	However,	there	are	some	reports	that	5 SCQs	 can	act	 as	pro-oxidants	at	higher	 concentrations	 (Genova	et	 al.	 2003,	King	et	 al.	6 2009).	To	assess	the	pro/antioxidant	capacity	of	our	test	compounds,	HepG2	cells	were	7 treated	with	10	µM	test	compounds	for	72	h	and	basal	 lipid	peroxidation	(BLP)	 levels	8 were	measured	using	BODIPY-C11	dye.	Although	idebenone	was	previously	reported	to	9 significantly	reduce	BLP	levels	down	to	40	%	in	primary	muscle	cells	(Erb	et	al.	2012),	10 we	only	observed	a	reduction	to	86	%	in	the	HepG2	cells	used	in	this	study	(data	shown	11 in	appendix	2,	Table	A10).	All	novel	SCQs	were	categorised	by	their	functional	groups	to	12 see	the	effects	of	tail	chemistry	on	BLP.	Although	most	SCQs	appeared	to	slightly	alter	13 BLP	levels,	none	of	them	showed	any	significant	changes	when	compared	to	sham-treated	14 cells	(Figure	23).	Complete	data	of	individual	test	compounds	are	listed	in	appendix	2,	15 Table	A10-A16.	16 
	17 
	18 
	19 
	20 
*	One	SCQ,	#33,	containing	aliphatic	ester	attached	to	the	side	chain	of	the	quinone	core	could	not	21 
be	tested	for	its	effect	on	BLP	levels	due	to	unavailability	of	the	compound	for	this	assay.	22 
	23 
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Figure	23:	Effect	of	novel	short-chain	naphthoquinones	(SCQs)	on	basal	lipid	peroxidation	3 
levels.	Effect	of	test	compounds	(10	µM,	categorised	based	on	functional	group,	A-G)	on	basal	4 lipid	peroxidation	levels.	Statistical	significance	was	calculated	by	using	Student	t-test	to	compare	5 the	effects	of	tail	chemistry	on	lipid	peroxidation	against	sham-treated	cells	(black	dotted	line).	6 Each	 data	 point	 represents	mean	 ±	 S.D.	 for	 each	 SCQ	 (n=3	 independent	 experiments	 with	 6	7 replicates	within	each	experiment).	Error	bars	were	omitted	for	clarity.	Data	of	individual	test	8 compounds	are	listed	in	appendix	2,	Table	A10-A16.	9 A,	Slight	polarity;	B,	Aliphatic;	C,	Acid;	D,	Aliphatic	ester;	E,	Amino	ester;	F,	Amino	acid;	G,	Amino	10 alcohol.	11 	12 	13 	14 	15 	16 	17 	18 
In	vitro	characterisation	
Novel short-chain quinones against mitochondrial dysfunction                     120 
 
2.4.1.6 The	influence	of	novel	SCQs	on	extracellular	lactate	levels	1 
 2 Under	 normal	 conditions,	 cultured	 cells	 predominantly	 generate	 energy	 by	 glycolysis	3 (Adam-Vizi	and	Chinopoulos	2006).	This	is	not	only	a	consequence	of	the	fact	that	many	4 cell	 lines	 are	 derived	 from	 cancer	 tissue,	 which	 inherently	 prefers	 glycolysis	 over	5 OXPHOS.	The	reliance	of	adherent	cultured	cells	on	glycolysis	is	also	a	consequence	of	6 significantly	reduced	oxygen	levels	in	cell	culture	where	the	cells	consume	oxygen	faster	7 that	it	can	be	supplied	by	diffusion	alone	(Kieninger	et	al.	2014).	This	effectively	produces	8 an	aerobic	zone	surrounding	the	cells,	unless	the	cell	culture	media	is	constantly	moved	9 (for	example	by	excessive	vibration	within	 the	 incubator).	To	maintain	glycolysis,	 cell	10 require	 NAD+	 for	 converting	 glucose	 to	 pyruvate.	 Under	 conditions	 of	 mitochondrial	11 dysfunction,	the	NAD+	required	to	maintain	glycolysis	process	is	generated	from	NADH	12 during	the	oxidation	of	pyruvate	to	lactate	(Figure	8)	(Heiden	et	al.	2009).		13 
Quinones	such	as	idebenone	are	reduced	to	the	hydroquinone	form	in	the	presence	of	14 cellular	reductases	 like	NQO1,	a	process	that	also	oxidises	NADH	to	NAD+	 (Figure	17).	15 This	quinone-generated	NAD+	could	theoretically	be	used	to	maintain	glycolysis	without	16 the	need	to	produce	the	potentially	toxic	lactate.	Hence,	it	was	of	interest	to	understand	17 if	 the	 novel	 SCQs	 could	 affect	 lactate	 levels	 (section	 1.1.2.6).	 Alternatively,	 it	 was	18 conceivable	that	the	SCQs	could	increase	glycolysis	 further	to	compensate	for	reduced	19 mitochondrial	ATP	synthesis	to	protect	cellular	viability,	which	could	result	in	increased	20 lactate	levels.	21 
	22 
	23 
	24 
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Developing	an	assay	to	measure	cellular	lactate	levels	1 
Lactate	levels	 in	the	cell	culture	supernatant	were	measured	by	establishing	a	method	2 reported	 previously	 (Dykens	 et	 al.	 2008).	 To	 ensure	 no	 background	 activity	 was	3 generated	by	any	of	the	individual	assay	components,	the	change	in	absorbance	of	each	4 component	was	 initially	measured	 separately	 at	 600	 nm.	 The	 base	 buffer	 (B,	 100	 µl,	5 composed	of	10	mM	KH2PO4	buffer,	pH	7.8	with	2	mM	EDTA,	1	mg/ml	BSA	and	0.5	mM	6 PMS)	 did	 not	 show	 any	 increase	 in	 absorbance	 (Figure	 24	 i).	 Stable	 absorbance	was	7 maintained	with	the	individual	addition	of	the	dye	DCPIP	(0.6	mM),	glutamate	pyruvate	8 transaminase	(GPT,	5	U/ml),	lactate	dehydrogenase	(LDH,	12.5	U/ml)	and	the	electron	9 acceptor	NAD+	 (0.8	mM)	 to	 the	 base	 buffer.	 Subsequently,	 a	 combination	 of	 different	10 components	was	tested	including,	base	buffer	with	5	U/ml	GPT	and	12.5	U/ml	LDH;	base	11 buffer	with	5	U/ml	GPT,	12.5	U/ml	LDH	and	0.8	mM	NAD+;	base	buffer	with	5	U/ml	GPT,	12 12.5	U/ml	LDH,	0.8	mM	NAD+	and	0.6	mM	DCPIP.		None	of	the	combinations	altered	the	13 absorbance	of	the	reaction	mixture	at	600	nm	(Figure	24	i)	suggesting	individual	assay	14 components	 did	 not	 change	 the	 absorption	 of	 the	 reaction	mixture	 in	 the	 absence	 of	15 lactate.		16 
After	confirming	 the	 lack	of	background	activity	 in	 the	base	buffer,	as	a	next	step,	 the	17 change	in	absorbance	over	time	was	measured,	representing	the	rate	of	the	reaction.	The	18 reaction	was	 initiated	 by	 adding	 10	 µl	 of	 11	mM	 lactate	 to	 90	 µl	 the	 reaction	 buffer	19 containing	10	mM	KH2PO4	pH	7.8,	1	mg/ml	BSA,	0.5	mM	PMS,	2	mM	EDTA,	0.6	mM	DCPIP,	20 0.8	mM	NAD+,	5	U/ml	GPT,	1.5	mM	glutamate	and	12.5	U/ml	LDH	to	measure.	However,	21 no	change	in	absorbance	was	recorded	(Figure	24	ii),	which	suggests	that	one	or	more	22 components	of	the	reaction	buffer	were	inactivated,	which	prevented	the	reaction	from	23 proceeding.	Since	all	enzymes	and	NAD+	were	added	fresh	to	the	reaction	buffer	before	24 
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every	experiment,	it	was	finally	established	that	PMS	was	unstable	over	repeated	freeze-1 thaw	cycles.	Therefore,	all	subsequent	assays	used	freshly	prepared	PMS	from	a	stock	2 solution	that	was	prepared	in	distilled	in	water	rather	than	KH2PO4	buffer,	as	suggested	3 by	the	manufacturer.	The	final	lactate	reaction	buffer	(LRB)	consisted	of	10	ml	of	10	mM	4 KH2PO4	pH	7.8,	1	mg/ml	BSA,	0.5	mM	PMS,	2	mM	EDTA,	0.6	mM	DCPIP,	0.8	mM	NAD+,	5	5 U/ml	GPT,	1.5	mM	glutamate	and	12.5	U/ml	LDH.	After	 these	 changes	 to	LRB,	 robust	6 change	in	absorbance	over	time	after	the	addition	of	10	µl	of	1.1	mM	and	11	mM	lactate	7 to	90	µl	 of	 LRB	were	measured	 and	 a	 linear	 reaction	 rate	was	observed	over	60	min	8 (Figure	24	iii).	Subsequently,	supernatants	from	regular	cell	cultures	were	also	measured	9 (Figure	24	iii).	A	rapid	decrease	in	absorbance,	with	a	steeper	slope	compared	to	the	11	10 mM	lactate	standard	was	observed.	Hence,	the	same	method	was	followed	for	measuring	11 lactate	accumulation	in	cells	after	72	h	treatment	with	SCQs.	12 
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Figure	24:	Method	development	for	measuring	cellular	lactate	in	cell	culture	media.	(i)	The	1 effect	 of	 individual	 components	 of	 the	 lactate	 reaction	 buffer	 on	 the	 final	 absorbance	 was	2 measured	by	adding	single	component	at	a	time	to	the	base	phosphate	buffer	(B).	(ii)	The	effect	3 of	the	addition	of	11	mM	lactate	to	the	complete	reaction	buffer.	(iii)	The	effect	of	the	addition	of	4 lactate	and	supernatant	from	cultured	cells	to	freshly	prepared	complete	lactate	reaction	buffer	5 (LRB).	Each	data	point	represents	the	average	of	three	wells.	Data	represents	the	mean	of	three	6 individual	wells.	Error	bars	omitted	for	clarity.	7 DCPIP, dichlorophenolindophenol;	 GPT,	 glutamate	 pyruvate	 transaminase;	 LDH,	 lactate	8 dehydrogenase;	 NAD,	 nicotinamide	 adenine	 dinucleotide;	 DMEM,	 Dulbecco’s	 modified	 eagle	9 medium	(complete	media	used	for	regular	cell	culture).	10 
	11 
Influence	of	novel	SCQs	on	basal	cellular	lactate	levels	12 
To	get	more	insights	into	the	influence	of	the	novel	SCQs	on	lactate	levels,	HepG2	cells	13 were	treated	with	novel	SCQs	for	72	h	before	the	lactate	accumulation	was	measured	in	14 the	cell	culture	supernatant	and	normalised	to	protein	content	(Figure	25).		15 
Using	sham-treated	cells,	the	lactate	levels	in	cell	culture	supernatant	were	67.3	±	8.05	16 µmol/mg	protein.	When	this	was	compared	to	the	novel	compounds,	most	SCQs	altered	17 cellular	 lactate	 levels	with	results	ranging	from	45	to	115	µmol/mg	protein.	However,	18 some	compounds	from	each	groups	A	and	B	increased	the	lactate	levels	to	more	than	165	19 µmol/mg	 protein	 (Figure	 25).	 On	 average,	 compounds	 from	 group	 D	 significantly	20 increased	lactate	levels,	whereas	compounds	from	group	F	significantly	decreased	lactate	21 levels,	while	the	other	categories	of	compounds	did	not	induce	any	statistically	significant	22 changes	(Figure	25).	Complete	data	of	individual	test	compounds	are	listed	in	appendix	23 2,	Table	A10-A16.	24 
	25 
	26 
(Note:	While	I	have	established	the	complete	assay	to	measure	lactate	levels,	the	influence	27 
of	SCQs	on	lactate	 levels	was	conducted	by	a	Master	of	Pharmaceutical	Sciences	student,	28 
Ayman	LA	Hemasa	under	my	guidance.	Data	analysis	was	done	by	myself.)	29 
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	1 
	2 
Figure	25:	Effect	of	novel	short-chain	naphthoquinones	(SCQs)	on	lactate	levels	in	the	cell	3 
culture	media.	Effect	of	test	compounds	(10	µM,	categorised	based	on	functional	group,	A-G)	on	4 cellular	 lactate	levels,	calculated	as	µmol/mg	protein.	Statistical	significance	was	calculated	by	5 using	Student	t-test	to	compare	the	effect	on	lactate	levels	by	the	different	groups	of	SCQs	against	6 sham-treated	cells	(black	dotted	line,	p*	<0.05).	Each	data	point	represents	mean	±	S.D.	for	each	7 SCQ	(n=3	independent	experiments	with	6	replicates	within	each	experiment).	Error	bars	were	8 omitted	for	clarity.	Data	of	individual	test	compounds	are	listed	in	appendix	2,	Table	A10-A16.	9 A,	Slight	polarity;	B,	Aliphatic;	C,	Acid;	D,	Aliphatic	ester;	E,	Amino	ester;	F,	Amino	acid;	G,	Amino	10 alcohol.	11 	12 	13 	14 	15 	16 
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2.4.1.7 The	 effect	 of	 SCQs	 on	 β-hydroxy	 butyrate	 levels	 in	 cell	 culture	1 
supernatant	2 	3 
In	the	absence	of	carbohydrates,	cells	can	also	utilize	fatty	acids	to	generate	ATP	via	the	4 β-oxidation	 of	 lipids.	 Fatty	 acids	 are	 oxidised	 to	 acetyl-CoA	 by	 β-oxidation	 and	 the	5 resultant	acetyl-CoA	can	enter	the	Krebs	cycle	and	react	with	oxaloacetate	to	form	citrate.	6 However,	under	conditions	of	increased	production	of	acetyl-CoA	in	the	liver	that	exceeds	7 the	 amount	 of	 available	 oxaloacetate	 for	 entry	 into	 the	 Krebs	 cycle,	 ketogenesis	 is	8 initiated	resulting	in	the	production	of	BHB,	acetoacetate	and	acetone,	collectively	known	9 as	ketone	bodies	(Nelson	et	al.	2008,	Gano	et	al.	2014).	These	ketone	bodies	are	exported	10 from	the	liver	to	tissues	with	high-energy	demand	such	as	the	brain.	The	major	ketone	11 body	BHB	can	be	catabolized	to	acetyl	CoA	that	can	be	further	used	for	energy	generation	12 in	tissues	such	as	brain	(Adeva-Andany	et	al.	2018).	Apart	from	energy	generation,	BHB	13 appears	 to	 have	 some	 protective	 activities.	 For	 example,	 a	 combination	 of	 BHB	 and	14 acetoacetate	(1	mM	each)	decreased	oxidative	damage	and	prevented	neuronal	death	in	15 rat	neocortical	neurons	exposed	to	glutamate	toxicity	(10	μM)	by	increasing	the	oxidation	16 of	 NADH	 in	 the	 mitochondrial	 ETC	 (Maalouf	 et	 al.	 2007).	 Similarly,	 a	 high	 fat,	 low	17 carbohydrate	 diet,	 known	 as	 ketogenic	 diet	 was	 shown	 to	 induce	 mitochondrial	18 biogenesis,	 to	 decrease	 oxidative	 stress	 in	 mitochondrial	 myopathy	 and	 improve	19 mitochondrial	function	(Ahola-Erkkilä	et	al.	2010,	Milder	and	Patel	2012).	Since	ketone	20 bodies	 are	 known	 to	 be	 predominantly	 metabolized	 in	 the	 mitochondria,	 the	 exact	21 mechanism	of	how	ketone	bodies	protect	against	mitochondrial	dysfunction	is	unclear	at	22 present.	One	hypothesis	simply	involves	increased	NAD+	levels	as	a	consequence	of	BHB	23 metabolism.	 In	 fact,	 this	 is	 a	 therapeutic	 strategy	 that	 is	 currently	 under	 clinical	24 
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investigation	to	counteract	mitochondrial	dysfunction	and	a	range	of	other	pathologies	1 (see	chapter	1.3.3).	2 
It	was	therefore	of	interest	to	analyse	if	our	novel	SCQs	increased	concentrations	of	BHB	3 in	 the	 cell	 culture	 supernatant	 to	 approach	 a	mode	 of	 action	 for	 their	 cytoprotective	4 activity	(Figure	18).	5 
	6 
Developing	an	assay	to	measure	BHB	levels	in	cell	culture	supernatant	7 
	8 
To	establish	an	assay	to	measure	BHB	in	cell	culture	supernatant,	I	used	a	previous	study	9 as	 reference	 (Hansen	 and	 Freier	 1978).	 The	 major	 components	 of	 the	 reaction	 mix	10 contained	PMS,	NAD+,	BHB-dehydrogenase	(BHBdh)	and	DCPIP	as	a	colorimetric	redox	11 detector	 in	 Tris	 buffer,	 pH	 7.8.	 The	 concentrations	 of	 individual	 components	 were	12 selected	based	on	my	previous	experience	with	the	lactate	assay	(Section	2.4.1.6).	Human	13 blood	 normally	 contains	 <50	 mg/ml	 BHB	 that	 can	 increase	 to	 >250	 mg/ml	 under	14 pathological	 conditions	 such	 as	 diabetic	 ketoacidosis	 (Elliott	 et	 al.	 2010).	 This	15 concentration	range	was	used	as	a	reference	to	determine	the	amount	of	BHBdh	enzyme	16 required,	based	on	the	enzyme	units’	information	provided	by	the	manufacturer	(Sigma	17 Aldrich,	Castle	Hill,	Australia).	The	product	information	stated	that	one	unit	of	BHBdh	will	18 oxidize	 1.0	μmole	 of	 BHB	 to	 acetoacetate	 per	 min	 at	 pH	7.8	 at	 37	°C.	 Based	 on	 this	19 information,	the	complete	ketone	reaction	buffer	(KRB)	initially	contained	0.5	mM	PMS,	20 2.5	mM	NAD+,	0.0000625	U	BHBdh,	0.2	mM	DCPIP	in	5	ml	of	100	mM	Tris	HCl	buffer	(B),	21 pH	 7.8.	 As	 before,	 all	 components	 were	 separately	 tested	 for	 their	 influence	 on	22 absorbance.	Neither	buffer	alone	(50	μl)	nor	buffer	with	the	remaining	KRB	components	23 
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(50	 μl	 total	 volume	 per	well)	 changed	 the	 absorbance	 of	 the	 reaction	mixture.	 Upon	1 addition	of	50	µl	of	200	mM	BHB	standard	per	well	to	50	μl	of	KRB,	a	clear	decrease	in	2 absorbance	was	seen	over	a	period	of	40	min	(Figure	not	shown).		3 
After	 confirming	 a	 working	 reaction	 mixture,	 the	 concentrations	 of	 individual	4 components	 were	 altered	 to	 see	 their	 influence	 on	 the	 rate	 of	 reaction.	 Firstly,	 the	5 concentration	of	NAD+	in	the	reaction	mix	was	reduced	to	1.25	mM	and	increased	up	to	6 10	mM	while	keeping	the	concentrations	of	other	components	constant.	Increasing	the	7 concentration	of	NAD+	above	2.5	mM	did	not	alter	the	rate	of	reaction,	hence	this	was	8 chosen	as	the	ideal	concentration	(Figure	26	ii).		9 
Next,	in	the	final	reaction	mixture	(5	ml),	the	amount	of	enzyme	BHBdh	was	increased	up	10 to	 0.00625	 U	 (in	 50	 μl	 KRB/well)	 keeping	 rest	 of	 the	 components	 constant.	 With	11 increased	BHBdh	in	the	reaction	mix,	the	rate	of	reaction	increased	upon	addition	of	BHB.	12 The	highest	concentration	of	enzyme	(0.00625	U	BHBdh	in	50	μl	KRB/well)	was	selected	13 to	improve	the	sensitivity	of	the	assay	to	measure	concentrations	of	BHB	such	as	0.3	mM	14 (Figure	26	ii).		15 
Finally,	concentration	of	the	electron	transporter	PMS	was	altered	from	0.5	mM	to	2.5	16 mM	 to	 determine	 its	 effect	 on	 the	 reaction	 rate.	 Unfortunately,	 increased	 PMS	17 concentrations	 negatively	 affected	 the	 linearity	 of	 the	 reaction.	 Only	 the	 lowest	18 concentration	of	PMS	(0.5	mM)	resulted	in	a	linear	reaction	rate	(over	10	min),	and	was	19 therefore	chosen	for	the	final	reaction	mixture	(Figure	26	ii).	20 
Based	on	these	results,	the	final	KRB	was	composed	of	5	ml	of	100	mM	Tris	HCl	buffer,	21 pH	7.8	with	 0.5	mM	PMS,	 2.5	mM	NAD+,	 0.00625	U	BHB-dehydrogenase	 and	 0.2	mM	22 DCPIP.	This	KRB	 (50	μl)	was	 subsequently	used	 to	measure	 the	effect	of	 SCQs	on	 the	23 amount	of	BHB	in	50	μl	of	cell	culture	supernatant.		24 
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	1 
	2 
	3 
Figure	 26:	 Method	 development	 for	measuring	 β-hydroxybutyrate	 levels	 (BHB)	 in	 cell	4 
supernatant.	(i)	The	effect	of	ketone	reaction	buffer	(KRB)	on	the	final	absorbance.	(ii)	The	effect	5 of	 different	 concentrations	 of	 BHB	 on	 absorbance	 at	 600	 nm.	 Each	 data	 point	 represents	 the	6 average	of	three	wells.	Error	bars	omitted	for	clarity.	7 B,	Tris	HCl	buffer;	DMEM,	Dulbecco’s	modified	eagle	medium	(complete	media	used	for	regular	8 cell	culture)	9 
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Influence	of	novel	SCQs	on	BHB	levels	in	cell	culture	supernatant	1 
	2 
To	measure	the	influence	of	the	novel	SCQs	on	BHB	levels,	HepG2	cells	were	treated	with	3 novel	 SCQs	 for	 72	 h	 before	 the	 BHB	 accumulation	 was	 measured	 in	 the	 cell	 culture	4 supernatant	and	normalised	to	protein	content	(Figure	18).		5 
Most	of	the	compounds	lead	to	approximately	1	to	3	µmol/mg	protein	in	cell	supernatant	6 (Figure	27).	However,	 one	SCQ	 from	each	 slightly	polar	 (A),	 amino	ester	 (E)	group	of	7 compounds	did	increased	BHB	levels	to	more	than	5	µmol/mg	(5.37	±	1.44,	5.14	±	0.15	8 µmol/mg,	respectively),	when	compared	to	sham-treated	cells	which	averaged	at	1.75	±	9 0.41	µmol/mg	protein.	Overall,	except	for	the	aliphatic	(B)	and	aliphatic	esters	(D),	all	10 other	SCQs	significantly	increased	BHB	accumulation	in	cells	(Figure	27).	Complete	data	11 of	individual	test	compounds	are	listed	in	appendix	2,	Table	A10-A16.	12 
	13 
	14 
	15 
	16 
	17 
	18 
(Note:	While	I	have	developed	the	complete	assay	to	measure	ketone	levels,	the	influence	of	19 
SCQs	on	ketone	 levels	was	conducted	by	an	Masters	of	Pharmaceutical	Sciences	 student,	20 
Sueanne	Chear,	under	my	guidance.	Complete	data	analysis	was	done	by	myself.)	21 	22 
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	3 
Figure	27:	Effect	of	novel	short-chain	naphthoquinones	(SCQs)	on	β-hydroxybutyrate	(BHB)	4 
levels	 in	 cell	 culture	 supernatant.	 Effect	 of	 test	 compounds	 (10µM,	 categorised	 based	 on	5 functional	 group,	 A-G)	 on	 BHB	 levels	 in	 cell	 supernatant,	 calculated	 as	 µmol/mg	 protein.	6 Statistical	significance	was	calculated	by	using	Student	t-test	to	compare	the	effect	on	BHB	levels	7 by	SCQs	against	sham-treated	cells	(black	dotted	line,	p*	<0.05,	p**<0.01,	p***<0.001).	Each	data	8 point	represents	mean	±	S.D.	for	each	SCQ	(n=3	independent	experiments	with	6	replicates	within	9 each	 experiment).	 Error	 bars	 were	 omitted	 for	 clarity.	 Complete	 data	 of	 individual	 test	10 compounds	are	listed	in	appendix	2,	Table	A10-A16.	11 A,	Slight	polarity;	B,	Aliphatic;	C,	Acid;	D,	Aliphatic	ester;	E,	Amino	ester;	F,	Amino	acid;	G,	Amino	12 alcohol.	13 	14 	15 	16 	17 	18 
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2.4.1.8 Mitochondrial	mass	1 	2 
During	the	growth	and	differentiation	of	normal	cells,	the	total	amount	of	mitochondrial	3 organelles	 per	 cell	 (=mitochondrial	 mass)	 is	 continuously	 adapting	 to	 the	 cellular	4 requirements	 (Heiden	 et	 al.	 2009).	 In	 addition,	 under	 conditions	 of	 mitochondrial	5 dysfunction,	 cells	 can	 upregulate	 mitochondrial	 mass	 (MM)	 as	 a	 compensatory	6 mechanism	to	ensure	metabolic	and	energy	demands	are	met	(Lee	et	al.	2002,	Noh	et	al.	7 2013).	This	opens	a	therapeutic	window	as	several	drugs	have	been	reported	to	influence	8 MM.	The	most	widely	described	classes	of	drugs	with	this	activity	are	the	fibrates	and	9 glitazones	 (Morel	 and	 Singer	 2014).	 However,	 in	 primary	 human	 muscle	 cells,	 the	10 benzoquinone	 idebenone	 was	 also	 able	 to	 increase	 mitochondrial	 mass	 in	 a	 dose-11 dependent	manner	(unpublished	observation,	N.	Gueven).		12 
To	understand	if	the	novel	SCQs	protect	against	mitochondrial	dysfunction	by	affecting	13 MM,	HepG2	cells	were	treated	with	selected	SCQs	(10	µM)	for	72	h	before	the	MM	was	14 measured.	Although	the	five	selected	SCQs	along	with	idebenone	(Ide),	menadione	(Mn)	15 and	vitamin	K	(VK)	as	control	compounds	appeared	to	slightly	alter	MM,	none	of	these	16 effects	were	statistically	significant	compared	to	sham-treated	cells	(Figure	28).	Since	the	17 mitoprotective	idebenone	and	randomly	selected	novel	SCQs	did	not	affect	MM	in	these	18 cells,	this	particular	approach	was	suspended	and	the	remaining	SCQs	were	not	tested.	19 
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	1 
	2 
Figure	28:	Effect	of	short-chain	naphthoquinones	(SCQs)	on	mitochondrial	mass.	Effect	of	3 selected	 SCQs	 (10	 µM)	 on	 mitochondrial	 mass,	 calculated	 as	 mitochondrial	 mass/protein,	4 expressed	 as	 percentage	 of	 sham-treated	 cells	 (Black	 dotted	 line).	 Statistical	 significance	was	5 calculated	by	using	Student	t-test	to	compare	the	effect	on	mitochondrial	mass	 levels	by	SCQs	6 against	sham-treated	cells	(p*	<0.05).	Each	data	point	represents	mean	±	S.D.	for	each	SCQ	(n=3	7 independent	experiments).	8 	9 	10 	11 	12 	13 	14 	15 	16 	17 	18 	19 
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2.4.2 Functional	activity	correlations	1 
 2 
2.4.2.1 Correlation	of	the	cytoprotective	ability	and	acute	rescue	of	ATP	levels	3 
by	SCQs	versus	the	compound’s	solubility	4 	5 
The	solubility	of	compounds	determines	their	ability	to	penetrate	cells	and	hence	affect	6 their	 efficacy.	 The	 current	 library	 of	 novel	 SCQs	 was	 developed	 by	 modifying	 the	7 functional	groups	attached	to	the	side	chain	which	was	attached	to	the	naphthoquinone	8 core.	Apart	from	changing	the	interaction	of	the	molecule	with	any	target	proteins,	these	9 functional	 groups	were	 also	predicted	 to	 change	 the	 solubility	 of	 the	 compounds.	 For	10 optimized	 cytoprotective	 activities,	 a	 previous	 report	 for	 short-chain	 benzoquinones	11 reported	a	log	D	range	between	2	and	4	(Erb	et	al.	2012).	Therefore,	it	was	important	to	12 analyse	 the	 influence	 of	 solubility	 of	 our	 naphthoquinones	 on	 their	 ability	 to	 protect	13 against	mitochondrial	dysfunction.	14 
When	 cytoprotection	 and	 acute	 rescue	 of	 ATP	 levels	 by	 SCQs	 in	 the	 presence	 of	 the	15 mitochondrial	inhibitor	rotenone	were	correlated	against	compound	solubility	(log	P	and	16 log	D)	no	obvious	correlations	were	observed	(Figure	29).	Surprisingly,	 in	contrast	 to	17 benzoquinones	(Erb	et	al.	2011)	a	rather	broad	solubility	range	was	associated	with	the	18 protective	activities	of	the	naphthoquinone	compounds	of	the	current	study.	A	compound	19 solubility	 between	 log	 P	 =	 1-7	 and	 log	 D	 =	 0-7	 was	 associated	 with	 at	 least	 60	 %	20 cytoprotection	(Figure	29	i,	iii)	and	80	%	of	ATP	level	rescue	(Figure	29	ii,	iv).	Complete	21 data	of	individual	test	compounds	are	listed	in	appendix	2,	Table	A10-A16.	22 
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	1 
	2 
Figure	 29:	 Correlation	 plot	 of	 cytoprotection	 and	 ATP	 rescue	 against	 solubility.	 (i-ii)	3 Protection	of	cellular	viability	and	acute	rescue	of	ATP	levels	by	test	compounds	(10	µM)	in	the	4 presence	of	rotenone	(1	µM	and	10	µM	respectively)	correlated	against	logP.	(iii-iv)	Protection	5 of	cellular	viability	and	acute	rescue	of	ATP	levels	by	test	compounds	(10	µM)	in	the	presence	of	6 rotenone	(1	µM	and	10	µM	respectively)	correlated	against	logD.	Each	data	point	represents	mean	7 for	each	SCQ	(n=3	 independent	experiments	with	6	replicates	within	each	experiment).	Error	8 bars	omitted	 for	clarity.	Complete	data	of	 individual	 test	compounds	are	 listed	 in	appendix	2,	9 Table	A10-A16.	10 
	11 
	12 
	13 
	14 
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2.4.2.2 Structure	activity	relationship	of	novel	SCQs	1 	2 
The	novel	 SCQs	were	 generated	 in	 batches	 as	 part	 of	 a	medicinal	 chemistry	 program	3 where	the	results	of	the	compound	characterisation	informed	the	chemical	synthesis	of	4 the	 subsequent	 molecules.	 In	 particular	 the	 cytoprotection	 data	 for	 each	 compound	5 directly	led	to	the	synthesis	of	new	compounds	with	modified	structures	to	improve	their	6 activity.	Initially,	the	generated	SCQs	were	grouped	into	slightly	polar,	aliphatic,	acids	and	7 aliphatic	 esters	 based	 on	 the	 functional	 group	 attached	 to	 the	 side	 chain	 of	 the	8 naphthoquinone	core	(Table	6)	and	tested	for	cytoprotection	and	ATP	rescue.	A	broad	9 grouping	of	the	SCQs	within	each	functional	group	was	observed.	While	the	slightly	polar	10 (brown	squares,	Figure	30)	and	acids	(yellow	squares,	Figure	30)	protected	viability	and	11 rescued	ATP	to	different	degrees,	the	aliphatic	compounds	(green	triangles,	Figure	30)	12 showed	cytoprotection	up	to	60%	of	sham-treated	cells	but	could	not	rescue	ATP	levels.	13 On	 the	 other	 hand,	 the	 aliphatic	 esters	 (blue	 triangles,	 Figure	 30)	 neither	 protected	14 viability	nor	rescued	ATP	levels.	15 
	Based	on	 these	 results,	 SCQs	were	optimized	via	 an	 iterative	process	 to	 achieve	high	16 levels	 of	 both	 cytoprotection	 as	well	 as	 rescue	of	ATP	 levels.	 In	 order	 to	 increase	 the	17 polarity	of	the	compounds,	amino	acid	fragments	were	added	to	the	tail	moiety	and	amino	18 esters,	acids	and	alcohols	were	generated.	Clearly,	the	addition	of	the	amino-functional	19 groups	increased	the	protective	activity	of	the	compounds.	The	most	polar	group,	which	20 contained	amino	acids	(pink	circles,	Figure	30),	protected	viability	between	30-100	%,	21 but	could	not	rescue	ATP	levels	beyond	65	%	compared	to	sham-treated	cells.	Slightly	22 less	polar	amino	esters	(purple	circles,	Figure	30)	and	amino	alcohols	(red	circles,	Figure	23 
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30)	 showed	 consistently	 good	 levels	 of	 protection	 of	 both	 viability	 and	 ATP	 rescue.	1 Complete	data	of	individual	test	compounds	are	listed	in	appendix	2,	Table	A10-A16.	2 
Therefore,	more	compounds	with	the	amino	acid	and	alcohols	attached	to	the	side	chain	3 were	 generated	 until	 consistently	 compounds	 were	 produced	 that	 protected	 cellular	4 viability	 as	 well	 as	 rescued	 ATP	 levels	 to	 a	 high	 degree.	 This	 gave	 our	 team	 a	 clear	5 understanding	 of	 the	 structure	 activity	 relationship	 of	 this	 class	 of	 compounds.	 It	 is	6 important	to	note	that	the	correlation	plot	(Figure	30)	therefore	illustrates	the	iterative	7 optimization	 of	 compound	 activity,	 which	 led	 to	 the	 synthesis	 of	 more	 and	 more	8 compounds	that	populated	the	top	right-hand	side	corner	of	the	plot.	Therefore,	despite	9 of	a	subjective	trend,	the	correlation	plot	of	protection	of	viability	versus	acute	rescue	of	10 ATP	levels	for	all	SCQs,	does	not	demonstrate	a	correlation	between	the	two	parameters	11 but	is	a	consequence	of	repeated	compound	optimization	(Figure	30).	12 
	13 
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Figure	30:	Correlation	of	cytoprotection	by	novel	short-chain	naphthoquinones	(SCQs)	versus	acute	rescue	of	adenosine	triphosphate	(ATP)	
levels	in	the	presence	of	rotenone.	Cytoprotection	and	acute	rescue	of	ATP	levels	by	test	compounds	(10	µM)	in	the	presence	of	rotenone	(1	µM,	10	µM	respectively)	was	measured	and	expressed	as	percentage	of	 sham-treated	HepG2	cells.	All	 SCQs	are	 classified	based	on	 the	 functional	 group	attached	to	the	naphthoquinone	core.	Each	data	point	represents	one	SCQ;	data	is	expressed	as	mean	±	S.D.	of	at	least	3	independent	experiments	with	6	replicates	within	each	experiment	(n=3).	Error	bars	were	omitted	for	clarity.	Complete	data	of	individual	test	compounds	are	listed	in	appendix	2,	Table	A10-A16
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2.4.2.3 Correlation	of	protection	of	viability	versus	the	rate	of	reduction	of	SCQs	1 
by	NQO1	2 	3 
Current	 opinion	 suggests	 that	 quinones	 should	 be	 bio-activated	 (reduced)	 from	 the	4 quinone	 to	 the	 hydroquinone	 form	 to	 be	 able	 to	 protect	 against	 mitochondrial	5 dysfunction	(Haefeli	et	al.	2011,	Prati	et	al.	2015).	This	would	imply	that	compounds	that	6 are	better	reduced	 inside	 the	cell	 should	show	more	cytoprotective	activity.	Hence,	 to	7 understand	if	the	rate	of	reduction	of	novel	SCQs	by	cellular	reductases	is	proportional	to	8 the	 cytoprotective	 ability	 of	 the	 compounds,	 a	 correlation	 was	 plotted	 (Figure	 31).	9 However,	in	contrast	to	the	hypothesis,	enzyme-dependent	reduction	of	quinones	to	their	10 hydroquinone	 forms	 did	 not	 correlate	 with	 their	 cytoprotective	 activities	 (R2	 =	 0.08,	11 Figure	31).	Complete	data	of	individual	test	compounds	are	listed	in	appendix	2,	Table	12 A10-A16.	13 
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	1 
Figure	 31:	 Correlation	 of	 cellular	 reduction	 of	 short-chain	 naphthoquinones	 (SCQs)	 by	2 
cellular	reductases	versus	cytoprotection	of	cellular	viability.	Bio-activation	of	SCQs	(10	µM)	3 by	cellular	reductases	was	measured	using	a	colorimetric	assay	(expressed	as	△	absorbance	at	4 450	nm)	and	correlated	against	protection	of	cell	viability	by	SCQs	(10	µM)	in	the	presence	of	5 rotenone	 (1	 µM).	 Each	 data	 point	 represents	 mean	 ±	 S.D.	 for	 each	 SCQ	 (n=3	 independent	6 experiments	 with	 6	 replicates	 within	 each	 experiment).	 Error	 bars	 were	 omitted	 for	 clarity.	7 Complete	data	of	individual	test	compounds	are	listed	in	appendix	2,	Table	A10-A16.	8 
 9 
 10 
2.4.2.4 Correlation	of	antioxidant	activity	with	cytoprotection			11 	12 
Most	of	the	research	on	SCQs	suggests	that	the	antioxidant	capacity	of	quinones	is	central	13 for	their	cytoprotective	activity	against	mitochondrial	dysfunction	(Ahmed	2014,	Smith	14 and	Murphy	2010,	Stelmashook	et	al.	2015).	To	understand	if	the	antioxidant	activity	of	15 SCQs	 to	 act	 as	 antioxidants	 was	 responsible	 for	 their	 cytoprotective	 capacity	 against	16 
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mitochondrial	dysfunction,	BLP	levels	were	correlated	with	the	cytoprotective	activity	of	1 SCQs	(both	normalised	to	sham-treated	cells)	(Figure	32).	This	approach	resulted	 in	a	2 random	distribution	of	data	points	all	across	the	graph,	which	indicated	that	these	two	3 parameters	did	not	correlate	 (R2	=	0.004,	Figure	32).	Complete	data	of	 individual	 test	4 compounds	are	listed	in	appendix	2,	Table	A10-A16.	5 
	6 
Figure	32:	Correlation	of	cytoprotection	and	basal	 lipid	peroxidation.	The	effect	of	 short	7 chain	naphthoquinones	(SCQs,	10	µM)	on	basal	lipid	peroxidation	levels	by	NQO1	was	measured	8 (expressed	as	percentage	of	total	reduction)	and	correlated	against	protection	of	cell	viability	by	9 SCQs	(10	µM)	in	the	presence	of	rotenone	(1	µM).	Each	data	point	represents	mean	±	S.D.	for	each	10 SCQ	(n=3	independent	experiments	with	6	replicates	within	each	experiment).	Error	bars	were	11 omitted	for	clarity.	Complete	data	of	individual	test	compounds	are	listed	in	appendix	2,	Table	12 A10-A16.	13 	14 
	15 
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2.4.2.5 Correlation	 of	 cytoprotection	 with	 lactate	 or	 beta-hydroxy	 butyrate	1 
levels		2 	3 
To	get	insights	into	the	mechanism	of	action	of	novel	SCQs	it	was	of	interest	to	understand	4 if	the	compounds	affected	glycolysis	or	beta-oxidation	pathways	of	energy	generation	to	5 protect	against	mitochondrial	dysfunction.	Hence,	lactate	and	BHB	levels	were	measured	6 and	correlated	to	cytoprotection	for	each	compound	(Figure	33).			7 
Compounds	that	protected	cellular	viability	to	at	least	60	%	of	control,	which	is	similar	to	8 the	cytoprotection	shown	by	idebenone,	affected	lactate	accumulation	between	65	%	to	9 140	%,	compared	 to	untreated	cells.	However,	 two	compounds	significantly	 increased	10 lactate	to	175	%	of	control	cells	(Figure	33	i).	For	compounds	that	protected	viability	to	11 more	than	70	%	of	control,	which	was	significantly	better	than	idebenone,	the	effect	on	12 cellular	 lactate	 levels	ranged	from	approximately	65	%	to	115	%,	with	one	compound	13 increasing	 lactate	 to	 about	 140	 %.	 As	 for	 previously	 tested	 parameters,	 no	 clear	14 correlation	 between	 cytoprotection	 and	 lactate	 levels	 in	 the	 cell	 supernatant	 were	15 observed	(R2	=	0.06,	Figure	33	i).	16 
A	final	option	that	was	tested	was	the	possibility	 that	 the	novel	compounds	protected	17 against	 mitochondrial	 dysfunction-induced	 cytotoxicity	 by	 upregulating	 ketone	 body	18 synthesis.	Most	of	the	SCQs	increased	BHB	accumulation	in	the	cell	culture	supernatant	19 (Figure	33	ii).	However,	these	increases	in	BHB	accumulation	were	clearly	not	associated	20 with	the	cytoprotective	effects	of	the	SCQs	(R2	=	0.00003,	Figure	33	ii).	Complete	data	of	21 individual	test	compounds	are	listed	in	appendix	2,	Table	A10-A16.	22 
	23 
	24 
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	1 
Figure	33:	Correlation	of	protection	of	cellular	viability	by	short-chain	naphthoquinones	2 
(SCQs)	 versus	 their	 effect	 on	 cellular	 lactate	 and	 β-hydroxybutyrate	 (BHB)	 levels.	3 Protection	of	cell	viability	by	SCQs	(10	µM)	in	the	presence	of	rotenone	(1	µM)	is	correlated	to	4 their	 effect	 on	 the	 accumulation	 of	 cellular	 lactate	 (i)	 and	 BHB	 (ii)	 levels.	 Each	 data	 point	5 represents	mean	±	S.D.	for	each	SCQ	(n=3	independent	experiments	with	6	replicates	within	each	6 experiment).	Error	bars	were	omitted	for	clarity.	Complete	data	of	individual	test	compounds	are	7 listed	in	appendix	2,	Table	A10-A16.	8 
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2.4.3 Structural	characterisation	of	novel	SCQ’s	1 	2 
Apart	from	characterising	our	novel	SCQs	for	their	ability	to	influence	cellular	parameters,	3 structural	aspects	were	also	studied	to	understand	the	importance	of	the	design	of	the	4 quinone	 core	 structure.	 For	 this	 characterisation,	 five	 SCQs,	 with	 different	 functional	5 groups	attached	to	the	side	chain	(R2-R6,	Table	7),	which	protected	viability	significantly	6 better	than	idebenone	were	chosen.	In	addition,	one	basic	SCQ,	where	the	quinone	core	7 was	attached	with	a	four-carbon	(4C)	side	chain	ending	in	hydroxyl	group,	without	any	8 functional	group	at	the	end	was	also	included	(R1,	Table	7).	Individual	components	of	the	9 structures	of	these	selected	SCQs	were	modified	to	analyse	their	effect	on	the	compound’s	10 ability	to	protect	cellular	viability	(Complete	structures	listed	in	Appendix	1,	Table	A8-11 A9).	12 
	13 
Table	7:	Structures	of	the	side-chains	of	selected	novel	SCQs	14 
	15 
R1	 	 R4	 	
R2	 	 R5	 	
R3	 	 R6	 	
	16 
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2.4.3.1 The	relevance	of	the	naphthoquinone	core	for	cytoprotection	1 	2 
The	major	problem	with	currently	researched	and	marketed	ubiquinones	like	CoQ10	and	3 idebenone	 is	 their	 solubility	 and	 their	 requirement	 to	 be	 bio-activated	 by	 cellular	4 reductases	like	NQO1.	Plastoquinones	like	SkQ1	and	vitamin	E	derivatives	such	as	EPI-5 743	 reportedly	 have	 to	 be	 bio-activated	 by	 NQO1	 as	 well	 to	 exert	 their	 protective	6 potential	(Anisimov	et	al.	2008,	Enns	et	al.	2012,	Manskikh	et	al.	2015,	Skulachev	et	al.	7 2009).	However,	inactivating	NQO1	polymorphism	are	present	to	a	significant	degree	in	8 the	general	population	(Lajin	and	Alachkar	2013).	In	these	individuals	it	would	therefore	9 be	expected	that	these	compounds	cannot	be	bio-activated	and	instead	undergo	a	one-10 electron	 reduction	 to	 the	 unstable	 semiquinone	 that	 gives	 rise	 to	 oxidative	 damage	11 (Martin	et	al.	2009).	12 
To	address	this	issue,	in	this	study,	novel	SCQs	were	developed	with	the	aim	to	increase	13 solubility	and	bioactivation.	In	particular,	we	aimed	to	generate	compounds	that	could	be	14 reduced	by	other	cellular	reductases	apart	from	NQO1,	to	differentiate	these	molecules	15 from	existing	ubiquinones	and	plastoquinones.	To	address	this	aim,	it	was	important	to	16 understand	 whether	 the	 presence	 of	 the	 functional	 group	 of	 the	 side	 chain	 or	 the	17 naphthoquinone	core	or	both	of	them	were	responsible	for	the	cytoprotective	ability	of	18 the	novel	SCQs.	Therefore,	five	of	the	most	cytoprotective	SCQs	were	chosen	and	their	19 quinone	core	was	modified	from	a	naphthoquinone	to	a	plastoquinone	and	ubiquinone	20 core	 while	 keeping	 the	 side	 chain	 (4-carbon,	 4C)	 and	 the	 functional	 groups	 (R1-R6)	21 identical	(Figure	34,	Table	7).	Complete	list	of	structures	located	in	Appendix	1,	Table	A8.		22 
For	 the	 set	 of	 compounds	with	R1,	 the	quinone	 core	 is	 attached	with	 a	4C	 side	 chain	23 ending	in	hydroxyl	group,	without	any	functional	group	at	the	end.	In	this	group,	none	of	24 
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the	three	compounds	protected	cellular	viability	against	rotenone	(Figure	34,	red	dotted	1 line).	 This	 suggested	 that	 the	 quinone	 core	 with	 the	 4C	 side	 chain	 did	 not	 have	 any	2 cytoprotective	 ability	 in	 the	 absence	 of	 a	 functional	 group	 at	 the	 end	 (Figure	 34).	3 Interestingly,	 in	 four	out	of	 the	 five	groups	of	compounds	with	 the	R2,	R3,	R5	and	R6	4 functional	groups,	the	naphthoquinone	core	showed	significantly	better	cytoprotection	5 compared	to	the	corresponding	plastoquinone	and	ubiquinone	derivatives	(Figure	34).	6 In	fact,	in	these	four	groups	(R2,	R3,	R5	and	R6),	changing	the	core	from	naphthoquinone	7 moiety	to	any	of	the	other	two	quinone	moieties	significantly	increased	the	cytotoxicity	8 of	 these	 compounds.	 These	 changes	 produced	 compounds	 that	 significantly	 reduced	9 viability	below	levels	of	rotenone-only	treated	cells	in	R2,	R3	and	plastoquinone	from	R6	10 group	 (Figure	 34).	 In	 the	 group	 of	 compounds	 with	 the	 R4	 functional	 group,	 the	11 compound	 with	 the	 plastoquinone	 core	 protected	 cell	 viability	 significantly	 better	12 compared	to	the	corresponding	naphthoquinone	(Figure	34).	13 
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	1 
	2 
	3 
Figure	 34:	 Cytoprotection	 by	 related	 quinones	 with	 different	 quinone	 cores	 in	 the	4 
presence	of	rotenone.	Side	chain	(R,	R1-R6,	Table	6)	from	select	naphthoquinones	(pink	bar)	5 was	 attached	 to	 different	 cores,	 i.e.	 plastoquinone	 (blue	 bar)	 and	 ubiquinone	 (green	 bar).	6 Cytoprotection	 by	 these	 test	 compounds	 (10	 µM)	 in	 the	 presence	 of	 rotenone	 (1	 µM)	 was	7 measured	and	expressed	as	percentage	of	sham-treated	(black	dotted	line)	HepG2	cells.	Each	bar	8 represents	 the	 activity	 of	 one	 compound,	 data	 is	 expressed	 as	mean	±	 S.D.	 (n=3	 independent	9 experiments	with	 6	 replicates	within	 each	 experiment).	 Significance	was	 calculated	 by	 using	10 Student	t-test	(p*	<0.05,	p**<0.01,	p***<0.001	cytoprotection	by	naphthoquinones	vs	the	related	11 plastoquinones	and	ubiquinones,	p#<0.05	cytoprotection	by	SCQs	against	rotenone-only	treated	12 cells	(red	dotted	line)).		13 	14 	15 
	16 
In	vitro	characterisation	
Novel short-chain quinones against mitochondrial dysfunction                     148 
 
2.4.3.2 The	relevance	of	the	methyl	group	on	the	naphthoquinone	core	1 	2 
Most	 of	 the	 currently	 researched	 quinones	 including	 CoQ10,	 idebenone,	 EPI-743	 and	3 MitoQ	have	a	methyl	group	attached	to	the	quinone	core	at	position	X	(Figures	13,	35),	in	4 contrast	to	SkQ1	that	lacks	this	methyl	group	(Figure	13).	To	understand	the	importance	5 of	a	methyl	group	(Me)	at	that	particular	position,	it	was	replaced	with	either	by	hydrogen	6 (H)	 or	 a	 hydroxyl	 (OH)	 group	 on	 the	 selected	 SCQs	 containing	 the	 R1-R5	 functional	7 groups	attached	to	their	side	chain	(see	appendix	1,	Table	A9	for	structures).	In	four	of	8 the	five	groups	of	naphthoquinones	(R2-R6),	the	compounds	with	the	Me	group	in	the	X-9 position	 showed	 significantly	 better	 cytoprotection	 when	 compared	 to	 their	10 corresponding	compounds	with	H	and	OH	groups	(Figure	35).	When	the	Me	group	was	11 replaced	with	the	OH	group	in	the	compounds	with	the	R5	functional	group,	a	significant	12 increase	in	cytotoxicity	was	observed	for	these	compound	(10.4	±	4.6	%),	compared	to	13 rotenone-only	treated	cells	(Figure	35).	Unfortunately,	in	the	group	of	compounds	with	14 the	R6	functional	group,	the	naphthoquinone	with	the	OH	group	in	the	X-position	could	15 not	 be	 synthesised	 and	 was	 therefore	 not	 tested	 (Figure	 35).	 Surprisingly,	 only	 for	16 compounds	with	 the	R1	 group,	 the	 replacement	 of	 the	Me	 group	with	H	 significantly	17 improved	 cell	 viability	 (Figure	 35).	 However,	 with	 44.55	 ±	 15.04	 %	 viability,	 this	18 compound	 still	 showed	 less	 protection	 than	 idebenone	 (66.2	 ±	 12.05	%).	 In	 contrast,	19 replacing	the	Me	group	with	a	OH	group	in	the	compound	with	the	R1	group,	reduced	the	20 cell	viability	to	15.6	±	6.8	%,	which	was	significantly	lower	than	rotenone-only	treated	21 cells	 (red-dotted	 line,	 Figure	 35).	 Consistently,	 for	 all	 synthesized	 compounds,	 the	22 addition	of	the	OH-group	in	the	X-position	increased	cytotoxicity.	23 
	24 
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	3 
Figure	35:	Effect	of	the	functional	group	in	the	X-position	for	cytoprotection.	The	functional	4 group	located	in	the	X-position	of	selected	SCQs	(R1-R6,	table	6)	was	replaced	from	the	original	5 methyl	 group	 (Me,	 pink	 bar)	 to	 hydrogen	 (H,	 blue	 bar)	 or	 a	 hydroxyl	 group	 (OH,	 green	 bar).	6 Cytoprotection	 by	 these	 test	 compounds	 (10	 µM)	 in	 the	 presence	 of	 rotenone	 (1	 µM)	 was	7 measured	and	expressed	as	percentage	of	sham-treated	HepG2	cells	(black	dotted	line).	Each	bar	8 represents	 the	 activity	 of	 one	 compound,	 data	 is	 expressed	 as	mean	±	 S.D.	 (n=3	 independent	9 experiments	with	 6	 replicates	within	 each	 experiment).	 Significance	was	 calculated	 by	 using	10 Student	t-test	(p*	<0.05,	p**<0.01,	p***<0.001	cytoprotection	by	naphthoquinones	containing	Me	11 group	 vs	 the	 related	 naphthoquinone	 with	 H	 and	 OH	 group	 at	 the	 X-position,	 p#<0.05	12 cytoprotection	by	SCQs	against	rotenone-only	treated	cells	(red	dotted	line)).		13 	14 	15 	16 	17 	18 
X 
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2.4.3.3 Effect	of	isomerization	of	the	side-chain	residue	on	cytoprotection	1 	2 
To	evaluate	the	importance	of	spatial	orientation	of	the	functional	group	attached	to	the	3 naphthoquinone	core,	five	naphthoquinones	were	selected	and	their	stereoisomers	for	4 the	side-chain	group	were	synthesised	(Table	8).	 In	four	out	of	the	five	tested	pairs	of	5 compounds,	 no	 significant	 cytoprotective	differences	were	observed	between	 the	 two	6 stereoisomers.	 However,	 in	 one	 pair,	 the	 L-isomer	 (#37)	 showed	 significantly	 better	7 cytoprotection	 (100.3	±	17.3	%)	when	compared	 to	 its	 corresponding	D-isomer	 (#94,	8 58.7	±	5.2	%)	(Figure	36).	9 
	10 
Table	8:	Structures	of	the	corresponding	pairs	of	short-chain	quinones	(SCQ)	that	11 
were	synthesised	as	L-	and	D-isomers	12 
	13 
SCQ	 							L-isomer	 SCQ	 							D-isomer	
#37	 	 #94	 	
#81	 	 #80	 	
#62	 	 #78	 		
#95	 	 #97	 	
#96	 	 #98	 		14 
	15 
	16 
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	1 
	2 
Figure	36:	Effect	of	isomerism	of	the	functional	group	on	cytoprotection.	Cytoprotection	by	3 the	five	pairs	of	L-	(solid	bar)	and	D-isomers	(striped	bar)	of	the	test	compounds	(10	µM)	in	the	4 presence	 of	 rotenone	 (1	 µM)	 was	 expressed	 as	 percentage	 of	 sham-treated	 HepG2	 cells	 (no	5 rotenone,	black	dotted	line).	Each	bar	represents	the	activity	of	one	compound,	data	is	expressed	6 as	 mean	 ±	 S.D.	 (n=3	 independent	 experiments	 with	 6	 replicates	 within	 each	 experiment).	7 Significance	was	calculated	by	using	Student	t-test	to	compare	cytoprotection	(p*	<0.05).	8 Red	dotted	line	represents	the	cytoprotection	by	rotenone-only	treated	cells.	9 	10 	11 
	12 
	13 
	14 
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2.5 	 Discussion	1 	2 
Mitochondrial	disorders	are	typically	associated	with	defects	in	OXPHOS,	reduced	ATP	3 levels,	increased	oxidative	stress	and	decreased	cellular	viability.	Under	these	conditions,	4 several	small-molecules	such	as	SCQs	are	currently	under	clinical	development	to	treat	5 mitochondrial	dysfunction	or	just	alleviate	disease	symptoms	(see	section	1.3).	A	limited	6 number	 of	 studies	 are	 published,	 justifying	 the	 effectiveness	 of	 SCQ	 molecules	 like	7 idebenone	(Klopstock	et	al.	2011,	Lynch	et	al.	2010)	and	EPI-743	(Chicani	et	al.	2013,	8 Zesiewicz	et	al.	2016)	in	a	clinical	setting.	Currently,	idebenone	is	the	only	marketed	SCQ	9 in	 Europe	 to	 specifically	 treat	 a	 mitochondrial	 disease,	 Leber’s	 Hereditary	 Optic	10 Neuropathy	 (LHON).	 SCQs	 are	 generally	 believed	 to	 protect	 against	 mitochondrial	11 dysfunction	 by	 rescuing	 ATP	 levels	 and	 ameliorating	 oxidative	 stress	 by	 acting	 as	12 antioxidants	(Anisimov	et	al.	2011,	Erb	et	al.	2012,	Gueven	et	al.	2017,	Krylova	et	al.	2016,	13 Smith	and	Murphy	2010).	However,	there	is	some	doubt	around	this	simplistic	view	and	14 their	precise	mechanism(s)	of	action	of	these	compounds	are	yet	to	be	understood	and	15 more	importantly	proven.		16 
The	main	goal	of	the	present	study	was	to	develop	and	characterise	improved	novel	SCQ	17 molecules,	while	working	towards	a	better	understanding	of	the	underlying	mechanism	18 of	action	of	these	SCQs	for	treating	mitochondrial	dysfunction.	In	the	current	chapter,	I	19 have	presented	the	data	of	the	in	vitro	characterisation	of	those	novel	SCQs	with	regards	20 to	 several	 cellular	 parameters	 that	 appear	 relevant	 in	 the	 context	 of	 mitochondrial	21 dysfunction.	 However,	 I	 have	 to	 acknowledge	 that	 this	 list	 of	 endpoints	 is	 likely	22 incomplete,	and	a	multitude	of	additional	endpoints	could	be	argued	for	(Discussed	in	23 
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detail	 in	 section	 2.5.4).	 The	 selection	 of	 these	 parameters	 tested	 in	 this	 study	 was	1 informed	by	the	current	(published)	understanding	of	the	molecular	activities	of	SCS.	2 
	3 
2.5.1 The	effect	of	novel	SCQs	on	protecting	cell	viability	and	rescue	ATP	levels	in	4 
the	presence	of	mitochondrial	dysfunction		5 	6 
Mitochondrial	 dysfunction	 is	 typically	 associated	 with	 OXPHOS	 defects	 that	 result	 in	7 reduced	mitochondrial	ATP	production.	Chronic	mitochondrial	dysfunction	can	lead	to	8 cell	death.	This	is	evident	from	my	results,	where	the	presence	of	the	mitochondrial	C-I	9 inhibitor,	 rotenone,	 significantly	 reduced	 cellular	 viability	 to	 less	 than	30	%	of	 sham-10 treated	 cells	 (Figure	 19).	 Therefore,	 to	 develop	 novel	 drugs	 to	 treat	 mitochondrial	11 dysfunction,	 it	 is	 important	 to	 investigate	 the	 efficacy	 of	 these	 compounds	 to	 protect	12 cellular	viability	under	defined	conditions	of	mitochondrial	dysfunction.		13 
Although	 mitochondrial	 cybrid	 cells	 are	 widely	 used,	 there	 are	 some	 limitations	14 associated	with	this	approach.	For	example,	a	consistent	reduction	of	cellular	ATP	levels	15 could	not	be	demonstrated	in	LHON	cybrids	under	basal	conditions	(Baracca	et	al.	2005,	16 Beretta	 et	 al.	 2004),	which	 is	 in	 contrast	 to	 peripheral	 blood	mononuclear	 cells	 from	17 LHON	patients	(Korsten	et	al.	2010).	In	addition,	the	exact	patho-mechanisms	of	diseases	18 associated	with	mitochondrial	dysfunction	are	not	clearly	known	at	present.	And	while	19 the	same	mtDNA	mutation	can	give	rise	to	different	phenotypes,	the	same	phenotype	can	20 be	the	consequence	of	different	mutations	(Blakely	et	al.	2005,	Taylor	and	Turnbull	2005,	21 Wallace	1992),	which	illustrates	that	a	multitude	of	factors	such	as	mutations	in	nDNA	22 and	 mtDNA	 as	 well	 as	 nuclear	 polymorphisms,	 mitochondrial	 haplotype,	 epigenetic	23 changes	in	tumor	cells,	and	environmental	factors	can	all	affect	disease	symptoms	and	24 
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etiology.	These	limitations	make	it	difficult	to	generate	a	cell	culture	model	of	a	specific	1 mitochondrial	 disease	 that	 shows	 sufficient	 face-,	 construct-	 and	 predictive	 validity	2 (Gazdar	 et	 al.	 2010,	 Gómez-Durán	 et	 al.	 2010).	 To	 prevent	 these	 limitations,	 I	 used	 a	3 widely	 used	 hepatic	 cell	 line	 combined	 with	 a	 well-known	 mitochondrial	 toxin	 to	4 generate	a	reliable	model	of	mitochondrial	dysfunction	that	could	be	reliably	used	over	5 extended	 periods	 of	 time	 to	 perform	 the	 comparative	 studies	 of	 this	 chapter.	 Since	6 quinones	are	known	to	undergo	first-pass	metabolism	(Becker	et	al.	2010,	Bodmer	et	al.	7 2009),	 I	 have	 chosen	 the	 hepatic	 cell	 line,	 HepG2	 to	 characterise	 our	 novel	 SCQs.	 In	8 addition,	HepG2	cells	are	also	known	to	express	high	 levels	of	NQO1	(Wilkening	et	al.	9 2003).	Inhibition	of	mitochondrial	C-I	with	rotenone	induces	ROS-mediated	toxicity	that	10 leads	to	apoptosis	(Li	et	al.	2002).	However,	I	have	to	acknowledge	that	this	approach	11 also	had	some	obvious	limitations	Firstly,	as	the	liver	is	known	for	detoxifying	various	12 metabolites,	it	would	have	significantly	different	defense	mechanisms	and	tolerance	to	13 oxidative	stress	that	may	not	be	replicated	by	other	cells	(Bando	et	al.	2005).		Moreover,	14 due	to	the	high	basal	antioxidant	capacity	of	liver	cells,	it	may	also	be	difficult	to	assess	15 the	 antioxidant	 capacity	 if	 our	 novel	 SCQs.	 Secondly,	 HepG2	 cells,	 being	 cancerous	 in	16 origin	are	known	to	have	very	high	glycolytic	capacity	(Marroquin	et	al.	2007)	and	high	17 levels	of	the	enzyme	NQO1	compared	to	normal	liver	which	could	over-emphasize	results	18 with	regards	to	bioactivation	and	metabolic	activity	(Cresteil	and	Jaiswal	1991).	While	19 majority	of	NQO1	is	localized	in	the	cytosol,	it	is	also	found	in	the	mitochondria	of	several	20 tissues	(Ellund	et	al.,	1982;	Ernster	et	al.,	1962).	Mitochondrial	NQO1	is	localized	in	the	21 matrix	and	was	reported	to	contribute	to	almost	15	%	of	the	total	cellular	activity	(Ellund	22 et	al.,	1982;	Ernster	et	al.,	1962).	Apart	from	NQO1,	KGDHC	in	the	mitochondrial	matrix	23 can	 also	 exhibit	 diaphorase-like	 activity	 (Klyachko	 et	 al.,	 2005;	Kiss	 et	 al.,	 2014).	 The	24 presence	of	these	reductases	in	the	mitochondrial	matrix	can	also	affect	the	activity	of	25 
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quinone	 compounds	 by	 mediating	 NAD+	 regeneration	 during	 C-I	 inhibition,	 hence	1 supporting	ATP	generation	via	substrate	level	phosphorylation.	2 
Lastly,	 in	 this	study,	 I	only	have	used	a	single	mitochondrial	C-I	 inhibitor,	 rotenone	to	3 induce	 mitochondrial	 dysfunction,	 similar	 to	 previously	 published	 study	 to	 test	4 idebenone	analogues	(Erb	et	al.	2012,	Giorgio	et	al.	2012,	Haefeli	et	al.	2011).	Idebenone	5 is	 believed	 to	 rescue	 ATP	 levels	 by	 bypassing	 mitochondrial	 C-I,	 in	 the	 presence	 of	6 rotenone-induced	mitochondrial	dysfunction.	However,	idebenone	could	not	rescue	ATP	7 levels	 in	 the	 presence	 of	 mitochondrial	 dysfunction	 induced	 by	 other	 toxins	 such	 as	8 antimycin	or	oligomycin	that	either	inhibit	mitochondrial	C-III	or	block	the	proton	pump	9 of	 ATP	 synthase	 respectively	 (Erb	 et	 al.	 2012).	 This	 replicates	 prior	 studies	 where	10 menadione	and	CoQ1	in	hepatocytes	(Chan	et	al.,	2002)	and	lymphocytes	(Dedukhova	et	11 al.,	1986,)	inhibited	the	cytotoxicity	caused	by	C-I	inhibition,	but	not	that	caused	by	the	12 inhibition	of	C-III	(Kiss	et	al.,	2014).	Since	our	novel	SCQs	belong	to	the	same	chemical	13 class	 as	 idebenone,	 we	 hypothesized	 that	 they	 would	 work	 by	 a	 similar	 mechanism.	14 However,	 this	 approach	 limits	 our	 results	 by	 not	 being	 able	 to	 extrapolate	 them	 to	15 mitochondrial	dysfunction	induced	by	other	toxins	or	even	other	respiratory	complexes.	16 The	results	described	in	this	study	are	therefore	indicative	to	the	effects	of	the	novel	SCQs	17 on	rotenone-treated	HepG2	cells	in	a	comparative	manner	only.	18 
To	measure	the	cytoprotective	activity	of	SCQs,	mitochondrial	dysfunction	was	induced	19 by	treating	cells	with	C-I	inhibitor,	rotenone	(1	µM).	Under	these	conditions,	co-treatment	20 with	idebenone,	increased	cell	viability	from	less	than	30	%	to	more	than	60	%.	Simply	21 changing	the	core	structure	of	idebenone	from	a	benzoquinone	to	a	naphthoquinone	(#2),	22 increased	cell	viability	 to	more	 than	60	%,	suggesting	 that	replacing	 the	quinone	core	23 from	benzoquinone	to	a	naphthoquinone	did	not	 increase	 toxicity,	while	retaining	 the	24 
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cytoprotective	potential	 of	 idebenone	 (Figure	19).	The	novel	 SCQs	 synthesised	 in	 this	1 project	are	structurally	similar	to	VK	only	based	on	the	presence	of	a	naphthoquinone	2 core	but	display	a	much	higher	solubility	due	to	a	shorter	side-chain	that	furthermore	3 incorporates	 solubilizing	 groups.	 In	 contrast	 to	 benzoquinones,	 naphthoquinones	 are	4 bioactivated	 not	 only	 by	 NQO1,	 but	 also	 by	 additional	 enzymes	 such	 as	 VK	 oxido-5 reductase	isoenzymes	(VKORCS1,	VKORL2)	(Tie	and	Stafford	2008,	Wallin	et	al.	2008).	6 Based	on	the	ability	to	be	bioactivated	by	additional	enzymes,	naphthoquinones	should	7 be	associated	 less	ROS-induced	toxicity	compared	to	benzoquinones	 in	 the	absence	of	8 NQO1.		Moreover,	VK	was	found	to	be	necessary	to	transfer	electron	in	the	mitochondria	9 of	Drosophila	resulting	in	efficient	ATP	production,	hence	rescuing	Pink1	deficiency	(Vos	10 et	al.	2012).	However,	VK-1,	when	tested	for	cytoprotection	in	the	presence	of	rotenone,	11 was	toxic	to	the	cells	at	10	µM	and	reduced	the	cell	viability	to	 levels	 lower	than	cells	12 treated	 with	 rotenone-only.	 As	 a	 transition	 to	 the	 novel	 SCQ	 library,	 testing	 the	13 naphthoquinone	core	on	its	own,	without	any	functional	groups	attached	also	(i.e.	#23),	14 did	not	protect	cell	viability	any	better	than	rotenone-treated	cells.	However,	introducing	15 a	 functional	 group	 at	 the	 4C	 chain	 attached	 to	 naphthoquinone	 core	 (like	 #24),	16 significantly	 improved	 cellular	 viability	 in	 the	 presence	 of	 rotenone	 (>	 70	%),	 when	17 compared	 to	 idebenone	 (Figure	 19).	 These	 results	 suggest	 that	 it	 is	 not	 just	 the	18 naphthoquinone	 core	 or	 any	 naphthoquinone	 molecule	 with	 long	 side-chains,	 but	 a	19 combination	of	both	the	naphthoquinone	core	with	selected	functional	groups	attached	20 to	a	side	chain	contribute	towards	the	cytoprotective	activity	of	the	compound.		Overall,	21 more	 than	20	novel	 SCQs	 showed	 significantly	better	 cytoprotection	 compared	 to	 the	22 marketed	idebenone	(Figure	19,	pink	data	points).	In	fact,	some	novel	SCQs	like	#37	and	23 #62	 were	 not	 only	 significantly	 better	 in	 protecting	 cellular	 viability	 compared	 to	24 idebenone,	but	fully	restored	viability	back	to	non-rotenone	treated.	From	these	results,	25 
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it	is	evident	that	novel	SCQs,	with	naphthoquinone	core	and	additional	functional	groups	1 on	 the	 side-chain	 can	 significantly	 protect	 cellular	 viability	 in	 the	 presence	 of	2 mitochondrial	 dysfunction.	 However,	 these	 results	 do	 not	 provide	 any	 further	3 information	how	these	compounds	work	at	the	molecular	level.		4 
	5 
Mitochondria	are	 involved	 in	a	multitude	of	 cellular	 functions	ranging	 from	supplying	6 chemical	energy	in	the	form	of	ATP	and	other	high,	energy-rich	molecules	such	as	NADH,	7 Ca2+-signaling,	 production	 of	many	metabolites	 and	 also	 ROS	 to	 the	 regulation	 of	 cell	8 death	 (Davis	 and	 Williams	 2012).	 Nevertheless,	 one	 of	 the	 main	 functions	 is	 ATP	9 production	(Vo	and	Palsson	2007).	The	reduced	form	of	SCQ	was	reported	to	maintain	10 ATP	 generation,	 in	 the	 presence	 of	 mitochondrial	 dysfunction	 by	 bypassing	11 mitochondrial	 C-I	 (Erb	 et	 al.	 2012).	Once	 the	 electrons	 are	 donated	 to	 C-III,	 some	 re-12 oxidised	quinones	can	shuttle	out	of	 the	mitochondria	 to	be	reduced	again	by	cellular	13 reductases	like	NQO1,	re-enter	the	cell	and	donate	more	electrons	to	C-III	(Erb	et	al.	2012).	14 This	process	 is	believed	to	act	as	a	continuous	shuttle	 in	and	out	of	 the	mitochondria,	15 donating	 electrons	 and	 hence	 rescuing	 cellular	 ATP	 levels	 in	 the	 presence	 of	16 mitochondrial	dysfunction	(Erb	et	al.	2012).	Consistent	with	these	finding,	the	authors	17 suggest	that	the	continuous	shutting	of	SCQ	requires	a	balanced	solubility	that	facilitates	18 membrane	 permeability.	 However,	 in	 contrast	 to	 their	 findings,	 neither	 a	 correlation	19 between	ATP	rescue	and	solubility	of	the	compounds,	nor	a	narrow	range	of	solubility	20 was	 observed	 with	 our	 SCQs.	 This	 suggests	 that	 SCQs	 may	 promote	 any	 other	21 compensatory	 mechanism	 within	 the	 mitochondria	 to	 maintain	 energy	 homeostasis	22 (Baracca	et	al.	2005,	Beretta	et	al.	2004).	23 
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If	 an	 SCQ	 can	 restore	 cell	 viability	 to	 100	 %	 under	 conditions	 of	 mitochondrial	1 dysfunction,	it	is	conceivable	that	this	could	correlate	to	its	ability	to	restore	cellular	ATP	2 levels.	This	notion	is	supported	by	the	observation	that	the	SCQ	idebenone	can	rescue	3 ATP	levels	under	conditions	of	mitochondrial	C-I	while	also	protecting	cell	viability	(Erb	4 et	al.	2012,	Geromel	et	al.	2002,	Gueven	et	al.	2017,	Haefeli	et	al.	2011,	Yu-Wai-Man,	et	al.	5 2017).	However,	the	results	from	the	present	study	indicate	that	for	a	large	number	of	6 SCQs,	 their	cytoprotective	capacity	does	not	correlate	with	 their	ability	 to	 rescue	ATP	7 levels	(Figure	30).	This	is	the	first	time	that	this	hypothesis	was	tested	and	my	results	8 clearly	question	this	long-held	assumption.	In	fact,	a	consistent	reduction	of	cellular	ATP	9 levels	could	not	be	demonstrated	in	LHON	cybrids	(Korsten	et	al.	2010).	Previous	in	vitro	10 and	ex	vivo	studies	also	reported	no	reduction	 in	ATP	 levels	suggesting	 that	cells	may	11 compensate	the	loss	of	ATP	levels	by	upregulating	other	pathways	for	energy	generation	12 in	 the	presence	of	mitochondrial	dysfunction	(Baracca	et	al.	2005,	Beretta	et	al.	2004,	13 Pommer	et	al.	2008).	Therefore,	 the	question	of	 the	molecular	mode	of	action	of	SCQs	14 remains	wide	open.	15 
	16 
As	a	first	step	for	a	drug	molecule	to	show	its	efficacy	in	vitro,	it	has	to	be	able	to	enter	the	17 cells	by	crossing	 the	plasma	membrane,	a	 function	 that	 is	significantly	affected	by	 the	18 solubility	 of	 the	 molecule	 (measured	 as	 logP,	 logD).	 A	 fine	 balance	 between	 both	19 hydrophilicity	and	lipophilicity	of	the	molecule	is	necessary	for	its	entry	into	the	cells,	20 which	can	influence	the	efficacy	of	the	molecule	if	the	target	is	intracellular.	A	previous	21 study	with	a	panel	of	benzoquinones	reported	that	the	logD	of	the	molecule,	rather	than	22 its	 structural	 features,	 strongly	 determined	 its	 ability	 to	 rescue	 ATP	 levels	 under	23 conditions	of	mitochondrial	dysfunction	(Erb	et	al.	2012).	In	contrast	to	this	study,	my	24 
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results	did	not	demonstrate	a	strong	association	between	cytoprotection	and	solubility	1 (Figure	29).	Compounds	that	were	at	least	as	protective	as	idebenone	fell	into	a	solubility	2 range	from	log	P	=	1	to	7	and	in	contrast	to	the	previous	study	with	benzoquinones	(Erb	3 et	al.	2012),	no	correlation	or	a	narrow	solubility	range	could	be	identified	(Figure	29).	4 The	 broad	 solubility	 range	 observed	 in	 the	 current	 study	 therefore	 only	 partially	5 supports	another	study	that	suggested	a	log	P	<	5	for	naphthoquinones	to	protect	against	6 neuronal	cell	death	due	to	oxidative	stress	and	mitochondrial	dysfunction	(Josey	et	al.	7 2013).	Although	 there	was	no	obvious	 correlation	between	 cytoprotective	 ability	 and	8 solubility	of	the	compounds,	a	complex	interplay	of	both	solubility	of	the	molecule	along	9 with	other	structural	aspects	(i.e.	quinone	core,	length	of	the	side	chain	and	the	type	of	10 functional	groups	attached	to	the	quinone	core)	that	result	 in	specific	electron	density	11 around	 the	 molecule,	 may	 allow	 some	 compounds	 to	 repeatedly	 shuttle	 through	 the	12 mitochondrial	membrane	to	rescue	ATP	levels.	13 
2.5.2	 SCQs	can	be	bioactivated	by	several	cellular	reductases		14 	15 
Once	SCQs	have	entered	the	cytoplasm,	they	are	believed	to	be	bioactivated	by	cellular	16 reductases	 such	 as	 NQO1	 to	 the	 active,	 hydroquinone	 form	 while	 simultaneously	17 producing	NAD+	 from	NADH	 (Haefeli	 et	 al.	 2011).	 In	 the	 absence	 of	 these	 2-electron-18 transferring	reductases,	SCQs	are	not	only	ineffective	as	a	cytoprotectants,	but	can	also	19 become	toxic	due	 to	semiquinone	 formation	 that	 results	 in	oxidative	stress	 (Erb	et	al.	20 2012,	 Ishihara	 et	 al.	 2012,	 O'brien	 1991).	 In	 contrast	 to	 the	 semiquinone,	 some	 fully	21 reduced	hydroquinones	can	directly	donate	electrons	to	C-III	of	the	mitochondrial	ETC.	22 Under	 conditions	 of	 C-I	 dysfunction,	 this	mechanism	 is	 particularly	 favorable,	 since	 it	23 maintains	electron	 flow	across	 the	ETC	and	enables	mitochondrial	ATP	synthesis.	For	24 
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SCQs	such	idebenone,	this	C-I	bypass	was	reported	to	be	dependent	on	NQO1	(Giorgio	et	1 al.	2012,	Haefeli	 et	 al.	2011).	 In	agreement	with	previous	 reports,	 the	majority	of	our	2 novel	SCQs	depended	on	NQO1	for	their	reduction	to	the	hydroquinone	form	(Figure	22).	3 However,	for	the	first	time,	we	demonstrate	that	in	our	compound	library,	around	20	%	4 of	our	compounds	do	not	depend	on	dicoumarol-sensitive	enzymes	(such	as	NQO1)	for	5 their	 reduction	 to	 the	 hydroquinone	 form	 (Figure	 22).	 Since	 our	 novel	 SCQs	 are	6 naphthoquinones	that	show	structural	similarity	to	VK,	it	is	conceivable	that	they	could	7 be	bioactivated	by	the	family	of	VK	reductases.	In	fact,	dependence	of	quinones	solely	on	8 NQO1	 for	 their	 bio-activation	 may	 be	 a	 matter	 of	 concern.	 Inactivating	 NQO1	9 polymorphism,	are	relatively	frequent	in	the	general	population,	with	some	ethnic	groups	10 such	 as	 the	 Chinese	 showing	 more	 than	 70	 %	 carriers	 for	 a	 single	 inactivating	11 polymorphism	 (C609T)	 (Chhetri	 et	 al.	 2018).	 In	 these	 individuals	 SCQs	 are	 likely	12 converted	 to	a	 larger	extent	 to	 the	highly	 reactive	 semi-quinone,	which	would	 induce	13 ROS-dependent	cellular	damage	(Gueven	et	al.	2015,	Jaber	and	Polster	2015,	Lewis	et	al.	14 2005).	I	hypothesized	that,	since	some	of	our	SCQs	are	reduced	by	reductases	other	than	15 NQO1	 (Figure	 22),	 this	 should	 reduce	 their	 toxicity	 compared	 to	 idebenone.	 This	 is	16 supported	by	the	IC50	data	of	our	SCQs	which	were	at	least	200	%	higher	in	high	reducing	17 capacity	cell	line,	HepG2,	when	compared	to	low	reducing	cell	line,	RGC5	(Conducted	by	18 another	 Master’s	 student,	 data	 not	 shown).	 However,	 given	 the	 large	 number	 of	19 compounds	 to	 be	 characterised	 and	 a	 general	 difficulty	 to	 assess	 in	 vitro	 toxicity	 of	20 quinones	 due	 to	 their	 interference	with	many	 standard	 viability	 assays	 (Discussed	 in	21 Chapter	4,	Section	4.2),	 it	was	not	possible	to	conduct	a	detailed	investigation	into	the	22 intrinsic	toxicity	for	all	compounds.	This	omission	has	to	be	noted	as	a	possible	limitation	23 of	 the	present	study	as	 is	currently	addressed	 in	detail	by	another	PhD	student	(Zikai	24 Feng).	However,	the	extent	of	chemical	reduction	of	SCQs	by	cellular	reductases	did	not	25 
In	vitro	characterisation	
Novel short-chain quinones against mitochondrial dysfunction                     161 
 
correlate	with	 the	measured	 cytoprotective	 or	ATP	 rescue	 activities	 of	 our	 new	SCQs	1 (Figure	31).	Therefore,	our	data	suggests	that	enzyme-dependent	reduction	of	quinones	2 may	not	actually	affect	 their	cytoprotective	abilities,	which	 is	a	surprising	 finding	and	3 quite	contrary	to	our	common	understanding	of	this	class	of	compounds.	4 
	5 
2.5.3	 Influence	of	antioxidant	activity	on	cytoprotection		6 	7 
Apart	 from	reduction	and	rescuing	ATP	levels,	quinones	 like	CoQ10	and	 idebenone	are	8 largely	believed	to	combat	free	radicals	and	hence	prevent	lipid	peroxidation	(Erb	et	al.	9 2012,	Giorgio	et	al.	2012,	Mordente	et	al.	1998).	In	contrast	to	this	widely	reported	view	10 and	previous	reports	that	supports	this	association	for	benzoquinones	(Erb	et	al.	2012,	11 Rahn	et	al.	2014),	none	of	the	novel	SCQs	in	the	present	study	significantly	affected	basal	12 levels	of	lipid	peroxidation.	Additionally,	as	the	effect	of	novel	SCQs	on	BLP	levels	did	not	13 correlate	 to	 their	cytoprotective	ability	 (Figure	32),	 for	 the	 first	 time	we	propose	 that	14 quinones	 are	 not	 just	 antioxidants,	 but	 they	 may	 be	 involved	 in	 a	 more	 complex	15 mechanism	 to	 protect	 against	 mitochondrial	 dysfunction.	 However,	 we	 have	 to	16 acknowledge	that	 the	HepG2	cell	 line	used	 for	 these	experiments	might	not	be	 ideally	17 suited	to	detect	antioxidant	effects.	HepG2	cells	are	human	liver-derived	cells	that	still	18 possess	 a	 large	 amount	 of	 their	 tissue	 heritage	 with	 regards	 to	 the	 detoxification	 of	19 xenobiotics	 (Guillouzo	 et	 al.	 2007).	 It	 is	 therefore	 not	 surprising	 that	 this	 cell	 line	20 possesses	significant	endogenous	antioxidative	defenses	(Bando	et	al.	2005)	that	might	21 make	it	impossible	to	detect	any	SCQ-induced	antioxidant	effects.	However,	my	results	22 and	interpretation	are	still	valid	since	we	observed	SCQ-induced	cytoprotection	 in	the	23 same	cell	line,	irrespective	of	their	endogenous	antioxidant	potential.	This	supports	my	24 
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interpretation	that	antioxidative	function	appears	to	be	irrelevant	for	cytoprotection	by	1 our	SCQs.	2 
	3 
2.5.4	 Effect	of	SCQs	on	different	energy	generating	pathways		4 	5 
To	get	a	deeper	insight	into	the	mechanism	of	action	of	the	novel	SCQs,	I	characterised	6 them	against	some	major	parameters	that	are	likely	to	be	influenced	by	mitochondrial	7 dysfunction,	such	as	lactate	and	ketone	levels.	Mitochondrial	dysfunction	forces	cells	to	8 meet	energy	demands	by	utilising	alternative	mechanisms,	such	as	increasing	the	rate	of	9 glycolysis.	Increased	glycolysis	requires	increased	levels	of	NAD+,	that	are	needed	for	the	10 central	 step	 of	 glycolysis,	 the	 conversion	 of	 glyeraldehyde-3-phosphate	 to	 1,3-11 bisphosphoglycerate.	Typically,	 this	NAD+	 is	supplied	by	the	conversion	of	pyruvate	to	12 lactate	(Figure	8	from	Chapter	1).	Although,	the	production	of	lactate	during	glycolysis	is	13 generally	seen	as	a	cytotoxic	byproduct	of	this	process	(Bodmer	et	al.	2008,	Brewer	1998,	14 Davidson	et	al.	1981,	Dienel	and	Hertz	2001,	Kaufmann	et	al.	2004,	Walker	et	al.	2009)	15 and	 a	 “dead-end”	 reaction,	 recent	 evidence	 suggests	 that	 cells	 from	 isolated	 rat	 liver,	16 cardiac	and	skeletal	muscle	oxidise	pyruvate	and	lactate	for	generating	energy	(Brooks	17 et	al.	1999,	Brooks	2016).	This	is	supported	by	an	abundance	of	lactate	oxidation	complex	18 in	rat-derived	muscle	cells	 (Hashimoto	et	al.	2006).	 In	 fact,	 lactate	was	described	as	a	19 preferred	energy	source	in	primary	neuronal	cultures	(Pellerin	2003)	and	in	vivo,	in	glial	20 cells	 in	 Cox10	 (protoheme	 IX	 farnesyltransferase)	 mutant	 mice	 (Feron	 2009,	21 Fünfschilling	et	al.	2012).	22 
Since	the	reduction	of	SCQs	by	cellular	reductases	is	also	accompanied	by	the	production	23 of	NAD+	from	NADH,	this	process,	at	least	in	theory,	could	replace	the	cellular	need	for	24 
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lactate	production.	If	this	scenario	could	be	induced	by	SCQs,	the	accumulation	of	lactate	1 in	cellular	supernatant	should	be	reduced.	This	hypothesis	is	supported	by	idebenone-2 induced	 reduced	 lactate	 levels	 in	 cybrids	 from	MELAS	 patients	 (Haefeli	 et	 al.	 2011).	3 However,	another	SCQ,	EPI-743	did	not	influence	lactate	levels	in	the	blood	of	LS	patients,	4 after	6	months	of	treatment	(Pastore	et	al.	2013).	Supporting	the	current	evidence,	n	this	5 study,	despite	a	general	reduction	of	all	novel	SCQs	in	cells,	only	some	of	the	SCQs	with	6 amino	acids	attached	to	the	alkyl	side-chain	significantly	decreased	lactate	levels	in	the	7 present	 study,	 while	 SCQs	 with	 aliphatic	 ester	 attached	 to	 the	 alkyl	 side-chain	8 significantly	 increased	 lactate	 levels	 in	 the	 cell	 culture	 supernatant	 (Figure	 25).	 In	9 addition,	no	obvious	correlation	between	protection	of	cellular	viability	and	the	influence	10 of	SCQ	on	lactate	levels	could	be	demonstrated	(Figure	33).	Despite	an	upregulation	of	11 lactate	levels	by	175	%	by	SCQs,	some	of	these	compounds	still	protected	viability	up	to	12 60	%,	whilst	 the	same	was	toxic	 for	other	SCQs.	Even	the	compounds	that	showed	no	13 changes	 on	 lactate	 levels	 compared	 to	 sham-treated	 cells,	 protected	 viability	 ranging	14 from	more	 than	90	%	 to	 less	 than	30	%	of	 sham	 treated	 cells.	 These	 results	 strongly	15 suggest	 that	 any	 effect	 by	 an	 SCQ	 on	 the	 accumulation	 of	 lactate	 in	 cell	 culture	16 supernatant	is	independent	of	the	SCQs	ability	to	protect	against	cellular	viability.		17 
An	alternate	source	of	cellular	energy	is	the	use	of	fatty	acids	via	β-oxidation	(Figure	5)	18 (Nelson	et	al.	2008).	While	this	process	happens	in	most	cells	to	different	degrees,	some	19 tissues	such	as	cardiac	tissue	satisfy	their	energy	demands	near	exclusively	from	fatty	20 acids	(Lopaschuk	et	al.	2010,	Watanabe	et	al.	2000).	Fatty	acids	are	a	high-energy	source	21 but	its	use	is	associated	with	increased	oxygen	demands	(Lopaschuk	et	al.	2010,	McGarry	22 and	Foster	1980).	A	high-fat,	low	carbohydrate	diet	called	ketogenic	diet,	recently	gained	23 a	lot	of	attention	due	to	its	reported	ability	to	protect	against	mitochondrial	dysfunction	24 (Lutas	and	Yellen	2013,	Wang	et	al.	2018).	Rodent	studies	showed	that	ketogenic	diet	25 
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decreased	oxidative	stress	and	increased	mitochondrial	mass,	associated	with	improved	1 mitochondrial	bioenergetics	(Bough	et	al.	2006,	Sullivan	et	al.	2004).	Although	the	exact	2 mechanism	of	how	fatty	acid	oxidation	combats	mitochondrial	dysfunction	is	not	known,	3 BHB	 decreased	 ROS	 production	 in	 vitro	 (Maalouf	 et	 al.	 2007)	 and	 ketone	 bodies	4 prevented	ROS-induced	cell	death	(Kim	et	al.	2007).	In	fact,	2	weeks	of	treatment	with	5 idebenone	slightly	increased	(p<0.05)	BHB	levels	in	the	blood	of	mice	(Unpublished	data,	6 N.	Gueven).	The	fact	that	five	out	of	seven	groups	of	novel	SCQs	increased	basal	ketone	7 levels	in	cell	culture	supernatant	upon	treatment	(Figure	27),	could	indicate	that	these	8 SCQs	may	promote	fatty	oxidation	as	a	source	of	energy.	Although	it	is	conceivable	that	9 the	increased	BHB	levels	could	be	cytoprotective	in	the	test	systems	of	the	present	study,	10 the	 influence	 of	 SCQs	 on	 the	 extent	 of	 BHB	 accumulation	 in	 cell	 supernatant	 did	 not	11 correlate	with	their	cytoprotective	effects	(Figure	33).	12 
Our	results	on	the	effect	of	SCQs	on	the	accumulation	of	lactate	or	ketone	levels	in	cellular	13 supernatant	suggest	 that	 the	mechanism	of	action	of	 these	SCQs	 in	protecting	cellular	14 viability	is	not	as	simple	donating	additional	electrons	to	ETC	or	maintaining	NAD+	levels	15 or	upregulating	BHB	levels.		16 
	17 
Overall,	more	than	20	novel	SCQs	were	significantly	more	effective	in	protecting	cellular	18 viability	compared	to	idebenone.	I	showed	that	novel	SCQs	can	be	bioactivated	by	other	19 cellular	reductases	apart	from	NQO1,	that	they	may	act	as	anti-oxidants	and	alter	lactate	20 and	 BHB	 levels	 in	 cell	 culture	 supernatant	 (Table	 7).	 However,	 since	 none	 of	 these	21 parameters	correlated	with	their	cytoprotective	activity,	this	strongly	suggests	that	these	22 individual	 factors	 are	 not	 related	 to	 the	 compounds’	 cytoprotective	 effects	 in	 the	23 presence	 of	 a	 C-I	 dysfunction.	 Surprisingly,	 slight	 differences	 in	 the	 structures	 of	 the	24 
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molecules	 did	 significantly	 influence	 their	 cellular	 effects.	 Therefore,	 the	 exact	1 mechanism	of	action	of	our	cytoprotective	SCQs	remains	unknown.		2 
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Table	7:	Overview	of	the	influence	of	SCQs	on	the	various	end-point	assays	
Functional	
group	
Protection	of	
viability	(%	Control)	
Acute	ATP	Rescue	
(%	Control)	
Reduction	by	cellular	
enzymes	(%)	
Basal	lipid	
peroxidation		 Lactate	levels		 BHB	levels		
A	 42.6	±	23.7	**	 49.2	±	30.9	**	 0.185	±	0.194	 0.93	±	0.08	 86.1	±	26.7	 2.5	±	1.1	###	
B	 36.3	±	20.4	 26.6	±	27.9	 0.053	±	0.057	 0.95	±	0.06	 79.4	±	30.0	 3.1	±	4.6	
C	 49.9	±	21.8	***	 51.7	±	33.8	**	 0.019	±0.033	 0.96	±	0.03	 72.0	±	29.6	 2.0	±	0.5	##	
D	 15.7	±	3	 15.1	±	6.9	 0.021	±	0.016	 0.95	±	0.05	 98.4	±	23.2	#	 1.8	±	0.7	
E	 64.8	±	8.2	***	 81.9	±	12.6	***	 0.150	±	0.115	 0.94	±	0.05	 63.2	±	13.6	 2.0	±	0.9	##	
F	 69.7	±	25.6	***	 59.4	±	12.6	***	 0.031	±	0.017	 0.92	±	0.06	 55.3	±	8.3	#	 1.9	±	0.4	#	
G	 76.5	±	15.9	***	 84.3	±	9	***	 0.223	±	0.104	 0.93	±	0.07	 59.8	±	18.7	 1.8	±	0.6	#		A:	Slight	polarity;	B:	Aliphatic;	C:	Acid;	D:	Aliphatic	ester;	E:	Amino	ester;	F:	Amino	acid;	G:	Amino	alcohol.	Each	value	represents	mean	±	S.D.	for	each	SCQ	(n=3	independent	experiments	with	6	replicates	within	each	experiment.	Student	t-test	to	compare	the	cytoprotection	by	SCQs	versus	rotenone-only	treated	cells	(p*	<0.05,	p**<0.01,	p***<0.001)	and	the	effect	of	SCQs	on	lipid	peroxidation,	lactate	and	beta-hydroxy	butyrate	(BHB)	levels	against	sham-treated	(no	SCQ)	cells	(p#	<0.05,	p##<0.01,	p###<0.001).
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All	endpoints	tested	in	this	study	appear	to	be	unrelated	to	the	cytoprotective	activity	of	1 the	 SCQs,	which	negatively	 affects	 the	 rational	 development	 of	 improved	 compounds.	2 Unless	new	mode(s)	of	action	or	even	protein	targets	are	identified,	progress	in	this	field	3 will	be	hampered	by	this	problem.	A	recent	patent	might	however	provide	a	new	lead	4 (Cortopassi	 and	 Tomilov	 2017).	 In	 this	 patent	 (patent	 number	 US	 9,750,705	 B2)	 the	5 benzoquinone	 idebenone	 is	 described	 as	 a	 potent	 inhibitor	 of	 p52Shc.	 Shc	 is	 an	6 intracellular	signaling	protein	that	is	a	part	of	a	larger	family	of	adaptor	proteins	that	are	7 involved	in	the	differentiation	and	mitogenic	signaling	of	a	range	of	receptor	kinases	to	8 downstream	 signaling	 entities.	 These	 receptors	 include	 the	 epidermal	 growth	 factor	9 receptor	 (EGFR),	nerve	growth	 factor	 receptor	 (NGFR),	platelet-derived	growth	 factor	10 receptor	(PGDFR)	and	the	insulin	receptor.	Upon	activation	of	the	receptor,	p52Shc	binds	11 to	 the	phosphorylated	receptor	 leading	a	 signaling	cascade	 that	ultimately	 lead	 to	 the	12 inhibition	of	mitogen-activated	protein	kinase	(MAPK)	pathway,	 that	 leads	 to	reduced	13 proliferation	(Ravichandran	2001,	Thomas	et	al.	1995).	14 
The	data	 in	 the	patent	describe	administering	a	p52Shc	antagonist	 like	 idebenone	 for	15 treating	 insulin	 sensitivity,	 impaired	 glucose	 tolerance	 or	 diabetes.	 Idebenone	 was	16 claimed	 to	 significantly	 inhibit	 p52Shc	 activation	 at	 nanomolar	 concentrations	 and	17 stimulate	insulin	sensitivity	in	vitro	and	in	vivo	in	a	dose	dependent	manner.	Idebenone,	18 administered	 to	 mice	 at	 20	 and	 50	 mg/kg	 PO	 was	 also	 claimed	 to	 increase	 insulin-19 dependent	phospho-Akt	 and	AMP-activated	protein	kinase	 (AMPK)	 activity	 in	 a	dose-20 dependent	manner.	Akt	activation	is	generally	seen	to	induce	a	survival	signal	(Gerber	et	21 al.	 1998,	 Wang	 et	 al.	 2000)	 and	 AMPK	 activation	 typically	 leads	 to	 mitogenesis	22 (Cortopassi	and	Tomilov	2017).		Consistent	with	this	model,	mice	with	reduced	p52Shc	23 expression	show	increased	brown-adipose	tissue	and	an	improved	survival	rate.	There	24 are	also	unpublished	observations	that	idebenone	can	increase	mitochondrial	mass	and	25 
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reduce	 proliferation	 in	 primary	 human	 muscle	 cells	 (N.	 Gueven,	 unpublished	1 observation).	 Therefore,	 p52Shc	 appears	 to	 regulate	 cellular	 survival,	mitogenesis,	 as	2 well	as	mitogenic	signals	(Atwal	et	al.	2000,	Besset	et	al.	2000,	Nelson	et	al.	2003,	Patrussi	3 et	al.	2005).	The	proposed	model	also	 suggests	 that	 inhibition	of	p52Shc	protein	may	4 increase	 insulin	 sensitisation	 and	 also	 increase	 fatty	 acid	 oxidation.	 Intriguingly,	 in	5 support	of	this	model,	insulin	sensitisation	by	idebenone	has	been	confirmed	in	vivo	(N.	6 Gueven,	 unpublished	 observation).	However,	 despite	 this	 evidence,	 the	 exact	 p52Shc-7 dependent	 signaling	mechanism	 that	would	 protect	 against	 the	 rotenone-induced	 C-I	8 dysfunction	in	our	cell	culture	model	remains	unclear	(Figure	37).	It	also	has	to	be	noted	9 that	these	results	are	derived	from	a	patent	and	have	not	been	published	yet.	Therefore,	10 they	 constitute	 non-peer-reviewed	 information	 that	 first	 has	 to	 be	 confirmed	11 independently.	Nevertheless,	the	fact	that	idebenone	might	significantly	decrease	p52Shc	12 activation	suggests	that	our	novel	structurally	similar	SCQs	could	have	similar	effects	on	13 Shc.	14 
	15 
	16 
	17 
	18 
	19 
	20 
	21 
	22 
	23 
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	1 
Figure	37:	Effect	of	SCQ,	idebenone	on	p52Shc.	Idebenone	inhibits	the	association	of	p52Shc	2 with	receptor	tyrosine	kinases,	which	in	turn	decreases	mitogenesis	and	activates	Akt-signaling	3 thereby	leading	to	an	increased	glucose	metabolism	and	cellular	survival.		4 IRS,	 insulin	 receptor	 substrates;	MAPK,	mitogen	 activated	 protein	 kinase;	 PI3K,	 phosphotidyl	5 inositol-3-kinase.	6 	7 
Another	potential	mechanism	of	action	of	the	novel	SCQs	was	just	recently	described.	In	8 a	mouse	model	of	retinal-ischemic	reperfusion	(RIR)	injury	idebenone	strongly	induced	9 Lin28A	 expression	 (Lei	 et	 al.	 2018).	 Together	with	 rasagiline,	 idebenone	 significantly	10 restored	retinal	thickness	and	retinal	ganglion	cell	survival,	which	was	associated	with	11 restored	visual	function	in	these	mice	(Lei	et	al.	2018).	This	effect	was	dependent	on	the	12 drug-induced	upregulation	of	Lin28A.	A	potential	mode	of	action	that	involves	Lin28A	is	13 
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an	attractive	possibility	to	explain	the	pleiotropic	effects	of	this	class	of	compounds	since	1 overexpression	 of	 Lin28A	 is	 reported	 to	 increase	 OXPHOS,	 insulin	 sensitivity,	2 neurogenesis	and	tissue	repair	in	general	(Shyh-Chang	et	al.	2013,	Zhu	et	al.	2011).	It	is	3 also	involved	in	glucose	metabolism	via	the	insulin-PI3K-mTOR	pathway	(Zhu	et	al.	2011)	4 and	the	ageing	process	(Jun-Hao	et	al.	2016)	but	most	importantly	Lin28A	defines	stem-5 ness	in	several	tissues	as	one	of	the	key	pluripotency	markers	(Shyh-Chang	and	Daley	6 2013).	 In	 another	 rodent	model,	 overexpression	of	 Lin28A	 in	diabetic	mice	 alleviated	7 mitochondrial	 dysfunction,	 enhanced	 ATP	 levels,	 ETC	 complex	 activities	 and	 also	8 inhibited	the	apoptosis	of	cardiomyocytes	when	compared	to	sham-diabetic	mice	(Sun	et	9 al.	 2016).	 Therefore,	 since	 our	 novel	 SCQs,	 belonging	 to	 the	 same	 chemical-class	 as	10 idebenone,	they	could	also	have	a	potential	effect	on	Lin28A	expression	to	improve	cell	11 viability	in	the	presence	of	mitochondrial	dysfunction.	However	upregulating	Lin28A	is	a	12 double-edged	 sword,	 since	 it	 is	 described	 to	 be	 an	 excellent	 marker	 for	 invasive	13 malignant	forms	of	a	large	range	of	cancers	(Balzeau	et	al.	2017).	Therefore,	it	would	be	14 surprising	 to	see	 it	associated	with	a	drug	such	as	 idebenone	with	an	excellent	 safety	15 profile	 and	 no	 indication	 at	 all	 that	 it	 could	 induce	 or	 promote	 the	 development	 of	16 malignancies	 in	 patients.	 Furthermore,	 Lin28A	 expression	 is	 generally	 described	 as	17 promoting	proliferation,	which	is	in	stark	contrast	to	the	effect	of	p52Shc-inhibition	and	18 our	 unpublished	 data	 showing	 reduced	 proliferation	 described	 above.	 Similar	 to	 the	19 evidence	for	p52Shc	inhibition,	it	has	to	be	noted	that	the	idebenone-Lin28A	interaction	20 was	so	far	only	described	in	a	single	paper	and	therefore	has	to	be	regarded	with	caution.	21 Whether	both	of	those	activities	described	for	idebenone	can	be	extended	to	our	SCQs	22 and	apply	to	other	models	and	even	tissues	remain	to	be	seen.	23 
	24 
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2.5.5	 Structure-activity	relationship	of	novel	SCQs		1 	2 
Although	the	mito-protective	properties	of	quinones	have	been	studied	for	decades	now,	3 the	 structure-activity	 relationship	 (SAR)	 of	 quinones	 has	 not	 been	 evaluated	 in	 great	4 detail	 based	 on	 the	 published	 literature.	 Using	 our	 novel	 SCQs,	 I	 worked	 towards	5 establishing	an	SAR	based	on	cytoprotection	and	acute	rescue	of	ATP	levels	by	SCQs	in	6 the	presence	of	the	mitochondrial	C-I	inhibitor,	rotenone	(Figure	30).	Despite	previous	7 claims	that	quinones	protect	cell	viability	by	rescuing	ATP	levels,	our	results	indicated	no	8 obvious	correlation	between	the	two	parameters	(Figure	30).	We	initially	started	with	9 SCQs	that	contained	slightly	polar,	aliphatic,	aliphatic	esters	and	acid	side-chain	groups.	10 These	compounds	generally	showed	a	wide	spread	across	the	correlation	plot	(Figure	30).	11 Although	SCQs	with	an	aliphatic	ester	side	chain	group	tightly	grouped	in	the	correlation	12 plot,	they	were	neither	cytoprotective	nor	could	they	rescue	ATP	levels.	Based	on	these	13 results,	the	next	compounds	were	generated	with	increased	polarity	by	adding	an	amino	14 fragment	at	the	end	of	the	alkyl	chain,	which	resulted	in	a	noticeable	trend	in	their	activity	15 by	 increasing	 both	 cell	 viability	 and	 ATP	 levels	 (Figure	 30).	 Although	 there	 was	 no	16 correlation	between	cytoprotection	and	acute	rescue	of	ATP	levels		(Figure	30),	addition	17 of	the	amino	ester	significantly	improved	both	cytoprotection	and	acute	rescue	of	ATP	18 levels,	when	compared	to	rotenone-only	treated	cells	(Figure	19).	These	results	formed	19 the	 basis	 of	 generating	 the	 amino	 alcohol-containing	 compounds	 with	 intermediate	20 polarity.	 Consistent	 with	 the	 previous	 results,	 SCQs	 with	 a	 terminal	 amino	 alcohol	21 functional	group	on	the	side	chain	protected	cell	viability	and	also	rescued	ATP	 levels	22 significantly	better	 than	 rotenone-only	 treated	cells	 (Figure	30).	Overall,	 these	 results	23 suggested	that	the	polarity	of	the	compounds	is	extremely	important	for	their	ability	to	24 protect	cell	viability	and	rescue	ATP	levels.		25 
In	vitro	characterisation	
Novel short-chain quinones against mitochondrial dysfunction                     172 
 
Quinones	 like	 CoQ10,	 idebenone	 and	 MitoQ	 contain	 an	 alkyl	 side	 chain	 attached	 to	1 ubiquinone	core,	while	MitoQ	and	SkQ1	contain	a	terminal	triphenyl	phosphonium	ion	2 attached	to	alkyl	side	chain	that	is	believed	to	target	the	molecule	into	mitochondria.	The	3 novel	 SCQs	 of	 this	 study	were	 optimized	 by	 exclusively	 altering	 the	 functional	 group	4 attached	 to	 the	 alkyl	 side-chain	 while	 containing	 the	 same	 naphthoquinone	 core.	 To	5 understand	 the	 importance	 of	 the	 quinone	 core	 for	 the	 compounds	 cytoprotective	6 activities,	 five	of	 the	best	compounds	(based	on	cytoprotection	and	ATP	rescue)	were	7 selected	 where	 the	 naphthoquinone	 core	 was	 replaced	 with	 ubiquinone	 and	8 plastoquinone	cores	respectively.	Overall	most	compounds	with	a	naphthoquinone	core	9 showed	 superior	 cytoprotection	 (Figure	34).	These	 results	 suggest	 that	 the	particular	10 combinations	 of	 naphthoquinone	 core	 and	 specific	 functional	 side	 chain	 groups	were	11 responsible	for	the	excellent	cytoprotective	ability	of	some	of	these	compounds.	To	our	12 knowledge,	this	is	the	first	time	that	this	direct	comparison	has	been	performed	as	most	13 investigators	 typically	only	compare	different	 side	chains	attached	 to	a	given	quinone	14 core	(Erb	et	al.	2012,	Rahn	et	al.	2014).	15 
The	next	structural	parameter	studied	was	the	importance	of	methyl	group	attached	to	16 the	 quinone	 core	 on	 position	 X	 (Figure	 35).	 The	 majority	 of	 the	 currently	 clinically	17 developed	quinones	including	CoQ10,	 idebenone,	MitoQ	and	EPI743	contain	the	methyl	18 group	 at	 position	 X,	 however	 this	 is	 absent	 in	 SkQ1	 and	 some	 reported	 Vitamin	 K	19 analogues	(Josey	et	al.	2013).	When	the	methyl	group	of	the	naphthoquinone	core	of	five	20 selected	naphthoquinone	was	replaced	with	a	hydrogen	or	hydroxyl	group	(Figure	35),	21 in	most	of	the	cases,	the	compounds	with	methyl	group	showed	significantly	increased	22 cytoprotection	compared	to	compounds	with	hydrogen	or	hydroxyl	groups.	Chemically,	23 it	 is	 conceivable	 that	 the	 presence	 of	 the	methyl	 group	 could	 potentially	 prevent	 the	24 metabolism	of	the	naphthoquinone	core.	However,	I	must	acknowledge	that	the	SAR	of	25 
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SCQs	discussed	 so	 far	would	apply	only	 to	our	novel	naphthoquinones	and	cannot	be	1 extended	to	other	quinones	such	as	benzoquinones	without	additional	experiments.	2 
	3 
2.6	 Conclusion	4 	5 
In	this	study,	we	successfully	developed	novel	short-chain	naphthoquinones	to	protect	6 against	mitochondrial	dysfunction.	For	 the	 first	 time,	we	could	generate	a	SAR	 for	 the	7 particular	 class	 of	 SCQs	 of	 the	 present	 study.	 The	 precise	 combination	 of	 a	8 naphthoquinone	core	with	a	methyl	group	and	an	alkyl	side	chain	with	specific	functional	9 groups	 of	 balanced	 charge	 and	 polarity	 determined	 their	 cytoprotective	 activity.	 The	10 developed	SCQs	protected	cellular	viability	and	rescued	ATP	levels	in	the	presence	of	a	11 mitochondrial	 C-I	 inhibitor,	 while	 influencing	 lactate	 and	 BHB	 levels	 in	 cell	 culture	12 supernatant	but	not	affecting	basal	lipid	peroxidation.	Importantly,	none	of	the	measured	13 parameters	correlated	with	the	cytoprotective	activities	observed.	Therefore,	in	contrast	14 to	the	current,	possibly	over-simplified	assumption	that	rescuing	ATP	levels	and	reducing	15 oxidative	stress	are	central	to	restoring	cell	viability,	my	results	suggest	that	SCQs	likely	16 act	 in	 a	 more	 complex	 fashion	 that	 could	 involve	 recently	 described	 novel	 signaling	17 pathways,	including	the	signaling	proteins	like	p52Shc	or	Lin	28A	(Figure	38).	18 
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Figure	 38:	 Influence	 of	 short-chain	 quinones	 on	 various	 metabolic,	 regulatory	 and	
signaling	 pathways	 that	 could	 potentially	 result	 in	 protecting	 cellular	 viability	 against	mitochondrial	dysfunction.		
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Chapter	3:	 	 Efficacy	of	 selected	 short-chain	quinones	3 
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3.1 	 Overview	and	rationale	1 	2 
The	in	vitro	results	described	in	the	previous	chapter	indicate	that	selected	novel	short-3 chain	 quinones	 (SCQs)	 restore	 cellular	 viability	 in	 vitro	 to	 almost	 100	%	 and	 rescue	4 adenosine	triphosphate	(ATP)	levels	in	the	presence	of	the	mitochondrial	complex-I	(C-I)	5 inhibitor,	rotenone.	In	order	to	translate	my	in	vitro	findings	to	an	in	vivo	disease	model,	6 two	 selected	 novel	 SCQs	 were	 tested	 in	 a	 mouse	 model	 of	 Leber’s	 hereditary	 optic	7 neuropathy	(LHON),	where	previously,	the	structurally	related	benzoquinone,	idebenone	8 significantly	 improved	 visual	 acuity	 (Heitz	 et	 al.	 2012).	 This	 experimental	model	was	9 particularly	 attractive,	 since	 blindness	 is	 induced	 by	 a	 single	 intraocular	 rotenone	10 injection	into	only	one	eye.	This	approach	does	not	lead	to	any	obvious	adverse	off-target	11 side	effects,	while	visual	acuity	can	be	measured	by	a	simple,	non-invasive,	behavioral	12 read-out	 (Heitz	 et	 al.	 2012).	 The	 cytoprotective	 ability	 of	 our	 novel	 SCQs	 along	with	13 positive	 results	 from	 the	 previously	 published	 study	 presented	 a	 strong	 rationale	 to	14 progress	some	of	our	best	SCQs	to	this	in	vivo	disease	model.	Therefore,	in	this	chapter,	15 the	efficacy	of	selected	novel	SCQs	in	this	murine	model	of	LHON	will	be	discussed.	16 
LHON	is	a	rare	inherited	mitochondrial	disorder,	caused	by	mutations	in	genes	that	code	17 for	 subunits	 of	 C-I	 of	 the	 mitochondrial	 electron	 transport	 chain	 (ETC).	 LHON	 is	18 characterised	by	an	acute	loss	of	visual	acuity	and	impaired	colour	vision	(Yu-Wai-Man	19 et	al.	2011)	(Detailed	in	section	1.2.1).	While	the	vision	loss	in	most	patients	is	permanent,	20 there	is	a	limited	chance	of	spontaneous	vision	recovery	that	can	occur	up	to	several	years	21 after	disease	onset	in	some	patients	(Spruijt	et	al.	2006,	Stone	et	al.	1992).	Therefore,	it	22 was	 hypothesized	 that	 the	 time	 interval	 between	 disease	 onset	 and	 spontaneous	23 recovery	could	enable	the	restoration	of	visual	acuity	using	pharmacological	approaches	24 
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(Gueven	 2014).	 Nevertheless,	 recent	 advances	 in	 our	 understanding	 of	 the	 disease	1 pathology	of	LHON	are	yet	 to	be	 translated	 in	 to	 safe	 and	effective	 treatment	options	2 while	 only	 a	 very	 limited	 number	 of	 therapeutic	 approaches	 for	 LHON	 patients	 are	3 currently	in	development	(Table	10).	4 
In	pre-clinical	studies,	idebenone	was	shown	to	be	a	potent	antioxidant,	inhibited	lipid	5 peroxidation	(Suno	and	Nagaoka	1984,	Yu-Wai-Man	et	al.	2017)	and	rescued	ATP	levels	6 by	 bypassing	 dysfunctional	 C-I	 in	 human	 hepatoma	 cells	 (HepG2),	 primary	 mouse	7 hepatocytes	(Erb	et	al.	2012,	Haefeli	et	al.	2011)	and	primary	fibroblast	cell	lines	from	8 LHON	 patients	 (Yu-Wai-Man	 et	 al.	 2017)	 (Detailed	 in	 section	 1.3).	 Based	 on	 these	9 promising	results	that	appear	to	overcome	the	central	molecular	defect	of	the	molecular	10 LHON	 pathology,	 idebenone	 was	 progressed	 to	 clinical	 trials.	 The	 first,	 phase	 2,	11 randomised,	double-blind,	placebo-controlled	study	(NCT00747487)	ever	performed	in	12 LHON	patients	included	85	patients	with	up	to	five	years	since	the	onset	of	vision	loss	13 (Klopstock	et	al.	2011).	Of	those,	55	patients,	were	treated	with	idebenone	(900	mg/day;	14 t.i.d.),	while	30	patients	received	a	corresponding	placebo.	The	primary	end-point	of	this	15 study,	 best	 recovery	 of	 visual	 acuity	 from	 the	 baseline	 to	 6	 months,	 did	 not	 show	16 statistically	significant	differences.	This	was	not	necessarily	surprising	given	that	some	17 patients	had	been	legally	blind	for	several	years	and	were	likely	in	the	chronic,	atrophic	18 state	of	the	disease	that	is	characterized	by	irreversible	loss	of	retinal	ganglion	cells	(RGC).	19 However,	a	post-hoc	responder	analysis	conducted	for	secondary	end	points	suggested	20 an	increase	in	visual	acuity	in	a	subgroup	of	patients.	Especially	in	patients	that	had	only	21 recently	experienced	a	decline	 in	visual	acuity	 in	 line	with	 the	natural	disease	course,	22 idebenone	appeared	to	protect	against	further	vision	loss	and	in	some	cases	significantly	23 restored	visual	acuity	when	compared	to	placebo	treated	patients	(Table	10)	(Klopstock	24 et	 al.	 2011).	 A	 follow-up	 study	 showed	 that	 this	 protective	 effect	 of	 idebenone	 was	25 
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maintained	 for	30	months	after	 the	 therapy	had	been	 terminated.	Consistent	with	 the	1 previous	report,	a	larger	treatment	effect	was	observed	in	patients	where	treatment	was	2 commenced	within	1	year	after	the	onset	of	disease	(Klopstock	et	al.	2013).	Idebenone	3 also	 improved	 tritan	 colour	 vision	 in	 a	 randomised	 double-blind,	 placebo-controlled	4 study	on	LHON	patients	(Rudolph	et	al.	2013).	The	effects	were	more	profound	in	patients	5 younger	than	30	years	and	with	less	than	one	year	since	the	onset	of	loss	of	colour	vision	6 (Rudolph	et	al.	2013).	7 
In	addition	to	idebenone	several	other	approaches	have	been	trialled	in	LHON	so	far.	In	8 contrast	 to	 idebenone,	 the	 Vitamin	 E-derived	 quinone	 EPI-743	 did	 not	 show	 any	9 significant	improvements	in	visual	acuity	in	small,	open-label	studies	(detailed	in	section	10 1.3.4)	 (Enns	 et	 al.	 2012,	 Sadun	 et	 al.	 2012).	 In	 another	 small	 study,	 6	 out	 of	 9	 LHON	11 patients	 (11778G>A	mutation)	showed	significantly	 increased	visual	acuity	and	visual	12 field	size	in	response	to	a	gene	therapy	approach	that	utilized	adeno-associated	virus	to	13 introduce	an	intact	ND4	subunit	of	C-I	(rAAV2-ND4)	(Table	10)	(Wan	et	al.	2016).	14 
	Other	molecules	such	as	cyclosporine	and	RP-103	have	also	been	tested	in	LHON	patients	15 (Table	10),	however,	they	did	not	result	in	any	improvement	in	visual	acuity	(Leruez	et	16 al.	2018,	Mancuso	et	al.	2010).	Currently,	there	are	five	ongoing	clinical	trials	in	LHON,	17 three	using	gene	therapy,	one	using	MTP-131	and	another	phase	4	trial	with	idebenone	18 (Table	10).		19 
Overall,	the	results	from	the	few	clinical	trials,	particularly	from	the	trial	using	idebenone	20 (NCT00747487),	support	the	hypothesis	that	targeting	mitochondrial	dysfunction	could	21 in	principle	be	beneficial	to	treat	LHON	patients	but	require	more	efficacious	molecules	22 and/or	strategies.		23 
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Table	10:	Therapeutic	approaches	in	clinical	trials	to	treat	LHON	(Status	July	2018)	
Treatment	
Trial	
identifier	 Study	type	
No.	of	
subjects	
Trial	
status	 Outcome	measurement	 Result	 Sponsor	
Idebenone	(900	mg/day)	 NCT00747487	
Phase	 2,	interventional,	randomised,	 double-blind,	 placebo-controlled,	 parallel	assignment	
85	 Completed	
Primary	 end-point,	 recovery	of	 visual	 acuity	 did	 not	 reach	statistical	 significance.	 Colour	contrast	and	retinal	thickness	improved	 significantly	 when	compared	 to	 placebo	(Klopstock	et	al.	2011).	
Primary	end-point	not	 met,	secondary	end-point	improved	significantly	
Santhera	Pharmaceuticals	
Curcumin	(500	mg/day)	 NCT00528151	
Phase	 3,	interventional,	randomised,	 double	blind,	 placebo-controlled	 parallel	assignment	
70	 Completed	 Expected:	 Improvement	 in	visual	acuity.	 N/A	 Mahidol	University	
rAAV2-ND4		 NCT01267422	 Interventional,	 open	label,	 single	 group	assignment	 9	 Completed	
No	adverse	events	reported,	6	patients	 showed	improvement	 in	 visual	 acuity	(Wan	et	al.	2016).	 End-point	met	
Huazhong	University	 of	Science	 and	Technology	
RP	103	(0.2-1.3	g/m2/d)	 NCT02023866	 Phase	 2,	interventional,	 open-label,	 single	 group,	dose-escalating	study.	 36	 Completed	
Significantly	 reduced	oxidative	 stress	 but	 no	significant	 improvement	 in	clinical	 scale	or	quality	of	 life	(Mancuso	et	al.	2010).	
End-point	not	met	 Horizon	Pharma	USA,	Inc.	
KH	176	(dose	N/A)	 NCT02544217	 Phase	 1,	interventional,	randomised,	 double- 30	 Completed	 KH176	was	well	 tolerated	 up	to	 800	 mg/d,	 however	significant	 changes	 in	 cardiac	 End-point	met	 Khondrion	BV	
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blind,	 placebo-controlled	 dose	escalating.	 electrophysiology	 were	observed	 at	 2000	 mg/d	 in	healthy	 volunteers	 (Koene	 et	al.	2017).		Cyclosporine	A	(2.5	mg/kg/day)	 NCT02176733	 Interventional,	 open	label,	 single	 group	assignment	 5	 Completed	
Oral	 cyclosporine	 did	 not	prevent	 second-eye	involvement	 (Leruez	 et	 al.	2018).	 End-point	not	met	 University	Hospital,	Angers	Idebenone	(900	mg/day)	 NCT01495715	 Phase	3,	interventional	 N/A	 Withdrawn	 N/A	 N/A	 Santhera	Pharmaceuticals	RP	103	(0.2-1.3	g/m2/d)	 NCT02473445	 Phase	 2,	 long-term,	open-label	 extension	study	 to	assess	 safety,	tolerability	 22	 Terminated	
Terminated	 due	 to	 lack	 of	efficacy	 in	 base	 study	(NCT02023866)	 End-point	not	met	 Horizon	Pharma	USA,	Inc.	
Idebenone	(dose	N/A)	 NCT02774005	 Phase	 4,	interventional,	 open	label,	 single	 group	assignment	 250	 Ongoing	
Expected:	 Safety	 and	 efficacy	of	 long-term	 idebenone	treatment	 N/A	 Santhera	Pharmaceuticals	
MTP	131	(1	%	ophthalmic	solution)	 NCT02693119	
Phase	 2,	interventional,	randomised,	 double-blind,	 placebo-controlled,	 parallel	assignment	
12	 Ongoing	 Expected:	 Safety,	 tolerability	and	 efficacy	 of	 MTP	 131	 in	patients	with	LHON	 N/A	 Stealth	BioTherapeutics	Inc.	
GS010	 NCT02064569	 Phase	 1/2,	interventional,	 open	label,	 single	 group	assignment	 21	 Ongoing	
Expected:	 Safety	 and	tolerability	 of	 GS010	 in	patients	with	LHON	 N/A	 GenSight	Biologics	
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NCT02652780	
Phase	 3,	interventional,	randomised,	 double	blind,	 placebo-controlled,	 parallel	assignment	
36	 Ongoing	 Expected:	 Efficacy	 of	 GS010	for	treating	vision	loss	from	7	months	 to	 1	 year	 after	 LHON	onset	 N/A	
NCT02652767	
Phase	 3,	interventional,	randomised,	 double	blind,	 placebo-controlled,	 parallel	assignment	
36	 Ongoing	 Expected:	 Efficacy	 of	 GS010	for	treating	vision	loss	from	0-6	months	after	LHON	onset	 N/A	
rAAV2-ND4	 NCT03428178	 Interventional,	 open	label,	 single	 group	assignment	 50	 Ongoing	
Expected:	 Efficacy	 of	 rAAV2-ND4	 for	 treating	 vision	 loss	within	 3	 months	 after	 LHON	onset	 N/A	
Huazhong	University	 of	Science	 and	Technology	N/A,	not	available.	
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3.2		 Aims	and	objectives	1 	2 
Currently,	only	a	few	drug	candidates	and	treatment	strategies	are	in	development	that	3 selectively	aim	to	restore	mitochondrial	function.	Therefore,	in	this	chapter,	two	of	the	4 most	promising	novel	SCQs,	#37	and	#77	that	protected	cellular	viability	in	vitro	to	100	%	5 of	 sham-treated	 cells,	 while	 rescuing	 ATP	 levels,	 in	 the	 presence	 of	 the	 C-I	 inhibitor,	6 rotenone,	 were	 tested	 in	 a	 mouse	 model	 of	 LHON.	 However,	 both	 compounds	 differ	7 significantly	 in	 solubility.	 The	 SCQ	 #37	 is	 a	 quinone	 with	 amino	 acid	 moiety	 as	 the	8 terminal	 group	 that	 corresponds	 to	 a	 theoretical	 log	 P	 and	 log	 D	 of	 3.42	 and	 0.12	9 respectively.	This	illustrates	that	solubility	of	#37	is	highly	pH	dependent	and	therefore	10 could	 affect	 absorption	 and	 tissue	 penetration.	 In	 contrast,	 the	 SCQ	 #77	 which	 is	 a	11 quinone	with	amino	alcohol	moiety	as	the	terminal	group	has	a	log	P	and	log	D	of	3.41.	12 the	SCQ	#77	illustrates	a	significantly	lower	solubility	that	is	less	likely	affected	by	tissue	13 pH	levels.	However,	a	logD	of	3.41	seems	ideal	for	brain	penetration	and	could	therefore	14 be	superior	with	regards	to	absorption	into	the	eye	compared	to	#37.	Therefore,	in	this	15 chapter,	I	aimed	to	translate	my	in	vitro	results	(Chapter	2)	to	an	in	vivo	mitochondrial	16 disease	model	and	compare	their	efficacy	to	the	currently	used	drug,	idebenone.	17 
To	achieve	this	aim,	in	this	chapter,	experiments	were	conducted	to	fulfill	the	following	18 objectives:	19 
v To	establish	 a	previously	described	mouse	model	of	drug-induced	acute	vision	20 loss,	in	our	lab	environment	21 
v To	measure	the	influence	of	oral	administered	SCQs	on	the	visual	acuity	of	mice	22 
v To	analyse	the	effect	of	SCQs	on	the	molecular	pathology	of	the	mouse	retina	23 
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3.3		 Materials	and	Methods	1 	2 
All	 reagents	were	 sourced	 from	 Sigma	Aldrich,	 Castle	Hill,	 Australia	 unless	 otherwise	3 specified.	4 
	5 
3.3.1	 Animals	6 	7 
Male,	C57Bl/6	mice,	aged	between	8-11	weeks,	with	an	average	body	weight	of	25	g	were	8 used	 for	 the	 current	 study.	 C57Bl/6	 mice	 were	 selected	 as	 they	 showed	 a	 robust	9 optomotor	 response	 in	 a	 previously	 published	 behavioural	 study	 that	 demonstrated	10 neuroprotection	 by	 idebenone	 (Heitz	 et	 al.	 2012).	 Female	 animals	 were	 deliberately	11 avoided	in	this	study	since	the	female	sex	hormone,	oestrogen	is	suspected	to	exert	some	12 neuroprotective	activity	in	the	retina	and	was	described	to	be	cytoprotective	in	vitro	in	13 cells	derived	from	LHON	patients	(Giordano	et	al.	2010).	This	hypothesis	is	supported	by	14 the	very	low	numbers	of	female	LHON	patients	who	have	been	described	in	the	literature	15 (Man	et	al.	2002,	Man	et	al.	2003).	Therefore,	I	aimed	to	approach	the	real-life	scenario	16 by	using	young,	male	mice	in	this	study.	All	procedures	were	performed	in	accordance	17 with	 the	Australian	 code	 for	 the	 use	 of	 animals	 for	 scientific	 purposes	 and	under	 the	18 required	animal	ethics	approval	from	the	University	of	Tasmania	(UTAS)	Animal	Ethics	19 Committee	(Approval	number	A0016080,	approval	permit	located	in	Appendix	3).	20 
	21 
	22 
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3.3.2		 Transport	and	housing	of	mice	1 	2 
All	mice	were	derived	from	stock	bred	at	the	UTAS	Cambridge	farm	facility	(CFF).	Animals	3 were	transported	in	cages	by	vehicle	from	the	CFF	to	the	L6	animal	holding	facility	at	the	4 UTAS	 Medical	 Sciences	 Precinct	 (MSP).	 Animals	 were	 given	 at	 least	 7	 days	 (d)	 to	5 acclimatise	to	the	MSP	facility	conditions	to	reduce	stress	induced	by	transportation	and	6 change	in	environment	before	they	were	used	for	the	experiments.		7 
All	mice	were	orally	supplied	with	test	compounds	by	mixing	them	into	individual	daily	8 food	portions	as	previously	described	(Heitz	et	al.	2012)	that	allowed	exact	dosing	for	9 each	animal.	This	approach	was	favoured	over	gavage	application	to	avoid	unnecessary	10 stress,	which	was	 essential	 to	 generate	meaningful	 behavioural	 data.	 To	 control	 drug	11 intake,	 mice	 were	 individually	 caged	 and	 provided	 with	 a	 physically	 enriched	12 environment	that	 included	housing	and	bedding	material,	small	 toys,	autoclaved	toilet	13 rolls,	 small	wooden	sticks	 for	gnawing	and	glass	marbles	 to	enable	natural	behaviour	14 (Baumans	2005).	15 
	16 
3.3.3	 Randomisation	of	mice	into	treatment	groups		17 	18 
To	avoid	bias,	all	mice	were	randomised	into	the	four	treatment	groups:	sham-treated,	19 idebenone-treated,	#37-treated	and	#77-treated	by	balancing	the	influence	of	baseline	20 characteristics	(covariates)	of	the	mice,	i.e.	their	parents	and	body	weight	as	previously	21 described	(Suresh	2011,	Hirst	et	al.	2014).	Depending	on	the	availability	of	mice	from	CFF,	22 whenever	possible	(33	out	of	40	mice	in	total),	littermates	were	allocated	into	different	23 treatment	groups	to	ensure	genetic	complexity	within	each	treatment	group.	The	goal	24 
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was	to	achieve	an	average	body	weight	of	approximately	25	g	and	an	average	age	of	10-1 weeks	within	each	group	of	10	mice	before	the	start	of	the	experiment.	Since	handling	all	2 40	mice	at	once	would	have	impaired	reliable	behavioural	data	(as	behaviour	was	only	3 assessed	between	8	-	10	am	to	avoid	circadian	influences),	mice	were	requested	in	five	4 separate	batches	at	different	time	points.	To	avoid	batch-to-batch	variation,	mice	within	5 individual	batches	were	allocated	to	all	4-treatment	groups,	where	possible	(for	details	6 of	individual	mouse	allocations	see	Appendix	4,	Table	A17-A20).		7 
	8 
3.3.4	 	Food	intake	experiments		9 	10 
Since	our	novel	SCQs	were	significantly	better	in	protecting	cellular	viability	and	rescuing	11 ATP	levels	in	vitro	compared	to	idebenone,	I	treated	the	mice	with	a	10-fold	lower	dose	12 (200	mg/kg)	than	previously	published	for	idebenone	(2000	mg/kg)	in	the	same	model	13 (Heitz	et	al.	2012).	All	mice	from	the	four	treatment	groups	were	pre-treated	with	the	14 respective	SCQs	or	sham-treated	at	200	mg/kg	idebenone	molar	dose	equivalents	every	15 day	for	7	d	before	exposure	to	the	mitochondrial	toxin,	rotenone,	and	subsequently	for	16 the	remainder	of	the	study	period.	Equivalent	dosage	(mg/kg	body	weight)	for	the	novel	17 SCQs	were	calculated	as	equimolar	doses	based	on	200	mg/kg	idebenone	and	the	specific	18 molecular	weights	of	the	novel	SCQs	(Table	11).	The	equimolar	dosages	were	calculated	19 as	200	mg/kg,	240	mg/kg	and	249	mg/kg	for	idebenone,	#37	and	#77	respectively	(Table	20 11).	21 
	22 
	23 
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Table	11:	Calculating	equivalent	dosage	for	novel	short-chain	quinones	1 
Test	
compound	
Molecular	weight	
(g/mol)	
Amount	of	test	
compound	(mmol/kg)	
Equivalent	dose	
(mg/kg)	Idebenone	 338.44	 0.59095	 200	37	 405.44	 0.59095	 240	77	 421.49	 0.59095	 249		2 
SCQs	were	 formulated	with	 food	powder	 (Speciality	 feeds,	WA,	Australia)	 to	 produce	3 individual	portions	and	were	given	once	a	day	as	previously	published	(Heitz	et	al.	2012).	4 Briefly,	 SCQs	were	 stirred	 overnight	 at	 4	 °C	 in	 500	ml	 0.5	%	 carboxymethylcellulose	5 sodium	 salt	 (CMC)	 in	 water	 to	 generate	 a	 20	 mg/ml	 solution.	 Then	 37.5	 ml	 of	 the	6 corresponding	SCQ	in	CMC	solution,	41.25	g	sucrose,	371.25	g	food	powder	and	0.5	%	7 CMC	solution	to	a	final	overall	weight	of	825g	were	mixed	to	prepare	a	food	mash	(Table	8 12).	In	the	last	step,	the	food	mixture	was	aliquoted	(5.5	g	each)	in	small	weighting	trays	9 and	individually	stored	at	–20	°C.	Sham-treated	animals	received	the	same	food	portions	10 excluding	drug.	The	aliquoted	food-SCQs	portions	were	stable	in	the	freezer	for	up	to	3	11 years.	All	mice	received	one	portion	of	the	aliquoted	food	mixture	per	day	(between	4	-	6	12 pm),	corresponding	 to	 their	 treatment	group	allocation.	Animals	rapidly	accepted	 this	13 form	of	food	supply	and	it	was	observed	that	this	food	was	eaten	preferentially,	while	ad	14 
libitum	supply	of	standard	food	pellets	(Speciality	feeds,	WA,	Australia)	and	water	was	15 also	ensured	throughout	the	study.	Idebenone	powder	was	kindly	donated	by	Santhera	16 Pharmaceuticals	(Muttenz,	Switzerland)	and	the	test	compounds	were	provided	by	the	17 Department	of	Chemistry	(Dr.	Krystel	Woolley,	UTAS)	in	sufficient	quantities	at	a	purity	18 of	>95	%.		19 
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Table	12:	Recipe	for	preparing	150	portions	of	drug	containing	food	mash	1 
		 Idebenone	 #37	 #77	Drug	solution	(20	mg/ml)	in	0.5	%	CMC*	(ml)	 37.5	 44.9	 46.70	Sucrose	(g)	 41.25	 41.25	 41.25	Food	powder	(g)	 371.25	 371.25	 371.25	0.5%	CMC	(ml)	 375	 367.85	 366.05	
Total	weight	(g)	 825	 825	 825	
Individual	portion	(g)	 5.5	 5.5	 5.5		2 *CMC,	carboxymethylcellulose,	sodium	salt	3 	4 	5 
Additional	food	intake	in	addition	to	the	food	mash	was	calculated	from	the	pellet	hopper	6 weight	and	is	presented	as	cumulative	additional	food	intake.	Body	weight	of	mice	and	7 food	 intake	was	measured	 every	 1	 to	 5	 d.	 Relative	 food	 intake	was	 calculated	 as	 the	8 cumulative	change	in	food	intake	(g)	relative	to	cumulative	change	in	body	weight	(g).	9 
	10 
3.3.5	 Intraocular	Injections	11 	12 
To	induce	rotenone-induced	blindness	in	the	animals,	mice	were	anaesthetised	in	a	flow	13 chamber	 with	 5	 %	 isoflurane	 and	 oxygen	 (600	 ml/min)	 until	 sedated.	 The	 foot	14 withdrawal	 reflex	 in	 response	 to	 foot	 pinch	 test	was	 used	 to	 determine	 the	 extent	 of	15 anaesthesia.	Upon	sedation,	a	nose-cone	delivering	2	%	 isoflurane	 (300	ml/min	using	16 oxygen)	was	placed	over	the	mouse's	nose	for	the	duration	of	surgery.	The	concentration	17 and	 rate	 of	 anaesthetic	 delivery	 were	 increased	 slightly	 (up	 to	 a	 maximum	 of	 5	 %	18 
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isoflurane,	 500	 ml/min)	 depending	 on	 the	 respiratory	 response	 of	 the	 anesthetized	1 mouse.	Prior-to	and	after	intraocular	injection,	cotton	buds	soaked	in	sterile	saline	were	2 used	to	clean	the	area	around	the	eyes.	For	intravitreal	injection,	a	31	-gauge	needle	was	3 first	 used	 to	puncture	 the	 sclera	 and	 the	 eye	was	 gently	massaged	 to	 remove	 a	 small	4 amount	 of	 vitreous	 and	 to	 prevent	 increased	 intraocular	 pressure.	 Then,	 a	 33	 -gauge	5 needle	adapted	to	a	10	µl	Hamilton	syringe	(Intraocular	 injection	kit,	World	Precision	6 Instruments,	USA)	was	used	to	introduce	1	µl	of	rotenone	(5	mM	in	dimethyl	sulphoxide,	7 DMSO)	 to	 the	 vitreous	 chamber	 of	 the	 left	 eye.	 The	 needle	 tip	 was	 inserted	 into	 the	8 superior	hemisphere	of	the	eye,	at	the	level	of	the	pars	plana	and	at	a	45	°	angle	through	9 the	sclera	into	the	vitreous	body.	This	route	of	administration	avoids	retinal	detachment	10 or	injury	to	eye	structures,	including	the	lens	and	the	iris.	After	the	surgery,	the	mice	were	11 allowed	to	recover	on	a	heating	pad	until	they	regained	consciousness	and	then	returned	12 to	their	home	cages.		13 
The	injections	were	performed	blinded	with	regards	to	the	treatment	group	allocation	of	14 individual	mice.	The	injected	eye	was	carefully	checked	once	a	day	for	7	d	post-surgery	15 for	any	signs	of	inflammation.		16 
	17 
3.3.6	 Behavioural	analysis	(optomotor	response)	18 	19 
To	assess	visual	acuity	in	the	animals,	their	optomotor	response	(OMR)	was	assessed	as	20 previously	 described	 (Heitz	 et	 al.	 2012).	 For	 two	 weeks	 before	 and	 10	 weeks	 after	21 rotenone	injection,	the	OMR	of	the	mice	was	repeatedly	tested	once	every	week	over	the	22 entire	duration	of	the	experiment.	For	this	purpose,	the	mice	were	individually	placed	on	23 
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a	small	platform	surrounded	by	a	motorized	drum	(30	cm	diameter)	with	vertical	black	1 and	white	stripes	(1	cm	thick,	Figure	39).		2 
	3 
Figure	39:	Experimental	setup	for	measuring	visual	acuity	of	mice.	Mice	were	placed	on	a	4 stable	platform	in	the	centre.	Visual	acuity	was	quantified	by	scoring	the	number	of	head-turns	5 while	rotating	the	stripes	of	the	optokinetic	drum	(with	the	centre	stage	remaining	stable)	for	6 two	min	 in	clockwise	(blue	arrow,	measures	 left	eye	 function)	and	anti-clockwise	(red	arrow,	7 measures	right	eye	function)	direction.	8 	9 
After	 10	min	 of	 adaptation	 to	 the	 system,	 the	 visual	 acuity	 testing	was	 performed	by	10 rotating	the	drum	clock-wise	and	counter-clock-wise	at	two	revolutions/min	for	2	min	in	11 each	direction	and	with	an	interval	of	30	sec	between	the	two	rotations.	Mouse	behaviour	12 was	 recorded	 with	 a	 digital	 video	 camera	 for	 subsequent	 scoring	 of	 head	 tracking	13 movements	as	previously	described	(Heitz	et	al.	2012).	All	videos	were	completely	de-14 
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identified	 by	 a	 person	 not	 involved	 in	 the	 project	 prior	 to	 manual	 scoring	 to	 avoid	1 investigator	bias.	After	the	full	analysis	of	all	videos,	the	data	was	decoded	and	the	results	2 analysed	 for	 the	 left	 (injected)	 and	 right	 (non-injected)	 eye	 and	 expressed	 as	 head	3 movements.	4 
	5 
3.3.7	 Responder	analysis		6 	7 
While	 vision	 loss	 in	 most	 LHON	 patients	 is	 permanent,	 there	 is	 a	 limited	 chance	 of	8 spontaneous	vision	recovery	that	can	either	occur	in	the	first	year	or	up	to	several	years	9 after	 disease	 onset	 in	 some	 patients	 (Spruijt	 et	 al.	 2006,	 Stone	 et	 al.	 1992).	 This	10 characteristic	is	replicated	by	the	mouse	model	used	in	this	study	and	is	dependent	on	11 the	 amount	 of	 injected	 rotenone	 (unpublished	 observation	 N.	 Gueven).	 Therefore,	 to	12 quantify	 the	 number	 of	 mice	 that	 regained	 visual	 acuity,	 either	 spontaneously	 or	 in	13 response	 to	 SCQ-treatment,	 a	 responder	 analysis	 was	 performed.	 At	 the	 end	 of	 the	14 observation	period	(71	d),	the	number	of	mice	that	showed	more	head-turns	compared	15 to	sham-treated	mice	at	1	d	post-rotenone	injection	were	considered	as	responders	and	16 reported	as	“Responders	(%)”.	In	a	second	assessment,	the	number	of	mice	that	showed	17 more	head-turns	at	the	end	of	treatment	period	(71	d)	than	sham-treated	mice	at	any	18 given	time	during	the	treatment	period	were	considered	as	responders	to	SCQ	treatment	19 and	reported	as	“Responders	to	SCQ-treatment	(%)”.	20 
 21 
 22 
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3.3.8	 Euthanasia	and	cardiac	perfusion		1 	2 
At	the	end	of	the	observation	period	all	mice	were	sacrificed	for	tissue	analysis.	Mice	were	3 terminally	 anaesthetised	with	 intraperitoneal	 sodium	pentobarbital	 (110	mg/kg	body	4 weight).	 For	 histology	 studies,	 mice	 were	 transcardially	 perfused	 with	 4	 %	5 paraformaldehyde	(PFA)	in	0.1	M	phosphate-buffered	saline	(PBS)	for	1	to	2	min	to	clear	6 the	 blood	 from	 the	 vasculature	 and	 effectively	 fix	 the	 tissues.	 Eyes	were	 immediately	7 collected	and	post-fixed	in	4	%	PFA	in	0.1	M	PBS	overnight	at	4	°C,	before	soaking	in	30	%	8 sucrose	0.1	M	PBS	for	24	h	followed	by	18	%	sucrose	in	0.1	M	PBS	for	another	24	h	at	4	°C.	9 Tissue	 samples	 were	 stored	 in	 0.1	 M	 PBS	 with	 0.02	 %	 sodium	 azide	 until	 used	 for	10 histology	studies.		11 
	12 
3.3.9	 Histological	analysis	of	mice	eyes	13 
 14 
 15 
3.3.9.1	 Tissue	processing	16 	17 
Eyes	 stored	 in	 PBS	 with	 0.02	 %	 sodium	 azide	 were	 processed	 using	 a	 tissue	 auto-18 processor	(A82310100,	Excelsior	AS	Tissue	Processor,	Thermo	Fisher	Scientific	Pty	Ltd,	19 VIC,	 Australia).	 The	 tissue	 processing	 involved	 a	 series	 of	 steps	 that	 started	 with	20 dehydration	 by	 an	 ethanol	 series,	 which	 was	 followed	 by	 clearing	 in	 xylene	 and	21 subsequent	infiltration	with	paraffin	wax	(Table	13).	22 
	23 
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Table	13:	Steps	for	tissue	processing.		1 
Solution	 Duration	(min)	 Temperature	(°C)	Ethanol	(70	%)	 15	 37	Ethanol	(95	%)	 30	 37	Ethanol,	absolute	 15	 37	Ethanol,	absolute	 15	 37	Ethanol,	absolute	 15	 37	Ethanol,	absolute	 20	 37	Xylene	 35	 37	Xylene	 35	 37	Paraplast	wax	 60	 60	Paraplast	wax	 60	 60	Paraplast	wax	 60	 60		2 
	3 
3.3.9.2	 Wax	embedding	of	tissue	and	microtomy	4 	5 
Processed	eyes	were	then	embedded	into	paraffin	blocks	using	stainless-steel	moulds.	A	6 semi-automatic	precision	microtome	(Leica	RM2235,	Leica	Microsystems	Pty	Ltd,	VIC,	7 Australia)	was	initially	adjusted	to	10	µm	for	coarse	sections	until	the	area	of	interest	was	8 reached	and	then	adjusted	to	4	µm	to	cut	thinner	sections	suitable	for	staining.	The	thin	9 sections	were	mounted	onto	adherent	glass	slides	(Dako,	NSW,	Australia)	and	dried	for	10 15	min	at	65	°C,	before	stored	at	room	temperature	until	stained.	11 
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3.3.9.3	 Haematoxylin	and	Eosin	(H	&	E)	staining	1 	2 
Paraffin	sections	on	glass	slides	were	dewaxed,	rehydrated	and	H	&	E	stained	at	room	3 temperature	using	an	auto-stainer	(Leica	Auto-stainer	XL,	Leica	Microsystems	Pty	Ltd,	4 VIC,	Australia)	(Table	14).	After	drying,	the	slides	were	mounted	with	mounting	agent	5 (Dako,	NSW,	Australia),	followed	by	a	coverslip	(Fronine	Pty	Ltd,	NSW,	Australia)	to	seal.	6 The	 stained	 slides	 were	 stored	 at	 room	 temperature	 until	 imaged	 using	 a	 light	7 microscope	(DM	2500,	Leica	Microsystems	Pty	Ltd,	VIC,	Australia).		8 
	9 
Table	14:	Steps	 for	dewaxing,	haematoxylin	and	eosin	(H	&	E)	staining	paraffin-10 
sectioned	mice	tissue.	11 
	12 
Solution	 Duration	(sec)	Xylene	 30	Xylene	 30	Ethanol,	absolute	 30	Ethanol	(95	%)	 30	Ethanol	(70	%)	 30	Water	wash	 30	Haematoxylin	 360	Water	wash	 30	Acid	alcohol	differentiator	 20	Water	wash	 30	Ammoniated	water	 60	
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Water	wash	 30	Ethanol	(70	%)	 30	1	%	Eosin	phosphate	staining	solution	 60		Ethanol,	absolute	 20	Ethanol,	absolute	 20	Ethanol,	absolute	 20	Xylene	 20	Xylene	 20		1 
	2 
3.3.10		 Analysis	of	stained	sections	3 	4 To	generate	comparable	photographic	representations	of	tissue	samples,	all	images	were	5 acquired	at	40	X	magnification	and	at	the	same	distance	from	the	retinal	periphery	as	6 suggested	 previously	 (Mead	 et	 al.	 2014).	 Subsequently,	 the	 number	 of	 RGCs	 in	 the	7 ganglion	cell	layer	(GCL)	were	scored	manually	for	the	entire	retinal	image	using	ImageJ	8 software	 and	 were	 reported	 as	 RGC/mm.	 The	 retinal	 thickness	 was	 calculated	 by	9 measuring	the	distance	from	the	innermost	border	of	the	GCL	to	the	outermost	border	of	10 the	photoreceptor	layer	(PL)	of	the	retina.	Retinal	thickness	was	measured	at	3	separate	11 points	on	each	 image,	 i.e.	 the	 left	 and	right	ends	and	 the	centre.	The	average	of	 three	12 measurements	 was	 calculated	 and	 reported	 as	 µm.	 Both	 RGC	 numbers	 and	 retinal	13 thickness	were	calculated	from	an	average	of	7-11	animals	per	treatment	group	(n=7-11,	14 one	section	per	mice).	Sections	with	obvious	retinal	damage	due	to	procedural	mistakes	15 (i.e.	cutting	artefacts	such	as	tissue	folding	and	tearing)	were	excluded	from	the	analysis.	16 
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All	 data	 are	 represented	 as	 mean	 or	 mean	 ±	 S.D.	 as	 denoted	 in	 the	 figure	 legends.	1 Statistical	analysis	to	measure	the	significance	between	different	groups	was	performed	2 using	Student	t-test	(GraphPad	prism	software;	GraphPad	Software	Inc.,	CA,	USA).	3 
	4 
	5 
	6 
	7 
	8 
	9 
	10 
	11 
	12 
	13 
	14 
	15 
	16 
	17 
	18 
	19 
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3.4 	 Results	1 	2 
3.4.1 Revisiting	in	vitro	data	for	idebenone,	#37	and	#77	from	previous	chapter	3 	4 
The	novel	SCQs	#37	and	#77	 (Figure	40	 ii,	 iii)	were	chosen	 to	be	 tested	 in	 the	LHON	5 mouse	model	as	both	compounds	restored	cellular	viability	in	vitro	to	almost	100	%	in	6 the	presence	of	rotenone,	which	was	significantly	better	than	idebenone.	In	addition,	both	7 compounds	differ	significantly	with	regards	to	their	physicochemical	characteristics.	The	8 SCQ	 #37	 is	 a	 quinone	 with	 amino	 acid	 moiety	 as	 the	 terminal	 group.	 This	 structure	9 corresponds	to	a	theoretical	log	P	and	log	D	of	3.42	and	0.12	respectively.	This	illustrates	10 that	solubility	of	#37	is	highly	pH	dependent	and	therefore	could	affect	absorption	and	11 tissue	penetration.	In	contrast,	the	SCQ	#77	which	is	a	quinone	with	amino	alcohol	moiety	12 as	the	terminal	group	has	a	log	P	and	log	D	of	3.41.	the	SCQ	#77	illustrates	a	significantly	13 lower	solubility	that	is	less	likely	affected	by	tissue	pH	levels.	However,	a	log	D	of	3.41	14 seems	 ideal	 for	 brain	 penetration	 and	 could	 therefore	 be	 superior	 with	 regards	 to	15 absorption	into	the	eye	compared	to	#37.	An	additional	point	of	difference	between	the	16 two	 compounds	 was	 their	 effect	 on	 β-hydroxy	 butyrate	 (BHB)	 levels	 in	 cell	 culture	17 supernatant.	 While	 the	 SCQ	 #37	 significantly	 reduced	 BHB	 levels	 in	 cell	 culture	18 supernatant,	 the	SCQ	#77	showed	a	 trend	 towards	 increased	BHB	 levels	 compared	 to	19 idebenone	 (Figure	 41	 i).	 Furthermore,	 reduction	 of	 SCQ	 #37	 by	 cellular	 reductases	20 occurred	at	a	significantly	 lower	 level	compared	to	 idebenone,	while	reduction	of	#77	21 occurred	at	a	significantly	higher	level	(Figure	41	ii).	For	all	other	assays,	no	significant	22 differences	 between	 the	 novel	 SCQs	 and	 idebenone	 were	 observed	 (Figure	 41	 i).	 I	23 hypothesized	that	 the	selective	use	of	 two	compounds	with	the	described	observed	 in	24 
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vitro	differences	would	enable	me	to	assess	the	significance	of	those	parameters	for	their	1 protective	efficacy	in	vivo.		2 
	3 
	4 
Figure	40:	Molecular	structures	of	(i)	idebenone,	(ii)	novel	short-chain	naphthoquinones	(SCQs)	5 #37,	(iii)	novel	SCQ	#77.	6 	7 
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Figure	41:	Summary	of	 results	 from	all	 in	vitro	 characterisation	assays	 for	 idebenone,	novel	 short-chain	quinones	 (SCQs)	#37	and	#77	
(Summary	of	data	from	Chapter	2).	(i)	Effect	of	SCQ	(10	µM)	on	cell	viability	in	the	presence	of	1	µM	rotenone,	acute	rescue	of	adenosine	triphosphate	(ATP)	levels	in	the	presence	of	10	µM	rotenone,	basal	lipid	peroxidation	(BLP)	levels,	lactate	levels	and	β-hydroxy	butyrate	(BHB)	levels	calculated	as	percentage	of	sham-treated	cells	(ii)	Reduction	of	SCQ	(10	µM)	by	cellular	reductases.	Data	is	expressed	as	mean	±	S.D.	(n=3	independent	experiments	with	6	replicates	within	each	experiment).	Significance	was	calculated	by	using	Student	t-test	to	compare	SCQ	against	 idebenone	using	GraphPad	Prism	software	(p*	<0.05).	
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3.4.2		 Randomisation	of	mice	into	treatment	groups		1 	2 
Initially,	 to	establish	 the	model	of	 rotenone-induced	vision-loss	at	UTAS	as	previously	3 reported	(Heitz	et	al.	2012),	the	animals	of	the	first	batch	of	mice	(n=8)	were	randomised	4 into	 sham	 and	 idebenone	 treatment	 groups.	 A	 significant	 loss	 of	 visual	 acuity	 was	5 observed	in	the	left,	rotenone	injected	eye	one	day	after	injection,	while	the	visual	acuity	6 of	right	(un-injected)	eye	remained	unchanged	in	all	mice	(Figure	49).	Mice	that	did	not	7 show	a	significant	loss	of	visual	acuity	after	rotenone	injection	(n=2)	were	excluded	from	8 the	study.	9 
After	 confirming	drug-induced	vision	 loss,	mice	 from	 the	 second	batch	onwards	were	10 randomly	allocated	to	all	four-treatment	groups	to	achieve	groups	that	contained	mice	of	11 approximately	10-week	of	age	with	an	average	body	weight	of	approximately	25	g	(n=10	12 mice/group)	(Appendix	4,	Table	A17-A20).		The	age	of	mice	within	individual	treatment	13 groups	was	70.1	±	6.0	d,	69.0	±	1.9	d,	67.2	±	6.3	d	and	67.8	±	6.7	d	within	sham,	idebenone,	14 #37	and	#77	treatment	groups	respectively	(Figure	42	i).	The	average	body	weights	were	15 23.5	±	1.8	g,	23.8	±	1.9	g,	23.3	±	1.1	g	and	23.9	±	1.0	g	within	sham,	idebenone,	#37	and	16 #77	treatment	groups	respectively	(Figure	42	ii).		17 
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	1 
Figure	42:	Allocation	of	mice	to	different	treatment	groups.	Average	(i)	age	(d)	and	(ii)	body	2 weight	(g)	of	mice	within	each	treatment	group	when	the	animals	were	included	in	the	study.	3 Each	data	point	represents	one	mouse.	4 
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3.4.3		 Influence	of	SCQ	treatment	on	food	intake	and	body	weight	of	mice		1 	2 
Since	the	novel	SCQs	were	tested	for	the	first	time	in	vivo,	it	was	important	to	monitor	for	3 any	SCQ-induced	toxicity.	For	example,	a	10	%	decrease	in	body	weight	was	considered	4 as	an	adverse	event,	however	such	a	decrease	was	not	observed	in	any	of	the	treated	mice.	5 Other	 adverse	 events	 such	 as	 changes	 to	mice	 behaviour,	 fur	 condition,	 any	 signs	 of	6 infection	in	the	eye	were	also	monitored	routinely.	No	adverse	events	were	observed	in	7 any	experimental	mice.		8 
Relative	food	intake	was	calculated	to	quantify	the	influence	of	SCQs	on	food	intake	and	9 body	weight	of	the	mice.	For	almost	one-week	post	rotenone	injection,	the	relative	food	10 intake	was	slightly	variable	within	the	treatment	groups	(Figure	43	ii).	For	example,	at	1	11 d	post	 rotenone	 injection,	 the	 relative	 food	 intake	was	31.85	±	80.91	 for	#77	 treated	12 group,	while	it	was	27.55	±	61.07	at	3	d	for	idebenone	treatment	group.	These	differences	13 arose	since	 in	a	 few	mice	 the	cumulative	 increases	 in	body	weights	were	much	 lower	14 when	compared	to	the	cumulative	increase	in	food	intake	(Figure	43	ii).	However,	from	15 the	 second	 week-post	 rotenone	 injection,	 the	 relative	 food	 intake	 was	 stable	 and	16 relatively	consistent	across	different	treatment	groups	(Figure	43	ii).	Overall,	the	average	17 relative	food	intake	was	6.02	±	4.17,	8.41	±	11.35,	4.72	±	0.86	and	5.4	±	12.9	for	sham,	18 idebenone,	#37	and	#77	treated	mice	respectively.	19 
	20 
	21 
	22 
	23 
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Figure	43:	Influence	of	short-chain	quinones	(SCQs)	on	relative	food	intake	of	mice.	(i)	All	mice	were	pre-treated	for	7	d	with	test	compound,	prior	to	intraocular	rotenone	injection	on	day	0,	followed	71	d	post-treatment.	(ii)	Relative	food	intake	of	mice	was	measured	as	the	ratio	of	cumulative	increase	in	food	pellet	intake	(g)	to	the	cumulative	increase	in	body	weight	(g).	Each	data	point	represents	the	average	of	5-11	mice	per	treatment	group	(n=5-11).
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3.4.4		 The	effect	of	SCQ	treatment	on	rotenone-induced	retinal	damage			1 	2 
After	the	end	of	treatment	period	(71	d),	mice	were	sacrificed	and	eyes	were	collected	for	3 histological	 analysis.	 In	order	 to	 investigate	 the	efficacy	of	 the	novel	 SCQs	against	 the	4 consequences	of	 rotenone-induced	 toxicity,	 the	number	of	RGCs	and	 retinal	 thickness	5 were	quantified	on	H	&	E	stained	eye	sections	using	ImageJ	software.	6 
The	 right,	 non-injected	 eye	 of	 the	 sham-treated	 mouse	 represented	 the	 molecular	7 pathology	of	a	normal,	healthy	mouse	and	was	therefore	used	as	internal	control	(Figure	8 44).	The	retinal	layers	are	composed	of	the	innermost	GCL	that	hosts	the	RGCs.	This	is	9 followed	 by	 the	 inner	 nuclear	 layer	 (INL)	 and	 outer	 nuclear	 layer	 (ONL)	 that	 are	10 separated	by	the	inner	plexiform	layer	(IPL)	and	outer	plexiform	layer	(OPL)	respectively.	11 The	nuclear	layers	are	attached	to	the	photoreceptor	(PR)	layer	that	is	composed	of	inner	12 segment	(IS)	and	outer	segment	(OS)	(Figure	44).13 
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Figure	44:		Retinal	layers	in	mouse	eye.	The	retina	of	a	normal,	healthy	mouse	is	composed	of	the	ganglion	cell	layer	(GCL),	inner	plexiform	layer	(IPL),	inner	nuclear	layer	(INL),	outer	plexiform	layer	(OPL),	outer	nuclear	layer	(ONL)	and	the	photoreceptor	(PR)	layer	that	consists	of	the	inner	segment	(IS)	and	outer	segment	(OS).	Image	was	taken	at	40	X	magnification.	Scale	bar	represents	20	µm.
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3.4.4.1		 The	effect	of	novel	SCQ	treatment	on	rotenone-induced	decrease	 in	1 
retinal	thickness	2 	3 
In	 sham-treated	 mice,	 significant	 changes	 in	 retinal	 histology	 were	 evident	 from	 the	4 images	 of	 H	 &	 E	 stained	 sections	 (Figure	 45,	 a(i)	 versus	 a(ii)).	 Rotenone	 injection	5 significantly	reduced	the	retina	thickness	in	left	eye	(Figure	45,	a(i)	versus	a(ii))	when	6 compared	to	right	eye	of	sham-treated	mice	(54.11	±	24.52	µm	vs	118.99	±	15.83	µm,	7 Figure	46	i).	It	is	worth	noting	that	no	significant	changes	in	the	retinal	thickness	of	the	8 non-injected,	right	eye	were	observed	across	all	treatment	groups	(Figure	46	ii).	9 
Upon	treatment	with	idebenone,	no	significant	differences	were	observed	in	the	retinal	10 thickness	of	the	left-eye	of	idebenone-treated	mice	when	compared	to	sham-treated	mice	11 (59.10	±	21.19	µm	vs	54.11	±	24.52	µm,	Figure	45	b(i)	and	b(ii),	Figure	46	i).	In	contrast,	12 treatment	 with	 both	 novel	 SCQs,	 #37	 and	 #77	 significantly	 protected	 against	 loss	 of	13 retinal	thickness	(85.61	±	24.78	µm,	92.84	±	18.76	µm	respectively)	when	compared	to	14 the	retinas	of	sham-treated	mice	(Figure	45	c	and	d,	Figure	46	i).	Overall,	in	all	treatment	15 groups,	71	d	post-rotenone	challenge,	the	average	retinal	thickness	of	the	left	eye	was	16 significantly	lower	when	compared	to	the	right	eye.	For	example,	54.11	±	24.52 µm	versus	17 118.99	±	15.83	µm	in	sham-treated	mice)	(Figure	46	iii).		18 
	19 
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	1 
Figure	 45:	 Histology	 of	 test-compound	 treated	 mice	 retina.	 Paraformaldehyde-fixed,	2 paraffin-embedded,	Haematoxylin	 (H)	 and	Eosin	 (E)	 stained,	 4	 µm-thick	 retinal	 sections.	 The	3 panel	is	composed	of	left	(i)	and	right	(ii)	eye	sections	of	one	representative	mouse	from	sham	4 (a),	idebenone	(b),	novel	short-chain	quinone	(SCQ)	#37	(c)	and	SCQ	#77	(d)	treated	mice.	All	5 images	were	taken	at	40	X	magnification.	Scale	bar	represents	20	µm.	6 
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Figure	46:	Quantification	of	retinal	thickness	of	experimental	mice.	Average	retinal	thickness	(µm)	of	left	(i)	and	right	eye	(ii)	measured	from	haematoxylin	and	eosin	(H	&	E)	stained,	40	X	magnified	image	of	4	µm	thick	sections	using	ImageJ	software.	Data	is	presented	as	the	mean	within	each	treatment	group	(n=7-11	per	treatment	group).	Each	data	point	represents	one	mouse.	Significance	was	calculated	by	comparing	the	average	of	each	treatment	group	with	sham-treated	mice	using	Student	t-test	on	GraphPad	Prism	software	(*	p<0.05,	**	p<0.01).	(iii)	Comparison	of	retinal	thickness	of	left	versus	right	eye	amongst	different	treatment	groups.	Data	is	presented	as	the	mean	±	SD	within	each	treatment	group	(n=7-11	per	treatment	group).	Significance	was	calculated	by	comparing	the	retinal	thickness	of	left	versus	right	eye	within	each	treatment	group	using	Student	t-test	on	GraphPad	Prism	software	(***	p<0.005).	L,	left	eye;	R,	right	eye.		
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3.4.4.2	 The	effect	of	novel	SCQ	treatment	on	rotenone-induced	loss	of	RGCs		1 	2 
In	sham-treated	mice,	significant	changes	in	the	number	of	RGCs	were	evident	from	the	3 images	 of	 H	 &	 E	 stained	 sections	 (Figure	 45,	 a(i)	 versus	 a(ii)).	 Rotenone	 injection	4 significantly	reduced	the	number	of	RGCs/	mm	in	left	eye	(Figure	45,	a(i)	versus	a(ii))	5 when	 compared	 to	 right	 eye	 of	 sham-treated	mice	 (70.62	 ±	 19.92	 vs	 176.71	 ±	 56.89,	6 Figure	47	i,	ii).	It	is	worth	noting	that	no	significant	changes	in	the	retinal	thickness	of	the	7 non-injected,	right	eye	were	observed	across	all	treatment	groups	(Figure	47	i,	ii).	8 
Overall,	in	sham,	idebenone	and	#77-treated	groups,	71	d	post-rotenone	challenge,	the	9 average	number	of	RGC/mm	in	the	left	eye	was	significantly	lower	when	compared	to	the	10 right	 eye.	 For	 example,	 70.62	 ±	 19.92	RGC/mm	 in	 the	 left-eye	 versus	 176.71	 ±	 56.88	11 RGC/mm	 in	 the	 right	 eye	 sham-treated	 mice	 (Figure	 47	 iii).	 Upon	 treatment	 with	12 idebenone,	no	significant	differences	were	observed	in	the	number	of	RGC/mm	in	the	left-13 eye	of	idebenone-treated	mice	when	compared	to	sham-treated	mice	(75.74	±	21.15/mm	14 vs	70.62	±	19.92/mm,	Figure	47	i).	Interestingly,	treatment	with	both	novel	SCQs,	#37	15 and	#77	significantly	protected	against	loss	of	RGC/mm	(118.74	±	55.34/mm,	106.55	±	16 26.45/mm	 respectively)	 when	 compared	 to	 sham-treated	 mice	 (Figure	 47	 i).	17 Interestingly,	 in	 the	 #37	 treated	 group,	 despite	 the	 rotenone	 injection,	 no	 significant	18 changes	were	observed	in	the	number	of	RGC/mm	when	comparing	the	left	with	the	right	19 eye,	(118.74	±	55.34/mm	versus	167.77	±	51.60/mm,	Figure	47	iii).	20 
	21 
	22 
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Figure	47:	Quantification	of	retinal	ganglion	cells	(RGC).	Average	number	of	RGC/mm	of	left	(i)	and	right	eye	(ii)	quantified	from	haematoxylin	and	eosin	(H	&	E)	stained	sections	at	40	X	magnification.	Data	is	presented	as	mean	within	each	treatment	group	(n=7-11	per	treatment	group),	each	data	point	represents	one	mouse.	Significance	was	calculated	by	comparing	the	average	of	each	treatment	group	with	sham-treated	mice	using	Student	
t-test	on	GraphPad	Prism	software	(*	p<0.05,	**	p<0.01).	(iii)	Comparison	of	number	of	RGC/mm	in	left	versus	right	eye	amongst	different	treatment	groups.	Data	is	presented	as	mean	±	SD	within	each	treatment	group	(n=7-11	per	treatment	group).	Significance	was	calculated	by	comparing	the	number	of	RGC/mm	in	the	left	versus	the	right	eye	within	each	treatment	group	using	Student	t-test	on	GraphPad	Prism	software	(***	p<0.005).	L,	left	eye;	R,	right	eye.	
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3.4.5		 Effect	of	novel	SCQs	on	rotenone-induced	loss	of	visual	acuity.		1 	2 
Rotenone-induced	reduction	in	retinal	thickness	and	loss	of	RGCs	could	together	result	3 in	the	loss	of	visual	acuity.	Consistent	with	a	previously	published	study	(Heitz	et	al.	2012),	4 intraocular	injection	of	5	mM	rotenone	into	the	left	eye	exclusively	abolished	the	OMR	of	5 sham-treated	mice	within	1	d,	when	compared	to	the	right	eye	(0.3	±	0.7	versus	19.8	±	6 4.7	head-turns,	Figure	48).	This	result	is	indicative	of	lost	visual	acuity	in	the	left	(injected)	7 eye.	 In	 contrast,	 no	 significant	 changes	 of	 visual	 acuity	were	 noted	 in	 the	 right,	 non-8 injected	 control	 eyes,	 either	 before	 or	 after	 rotenone	 injection.	 Once	 the	 model	 of	9 rotenone-induced	vision	loss	was	established	in	our	laboratory	environment,	the	same	10 injection	protocol	was	 followed	 for	all	 treatment	groups	 to	 induce	blindness.	One	day	11 post-rotenone	injection,	no	significant	differences	were	observed	in	the	OMR	of	the	left	12 eye	 of	 the	 SCQ-treated	 mice,	 when	 compared	 to	 sham-treated	 mice	 (Figure	 48).	13 Comparable	to	sham-treated	mice,	all	SCQ-treated	mice	also	showed	a	significant	drop	in	14 visual	acuity	in	the	left	eye,	when	compared	to	the	right	eye	(Figure	48).	On	average,	one	15 day	post-rotenone	injection,	only	0.4	±	0.7,	1.4	±	2.4	and	2.1	±	3.2	head	turns	were	counted	16 in	the	left	eye	for	idebenone-,	#37-	and	#77-treated	mice	respectively,	whereas	the	right	17 eye	showed	19.6	±	5.8,	19.1	±	3.3	and	18.3	±6.7	head-turns	respectively.	Mice	that	did	not	18 show	a	significant	drop	in	visual	acuity	upon	rotenone	injection,	were	excluded	from	the	19 study	(n=3,	out	of	a	total	43).		20 
	21 
	22 
	23 
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Figure	48:	Effect	of	intraocular	rotenone	injection	on	visual	acuity.	Visual	acuity	of	mice	was	3 measured	one	day	after	injecting	1	µl	of	5	mM	rotenone	solution	in	the	left-eye	of	all	mice	while	4 the	right	eye	remained	as	internal	control	for	each	mouse.	Visual	acuity	was	quantified	by	scoring	5 the	number	of	head-turns	by	mice	while	rotating	the	stripes	of	the	optokinetic	drum	for	2	min	in	6 clockwise	(left-eye,	L)	and	anti-clockwise	(right	eye,	R)	direction.	Each	bar	represents	the	head-7 turns	 corresponding	 to	 each	eye	of	 the	mouse.	Data	 is	 expressed	as	mean	±	 SD,	n=9-11	mice	8 within	 each	 treatment	 group.	 Significance	was	 calculated	 by	 using	 Student	 t-test	 to	 compare	9 number	 of	 head-turns	 of	 right	 versus	 left	 eye	within	 each	 treatment	 group	 (black	 stars,	p***	10 <0.001)	 and	 between	 left	 eye	 of	 sham	 versus	 left	 eye	 of	 SCQ-treated	 mice	 (grey,	 ns,	 non-11 significant).		12 	13 
Consistent	with	 a	 significant	 reduction	 of	 retinal	 thickness	 and	 loss	 of	 RGCs	 in	 sham	14 treated	mice,	a	significant	loss	of	visual	acuity	was	observed	(Figure	48).	Replicating	the	15 natural	 phenomenon	 of	 LHON	 in	 clinical	 patients,	 some	mice	 from	 the	 sham-treated	16 group	started	to	regain	visual	acuity	spontaneously.	When	compared	to	one	day	post-17 
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rotenone,	significant	improvements	in	visual	acuity	were	seen	after	5,	7,	9	and	10	weeks	1 post-rotenone	 injection	 in	 sham-treated	mice	 (Figure	49	 a).	No	 significant	 changes	 in	2 visual	acuity	were	observed	in	the	non-injected,	right	eye	of	sham	treated	mice	(Figure	3 49	a).		4 
Although	 no	 significant	 changes	 were	 observed	 in	 retinal	 thickness	 or	 RGC	 numbers	5 (Figure	 46,	 47)	 in	 idebenone-treated	 mice,	 significantly	 improved	 visual	 acuity	 was	6 observed	from	six-weeks	post-rotenone	injection	in	the	left	eye	when	compared	to	1	done	7 day	post-rotenone,	with	no	significant	changes	observed	in	the	right	eye	(Figure	49	b).	8 On	average,	the	visual	acuity	of	idebenone-treated	mice	was	less	than	5	head	turns	in	the	9 left	eye,	compared	to	around	20	head	turns	counted	in	the	right	eye	(Figure	49	b).		10 
When	compared	to	one	day	post-rotenone,	mice	treated	with	SCQs	#37	and	#77	on	an	11 average	started	to	show	significantly	improved	visual	acuity	from	eight-weeks	and	two-12 weeks	post-rotenone	injection,	respectively	(Figure	49	c).	 Interestingly,	only	two	mice	13 from	each	#37	and	#77	treated	groups	recovered	visual	acuity	to	the	same	levels	as	the	14 non-injected,	right	eye	of	sham-treated	mice	(Figure	49	c,	d),	which	is	reminiscent	of	the	15 patient-specific	responses	in	idebenone-treated	LHON	patients.	No	significant	changes	in	16 visual	acuity	were	observed	for	the	right	eyes	of	mice	from	all	treatment	groups,	when	17 compared	to	sham-treated	mice	(Figure	49	a-d).		18 
	19 
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Figure	49:	Effect	of	SCQs	on	visual	acuity	following	rotenone-induced	vision	loss.	Following	1 intraocular	rotenone	injection	in	the	left	eye,	visual	acuity	was	measured	once	every	week	over	2 the	entire	study	period	for	all	treatment	groups,	i.e.	sham	(a),	idebenone	(b),	#37	(c)	and	#77	(d).	3 The	right	eye	was	used	as	internal	control	within	each	mouse.	Visual	acuity	was	quantified	by	4 scoring	the	number	of	head-turns	while	rotating	the	stripes	of	the	optokinetic	drum	for	2	min	in	5 clockwise	(represents	the	left-eye)	and	anti-clockwise	(represents	the	right	eye)	direction.	Each	6 data	point	represents	one	mouse.	Data	 is	expressed	as	mean	of	n=9-11	mice.	Significance	was	7 calculated	using	Student	t-test	to	compare	the	number	of	head-turns	against	the	number	one	day	8 post-rotenone	injection	within	each	group	(p*	<0.05,	p**	<0.01,	p***	<0.001).	9 	10 	11 
Overall,	calculating	the	average	OMRs	from	the	left	eyes,	no	significant	improvements	in	12 visual	acuity	was	observed	in	idebenone-treated	mice	when	compared	to	sham-treated	13 mice,	until	the	end	of	the	study	period	(Figure	50).	Importantly,	when	compared	to	sham-14 treated	mice,	significant	 improvements	 in	visual	acuity	were	observed	 in	mice	treated	15 with	#77	from	only	one-week	post-rotenone	injection,	while	#37-treated	mice	showed	16 significant	improvements	five,	eight	and	10-weeks	post-rotenone	injection	(Figure	50).17 
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Figure	 50:	 Influence	 of	 novel	 short-chain	 quinones	 (SCQ)	 on	 visual	 acuity	 after	 rotenone-induced	 vision	 loss.	 Visual	 acuity	 of	mice	was	measured	one	day	before	and	after	rotenone	injection	into	the	left-eye	of	all	mice.	This	was	followed	by	visual	acuity	measurements	once	every	week.	The	visual	acuity	of	the	left	eye	was	quantified	by	scoring	the	number	of	head-turns	while	rotating	the	stripes	of	the	optokinetic	drum	in	clock-wise	direction	for	in	2	min.	Each	data	point	represents	one	mouse.	Data	is	expressed	as	the	mean	of	n=9-11	mice.	Significance	was	calculated	using	Student	
t-test	to	compare	the	number	of	head-turns	against	sham-treated	mice	at	the	particular	time-point	(p*	<0.05)
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3.4.6		 Responder	analysis	for	SCQ-dependent	improvements	of	visual	acuity	after	1 
rotenone-induced	vision	loss.		2 	3 
One	day	after	rotenone	injection,	the	average	number	of	head-turns	in	sham-treated	mice	4 was	0.7	±	0.3.	Therefore,	mice	who	showed	more	than	one	head-turn	71	d	post-rotenone	5 injection	were	considered	as	responders.	Consistent	with	the	published	literature	(Heitz	6 et	al.	2012),	spontaneous	recovery	of	visual	acuity	was	observed	in	sham-treated	mice,	7 with	65	%	responders.	However,	as	noted	before	these	responders	typically	showed	very	8 low	head-turn	numbers	overall.	In	contrast,	the	novel	SCQs,	#37	and	#77	increased	the	9 percentage	 of	 responders	 to	 90	 %	 and	 100	 %	 respectively	 under	 conditions	 where	10 idebenone	treatment	did	not	improve	the	percentage	of	responders	(60	%)	over	sham-11 treated	mice	(Figure	51	i).	12 
Due	 to	 spontaneous	 recovery	 of	 vision,	mice	 from	 the	 sham-treated	 group	 showed	 a	13 maximum	of	7	head-turns	during	the	entire	treatment	period	(Figure	49	a).	Therefore,	I	14 defined	 mice	 from	 the	 SCQ-treated	 groups	 that	 showed	 more	 than	 7	 head-turns	 as	15 responders	to	SCQ-treatment,	which	were	reported	as	“%	responders	to	SCQ-treatment”	16 (Figure	51	ii).	When	using	this	definition,	40	%	and	70	%	of	mice	responded	to	the	novel	17 SCQs	#37	and	#77	respectively,	while	no	mice	(0	%)	responded	to	idebenone	treatment	18 (Figure	51	ii).19 
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Figure	51:	Responder	analysis.	At	the	end	of	the	treatment	period,	71	d	post-rotenone	injection,	(i)	mice	showing	more	head-turns	than	sham-treated	mice	at	1	d	post-rotenone	(one	head-turn)	were	considered	as	responders	and	were	reported	as	Responders	(%)	within	each	treatment	group	and	(ii)	the	number	of	SCQ-treated	mice	that	showed	more	than	the	maximum	number	of	head-turns	showed	by	sham-treated	mice	throughout	the	treatment	period	(7	head-turns)	were	considered	as	responders	to	SCQ	treatment	and	reported	as	Responders	to	SCQ	treatment	(%)	(n=9-11	mice	within	each	group).
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3.5		 Discussion	1 	2 
LHON	is	one	of	the	most	common	mitochondrial	disorders	that	is	characterised	by	acute	3 loss	 of	 visual	 acuity	 and	 loss	 of	 colour	 vision	 (Yu-Wai-Man	 et	 al.	 2011).	 The	 disease	4 progression	 of	 LHON	 can	 be	 divided	 into	 three	 stages	 (Figure	 52).	 The	 first,	 pre-5 symptomatic	phase	of	LHON	is	only	characterised	by	peripapillary	angiopathy	without	6 affecting	visual	acuity.	The	second,	acute	phase	of	the	disease	is	initiated	by	one	of	the	7 LHON	 mutations	 in	 combination	 with	 secondary	 genetic	 and	 environmental	 factors	8 (Hudson	et	al.	2007,	Kirkman	et	al.	2009).	This	phase	is	typically	characterised	by	rapid	9 loss	of	visual	acuity,	which	is	also	associated	with	the	swelling	of	retinal	nerve	fibre	layer	10 (RNFL),	 energy	 deficiency	 and	 oxidative	 stress.	 Increased	 oxidative	 stress	 due	 to	11 accumulation	of	reactive	oxygen	species	(ROS)	and	reduced	oxidative	phosphorylation	12 (OXPHOS)	and	energy	levels	is	believed	to	lead	to	RGC	dysfunction	(Chrysostomou	et	al.	13 2013,	 Gueven	2014,	Mehta	 et	 al.	 2013).	 This	 could	 lead	 to	 an	 inability	 by	 the	RGC	 to	14 transmit	optical	information	to	the	brain	despite	the	cells	being	still	alive.	Elevated	ROS	15 levels	and	resultant	excitotoxicity	over	a	prolonged	period	during	the	acute	phase	of	the	16 disease	is	believed	to	subsequently	initiate	the	final	phase	of	the	disease	progression	that	17 is	characterised	by	the	irreversible	death	of	RGCs	(Ghelli	et	al.	2003).	The	apoptotic	loss	18 of	 RGC	 occurs	 in	 the	 final,	 atrophic	 phase	 followed	 by	 the	 functional	 impairment	 of	19 individual	fibres,	which	leads	to	optic	nerve	atrophy	(Barboni	et	al.	2010,	Barcella	et	al.	20 2010).	 This	 is	 supported	by	histological	 post-mortem	analysis	 of	 optic	 nerve	 samples	21 from	patients	with	LHON	that	show	degeneration	of	retinal	ganglion	cells,	demyelination	22 and	fibre	loss	in	the	optic	nerve	(Saadati	et	al.	1998).	This	hypothesis	of	discrete	stages	23 between	onset	of	symptoms	and	irreversible	vision	loss	helps	to	postulate	a	window	of	24 opportunity	during	which	spontaneous	vision	recovery	 is	 (at	 least	 in	 theory)	possible	25 
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(Gueven	et	al.2014).	In	some	patients,	spontaneous	vision	recovery	can	occur	during	the	1 first	year	after	disease	onset	(Acaroğlu	et	al.	2001,	Spruijt	et	al.	2006,	Stone	et	al.	1992).	2 However,	 in	some	rare	cases,	spontaneous	vision	recovery	was	reported	several	years	3 after	disease	onset	(Spruijt	et	al.	2006,	Stone	et	al.	1992).	The	potential	window	between	4 disease	 onset	 and	 estimated	 spontaneous	 recovery	 is	 the	 area	 where	 potential	5 therapeutics	might	 be	 used	 to	 facilitate	 this	 naturally	 but	 rarely	 occurring	 process	 to	6 restore	visual	acuity	(Figure	52).	7 
Based	 on	 this	 understanding	 of	 the	 LHON	 pathology,	 therapeutic	 options	 have	 been	8 trialled	 in	 both	 preclinical,	 in	 vivo	 models	 of	 LHON	 and	 in	 clinical	 trials	 with	 LHON	9 patients	 to	 actually	 restore	 or	 facilitate	 the	 naturally	 occurring	 mechanism	 of	 vision	10 recovery.	The	SCQ	idebenone	was	reported	to	protect	visual	acuity	and	retinal	pathology	11 of	mice	under	conditions	of	impaired	mitochondrial	C-I	by	intraocular	rotenone	injection	12 (Heitz	 et	 al.	 2012).	 These	 protective	 effects	 of	 idebenone	were	 partly	 replicated	 in	 a	13 clinical	 trial	 in	 LHON	 patients.	 In	 this	 study,	 although	 not	 statistically	 significant,	 an	14 increase	in	visual	acuity	was	observed	in	some	LHON	patients	(Klopstock	et	al.	2011),	15 that	was	maintained	even	30	months	after	 idebenone	treatment	had	been	terminated.	16 This	protective	effect	of	idebenone	was	mainly	observed	in	patients	where	treatment	was	17 commenced	less	than	one	year	after	disease	onset	(Klopstock	et	al.	2013).	These	results	18 could	suggest	that	SCQ	treatment	might	initiate	the	spontaneous	recovery	of	visual	acuity	19 that	is	sustained	for	a	long	duration	even	after	terminating	the	treatment.	This	hypothesis	20 is	 supported	 by	 the	 results	 of	 the	 present	 study	 where	 our	 novel	 SCQs	 showed	 a	21 significantly	higher	responder	rates	compared	to	the	naturally	occurring	rate	of	vision	22 recovery	associated	with	this	animal	model.	23 
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Figure	 52:	 Simplified	 etiology	 of	 Leber’s	 hereditary	 optic	 neuropathy	 (LHON).	 Primary	mitochondrial	 DNA	 (mtDNA)	mutations	 along	with	etiologic	factors	result	in	impaired	energy	(adenosine	triphosphate,	ATP)	production,	excess	reactive	oxygen	species	(ROS)	and	electron	transport	chain	(ETC)	dysfunction	along	with	other	risk	factors	to	impair	retinal	ganglion	cell	(RGC)	function	in	the	acute	phase	of	LHON.	At	this	stage,	vision	may	 recover	 spontaneously	or	by	 therapeutic	 intervention.	However,	without	 interventions,	RGC	dysfunction	eventually	 leads	 to	RGC	 loss	by	 an	apoptotic	cell	death	mechanism	(Gueven	2014,	Sanchez	et	al.	2016).	
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To	 provide	 supporting	 evidence	 for	 these	 protective	 effects	 of	 SCQs,	 it	 is	 essential	 to	1 utilise	an	in	vivo	model	of	LHON	that	should	allow	us	to	investigate	not	only	efficacy	of	2 therapeutic	interventions,	but	also	to	generate	detailed	data	on	the	timing	of	events	and	3 the	molecular	pathologies	associated	with	different	stages	of	disease.		4 
Based	on	our	current	understanding	of	the	LHON	pathology,	several	murine	models	have	5 been	 established	 that	 aim	 to	 mimic	 the	 characteristic	 pathologies	 of	 LHON.	 The	6 approaches	include	mimicking	mitochondrial	dysfunction	by	genetic	modelling	or	toxin	7 exposure	 to	 inhibit	 mitochondrial	 C-I.	 Two	 genetic	 models	 of	 C-I	 dysfunction	 were	8 developed	by	 introducing	mutations	 into	 two	genes	 that	encode	subunits	of	C-I	of	 the	9 mitochondrial	 ETC,	 ND4	 and	 ND6.	 However,	 these	 genetic	models	 do	 not	 completely	10 replicate	 the	pathology	of	 LHON	and	 therefore	 lack	 face	 validity.	 In	 the	mouse	model	11 characterised	by	 a	mutation	 in	ND6	 (P25L),	 synaptosome	analysis	 revealed	 increased	12 ROS	production,	while	ATP	levels	in	the	synaptosomes	remained	unchanged	(Lin	et	al.	13 2012).	 In	 another	 study	 conducted	 on	 rats	 harbouring	 a	 mutated	 ND4	 gene,	 a	14 degeneration	of	RGCs	along	with	reduction	of	visual	acuity	were	observed	(Ellouze	et	al.	15 2008).	 However,	 it	 has	 to	 be	 noted	 that	 these	 genetic	 models	 are	 not	 necessarily	16 replicating	the	situation	in	LHON	patients,	where	mutation	carrier	does	not	necessarily	17 develop	the	disease.	For	example,	levels	of	penetrance	as	low	as	26	%	for	males	and	6	%	18 for	females	have	been	reported	for	the	m11778G>A	mutation	in	Finland	(Puomila	et	al.	19 2007).	In	addition,	only	70	%	of	the	RGCs	in	the	ND4	model	expressed	the	mutation	for	20 only	up	to	50	d,	which	severely	limits	the	use	of	this	model	to	test	novel	therapeutics	over	21 periods	longer	than	50	d	(Ellouze	et	al.	2008).	22 
Another	approach	to	mimic	LHON	is	the	use	of	the	C-I	 inhibitor,	rotenone.	Injection	of	23 rotenone-loaded	microspheres	into	the	optic	layer	of	the	superior	colliculus	of	the	brain	24 
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of	rats,	significantly	reduced	the	visual	acuity	after	2	weeks,	with	an	indication	of	elevated	1 levels	of	ROS.	However,	this	study	was	unable	to	measure	any	effects	of	this	treatment	on	2 the	number	of	RGC	cells	(Marella	et	al.	2010).	Since	this	model	is	not	only	time	consuming	3 and	 requires	 the	 specialised	 production	 of	 microspheres	 (which	 necessitates	 control	4 measures	to	avoid	batch	to	batch	variation	and	continuous	stability	controls),	 I	used	a	5 simplified	 approach	 that	 included	 the	 direct	 intravitreal	 injection	 of	 rotenone.	 This	6 approach	 was	 previously	 described	 to	 result	 in	 RGCs	 loss,	 reduced	 RNFL	 thickness,	7 reactive	gliosis	and	loss	of	visual	acuity	(Heitz	et	al.	2012,	Rojas	et	al.	2008,	Zhang	et	al.	8 2002).	I	also	selected	this	model	as	it	not	only	mimics	the	major	pathological	changes	in	9 LHON,	 but	 the	 rotenone	 concentration	 can	 be	 titrated	 to	 enable	 spontaneous	 vision	10 recovery	(unpublished	data	N.	Gueven),	similar	to	the	situation	in	some	LHON	patients,	11 which	has	not	been	described	for	the	models	listed	above.	In	addition,	this	approach	was	12 previously	used	to	demonstrate	the	protective	activity	of	the	benzoquinone,	idebenone	13 (Heitz	 et	 al.	 2012).	 However,	 I	 have	 to	 acknowledge	 that	 this	model,	 like	 the	 genetic	14 models	 described	 above	 do	 not	 require	 additional	 (i.e.	 etiologic)	 factors	 that	 in	15 conjunction	with	C-I	inhibition	leads	to	loss	of	visual	acuity.	In	this	sense,	the	results	of	16 this	study	cannot	be	directly	translated	to	the	situation	in	LHON	patients.	17 
So	 far,	 the	 efficacy	 of	 naphthoquinones	 to	 treat	 mitochondrial	 disorders	 has	 been	18 discussed	 in	 vitro	 and	 in	 animal	models	 of	 neurological	 disorders	 like	 epilepsy,	 since	19 decreased	 ATP	 levels	 and	 elevated	 ROS	 levels	 due	 to	 mitochondrial	 dysfunction	 can	20 increase	neuronal	excitability	and	induce	seizures	(Josey	et	al.	2013,	Rahn	et	al.	2014).	In	21 these	 studies,	 vitamin	 K	 analogues	 reportedly	 reduced	 seizures	 with	 no	 observable	22 toxicity	 in	 a	 mouse	 model	 of	 pentylenetetrazole	 (PTZ)-induced	 seizures.	 Since	 these	23 compounds	 increased	 total	 cellular	 ATP	 levels	 in	 a	 mouse	 hippocampal	 cell	 line,	 the	24 authors	 suggested	 that	 this	 activity	 is	 the	 potential	 mechanism	 of	 action	 of	 the	25 
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naphthoquinones	of	this	study	(Rahn	et	al.	2014).	Although,	these	results	support	the	use	1 of	 naphthoquinones	 in	 treating	 mitochondrial	 disorders	 in	 general,	 the	 detailed	2 mechanism	of	action	of	these	compounds	is	yet	to	be	understood.	3 
In	 the	 current	 study,	 for	 the	 first	 time,	 I	 investigated	 the	 efficacy	 of	 novel	4 naphthoquinones	in	a	mouse	model	of	rotenone-induced	loss	of	visual	acuity.	A	previous	5 report	used	this	model	to	show	the	protective	activity	of	high	doses	of	idebenone	(2000	6 mg/kg)	 and	 included	 a	 3-week	 pre-treatment	 period	 with	 idebenone	 prior	 to	 the	7 rotenone	 challenge	 (Heitz	 et	 al.	 2012).	 This	 pre-treatment	 with	 idebenone	 protected	8 against	loss	of	RGC,	retinal	thickness	seven	days	post	rotenone	challenge	and	promoted	9 a	significant	improvement	of	visual	acuity	seventy	days	post	rotenone	challenge	(Heitz	et	10 al.	 2012).	 In	 this	 study,	 a	 3-week	 pre-treatment	 was	 selected,	 since	 at	 the	 time,	 no	11 information	was	 available	 on	 the	 pharmacokinetics	 of	 idebenone	with	 regards	 to	 eye	12 fluids	and	it	was	speculated	that	prolonged	pre-treatment	would	provide	stable	trough	13 levels	 (something	 that	 the	same	authors	could	disprove	 in	 the	same	study;	N.	Gueven	14 unpublished	 observation;	 Heitz	 et	 al.	 2012).	 Based	 on	 a	 better	 understanding	 of	15 idebenone	 eye	 pharmacokinetics,	 but	 no	 information	 on	 the	 pharmacokinetics	 of	 our	16 novel	SCQs,	we	decided	to	pre-treat	 the	mice	 for	only	one-week	prior	 to	 the	rotenone	17 challenge.	 Similar	 to	 the	 previous	 study	 (Heitz	 et	 al.	 2012),	 all	 SCQs	 were	 orally	18 administered	through	the	food.	However,	in	contrast	to	the	previous	study	(Heitz	et	al.	19 2012)	I	used	only	1/10th	of	the	SCQ	dose	based	on	the	significantly	increased	activity	of	20 our	novel	SCQs	in	vitro.	In	line	with	this	reduction,	all	new	SCQs	were	administered	at	a	21 dose	equivalent	to	200	mg	idebenone/kg,	in	contrast	to	the	previously	used	2000	mg/kg	22 (Heitz	et	al.	2012).		23 
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In	 principle	 any	 SCQ	 pre-treatment	 could	 be	 seen	 to	 protect	 cells	 against	 a	 rotenone	1 challenge.	 If	 this	were	 the	 case,	 any	 subsequent	 changes	 in	 visual	 acuity	 could	be	 the	2 result	 of	 this	 difference	 in	 viability	 or	 cellular	 stress	 status	 one	 day	 after	 rotenone	3 injection.	This	would	also	mean	that	instead	of	interpreting	our	data	as	a	time-dependent	4 recovery	of	vision	by	the	novel	SCQs,	the	results	could	simply	be	seen	as	a	differential	5 level	 of	 damage	on	day	one	with	 consequently	different	 kinetics	 of	 recovery	over	 the	6 course	of	the	study.		However,	no	significant	differences	in	visual	acuity	were	observed	7 in	 the	 left,	 rotenone-injected	eye,	one	day	after	 the	rotenone	challenge	 in	SCQ	 treated	8 mice,	 when	 compared	 to	 sham-treated	mice.	 Although,	 it	 appears	 that	 the	 protective	9 effects	 of	 SCQs	 are	 associated	with	 their	 ongoing	presence	 in	 the	 animals,	 the	 former	10 possibility	should	not	be	 ignored	and	assessed	by	 future	experiments	 that	should	 test	11 different	pre-	and	post-treatment	 times.	These	experiments,	as	well	as	different	doses	12 were	not	included	in	the	present	study	due	to	time	constraints.	Overall,	the	necessity	of	13 the	one-week	SCQ	pre-treatment	is	unclear	at	this	stage.	14 
The	 potential	 benefits	 due	 to	 SCQ	 pre-treatment	 is	 in	 agreement	 with	 previously	15 published	 literature	where	one	day	pre-treatment	with	 idebenone	reduced	ROS	 levels	16 and	 prevented	 apoptosis	 in	 cultured	 retinal	 neurons	 (Gil	 et	 al.	 2003).	 In	 other	 study	17 conducted	 on	 fibroblast	 cell	 lines	 from	 LHON	 patients,	 one	 day	 pre-treatment	 with	18 idebenone	significantly	increased	the	activity	of	mitochondrial	C-I	(Angebault	et	al.	2011).	19 Idebenone	was	also	administered	3	weeks	prior	to	injecting	rotenone	in	an	in	vivo	mouse	20 model	of	LHON,	in	which	significant	improvement	of	retinal	thickness	and	the	number	of	21 RGCs,	was	observed	7	d	post	rotenone	challenge	(Heitz	et	al.	2012).	However,	in	all	these	22 studies,	the	reason	for	pre-treatment	was	not	discussed.	In	a	recently	published	study,	23 idebenone	 strongly	 induced	 the	 expression	 of	 Lin28A	 and	 significantly	 restored	 RGC	24 survival	and	retinal	thickness	in	combination	with	rasagiline	(Lei	et	al.	2018).	Lin	28A	is	25 
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a	 highly	 conserved	 regulator	 of	 many	 cellular	 RNAs.	 With	 this	 function,	 Lin28A	1 fundamentally	affects	metabolism,	ageing,	stress	response,	survival	and	the	capacity	for	2 tissue	repair	(Shyh-Chang	et	al.	2013).	Tissue	repair	capacity	in	particular	is	dependent	3 on	increased	mitochondrial	function	(OXPHOS),	improved	glucose	metabolism,	increased	4 insulin	sensitivity,	Akt-activation	and	reduced	autophagy	(Zhu	et	al.	2011),	which	could	5 well	explain	 the	multiple	SCQ-induced	protective	activities	we	and	others	observed	 in	6 different	pre-clinical	models	of	mitochondrial	dysfunction.	However,	Lin28A	 is	mostly	7 known	for	its	binding	to	the	pre-let-7	miRNA,	which	prevents	its	processing	(Heo	et	al.	8 2008).	 Lin28A	 therefore	 reduces	 let-7	 miRNA	 levels,	 which	 upregulates	 several	9 oncogenes	 such	 as	MYC,	 RAS	 and	 HMGA2	 (Balzeau	 et	 al.	 2017).	 Consistent	 with	 this	10 function,	ectopic	Lin28	expression	was	reported	to	drive	or	accelerate	tumorigenesis	via	11 a	 let-7	 dependent	mechanism	 (Heo	 et	 al.	 2008)	 The	 idebenone-Lin28A	 connection	 is	12 surprising	and	in	stark	contrast	to	the	clinical	data	obtained	with	idebenone.	Idebenone	13 is	characterized	by	an	exceptionally	good	safety	profile	and	after	1000s	of	patient-years	14 no	 connection	 to	 any	 type	 of	 malignancy	 has	 ever	 been	 observed	 or	 reported.	15 Nevertheless,	in	light	of	this	recent	report,	it	is	essential	to	evaluate	the	potential	cancer	16 risk	for	our	novel	SCQs	that	could	arise	from	a	Lin28A-let-7-dependent	mechanism.			17 
Overall,	it	could	nevertheless	be	hypothesised	that	SCQ-pre-treatment	is	needed	to	allow	18 for	 a	 time-consuming	 gene	 expression	 step	 before	 SCQ-dependent	 protection	 is	 seen.	19 However,	 this	 hypothesis	 has	 to	 be	 treated	with	 extreme	 caution	 since	 the	 published	20 evidence	supporting	the	idebenone-induced	Lin28A	overexpression	is	so	far	based	on	a	21 single	report	and	does	not	fit	the	clinical	evidence.	22 
In	 this	 study,	 two	 selected	novel,	 highly	protective	 SCQs	 (Figure	41)	were	 tested	 in	 a	23 mouse	 model	 of	 rotenone-induced	 blindness.	 Although	 this	 model	 is	 widely	 used	 to	24 
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replicate	many	aspects	of	the	LHON	pathology,	certain	limitations	must	be	acknowledged.	1 Rotenone	is	believed	to	bind	on	the	quinone-binding	site	of	mitochondrial	C-I,	however,	2 the	exact	binding	site	within	C-I	is	not	established	yet	(Friedrich	et	al.	1994,	Prieur	et	al.	3 2001).	Therefore,	it	is	unclear	if	the	sub-unit	of	C-I,	inhibited	by	rotenone	is	same	as	the	4 one	encoded	by	genes	that	associated	with	LHON.	This	is	of	specific	importance	since	not	5 all	mutations	in	C-I	are	associated	with	LHON	but	can	be	responsible	for	disorders	with	6 pathologies	distinctly	different	 to	LHON.	Although	rotenone	 inhibits	mitochondrial	C-I	7 and	elevates	ROS	levels	(Beretta	et	al.	2006,	Li	et	al.	2003),	rotenone	also	has	off-target	8 effects	like	any	other	small	molecule,	such	as	disrupting	Ca2+	homeostasis	(Freestone	et	9 al.	2009,	Wang	and	Xu	2005)	and	induce	apoptosis	(Beretta	et	al.	2006,	Li	et	al.	2003)	that	10 could	conceivably	modify	the	pathology	of	this	animal	model.		It	has	to	be	noted	that	at	11 present	there	is	no	perfect	pre-clinical	model	for	LHON	that	would	replicate	all	patient	12 characteristics	such	as	incomplete	penetrance,	gender	bias,	need	for	additional	factors	in	13 addition	 to	 the	 reproduction	 of	 the	molecular	 pathology.	 Since	 the	 rotenone-injection	14 model	mimics	the	major	pathological	features	of	LHON,	like	loss	of	RGCs,	reduced	retinal	15 thickness	and	loss	of	visual	acuity	and	was	used	previously	to	test	the	efficacy	idebenone	16 (Heitz	et	al.	2012),	this	model	was	opted	in	the	current	study.	It	has	to	be	acknowledged	17 that	a	possible	limitation	of	this	animal	model	is	the	procedure	of	intraocular	injection	of	18 rotenone.	 Since	 the	 injection	was	 performed	manually,	 unintentional	 errors	 could	 be	19 introduced,	such	as	leakage	of	rotenone	out	of	the	vitreous	after	injection,	minor	changes	20 in	applied	rotenone	dose	(given	that	only	one	microliter	is	injected)	or	inaccurate	angle	21 of	 injection	resulting	in	altered	site	of	rotenone	delivery.	These	factors	can	potentially	22 lead	to	inaccurate	rotenone	dosing.	This	was	the	reason	why	mice	without	significant	loss	23 of	 visual	 acuity	 one	 day	 post-rotenone	 challenge	 were	 excluded	 from	 the	 study.	24 
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Nevertheless,	 I	 cannot	 exclude	 that	 intra-animal	 variation	 was	 the	 result	 of	 minor	1 inaccuracies	of	the	injection	process.		2 
At	the	end	of	the	study	period,	while	collecting	eyes,	processing	tissues	or	cutting	sections	3 for	histological	analysis,	unintentional	structural	damage	to	the	retina	was	observed	for	4 some	eyes.	Sections,	where	obvious	handling	artefacts	resulted	in	significant	variability	5 of	 the	 tissue	 histology,	 were	 excluded	 from	 the	 analysis	 since	 retinal	 detachment	6 restricted	the	ability	to	identify	and	quantify	the	same	area	on	all	retinal	sections.	Initial	7 H	 &	 E	 stained	 images	 showed	 obvious	 changes	 in	 the	 tissue	 histology	 between	 the	8 rotenone	challenged	left	versus	non-injected	right	eye	(Figure	45).	Consistent	with	the	9 previously	published	studies	(Heitz	et	al.	2012,	Rojas	et	al.	2008,	Zhang	et	al.	2002),	a	10 significant	loss	of	retinal	thickness	and	RGC	numbers	was	observed	in	sham-treated	mice	11 upon	rotenone	injection	(Figure	46,	47).	It	is	important	to	point	out	that	due	to	the	timing	12 of	 sample	 preparation	 only	 seventy	 days	 after	 the	 rotenone	 challenge	 only	 a	 disease	13 pathology	reminiscent	of	the	atrophic	phase	of	the	disease	was	observed	in	the	animals	14 that	included	loss	of	RGCs	and	reduced	retinal	thickness	(Barboni	et	al.	2010,	Barcella	et	15 al.	 2010,	 Ghelli	 et	 al.	 2003).	 In	 contrast,	 the	 acute	 phase	 of	 LHON	 would	 have	 been	16 associated	with	 elevated	 levels	 of	 ROS	 and	 swollen	 RNFL	 (Chrysostomou	 et	 al.	 2013,	17 Gueven	2014,	Mehta	et	al.	2013)	but	was	not	assessed	in	this	study.	Nevertheless,	despite	18 showing	signs	indicative	of	the	atrophic	phase	at	the	end	of	the	study,	spontaneous	vision	19 recovery	was	observed	 in	 sham-treated	mice.	This	 indicates	 that	 this	model	might	be	20 associated	at	an	earlier	time	point	with	an	acute	phase	similar	to	LHON	patients,	which	21 suggests	that	recovery	of	visual	acuity	is	principally	possible.	This	also	supports	the	idea	22 that	 in	 this	 window	 of	 opportunity	 a	 pharmacological	 intervention	 to	 induce	 this	23 physiological	 process	 is	 a	 possibility.	 Interestingly,	 both	 novel	 SCQs,	 #37	 and	 #77	24 significantly	increased	visual	acuity,	retinal	thickness	and	RGC	numbers	when	compared	25 
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to	 sham-treated	cells	under	 conditions	where	 idebenone	did	not	 show	any	 significant	1 changes.	Unlike	the	previously	published	study	(Heitz	et	al.	2012),	the	lack	of	protection	2 by	idebenone	in	our	study	is	most	likely	the	consequence	of	the	significantly	lower	dose	3 used.		4 
Both	loss	of	RGCs	and	reduced	retinal	thickness	due	to	mitochondrial	dysfunction	results	5 in	the	loss	of	visual	acuity.	This	was	demonstrated	in	our	study	where	all	mice	drastically	6 lost	visual	acuity	one	day	after	the	rotenone	challenge	(Figure	48).	7 
Unfortunately,	neither	my	in	vitro	nor	my	in	vivo	data	have	shed	light	on	the	molecular	8 mode	of	action	of	the	novel	SCQs.	What	was	observed	is	that	all	the	previously	proposed	9 modes	of	action	such	as	antioxidant	activity	and	effects	on	ATP	levels	are	likely	unrelated	10 to	 the	cytoprotective	 function	of	 this	class	of	 compounds.	Therefore,	at	 this	 stage	 it	 is	11 unclear	if	the	novel	SCQs	are	more	potent	than	idebenone	or	act	via	a	completely	different	12 mechanism.	While	Lin28A	may	be	involved	in	the	mechanism	of	action	of	novel	SCQs,	it	13 raises	 the	 question	 about	 the	 necessity	 of	 a	 pre-treatment	 period	 with	 SCQs,	 which	14 requires	further	detailed	investigations	and	are	currently	underway	in	my	supervisor’s	15 laboratory.		16 
The	fact	that	none	of	the	SCQs	induced	any	significant	changes	in	the	non-injected	right	17 eye	 suggests	 that	 the	 SCQs	 do	 not	 show	 any	 adverse	 effects	per	 se	 in	 the	 absence	 of	18 mitochondrial	dysfunction.	However,	this	result	is	in	contrast	to	a	previous	study	where	19 visual	 function	 was	 impaired	 in	 wild-type	 mice	 treated	 with	 2000	mg/kg	 idebenone	20 compared	 to	 Opa1	 mutant	 mice	 (Smith	 et	 al.	 2016).	 Although	 this	 effect	 was	 not	21 statistically	significant,	it	is	in	contrast	to	my	results,	which	could	be	attributed	to	the	use	22 of	a	much	lower	dose	of	idebenone	in	our	study.	23 
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Overall,	our	novel	SCQs	did	not	impose	any	obviously	visible	adverse	effects	on	mice	at	1 the	dosage	administered	for	the	treatment	duration.	Nevertheless,	since	our	novel	SCQs	2 are	naphthoquinones	and	therefore	Vitamin	K	analogues	in	the	widest	sense,	they	could	3 have	 potentially	 affected	 blood	 coagulation	 as	 vitamin	 K	 is	 integral	 to	 the	 blood	4 coagulation	 cascade.	 Therefore,	 another	 limitation	 of	 this	 study	 that	 has	 to	 be	5 acknowledged	was	that	the	effects	of	the	novel	SCQs	on	blood	coagulation	or	other	organ	6 functions	 were	 not	 assessed.	 Further	 studies	 analysing	 the	 safety,	 tolerability,	7 pharmacodynamics	 and	 pharmacokinetics	 of	 the	 novel	 SCQs	 in	much	more	 detail	 are	8 required	and	in	fact	underway	by	another	PhD	student	(Zikai	Feng).	In	summary,	my	data	9 in	this	chapter	presents	compelling	evidence	that	supports	the	development	of	our	novel	10 SCQs	towards	clinical	use	in	mitochondrial	indications	such	as	LHON	but	also	describes	11 the	necessity	for	a	significant	safety	assessment	of	this	class	of	molecules	in	general.	12 
	13 
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4.1		 Conclusion	1 	2 
Mitochondria	are	multifunctional	organelles	that	mainly	satisfy	the	majority	of	cellular	3 energy	demands	(Campbell	and	Reece	2005,	Wallace	et	al.	2010),	while	also	representing	4 a	major	source	of	reactive	oxygen	species	(ROS)	(Maurya	et	al.	2015,	Zorov	et	al.	2014).	5 In	 addition,	 mitochondria	 contribute	 to	 thermoregulation	 (Chouchani	 et	 al.	 2016,	6 Nedergaard	 et	 al.	 2001),	 Ca2+	 homeostasis	 (Giorgio	 et	 al.	 2017,	 Ichas	 et	 al.	 1994)	 and	7 regulate	 cell	 death	 mechanisms	 (Vakifahmetoglu-Norberg	 et	 al.	 2017,	 Wojtczak	 and	8 Zabłocki	2008).	Any	physical	or	chemical	insult	or	a	genetic	predisposition	that	leads	to	9 mitochondrial	dysfunction	can	result	in	a	wide	range	of	pathologies	and	disorders	(Carelli	10 et	al.	2002,	Gueven	2014,	Legault	et	al.	2015,	Lin	and	Beal	2006,	Sadeghian	et	al.	2016).	It	11 is	 therefore	 surprising	 that	 only	 a	 very	 limited	 number	 of	 drug	 candidates	 are	 in	12 development	that	aim	to	protect	mitochondrial	function.	The	chemical	class	of	quinones	13 is	 known	 for	 their	 antioxidant	 activity	 and	 their	 ability	 to	 restore	 cellular	 ATP	 levels	14 (Antonenko	et	al.	2008,	Erb	et	al.	2012,	Smith	and	Murphy	2010,	Yu-Wai-Man	et	al.	2017).	15 In	 addition,	 quinones	 can	 act	 as	 signaling	 molecules	 and	 enzymatic	 co-factors	 upon	16 bioactivation	 by	 cellular	 reductases	 (Ayer	 et	 al.	 2015,	 Dominy	 and	 Puigserver	 2013,	17 Marriage	 et	 al.	 2003).	 The	 short-chain	 benzoquinone,	 idebenone	 (Figure	 14	 ii)	 was	18 developed	by	Takeda	in	the	1980s	as	a	Coenzyme	Q10	(CoQ10)	analogue	with	the	aim	to	19 protect	energy	generation	and	act	as	an	antioxidant	under	conditions	of	mitochondrial	20 dysfunction	 (Miyamoto	 et	 al.	 1999,	 Suno	 and	Nagaoka	 1984).	 These	 two	 activities	 of	21 idebenone	were	largely	postulated	based	on	the	assumption	that	idebenone,	as	a	CoQ10	22 analogue,	 would	 share	 the	 known	 biological	 activities	 of	 CoQ10.	 Unfortunately,	 this	23 assumption	was	never	really	questioned	(Gueven	et	al.	2015).	Although,	idebenone	did	24 not	produce	consistent	results	in	the	early	clinical	trials	in	Alzheimer’s	disease	patients	25 
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(Gutzmann	and	Hadler	1998,	Thal	et	al.	2003),	later	trials	in	mitochondrial	diseases	were	1 more	encouraging	(Klopstock	et	al.	2011,	Liu	and	Wang	2014,	Rudolph,	Dimitriadis	et	al.	2 2013).	A	number	of	small	trials	with	idebenone	and	other	short-chain	quinones	(SCQs)	3 overall	support	the	hypothesis	that	targeting	mitochondrial	function	could	in	principle	4 be	beneficial	to	treat	diseases	associated	with	mitochondrial	dysfunction	(Brzheskiy	et	al.	5 2015,	Enns	et	al.	2012,	Gueven	et	al.	2017,	Sadun	et	al.	2012).	6 
However,	despite	some	encouraging	protective	effects	by	SCQs	seen	in	pre-clinical	and	7 clinical	 trials,	no	causative	modes	of	action	have	been	scientifically	 confirmed	 for	 this	8 class	of	molecules	that	go	beyond	pure	associations.	This	lack	of	understanding	is	not	only	9 a	major	 limitation	 for	 the	 rational	 development	 of	 improved	 SCQs	but	 also	 limits	 our	10 ability	to	predict	their	possible	side	effect	profiles.	Therefore,	the	real	and	urgent	need	to	11 develop	 improved	 drug	 candidates	 tailored	 to	 patients	 with	 specific	 mitochondrial	12 diseases	 is	 limited	 by	 the	 lack	 of	 fundamental	 understanding	 around	 the	 molecular	13 mode(s)	of	action	of	SCQs.	14 
In	 this	 study,	 we	 successfully	 developed	 a	 range	 of	 novel	 SCQs	 based	 on	 a	15 naphthoquinone	scaffold	by	an	iterative	medicinal	chemistry	drug	discovery	approach.	16 These	novel	SCQs	were	highly	effective	 in	protecting	cellular	viability	and	normalising	17 ATP	levels	in	the	presence	of	a	mitochondrial	C-I	inhibitor,	in	vitro.	At	the	same	time,	these	18 compounds	also	influenced	lactate	and	beta-hydroxy	butyrate	(BHB)	levels	in	cell	culture	19 supernatant	 but	 did	 not	 affect	 basal	 levels	 of	 lipid	 peroxidation.	 Importantly,	 none	 of	20 these	 measured	 parameters	 correlated	 with	 the	 cytoprotective	 activities	 observed.	21 Therefore,	in	contrast	to	the	current,	possibly	over-simplified	assumption	that	rescuing	22 ATP	levels	and	reducing	oxidative	stress	are	central	to	restoring	cell	viability	by	SCQs,	my	23 results	 suggest	 that	 SCQs	 either	 act	 in	 a	 more	 complex	 fashion	 where	 different	24 
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compounds	of	 the	same	chemical	class	could	have	one	or	several	different	mode(s)	of	1 action	or	could	involve	entirely	new	modes	of	action.	These	novel	modes	of	action	could	2 involve	two	recently	described	signaling	pathways	that	are	influenced	by	SCQs,	namely	3 inhibition	of	p52Shc	and	activation	of	Lin	28A	(Figure	37).	4 
In	the	present	study,	I	was	able	to	generate	a	structure	activity	relationship	(SAR)	for	the	5 particular	 class	 of	 SCQs	 used	 in	 the	 present	 study,	which	was	 never	 reported	 in	 this	6 amount	of	detail	before.	The	precise	combination	of	a	naphthoquinone	core	with	a	methyl	7 group	 and	 an	 alkyl	 side	 chain	with	 specific	 functional	 groups	 of	 balanced	 charge	 and	8 polarity	were	identified	as	the	main	determinants	of	their	cytoprotective	activity	of	this	9 class	of	compounds.		10 
To	translate	my	in	vitro	results	(Chapter	2)	to	an	in	vivo	mitochondrial	disease	model,	I	11 investigated	the	efficacy	of	two	selected	novel,	highly	protective	naphthoquinones	(#37	12 and	#77)	in	a	mouse	model	of	LHON	(Chapter	3).	Consistent	with	their	cytoprotective	13 activity	in	vitro,	both	novel	SCQs,	#37	and	#77	significantly	increased	visual	acuity,	retinal	14 thickness	and	protected	retinal	ganglion	cell	(RGC)	numbers.	Importantly,	under	these	15 conditions	idebenone	did	not	show	any	significant	protection.	In	fact,	in	vivo	protection	16 by	our	SCQs	was	observed	at	1/10th	of	the	dose	of	idebenone	used	in	previously	published	17 study	(Heitz	et	al.	2012).	This	suggests	that	our	novel	SCQs	are	either	significantly	more	18 effective	than	idebenone	or	act	via	a	completely	different	mechanism.	Comparable	to	the	19 very	 good	 in	 vivo	 safety	 profile	 of	 idebenone,	 our	 novel	 SCQs	 did	 not	 result	 in	 any	20 obviously	adverse	effects	over	the	treatment	duration.		21 
While	the	exact	molecular	mode	of	action	of	the	novel	SCQs	is	still	unclear,	for	the	first	22 time,	my	results	strongly	suggest	that	all	the	previously	proposed	modes	of	action	such	23 as	 antioxidant	 activity	 and	 effects	 on	 ATP	 levels	 are	 likely	 unrelated	 to	 the	 in	 vitro	24 
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cytoprotective	 function	 of	 this	 class	 of	 compounds.	 Nevertheless,	 the	 in	 vitro	1 cytoprotective	 ability	 of	 our	 novel	 SCQs	 could	be	 successfully	 translated	 to	 an	 in	 vivo	2 model	 of	mitochondrial	 dysfunction	 induced	 loss	 of	 visual	 acuity.	 Therefore,	my	 data	3 presents	 compelling	 evidence	 that	 supports	 the	 development	 of	 some	 selected	 SCQs	4 towards	 clinical	 use	 in	 mitochondrial	 indications	 such	 as	 LHON.	 However,	 further	5 characterisation	of	our	SCQs	with	regards	to	general	ADME	characteristics	and	toxicity	6 will	be	required	to	support	this	selection	process.	7 
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4.2		 Limitations	of	the	Study	1 	2 
The	 current	 study	 aimed	 to	 develop	 and	 characterise	 novel	 SCQs	 for	 their	 ability	 to	3 protect	against	mitochondrial	dysfunction	and	work	towards	understanding	their	SAR	4 and	mode	of	action.	Although	I	have	addressed	all	the	aims	and	objectives,	a	number	of	5 limitations	inherent	to	this	study	need	to	be	considered.		6 
A	common	approach	to	drug	discovery	for	mitochondrial	disorders	is	the	use	of	cybrid	7 cell	 lines	 that	 harbour	 different	 mtDNA	 with	 the	 same	 nuclear	 DNA	 background.	8 Therefore,	trans-mitochondrial	cybrids	carrying	one	of	the	three	LHON	mutations	that	9 showed	C-I	dysfunction-induced	oxidative	stress	(Carelli	et	al.	2004,	Floreani	et	al.	2005,	10 Wong	et	al.	2002)	could	have	been	used	to	characterise	the	protective	activities	of	our	11 novel	 SCQs.	 However,	 a	 consistent	 reduction	 of	 cellular	 ATP	 levels	 could	 not	 be	12 demonstrated	in	LHON	cybrids	(Korsten	et	al.	2010).	Furthermore,	the	tumor	cells	used	13 to	 generate	 the	 available	 LHON	 cybrids	 are	 characterized	 by	 extremely	 low	 levels	 of	14 NQO1,	 which	 would	 have	 significantly	 impaired	 the	 bioactivation	 of	 our	 compounds	15 (Brown	et	al.	2000).	Primary	cell	lines	are	also	associated	with	other	problems	such	as	16 senescence,	and	unsteady	growth	rates,	which	can	be	avoided	by	using	a	cell	line.		17 
Moreover,	 the	 exact	 patho-mechanisms	 of	 diseases	 associated	 with	 mitochondrial	18 dysfunction	are	not	clearly	known	at	present.	A	multitude	of	factors	such	as	mutations	19 and	polymorphisms	in	nDNA	and	mtDNA,	mitochondrial	haplotype,	epigenetic	changes	20 in	tumor	cells	and	environmental	factors	all	affect	disease	symptoms	and	etiology	(Burté	21 et	 al.	 2015,	 DiMauro	 et	 al.	 2013,	 Larsson	 and	 Clayton	 1995,	 Vafai	 and	Mootha	 2012,	22 Zeviani	and	Di	Donato	2004).	These	limitations	make	it	difficult	to	generate	a	cell	culture	23 model	 of	 a	 specific	 mitochondrial	 disease	 that	 shows	 sufficient	 face-,	 construct-	 and	24 
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predictive	validity	(Gazdar	et	al.	2010).	However,	the	availability	of	a	reliable	cell	culture	1 model	was	essential	to	consistently	perform	comparative	studies	over	extended	periods	2 of	time	during	the	duration	of	my	project.	Therefore,	I	used	a	widely	used	hepatic	cell	line	3 combined	 with	 a	 well-known	 mitochondrial	 toxin	 to	 generate	 a	 reliable	 model	 of	4 mitochondrial	dysfunction.	Moreover,	 since	quinones	are	known	to	undergo	 first-pass	5 metabolism	 (Becker	 et	 al.	 2010,	 Bodmer	 et	 al.	 2009),	 I	 have	 chosen	 HepG2	 cells	 to	6 characterise	our	novel	SCQs.	7 
While	cybrid	cells	largely	do	not	express	NQO1	at	detectable	levels,	HepG2	cells	on	the	8 other	hand	are	known	to	express	higher	levels	of	NQO1	compared	to	normal	liver	cells.	9 This	 overexpression	 could	 conceivably	 over-emphasize	 results	 with	 regards	 to	 SCQ	10 bioactivation	and	metabolic	activity	(Cresteil	and	Jaiswal	1991).	Therefore,	my	results	11 cannot	be	easily	extrapolated	to	other	established	cell	lines	containing	low	NQO1	levels	12 such	as	neuronal	cells	(RGC5	or	SHSY5Y)	or	human	embryonic	kidney	cell	line	(HEK293).	13 Despite	the	high	NQO1	levels	of	HepG2	cells,	the	dependence	of	quinones	on	NQO1	for	14 their	 cytoprotective	 ability	 has	 not	 been	 proven	 beyond	 doubt.	 The	 dependence	 of	15 idebenone	reduction	by	NQO1	for	acute	rescue	of	ATP	levels	in	rat	myoblasts	has	been	16 published	(Erb	et	al.	2012).	However,	the	same	research	team	showed	cytoprotection	of	17 RGC5	cells	(that	only	contain	minimal	levels	of	NQO1)	by	idebenone	in	the	presence	of	18 rotenone	 (Heitz	 et	 al.	 2012).	 This	 contradiction	questions	 at	 least	 the	dependence	 on	19 NQO1	for	the	reduction	of	idebenone	to	enable	its	cytoprotective	activity	but	does	open	20 the	possibility	that	other	reductases	could	compensate	for	a	loss	of	NQO1.	The	possibility	21 that	 the	 reduction	of	 SCQs	by	 cellular	 reductases	 is	 not	necessarily	 required	 for	 their	22 cytoprotective	ability	is	supported	by	my	results	that	failed	to	demonstrate	a	correlation	23 between	reduction	and	cytoprotection.	24 
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To	 measure	 the	 cytoprotective	 ability	 of	 the	 novel	 SCQs,	 I	 have	 used	 only	 a	 single	1 mitochondrial	 C-I	 inhibitor,	 rotenone	 to	 induce	 a	 defined	 state	 of	 mitochondrial	2 dysfunction,	 similar	 to	 previously	 published	 studies	 that	 tested	 idebenone	 and	 its	3 analogues	(Erb	et	al.	2012,	Giorgio	et	al.	2012,	Haefeli	et	al.	2011).	Idebenone	is	believed	4 to	rescue	ATP	levels	by	bypassing	mitochondrial	C-I,	in	the	presence	of	rotenone-induced	5 mitochondrial	 dysfunction	 (Haefeli	 et	 al.	 2011).	 While	 this	 is	 also	 true	 for	 other	 C-I	6 inhibitors	such	as	metformin	(Haefeli	et	al.	2011,	unpublished	observation),	idebenone	is	7 unable	 to	 protect	 ATP	 levels	 in	 the	 presence	 of	 other	 mitochondrial	 toxins	 such	 as	8 antimycin	or	oligomycin	that	either	inhibit	C-III	or	block	the	ATP	synthase	respectively	9 (Erb	et	al.	2012).	Since	our	novel	SCQs	belong	to	the	same	chemical	class	as	idebenone,	10 we	 hypothesized	 that	 they	 would	 work	 by	 a	 similar	 mechanism.	 Moreover,	 most	11 mitochondrial	disorders	and	diseases	with	mitochondrial	dysfunction	are	characterised	12 by	 C-I	 dysfunction	 (Lin	 and	 Beal	 2006).	 Therefore,	 I	 screened	 all	 novel	 SCQs	 against	13 rotenone-induced	mitochondrial	dysfunction,	which	also	allowed	me	to	easily	translate	14 my	in	vitro	results	to	an	in	vivo	model	of	LHON	that	uses	rotenone	to	induce	vision	loss	in	15 mice.	16 
In	 this	study,	all	novel	SCQs	were	characterised	 in	vitro	at	10	µM	 in	 the	 initial	 screen.	17 Bearing	in	mind	the	large	number	of	compounds	to	be	characterised,	efficacy	of	the	novel	18 SCQs	was	measured	 at	 a	 single	 concentration,	 similar	 to	previously	published	 studies	19 using	 idebenone	 (Erb	 et	 al.	 2012,	 Haefeli	 et	 al.	 2011).	 Based	 on	 my	 results,	 our	20 compounds	showed	significantly	better	 in	vitro	cytoprotection	compared	to	idebenone	21 and	restored	visual	acuity	of	mice	at	1/10th	the	dose	of	previously	published	study	using	22 idebenone.	 This	 suggests	 that	 our	 novel	 SCQs	 may	 be	 more	 potent	 compared	 to	23 idebenone.	 While	 some	 SCQs	 were	 tested	 at	 lower	 doses,	 the	 efficacy	 of	 other	24 cytoprotective	SCQs	when	used	at	lower	concentrations	is	yet	to	be	tested.	25 
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To	measure	the	cytoprotective	ability/toxicity	of	drugs	the	standard	dye-based,	MTT	(3-1 [4,5-dimethylthiazol-2-yl]-2,5-diphenyl	 tetrazolium	 bromide)	 assay	 frequently	 used.	2 This	assay	assumes	that	mitochondrial	dehydrogenases	of	viable	cells	reduce	the	MTT-3 tetrazolium	salt	to	formazan,	which	is	measured	optically	as	a	surrogate	marker	of	the	4 number	of	living	cells	(Chan	et	al.	2013,	van	Meerloo	et	al.	2011).	However,	compounds	5 that	increase	cellular	NADH	levels,	can	enhance	the	production	of	formazan	resulting	in	6 false	 negative	 results	 (Chan	 et	 al.	 2013).	 MTT	 is	 also	 known	 to	 be	 reduced	 outside	7 mitochondria	 in	 the	 extracellular	 environment,	 resulting	 false	 negative	 results	8 (Bruggisser	 et	 al.	 2002).	 The	 rate	 of	 reduction	 of	 MTT	 is	 also	 influenced	 by	 the	9 concentrations	of	glucose,	pyridine	and	even	the	pH	of	the	culture	medium	(Vistica	et	al.	10 1991).	 In	 addition,	 the	 reduced	 form	 of	 quinones	 (hydroquinones)	 can	 also	 directly	11 reduce	the	MTT	dye	and	similar	redox	dyes	such	as	WST-1	(N.	Gueven,	unpublished	data;	12 Tan	and	Berridge	2010)	(Figure	16),	which	can	result	in	the	generation	of	false	negative	13 results	 (Petty	 et	 al.	 1995).	 Since	 our	 novel	 SCQs	 are	 reduced	 by	 cellular	 reductases,	14 influenced	 cellular	 metabolic	 pathways	 (Chapter	 2)	 that	 could	 alter	 glucose	15 concentration	 in	 the	 cell	 culture	 media,	 all	 of	 which	 are	 likely	 to	 alter	 formazan	16 production,	this	experimental	approach	was	not	followed.	17 
Another	standard	assay	used	to	measure	cell	viability	is	by	staining	cells	using	dyes	such	18 as	 trypan	 blue.	 Unlike	 in	 healthy	 cells,	 damaged	 membranes	 would	 allow	 the	 bulky,	19 charged	dye	molecules	 to	enter	within	 the	cytoplasm	and	stain	 the	cells	purple-violet.	20 This	can	be	identified	under	a	bright-field	microscope	(Cook	and	James,	1989).	However,	21 a	 serious	 limitation	 of	 this	 assay	 is	 that	 most	 cytotoxic	 agents	 initiate	 the	 damage	22 intracellularly	and	membrane	damage	may	not	be	evident	immediately.	Therefore,	this	23 assay	might	underestimate	cytotoxicity	(Hynes	et	al.,	2003).	Moreover,	this	assay	relies	24 on	 careful	 preparation	 of	 single	 cell	 suspension	 of	 cells	 and	 accurate	 counting	 of	25 
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individual	 samples	 using	 a	 hemocytometer.	 Consequently,	 this	 assay	 is	 not	 suited	 for	1 higher	throughput	testing.	In	light	of	the	large	number	of	compounds	that	were	assessed	2 in	parallel	and	the	uncertainty	of	the	accuracy	of	results	associated	with	this	assay,	this	3 experimental	approach	was	avoided.	4 
Instead,	an	ATP-based	assay	was	chosen	to	measure	cell	viability.	As	ATP	levels	degrade	5 rapidly	 during	 the	 process	 of	 cell	 death,	 ATP-dependent	 luminescence	 per	 well	 was	6 measured	 as	 a	 readout	 of	 viability,	 which	 was	 then	 normalised	 to	 the	 luminescence	7 generated	by	sham-treated	cells	for	comparison.	This	assay	was	also	selected	since	ATP-8 based	assay	showed	higher	sensitivity,	linearity	and	reproducibility	when	compared	to	9 MTT	assay	in	a	previous	study	(Petty	et	al.	1995).	10 
Although,	 ATP-measurement	 was	 employed	 for	 assessing	 cytoprotection	 and	 acute	11 rescue	 of	 ATP	 levels,	 both	 assays	 are	 not	 assessing	 the	 same	 due	 to	 their	 inherent	12 experimental	designs.	Cytoprotection	was	measured	(after	2	days	of	preincubation	with	13 SCQs)	one	day	after	a	seven-hour	rotenone	challenge,	while	in	contrast	acute	rescue	of	14 ATP	levels	was	measured	after	only	one	hour	of	co-exposure	of	cells	to	SCQs	and	rotenone.	15 The	independence	of	both	assays	is	supported	by	the	obvious	lack	of	correlation	between	16 the	results	from	these	two	assays	(Figure	30).	While	some	compounds	combined	good	17 ATP	rescue	activity	and	poor	cytoprotection,	others,	especially	those	with	amino	acid	and	18 alcohol	side	chain	moieties,	were	highly	cytoprotective	and	rescued	ATP	levels	to	more	19 than	 80	 %.	 This	 led	 us	 to	 synthesize	 more	 compounds	 with	 these	 side-chain	20 functionalities	that	subsequently	populated	the	top	right	corner	of	the	plot	(Figure	30).	21 Therefore,	 despite	 of	 a	 subjective	 correlation	 in	 this	 figure,	 the	 correlation	 plot	 of	22 cytoprotection	 versus	 acute	 rescue	 of	 ATP	 levels	 for	 all	 SCQs	 (Figure	 30),	 does	 not	23 
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demonstrate	a	real	correlation	between	the	two	parameters	but	is	a	direct	consequence	1 of	repeated	rounds	of	compound	optimization.	2 
As	a	typical	approach	to	measure	the	anti-oxidative	capacity	of	novel	SCQs	in	a	cellular	3 context,	 oxidative	 stress	 could	 be	 induced	 by	 pro-oxidants	 to	 overcome	 the	 in-built	4 cellular	antioxidant	defense	mechanism.	However,	as	the	main	function	of	liver	cells	is	to	5 detoxify	 xenobiotics,	 these	 cells	 naturally	 display	 significantly	 higher	 defense	6 mechanisms	and	tolerance	to	oxidative	stress	(Cresteil	and	Jaiswal	1991,	Marroquin	et	al.	7 2007,	Mersch-Sundermann	 et	 al.	 2004).	 Consistent	with	 this	 reasoning,	 no	 significant	8 increases	 in	 oxidative	 stress-induced	 lipid	 peroxidation	were	 observed	 upon	 treating	9 HepG2	cells	with	H2O2	in	this	study	(data	not	shown).	Instead	of	inducing	ROS	by	external	10 addition	 of	 pro-oxidants,	 we	 measured	 the	 effect	 of	 SCQs	 on	 basal	 levels	 of	 lipid	11 peroxidation.	This	indirect	measure	for	antioxidant	capacity	was	chosen	over	traditional	12 assays	that	use	redox	dyes	such	as	CM-H2DCFDA,	since	idebenone	can	interact	with	this	13 redox	dye	 to	 completely	quench	 its	 fluorescence	 independent	of	a	 cellular	 context	 (N.	14 Gueven	unpublished	observation,	R.	Haefeli,	PhD	thesis,	unpublished).	Since	our	novel	15 SCQs	belong	 to	 the	 same	chemical	 class	of	quinones	and	 could	 therefore	have	 similar	16 characteristics,	I	selected	basal	lipid	peroxidation	as	a	readout	for	antioxidant	capacity	as	17 previously	reported	for	myocytes	(Erb	et	al.	2012).	Since	liver	cells	display	significantly	18 different	defense	mechanisms	and	tolerance	to	oxidative	stress,	these	results	may	not	be	19 replicated	by	other	cells.	I	can	therefore	not	exclude	the	possibility	that	the	novel	SCQs	20 may	 display	 potent	 antioxidant	 activity	 in	 other	 cell	 lines	 with	 lower	 tolerance	 to	21 oxidative	 stress	 in	 contrast	 to	 HepG2	 cells,	 where	 novel	 SCQs	 did	 not	 significantly	22 influenced	basal	lipid	peroxidation	levels.	23 
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It	 has	 to	be	noted	 that	HepG2	cells	do	not	 represent	normal	 tissue	 responses	 as	 they	1 originate	from	a	hepatic	cancer	and	have	a	very	high	glycolytic	capacity	(Marroquin	et	al.	2 2007).	 Increased	 glycolysis	 requires	 increased	 levels	 of	NAD+	 that	 are	needed	 for	 the	3 central	 step	 of	 glycolysis,	 the	 conversion	 of	 glyeraldehyde-3-phosphate	 to	 1,3-4 bisphosphoglycerate.	Typically,	this	NAD+	 is	supplied	by	the	conversion	of	pyruvate	to	5 lactate,	which	therefore	leads	to	lactate	accumulation	(Figure	8	from	Chapter	1)	(Bodmer	6 et	al.	2008,	Brewer	1998,	Davidson	et	al.	2009,	Dienel	and	Hertz	2001,	Kaufmann	et	al.	7 2004,	Rehncrona	et	al.	1981).	Consequently,	the	non-significant	changes	to	basal	lactate	8 levels	 that	 I	 found	 associated	 with	 some	 SCQs	 in	 cell	 culture	 supernatant	 might	 be	9 impossible	to	extrapolate	to	other	cell	lines.		10 
The	current	study	represents	the	initial	characterisation	of	a	range	of	novel	SCQs,	as	first	11 step	towards	the	identification	of	the	best	compounds	to	treat	mitochondrial	dysfunction.	12 Given	 the	 large	 number	 of	 compounds	 to	 be	 characterised	 and	 a	 general	 difficulty	 to	13 assess	in	vitro	toxicity	of	quinones	due	to	their	interference	with	practically	all	standard	14 viability	assays,	it	was	not	possible	to	conduct	a	detailed	investigation	into	the	intrinsic	15 toxicity	for	these	compounds,	which	has	to	be	regarded	as	another	limitation	of	this	study.	16 Out	of	the	best	compounds,	I	selected	two	that	showed	sufficient	differences	in	chemistry	17 to	 confirm	 their	 protective	 activity	 in	 vivo.	 While	 systemic	 administration	 of	 these	18 compounds	did	not	show	any	overt	signs	of	toxicity,	another	PhD	student	(Zikai	Feng)	19 will	conduct	a	more	detailed	assessment	of	their	in	vivo	toxicity.	20 
To	translate	my	in	vitro	findings	to	an	in	vivo	model,	two	selected	novel,	highly	protective	21 SCQs	were	tested	in	a	mouse	model	of	rotenone-induced	blindness.	Although	this	model	22 was	used	previously	to	replicate	many	aspects	of	the	LHON	pathology,	certain	limitations	23 must	be	acknowledged.	Rotenone	is	believed	to	bind	covalently	to	the	quinone-binding	24 
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site	of	mitochondrial	C-I,	although,	the	exact	binding	site	within	C-I	is	not	established	yet	1 (Friedrich	et	al.	1994,	Prieur	et	al.	2001).	Therefore,	 it	 is	unclear	 if	 the	subunit	of	C-I,	2 inhibited	by	rotenone	is	same	as	the	one	encoded	by	genes	that	are	associated	with	LHON.	3 This	is	of	specific	importance	since	not	all	mutations	in	C-I	are	associated	with	LHON	but	4 can	also	be	responsible	for	disorders	with	pathologies	distinctly	different	to	LHON.	For	5 example,	 the	mtDNA	3243G>A	mutation,	 that	 causes	MELAS	 affects	 the	 translation	of	6 mitochondrially	 encoded	 proteins	 (Testai	 and	 Gorelick	 2010).	 The	 impairment	 of	 C-I	7 activity	forces	MELAS	cybrid	cells,	in	vitro,	to	rely	on	anaerobic	glycolysis	to	compensate	8 for	the	ATP	demand,	leading	to	the	accumulation	of	lactate	and	lactic	acidosis,	that	is	the	9 hallmark	of	MELAS	(Davidson	et	al.	2009,	Kaufmann	et	al.	2004).		Since	complex	I	holds	10 majority	of	the	subunits	encoded	by	mtDNA,	it	is	more	likely	to	be	impaired	in	its	function,	11 while	the	compensatory	activities	of	other	complexes	(C-III,	IV	and	V)	are	controversially	12 discussed	(Malfatti	et	al.	2007,	Sano	et	al.	1995).	13 
Although	 rotenone	 inhibits	 mitochondrial	 C-I	 and	 elevates	 ROS	 levels,	 similar	 to	 the	14 situation	in	LHON	(Degli	Esposti	1998,	Fato	et	al.	2009,	Testa	et	al.	2005,	Treberg	and	15 Brand	2011),	rotenone	also	has	off-target	effects	like	any	other	small	molecule,	such	as	16 disrupting	 Ca2+	 homeostasis	 (Freestone	 et	 al.	 2009,	 Wang	 and	 Xu	 2005)	 that	 could	17 conceivably	modify	the	pathology	of	this	animal	model.	18 
It	has	to	be	noted	that	at	present	there	is	no	perfect	pre-clinical	model	of	LHON	that	would	19 replicate	all	patient	characteristics	such	as	incomplete	penetrance,	gender	bias,	need	for	20 additional	factors	as	well	as	reproducing	the	molecular	pathology	of	the	disease.	Since	21 the	rotenone-injection	model	used	in	the	present	study	mimics	the	major	pathological	22 features	of	LHON,	such	as	loss	of	RGCs,	reduced	retinal	thickness	and	loss	of	visual	acuity	23 and	was	used	previously	to	test	the	efficacy	idebenone	(Heitz	et	al.	2012),	this	model	was	24 
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selected	for	the	current	study.	It	has	to	be	acknowledged	that	another	possible	limitation	1 of	 this	 animal	 model	 is	 the	 procedure	 of	 intraocular	 injection	 of	 rotenone.	 Since	 the	2 injection	 was	 performed	 manually,	 unintentional	 errors	 could	 be	 introduced	 by	 the	3 investigator,	 such	 as	 leakage	 of	 rotenone	 out	 of	 the	 vitreous	 after	 injection,	 minor	4 alterations	of	rotenone	dosing	(given	that	only	one	microliter	is	injected)	or	inaccurate	5 angle	 of	 injection	 resulting	 in	 altered	 site	 of	 rotenone	 delivery.	 These	 factors	 can	6 potentially	 lead	 to	 inaccurate	 rotenone	dosing.	While	 it	was	attempted	 to	avoid	 these	7 problems	 and	 no	 obvious	 evidence	 was	 observed	 that	 these	 problems	 could	 have	8 compromised	the	current	study,	they	cannot	be	ruled	out	as	modifying	factors.	9 
Although	our	novel	SCQs	did	not	show	any	obvious	adverse	effects	over	the	treatment	10 duration,	 any	 potential	 SCQ-induced	 delayed	 effects	 cannot	 be	 ruled	 out.	 I	 have	 only	11 assessed	 SCQ-treatment-induced	 changes	 to	 body	weight,	 food	 intake	 and	 behaviour.	12 However,	since	our	novel	SCQs	are	naphthoquinones	and	structurally	similar	to	vitamin	13 K	(VK),	they	may	increase	blood	coagulation	and	potentially	clotting	since	VK	is	integral	14 to	the	blood	coagulation	cascade.	Although	no	suggestions	for	this	putative	effect	have	15 been	observed	 in	 the	present	 study,	 this	possibility	 cannot	be	 excluded	and	warrants	16 more	in-depth	studies.	17 
It	 is	 also	 worth	 noting	 the	 growing	 evidence	 from	 several	 cancer	 cell	 lines	 that	 VK2	18 exhibits	some	anticancer	activity	(Wei	et	al.	2010,	Yoshida	et	al.	2003),	which	is	believed	19 to	be	mediated	by	ROS	(Duan	et	al.	2016).	Synthetic	VK	analogues	were	developed	 to	20 increase	selective	toxicity	to	cancerous	cell	lines	(IC50	0.24	–	3.83	μM)	as	opposed	to	non-21 cancerous	cell	lines	(IC50	11.9	–	17.1	μM)	(Prati	et	al.	2015).	However,	only	11	%	of	the	22 SCQs	screened	for	functional	characterisation	(9	out	of	the	tested	83)	were	toxic	to	cells	23 at	10	μM	(Figure	19).	This	effect	is	in	line	with	the	cytoprotective	role	of	VK2,	that	was	24 
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reported	 to	 prevent	 oxidative	 stress-induced	 cell	 death	 in	 vitro	 in	 cultured	1 oligodendrocytes	and	neurons	by	decreasing	ROS	production	(Li	et	al.	2003,	Sakaue	et	al.	2 2011).	Synthetic	naphthoquinone	derivatives	were	also	shown	to	be	protective	against	in	3 
vitro	 oxidative	 stress	 in	 a	 neuronal	 cell	 line	 (Josey	 et	 al.	 2013),	 increased	 the	 in	 vitro	4 mitochondrial	ATP	turn-over	and	overall	respiration	in	a	mouse	neuronal	cell	line	and	5 reduced	seizure	activity	in	both	zebrafish	and	mouse	models	(Chou	et	al.	2013,	Rahn	et	6 al.	2014).	VK	is	also	reported	to	serve	as	an	electron	carrier	that	maintains	ATP	levels	in	7 fruit	 flies	 (Vos	 et	 al.	 2012).	 These	 conflicting	 results	 suggest	 that	 although	 energy	8 production	 and	 mitochondrial	 function	 can	 be	 a	 good	 target	 to	 develop	 new	9 naphthoquinone-based	therapeutics	to	treat	mitochondrial	dysfunction,	the	possibility	of	10 naphthoquinone-induced	toxicity	cannot	be	completely	ruled	out.		11 
	12 
4.3		 Future	directions	13 	14 
The	results	of	this	study	for	the	first	time	demonstrate	a	SAR	for	the	cytoprotective	ability	15 of	 novel	 short-chain	 naphthoquinones.	 Importantly,	 detailed	 characterisation	 of	 the	16 effect	 of	 novel	 SCQs	 on	 various	 cellular	 parameters,	 revealed	 that,	 in	 contrast	 to	 the	17 current,	 possibly	 over-simplified	 assumption	 that	 rescuing	 ATP	 levels	 and	 reducing	18 oxidative	stress	are	central	to	restoring	cell	viability,	my	results	suggest	that	SCQs	likely	19 act	 in	 a	 more	 complex	 fashion	 that	 could	 involve	 recently	 described	 novel	 signaling	20 pathways,	including	the	signaling	proteins	like	p52Shc	or	Lin	28A.	Consequently,	future	21 studies	 need	 to	 investigate	 this	 hypothesis	 in	more	 detail	 to	 assess	 if	 and	 how	 these	22 signaling	 pathways	 convey	 cytoprotective	 and	mito-protective	 activities.	 Moreover,	 it	23 will	be	essential	to	identify	the	mechanism	of	how	exactly	SCQs	increase	cellular	levels	of	24 
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Lin28A.	 In	 fact,	 expression	 control	 of	 Lin28A	 in	 general	 is	 a	 topic	 where	 limited	1 information	is	reported.	In	line	with	the	hypothesis	that	SCQs	require	a	certain	time	to	2 allow	for	signaling	and	gene	expression	events	to	take	place,	it	will	be	important	to	assess	3 the	 correlation	 between	 different	 pre-treatment	 times	 and	 cytoprotective	 activity.	4 Although	the	data	of	this	study	suggest	that	our	SCQs	are	potentially	more	potent	than	5 idebenone,	it	will	be	imperative	to	perform	controlled	dose	dependency	studies	to	obtain	6 detailed	information	about	potency	and	EC50	of	the	novel	SCQs.	The	novel	SCQs	should	7 also	be	further	characterised	with	regards	to	their	effects	on	energy	generating	pathways	8 in	 the	 presence	 of	 mitochondrial	 dysfunction	 in	 vitro,	 to	 give	 real	 insights	 into	 the	9 mechanism	of	action	of	these	compounds.	However,	this	will	be	largely	influenced	by	the	10 mode	of	action	considerations	explained	above.	11 
In	this	study,	I	showed	the	efficacy	of	the	selected	SCQs	on	restoring	visual	acuity	of	mice	12 by	 1-week	 pre-treatment	 and	 10	 weeks	 post-treatment	 following	 rotenone	 injection.	13 Since	 our	 SCQs	 show	 significantly	 better	 activity	 when	 compared	 to	 idebenone,	 the	14 necessity	of	pre-treating	the	mice	with	SCQs	should	be	reinvestigated.	This	information	15 along	with	the	levels	of	signaling	proteins	in	murine	tissues	will	be	invaluable	to	support	16 the	in	vitro	claims	around	the	mechanism(s)	of	action	of	these	compounds.	17 
Since	 in	 this	study	the	novel	SCQs	were	administered	orally,	 they	would	undergo	 first	18 pass	metabolism	that	can	alter	the	efficacy	of	the	drug.	Therefore,	using	a	different	route	19 of	 administration	 will	 likely	 provide	 valuable	 insights	 into	 the	 effect	 of	 first	 pass	20 metabolism	 of	 these	 compounds	 and	 the	 effective	 dosage	 required.	 For	 example,	21 administering	the	SCQs	locally	as	eye	drops	in	treating	LHON	would	not	only	lower	the	22 dose	required	(and	hence	the	costs	 incurred)	but	also	avoid	any	metabolic	effects	and	23 could	 potentially	 reduce	 any	 adverse	 effects	 as	well.	 The	 effective	 dose	 required	 and	24 
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route	of	administration	for	the	novel	SCQs	would	provide	a	rationale	and	starting	point	1 to	 investigate	 tissue-specific	 pharmacokinetics	 such	 as	 uptake	 into	 the	 eye	 and	brain.	2 Moreover,	 since	 any	 therapeutics	 for	 LHON	 (with	 the	 exception	 of	 gene	 therapy)	 are	3 likely	 to	be	 taken	 for	many	years,	developing	a	 local	dosage	 form	has	 the	potential	 to	4 improve	patient	compliance	and	reduce	the	costs	incurred.	5 
Since	our	compounds	appear	to	effectively	protect	against	mitochondrial	dysfunction,	it	6 appears	obvious	that	they	should	be	trialed	in	other	disease-models	that	are	associated	7 with	mitochondrial	dysfunction	such	as	diabetic	retinopathy	and	ulcerative	colitis.	In	this	8 context,	 individual	 compounds	 could	 be	 selected	 based	 on	 physicochemical	9 characteristics	for	use	in	particular	indications.	For	example,	compounds	with	a	lower	log	10 D	around	0	to	1,	such	as	the	acids	among	our	SCQs,	could	be	used	orally	to	treat	conditions	11 such	as	colitis	that	do	not	require	absorption	into	the	systemic	circulation.	This	approach	12 would	 in	 fact	 even	 be	 beneficial	 to	 reduce	 adverse	 systemic	 effects.	 In	 contrast,	13 cytoprotective	compounds	with	a	log	D	of	more	than	3	would,	at	least	in	theory,	be	more	14 suited	 to	 enable	penetration	of	 the	blood-brain-and	 the	 similar	blood-eye-barrier	 and	15 could	therefore	be	superior	with	regards	to	the	treatment	of	ophthalmological	conditions.		16 
Apart	from	testing	the	efficacy	of	novel	SCQs	in	different	pre-clinical	models,	thorough	17 testing	of	basic	safety,	pharmacology,	toxicology	and	drug-drug	interactions	are	required	18 to	 be	 able	 to	 progress	 selected	 compounds	 towards	 Investigational	 New	 Drug	 (IND)	19 status.	Currently,	a	detailed	investigation	into	the	intrinsic	toxicity	of	the	novel	SCQs	is	20 currently	 addressed	 by	 another	 PhD	 student	 (Zikai	 Feng),	 who	 analyzes	 the	 safety,	21 tolerability,	pharmacodynamics	and	pharmacokinetics	of	the	novel	SCQs	using	a	range	of	22 
in	vitro	and	in	vivo	assays.	Another	PhD	student	(Abraham	Daniel)	has	developed	an	eye	23 
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drop	 formulation	 of	 two	 selected	 SCQs	 and	 is	 testing	 their	 efficacy	 in	 a	 rat-model	 of	1 diabetic	retinopathy.	2 
Overall,	my	results	have	provided	a	promising	starting	point	for	a	rational	development	3 of	this	class	of	SCQ	compounds	towards	therapeutic	drug	candidates	in	an	area	that	is	4 currently	still	characterized	by	an	obvious	lack	of	therapeutic	options.	5 
	6 
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Appendix	1:	Structures	of	novel	short-chain	quinones	(SCQs)	
 
 
Table	A1:	Structures	of	slightly	polar	SCQs	
UTA#	 Structure	 UTA#	 Structure	
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Table	A2:	Structures	of	aliphatic	SCQs	
UTA#	 Structure	 UTA#	 Structure	
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Table	A3:	Structures	of	acid	SCQs	
UTA#	 Structure	 UTA#	 Structure	
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Table	A4:	Structures	of	aliphatic	ester	SCQs	
UTA#	 Structure	 UTA#	 Structure	
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Table	A5:	Structures	of	amino	ester	SCQs	
UTA#	 Structure	 UTA#	 Structure	
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Table	A6:	Structures	of	amino	acid	SCQs	
UTA#	 Structure	 UTA#	 Structure	
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Table	A7:	Structures	of	amino	alcohol	SCQs	
UTA#	 Structure	 UTA#	 Structure	
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Table	A8:	Structures	of	SCQs	with	different	quinone	cores	
Naphthoquinone	 Plastoquinone	 Ubiquinone	
UTA#	 Structure	 UTA#	 Structure	 UTA#	 Structure	
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Table	A9:	Structures	of	SCQs	with	different	methyl	group	on	quinone	core	substituted	
Naphthoquinone	 Plastoquinone	 Ubiquinone	
UTA#	 Structure	 UTA#	 Structure	 UTA#	 Structure	
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Appendix	2:	Summary	of	in	vitro	characterisation	
	
Table	A10:	Summary	of	in	vitro	characterisation	of	slightly	polar	compounds	
UTA#	 LogP		 LogD		
Viability		
(%	Control)	
ATP	levels		
(%	Control)	
Reduction	
(△A450	nm)	 Basal	lipid	peroxidation	
(FU)	
Lactate	levels	
(µmol/mg)	
Beta-hydroxy	
butyrate	levels	
(µmol/mg)	
Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	
Idebenone	 3.57	 3.57	 66.19	 11.98	 80.97	 10.07	 0.13	 0.05	 0.75	 0.06	 75.37	 20.72	 1.61	 0.83	
2	 4.85	 4.85	 68.90	 12.40	 6.44	 1.52	 0.07	 0.01	 1.05	 0.12	 71.99	 6.39	 2.01	 0.78	
8	 4.94	 4.94	 52.47	 7.32	 19.84	 4.79	 0.01	 0.07	 0.92	 0.06	 68.79	 18.64	 1.26	 0.55	
16	 2.02	 2.02	 48.24	 5.87	 54.49	 14.45	 0.41	 0.08	 0.94	 0.04	 82.57	 1.54	 2.81	 0.88	
18	 6.04	 6.04	 15.23	 2.62	 3.51	 1.56	 0.01	 0.00	 0.89	 0.09	 114.73	 7.43	 5.37	 1.44	
20	 3.55	 3.55	 39.57	 3.77	 44.46	 5.58	 0.26	 0.05	 1.03	 0.12	 78.40	 3.44	 3.19	 0.35	
24	 2.15	 2.15	 72.80	 12.74	 47.44	 14.22	 0.13	 0.02	 0.95	 0.17	 90.47	 5.08	 2.15	 1.17	
25	 2.18	 2.18	 56.68	 6.75	 34.21	 6.16	 0.15	 0.02	 0.92	 0.05	 97.40	 9.45	 1.55	 0.37	
40	 2.59	 1.51	 21.33	 10.19	 79.87	 5.83	 0.64	 0.15	 0.92	 0.07	 65.30	 6.61	 2.16	 1.02	
49	 5.27	 5.27	 23.80	 4.77	 89.30	 16.43	 0.11	 0.03	 N/A	  148.96	 20.77	 1.94	 0.25	
69	 0.87	 0.87	 3.34	 0.32	 80.12	 13.29	 0.01	 0.00	 0.97	 0.06	 52.78	 3.29	 3.10	 0.77	
Mean	 3.46	 3.36	 42.59	 		 49.15	 		 0.17	 		 0.93	 		 86.07	 		 2.47	 0.76	
SD	 1.64	 1.73	 23.65	 		 30.94	 		 0.19	 		 0.08	 		 26.73	 		 1.15	 0.37	
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Table	A11:	Summary	of	in	vitro	characterisation	of	aliphatic	compounds	
UTA#	 LogP		 LogD		
Viability		
(%	Control)	
ATP	levels		
(%	Control)	
Reduction	
(△A450	nm)	 Basal	lipid	peroxidation	(FU)	 Lactate	levels	(µmol/mg)	 Beta-hydroxy	butyrate	levels	(µmol/mg)	
Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	
1	 6.29	 6.29	 5.57	 1.00	 1.97	 0.49	 -0.01	 0.00	 0.97	 0.04	 63.84	 4.00	 1.38	 0.89	
4	 5.98	 5.98	 34.11	 2.21	 3.41	 0.84	 0.07	 0.01	 0.89	 0.04	 106.20	 2.47	 1.92	 0.74	
5	 5.40	 5.40	 50.99	 5.79	 6.64	 1.52	 0.02	 0.01	 1.06	 0.08	 67.37	 5.72	 2.33	 0.77	
6	 4.51	 4.51	 42.89	 5.46	 14.51	 9.64	 0.05	 0.00	 N/A	  57.79	 1.98	 	  
14	 9.04	 9.04	 6.19	 0.64	 2.11	 0.38	 0.01	 0.00	 0.94	 0.02	 56.35	 9.99	 1.54	 0.74	
15	 3.32	 3.32	 52.15	 10.42	 22.37	 4.55	 0.16	 0.04	 0.92	 0.01	 67.49	 3.78	 2.09	 0.20	
17	 4.75	 4.75	 18.25	 1.18	 16.58	 1.91	 0.05	 0.01	 0.94	 0.04	 73.08	 11.45	 2.85	 0.43	
19	 3.91	 3.91	 24.90	 1.50	 4.15	 0.85	 0.03	 0.01	 0.87	 0.05	 65.19	 2.00	 2.08	 0.26	
21	 4.95	 4.95	 33.88	 5.62	 19.60	 6.11	 0.02	 0.01	 0.95	 0.13	 75.49	 0.99	 1.44	 0.51	
22	 4.33	 4.33	 25.68	 3.36	 32.99	 11.15	 0.06	 0.01	 N/A	  72.82	 2.05	 1.08	 0.95	
26	 5.53	 5.53	 56.77	 6.04	 11.69	 0.73	 -0.01	 0.01	 0.86	 0.03	 154.41	 2.40	 2.52	 0.78	
38	 5.53	 5.53	 63.93	 3.47	 32.70	 6.06	 0.00	 0.00	 1.05	 0.02	 75.14	 6.10	 	  
39	 3.51	 3.51	 65.93	 8.35	 79.30	 8.41	 0.11	 0.03	 0.94	 0.03	 67.35	 9.18	 1.84	 1.03	
41	 3.36	 3.36	 51.70	 3.71	 73.50	 4.75	 0.17	 0.02	 0.94	 0.03	 51.16	 3.55	 1.47	 0.41	
79	 4.55	 4.55	 11.85	 1.11	 78.16	 7.27	 0.05	 0.01	 1.00	 0.04	 138.00	 16.53	 18.38	 6.06	
Mean	 5.00	 5.00	 36.32	 		 26.65	 		 0.05	 		 0.95	 		 79.45	 		 3.15	 1.06	
SD	 1.45	 1.45	 20.42	 		 27.90	 		 0.06	 		 0.06	 		 29.96	 		 4.60	 1.53	
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Table	A12:	Summary	of	in	vitro	characterisation	of	acid	compounds	
UTA#	 LogP		 LogD		
Viability		
(%	Control)	
ATP	levels		
(%	Control)	
Reduction	
(△A450	nm)	 Basal	lipid	peroxidation	
(FU)	
Lactate	levels	
(µmol/mg)	
Beta-hydroxy	
butyrate	levels	
(µmol/mg)	
Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	
23	 2.30	 -0.93	 21.30	 2.98	 19.13	 1.68	 -0.02	 0.01	 0.91	 0.02	 113.02	 1.31	 2.67	 0.70	
28	 1.85	 -1.40	 32.03	 3.34	 13.29	 1.29	 0.02	 0.01	 0.94	 0.11	 122.87	 2.95	 1.82	 0.27	
46	 1.88	 -1.43	 80.50	 11.47	 53.70	 7.13	 0.06	 0.01	 0.94	 0.03	 56.31	 3.10	 1.23	 0.63	
50	 0.77	 -2.53	 47.00	 10.03	 27.30	 6.92	 0.00	 0.00	 1.00	 0.08	 74.72	 1.51	 2.10	 0.58	
58	 2.31	 -4.03	 32.28	 10.77	 31.32	 7.96	 -0.01	 0.00	 0.97	 0.05	 56.28	 1.30	 2.20	 0.25	
59	 1.90	 -1.37	 44.55	 15.04	 79.88	 20.17	 0.01	 0.00	 0.99	 0.02	 48.12	 1.52	 2.13	 0.65	
67	 2.74	 -0.49	 74.89	 18.46	 97.09	 18.97	 0.08	 0.02	 0.96	 0.04	 50.08	 1.22	 2.81	 0.11	
70	 3.19	 0.02	 66.82	 5.96	 91.79	 20.18	 0.02	 0.01	 0.98	 0.05	 54.32	 2.95	 1.93	 0.71	
Mean	 2.12	 -1.52	 49.92	 		 51.69	 		 0.03	 		 0.96	 		 71.96	 		 2.11	 0.49	
SD	 0.72	 1.26	 21.82	 		 33.83	 		 0.03	 		 0.03	 		 29.60	 		 0.49	 0.24	
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Table	A13:	Summary	of	in	vitro	characterisation	of	aliphatic	ester	compounds	
UTA#	 LogP		 LogD		
Viability		
(%	Control)	
ATP	levels		
(%	Control)	
Reduction	
(△A450	nm)	 Basal	lipid	peroxidation	
(FU)	
Lactate	levels	
(µmol/mg)	
Beta-hydroxy	
butyrate	levels	
(µmol/mg)	
Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	
29	 2.36	 2.36	 10.33	 2.31	 27.35	 7.34	 0.04	 0.00	 0.94	 0.07	 113.43	 16.63	 2.56	 0.31	
30	 3.32	 3.32	 17.74	 0.63	 11.77	 2.72	 0.02	 0.01	 0.98	 0.04	 111.28	 3.06	 0.86	 0.35	
31	 4.21	 4.21	 16.10	 1.48	 8.96	 2.91	 0.01	 0.00	 0.96	 0.13	 107.13	 2.70	 1.71	 0.15	
32	 2.80	 2.80	 15.69	 1.22	 15.37	 2.00	 0.04	 0.01	 0.88	 0.14	 104.42	 1.20	 1.51	 0.56	
33	 3.77	 3.77	 15.14	 1.41	 9.64	 1.50	 0.01	 0.00	 N/A	  102.32	 3.70	 2.64	 0.20	
34	 4.66	 4.66	 18.91	 1.06	 17.79	 11.55	 0.01	 0.00	 1.01	 0.08	 51.89	 2.62	 1.66	 0.18	
Mean	 3.52	 3.52	 15.65	 		 15.15	 		 0.02	 		 0.95	 		 98.41	 		 1.82	 0.29	
SD	 0.87	 0.87	 2.96	 		 6.87	 		 0.02	 		 0.05	 		 23.16	 		 0.68	 0.15	
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Table	A14:	Summary	of	in	vitro	characterisation	of	amino	ester	compounds	
UTA#	 LogP		 LogD		
Viability		
(%	Control)	
ATP	levels		
(%	Control)	
Reduction	
(△A450	nm)	 Basal	lipid	peroxidation	
(FU)	
Lactate	levels	
(µmol/mg)	
Beta-hydroxy	
butyrate	levels	
(µmol/mg)	
Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	
35	 3.56	 3.56	 76.20	 17.28	 76.67	 7.58	 0.05	 0.01	 0.96	 0.03	 56.88	 5.09	 1.96	 0.41	
36	 4.62	 4.62	 54.50	 12.06	 81.03	 9.41	 0.18	 0.03	 0.84	 0.09	 56.46	 3.11	 2.97	 0.53	
42	 3.23	 3.23	 64.68	 6.54	 79.07	 9.32	 0.23	 0.04	 0.96	 0.05	 46.96	 1.07	 1.86	 0.13	
44	 3.93	 3.39	 60.36	 7.41	 80.47	 14.03	 0.28	 0.05	 0.95	 0.04	 47.18	 1.32	 2.50	 0.38	
47	 2.39	 2.39	 74.40	 5.64	 76.40	 5.24	 0.42	 0.11	 0.90	 0.01	 75.94	 6.59	 1.69	 0.64	
51	 2.04	 2.04	 55.30	 13.81	 46.50	 8.01	 0.00	 0.00	 0.98	 0.09	 69.16	 12.95	 1.74	 0.61	
53	 4.22	 4.22	 57.17	 12.05	 87.60	 5.02	 0.20	 0.05	 0.97	 0.06	 92.51	 6.42	 2.10	 0.10	
55	 4.31	 4.31	 78.60	 14.13	 94.76	 4.14	 0.11	 0.02	 0.94	 0.07	 75.48	 3.79	 1.02	 0.48	
57	 6.75	 6.75	 59.97	 26.86	 79.18	 9.43	 0.03	 0.01	 N/A	  53.66	 1.39	 1.60	 0.26	
64	 4.22	 4.22	 69.40	 14.49	 84.41	 16.90	 0.14	 0.02	 0.97	 0.07	 61.31	 3.92	 1.71	 0.10	
65	 4.17	 4.17	 60.08	 13.52	 91.07	 17.51	 0.14	 0.03	 0.89	 0.04	 76.58	 1.95	 1.34	 0.46	
71	 5.06	 5.06	 70.53	 19.51	 92.22	 10.29	 0.07	 0.01	 0.87	 0.06	 56.47	 12.41	 5.14	 0.15	
75	 5.51	 5.51	 61.35	 7.27	 95.42	 18.61	 0.07	 0.02	 0.95	 0.06	 53.57	 1.66	 1.77	 1.16	
Mean	 4.15	 4.11	 64.81	 		 81.91	 		 0.15	 		 0.93	 		 63.24	 		 2.11	 0.42	
SD	 1.24	 1.26	 8.16	 		 12.60	 		 0.12	 		 0.05	 		 13.62	 		 1.03	 0.29	
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Table	A15:	Summary	of	in	vitro	characterisation	of	amino	acid	compounds	
UTA#	 LogP		 LogD		
Viability		
(%	Control)	
ATP	levels		
(%	Control)	
Reduction	
(△A450	nm)	 Basal	lipid	peroxidation	
(FU)	
Lactate	levels	
(µmol/mg)	
Beta-hydroxy	
butyrate	levels	
(µmol/mg)	
Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	
37	 3.42	 0.12	 100.30	 17.34	 64.20	 3.95	 0.03	 0.01	 0.90	 0.04	 50.31	 4.80	 1.72	 0.43	
43	 2.04	 -1.32	 92.70	 7.59	 46.57	 5.67	 0.03	 0.01	 0.98	 0.03	 50.50	 3.46	 1.93	 0.57	
45	 2.73	 -0.58	 61.00	 19.11	 45.90	 8.31	 0.02	 0.01	 0.94	 0.03	 44.40	 1.27	 1.96	 0.34	
48	 1.19	 -2.18	 53.63	 22.46	 56.60	 13.49	 0.06	 0.01	 0.91	 0.06	 64.02	 4.66	 2.27	 0.33	
54	 3.02	 -0.26	 98.70	 10.87	 66.10	 12.64	 0.01	 0.01	 0.97	 0.08	 64.75	 3.04	 1.84	 0.28	
56	 3.12	 -0.26	 29.73	 12.23	 54.49	 8.36	 0.01	 0.00	 0.96	 0.05	 68.25	 7.98	 1.72	 0.22	
60	 3.15	 -0.08	 34.78	 6.24	 50.70	 5.83	 0.02	 0.01	 0.88	 0.08	 57.73	 9.26	 1.99	 0.59	
66	 2.97	 -0.39	 66.94	 3.91	 73.31	 23.74	 0.05	 0.01	 0.95	 0.06	 48.91	 1.53	 1.97	 0.98	
72	 3.86	 0.74	 90.75	 15.62	 84.80	 29.49	 0.05	 0.03	 0.89	 0.13	 46.77	 1.19	 1.74	 0.15	
76	 4.31	 1.25	 68.12	 14.11	 51.44	 6.95	 0.01	 0.01	 0.96	 0.04	 57.17	 3.02	 2.80	 0.86	
Mean	 2.98	 -0.30	 69.66	 		 59.41	 		 0.03	 		 0.93	 		 55.28	 		 1.99	 0.47	
SD	 0.88	 0.96	 25.62	 		 12.58	 		 0.02	 		 0.04	 		 8.32	 		 0.33	 0.27	
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Table	A16:	Summary	of	in	vitro	characterisation	of	amino	alcohol	compounds	
UTA#	 LogP		 LogD		
Viability		
(%	Control)	
ATP	levels		
(%	Control)	
Reduction	
(△A450	nm)	 Basal	lipid	peroxidation	(FU)	 Lactate	levels	(µmol/mg)	 Beta-hydroxy	butyrate	levels	(µmol/mg)	
Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	
61	 1.71	 1.71	 100.70	 28.37	 78.57	 5.12	 0.23	 0.07	 0.93	 0.03	 56.42	 2.18	 2.15	 0.72	
62	 3.10	 3.10	 93.08	 13.67	 91.22	 7.23	 0.22	 0.03	 0.90	 0.07	 67.05	 2.17	 2.40	 0.29	
73	 3.83	 3.83	 86.22	 9.41	 96.07	 8.30	 0.12	 0.03	 0.96	 0.04	 51.85	 3.62	 1.04	 0.48	
74	 3.43	 3.43	 91.73	 15.63	 100.67	 16.01	 0.20	 0.06	 0.87	 0.07	 50.91	 1.72	 1.69	 0.38	
77	 3.41	 3.41	 95.92	 19.39	 99.12	 19.16	 0.21	 0.06	 0.76	 0.11	 46.33	 1.39	 2.60	 0.40	
78	 3.10	 3.10	 79.95	 21.09	 84.23	 9.15	 0.13	 0.04	 0.96	 0.05	 44.66	 0.91	 2.04	 0.27	
80	 2.81	 2.81	 87.57	 19.67	 89.06	 10.87	 0.22	 0.04	 0.94	 0.07	 63.23	 8.98	 1.96	 0.36	
81	 2.81	 2.81	 83.77	 19.93	 89.90	 11.74	 0.25	 0.07	 0.88	 0.05	 81.79	 11.95	 1.42	 0.60	
82	 3.73	 3.73	 64.12	 2.88	 84.29	 6.47	 0.44	 0.04	 0.80	 0.08	 77.84	 1.03	 1.78	 0.44	
83	 3.54	 3.53	 60.30	 7.55	 73.45	 15.95	 0.43	 0.05	 0.95	 0.03	 101.77	 4.42	 3.78	 1.50	
84	 3.99	 3.99	 74.36	 3.77	 90.41	 6.06	 0.34	 0.02	 0.93	 0.12	 40.19	 2.82	 1.86	 0.26	
85	 1.28	 1.28	 61.42	 9.62	 79.28	 3.18	 0.17	 0.02	 0.91	 0.08	 45.96	 2.04	 2.14	 0.35	
86	 0.86	 0.86	 49.50	 10.68	 78.40	 11.02	 0.04	 0.01	 0.98	 0.05	 48.43	 3.09	 1.28	 0.23	
87	 3.86	 3.86	 63.55	 14.70	 79.40	 19.91	 0.34	 0.06	 0.97	 0.02	 50.44	 1.41	 2.53	 0.42	
88	 3.87	 3.87	 91.81	 9.85	 80.17	 15.58	 0.18	 0.03	 0.90	 0.06	 42.92	 4.34	 2.18	 0.71	
89	 4.31	 4.31	 85.17	 9.46	 89.96	 11.51	 0.15	 0.04	 0.93	 0.06	 37.92	 1.31	 1.03	 0.17	
90	 4.30	 4.30	 68.03	 8.02	 87.59	 13.13	 0.18	 0.06	 0.93	 0.04	 45.50	 3.18	 1.79	 0.67	
91	 3.04	 3.04	 82.01	 7.11	 77.44	 8.83	 0.17	 0.04	 0.93	 0.05	 73.75	 3.83	 1.66	 0.62	
92	 0.92	 0.92	 40.47	 3.63	 72.43	 10.41	 N/A	  0.96	 0.02	 102.15	 3.19	 1.80	 0.39	
93	 1.03	 1.03	 74.38	 4.11	 82.67	 8.12	 N/A	  0.93	 0.03	 67.23	 5.09	 1.42	 0.14	
94	 3.42	 0.12	 71.70	 7.39	 65.32	 3.80	 N/A	  0.85	 0.18	 59.68	 3.49	 1.65	 0.18	
Mean	 2.97	 2.81	 76.47	 		 84.27	 		 0.22	 		 0.91	 		 59.81	 		 1.91	 0.46	
SD	 1.13	 1.28	 15.86	 		 8.97	 		 0.10	 		 0.06	 		 18.71	 		 0.61	 0.30	
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Appendix	3:	Animal	Ethics	approval	
 
 
 
Appendices	
 266 
 
 
 
 
 
 
Appendices	
 267 
Appendix	4:	Summary	of	mice	information	
	
Table	A17:	Mice	from	sham-treated	group	
Batch	 Mice	code	 Parents	 Age	(d)	 Body	weight	(g)		B1	 4596	 3787*4036	 77	 25.01	B1	 4597	 3787*4036	 77	 23.99	B1	 4622	 4233*4021	 74	 22.70	B2	 4662	 4123*2796	 63	 24.30	B3	 4935	 3984*3909	 79	 27.39	B4	 4967	 4690*4686	 67	 22.06	B4	 4975	 4692*4688	 66	 22.30	B5	 4985	 4693*4689	 67	 21.88	B5	 4992	 3787*4036	 66	 21.77	B5	 4998	 4691*4687	 65	 23.50		 Mean	 70.1	 23.5		 SD	 6.0	 1.8		
	
Table	A18:	Mice	from	idebenone-treated	group	
Batch	 Mice	code	 Parents	 Age	(d)	 Body	weight	(g)		B1	 4624	 4233*4021	 74	 26.40	B1	 4625	 4233*4021	 74	 22.57	B1	 4626	 4233*4021	 74	 23.12	B2	 4674	 4122*4013	 61	 25.88	B3	 4937	 3984*3909	 79	 26.49	B4	 4968	 4690*4686	 67	 23.26	B4	 4977	 4692*4688	 66	 22.13	B4	 4982	 4693*4689	 64	 21.48	B5	 4991	 3787*4036	 66	 22.01	B5	 4999	 4691*4687	 65	 25.05	
	 	 Mean	 69.0	 23.8	
	 	 SD	 5.8	 1.9	
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Table	A19:	Mice	from	#37-treated	group	
Batch	 Mice	code	 Parents	 Age	(d)	 Body	weight	(g)		B2	 4659	 4123*2796	 63	 24.27	B2	 4660	 4123*2796	 63	 25.32	B2	 4668	 3787*4036	 63	 22.73	B3	 4928	 4227*4362	 79	 24.29	B3	 4936	 3984*3909	 79	 22.79	B4	 4978	 4692*4688	 66	 22.93	B4	 4983	 4693*4689	 64	 22.98	B5	 4986	 4693*4689	 64	 21.19	B5	 4990	 3787*4036	 66	 22.59	B5	 5000	 4691*4687	 65	 23.55	
	 	 Mean	 67.2	 23.9	
	 	 SD	 6.3	 1.0		
	
Table	A20:	Mice	from	#77-treated	group	
Batch	 Mice	code	 Parents	 Age	(d)	 Body	weight	(g)		B2	 4661	 4123*2796	 63	 24.63	B2	 4669	 3787*4036	 63	 23.61	B2	 4673	 4122*4013	 61	 25.10	B3	 4929	 4227*4362	 79	 23.51	B3	 4952	 3990*3915	 74	 25.17	B4	 4949	 3990*3915	 80	 25.24	B4	 4976	 4692*4688	 66	 23.38	B4	 4984	 4693*4689	 64	 23.90	B5	 4987	 4693*4689	 67	 22.58	B5	 4989	 3787*4036	 66	 22.66	B5	 5006	 3991*3914	 63	 23.38	
	 	 Average	 67.8	 23.9	
	 	 SD	 6.7	 1.0		
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